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Summary 
Lung cancer is the leading cause of cancer death worldwide. Patients with lung cancer have a 
very poor outcome compared to other common cancers. The aim of this project is to identify 
whether CT data accumulated by patients with Non-Small Cell Lung Cancer (NSCLC) provide 
an untapped resource that can improve their quality of care, by generating more information 
from existing imaging. Extracting additional data from imaging is termed radiomics. One way 
of extracting this data is using mathematical descriptions of an image or regions of interest 
within an image. This type of assessment is termed Textural Analysis (TA).  
The experimental work described in this thesis uses a second order TA technique to analyse 
CT (Computer Tomography) imaging data from patients with NSCLC. The software developed 
as part of this project uses a voxel by voxel analysis of CT imaging, by comparing grey levels 
using grey level co-occurrence matrices (GLCMs). 
Three approaches (themes 1-3) were explored. The first approach shows that TA can help 
differentiate between tumour and Radiation Induced Lung Injury (RILI) after Stereotactic 
Ablative Body Radiotherapy (SABR) in early stage lung cancer. The second approach suggests 
that assessing muscle loss on diagnostic imaging can help predict outcome in advanced 
NSCLC. The third and final approach uses TA to generate a functional assessment of lung 
function. TA is able to differentiate between patients who are fit or unfit for radical 
radiotherapy, based on TA of lung tissue on CT imaging, rather than formal lung function tests.  
TA technique described in this thesis is a novel intervention in gaining functional data from 
CT imaging. It is particularly attractive as the analysis is generated from routine oncological 
imaging. As a result these tools have the potential to be cost effective and could be integrated 
into a standard radiology workflow.   
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Glossary 
BMI    Body Mass Index  
CBCT    Cone Beam Computer Tomography Scan  
CERR   Computational Environment for Radiotherapy Research, software. 
CT    Computer Tomography  
CTE    Commissioning through evaluation  
CVSSP    Centre for Vision, Speech and Signal Processing, Univ of Surrey  
EBRT    External Beam Radiotherapy  
Entropy   A texture analysis marker, which is a measure of disorder 
Filter kernel/size  Is the size of the window the software uses to analyse each voxel 
Gy   Gray, unit of radiotherapy dose 
GTV   Gross Tumour Volume  
HR    Hazard Ratio  
IMRT    Intensity Modulated Radiotherapy  
ITV    Internal Target Volume  
LMQ Lloyd Max Quantiser, method of quantisation in which the specific 
values at which the levels are chosen to minimise the difference 
between the quantised image and the original image.  
NSCLC    Non-Small Cell Lung Cancer  
PD-L1   Programmed Death Ligand 1 
PET-CT scan   Positron Emission Tomography-Computer Tomography Scan  
PTV    Planning Target Volume  
Quantisation  Dividing a continuous variable into a pre-set number of discrete levels 
ROI   Region of interest 
RILI   Radiation induced lung injury 
RSCH    Royal Surrey County Hospital  
SABR    Stereotactic Ablative Radiotherapy  
TKI   Tyrosine Kinase Inhibitor 
VMAT    Volumetric Modulated Arc Therapy 
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Thesis structure 
 
Figure 1, thesis structure. TA = Textural analysis .SABR= Stereotactic Ablative Body 
Radiotherapy, NSCLC= Non-Small Cell Lung Cancer, TEXAS trial=TEXtural Analysis Stereotactic 
radiotherapy trial, DAIL trial= Dietetic Assessment and Intervention in Lung cancer trial, TEAL 
trial= TExtural Analysis and Lung function trial.  
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1.1 Project aim 
The aim of this project is to identify whether CT data accumulated in a patient’s Non -Small 
Cell Lung Cancer (NSCLC) journey offers an untapped resource that can improve their quality 
of care, by generating more information from existing imaging. This could lead to greater 
information concerning the patient and their cancer, their prognosis and patient fitness. 
Furthermore it could reduce the number of tests that may be required and explore whether 
imaging biomarkers could help predict treatment risk and outcome. These tools would be cost 
effective as the investigations would already be complete and additional analysis could be 
integrated into a standard radiology workflow.  The relationship between different parts of 
the project are illustrated in figure 1.  
 
Figure 1, a diagrammatic representation of this thesis showing the 3 main themes of the 
project, understanding more about responses to SABR, predicting lung function and 
identifying sarcopenia.  
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1.2 Background to lung cancer:  
1.2.1 Who gets lung cancer? 
Lung cancer is the second most common form of cancer diagnosed in the UK in both men and 
women. Over 43,000 cases are diagnosed in the UK each year with over 35,000 deaths 
annually. Five year and ten year survival rates are 10% and 5% respectively (UK, 2015).  It is 
the most common cancer diagnosis worldwide, and is the leading cause of cancer mortality 
(Ferlay et al., 2015). Lung cancer would be a rare disease were it not for smoking, which causes 
80-90% of cases (Alberg and Nonemaker, 2008). 
Lung cancer occurs in a vulnerable population. It is more common in older patients. More 
than 80% of new cases of lung cancer are diagnosed in the over 60s. More than 40% are 
diagnosed in men and women over 75 years. The number of cases of lung cancer in patients 
aged over 60 years old is rising (Foundation, 2017), particularly in those aged 81 or older, 
where cases have risen by nearly 1.5 times from 446 per 100,000 in 2004 to 666 per 100,000 
in 2012. 
Lung cancer is a disease of poverty (Li et al., 2015, Cooley and Jennings-Dozier, 1998, Gadgeel 
and Kalemkerian, 2003, Gadgeel et al., 2001) and risk of lung cancer is inversely proportional 
to socio-economic status. Lower socio-economic status is also associated with a higher 
prevalence of smoking, greater use of cigarettes that have a higher tar content or no filter 
and lower smoking cessation rates (Gadgeel and Kalemkerian, 2003) (Gadgeel et al., 2001). 
As well as greater active smoking behaviour, this population is more likely to be exposed to 
other risk factors such as higher passive smoking rates, occupational exposure, less healthy 
diets and occupational/environmental carcinogens (Cooley and Jennings-Dozier, 1998). The 
UK is a case in point, where it is estimated there would be 9,900 fewer cases of lung cancer if 
those worst off had the same incidence of lung cancer as the most affluent section of society 
(taskforce, 2015).  
As the majority of lung cancers are associated with tobacco exposure, these patients are more 
likely to have multiple co-morbidities also caused by smoking. However, 20% of patients dying 
from lung cancer are not smoking related. Non-smoking related lung cancer is still in t he top 
10 causes of cancer related mortality in the USA. Exposure to tobacco is associated with 
numerous co-morbidities including Ischemic Heart Disease (IHD), Chronic Obstructive 
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Pulmonary Disease (COPD) and other primary cancers such as bladder cancer. Recent 
research suggests that nearly a fifth of patients (18%) have 4 of more co-morbidities (Gould 
et al., 2017). As well as occurring in a vulnerable, less fit population, lung cancer is difficult to 
diagnose in the early stage of the disease. Approximately half of patients present with 
advanced disease (Gould et al., 2017, UK, 2015), this has been confirmed in local audit data 
collated as part of the introductory work for this project (Ezhil, 2016).  
Non-Small Cell Lung Cancer (NSCLC) is the most common pathological sub type of lung cancer, 
as a result, this project focuses on NSCLC. 
1.2.2 Treatment outcomes 
Table 1 shows stage at presentation and 5 year survival for lung cancer and breast cancer. It 
shows that the most common presentation with lung cancer is stage IV metastatic disease, 
whereas patients with breast cancer commonly present with localised (stage I and II disease). 
Figure 2 shows the 5 year survival for the 3 most common cancers diagnosed in the UK; breast, 
prostate and lung cancer.  
 Stage at 
presentation 
lung cancer 
(%) 
Stage at 
presentation 
breast cancer 
(%) 
5 year survival 
lung cancer 
(%) 
5 year survival 
breast cancer 
(%) 
Stage I 15 40 35 100 
Stage II 7 36 21 99 
Stage III 19 8 6 95 
Stage IV 48 5 Unknown 63 
Unknown 10 11 10 85 
Table 1, stage at presentation and survival data for lung cancer in England, adapted from 
CRUK cancer statistics (UK, 2015) 
When lung cancer is compared to breast cancer (leading cancer diagnosed in women in the 
UK) and prostate cancer (leading cancer diagnosed in men in the UK), it shows how poor the 
outcomes are for lung cancer. 
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Figure 2, comparing 5 y overall survival (OS) for 3 most common cancers diagnosed in the UK.  
1.3 Improving outcomes for patients with Non-Small Cell Lung Cancer (NSCLC) 
Lung cancer outcomes are poor and have the potential for improvement. In the longer term, 
increased rates of smoking cessation and control of tobacco are likely to have a big impact on 
incidence rates of lung cancer.  
In terms of improving early diagnosis of lung cancer, low dose CT screening of high risk 
individuals has been shown to improve lung cancer mortality in data from the Lung Screening 
Trial in the USA (Aberle et al., 2011). Feasibility projects have been completed in the UK, 
including the UK Lung Cancer Screening Trial (Field et al., 2016a, Field et al., 2016b). However, 
at present, there is not a national screening programme in the UK for lung cancer. 
Current lung cancer treatment is broadly divided into radical treatment: aiming to get rid of 
the cancer or provide long term control and palliative treatment: aiming to control the cancer 
and improve overall survival.  
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1.3.1 Radical treatment 
 For early stage NSCLC (T1-2N0-1M0), treatment often involves a single modality, either 
surgical resection (with adjuvant chemotherapy in tumours greater than 4cm or the presence 
of regional lymph node metastases) or radiotherapy alone. Radiotherapy delivers high dose 
x-rays with high precision. For smaller (often peripheral) lung tumours a specific radiotherapy 
technique called Stereotactic Ablative Body Radiotherapy (SABR) can be used in preference 
to standard radiotherapy. It is also suitable for patients not medically fit for radical 
fractionated radiotherapy or surgery (Nanda et al., 2015, Palma et al., 2012, Palma et al., 
2010, Palma et al., 2011). For locally advanced NSCLC (T1-4N2M0) radiotherapy is often 
combined with systemic chemotherapy, either sequentially or concurrently.  
1.3.2 Palliative treatment 
Before starting systemic drug treatment, early referral to palliative care and symptom 
management improves length of overall survival in patients with advanced (incurable) lung 
cancer (Temel et al., 2010). The majority of NSCLC tumours are either squamous cell 
carcinomas or adenocarcinomas. At present radical treatment is not significantly altered by 
NSCLC sub-type. However, palliative treatment can be significantly altered by presence or 
absence of specific markers, specifically the presence of PDL-1 in all NSCLC and the presence 
of EGFR mutations and ALK rearrangements in non-squamous cancers. Systemic therapy is at 
present the backbone of treatment in advanced NSCLC, for patients that are sufficiently fit to 
tolerate treatment (Zappa and Mousa, 2016). The most commonly used treatments are 
cytotoxic chemotherapy, immunotherapy (Reck et al., 2016) and targeted therapies such as 
tyrosine kinase inhibitors (TKIs). TKIs are first line treatment for patients with non-squamous 
tumours with a genetic alteration such as an ALK rearrangement or EGFR mutation (Solomon 
et al., 2014) (Yang et al., 2017). 
Both immunotherapy and TKIs are given continuously and over a longer period when 
compared to chemotherapy. Patients are more likely to have more imaging with a prolonged 
treatment. Response assessment is more complex with immunotherapy, instead of simply 
categorising the outcome of treatment as a response, stable disease or progression, patients 
can undergo other reactions, such as the development of new lesions followed by a delayed 
response or a differential response  (Wolchok et al., 2009). These different response patterns 
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may then affect the outcome. Multi-modality treatment is becoming increasingly common. 
For example treatment could include a combination of chemotherapy, radiotherapy and 
surgery in radical treatment, as well as chemotherapy with local treatment such as SABR in 
advanced disease. Recent data has shown that chemotherapy followed by SABR improves 
progression free survival from 3.9 months to 11.9 months, when compared to chemotherapy 
followed by further maintenance treatment in metachronous oligometastatic NSCLC (Gomez 
et al., 2016). This increasing complexity of treatment means that interpreting imaging is more 
complex, therefore tools to aid image interpretation are attractive.  
1.4 Advanced analysis of CT images  
Patients undergo regular cross-sectional imaging to diagnose, stage, assess response and in 
many cases undertake surveillance after treatment for lung cancer. This leads to a pool of 
imaging data that potentially has significant value beyond accurate staging of the patient. The 
most frequently used cross sectional imaging is a Computer Tomography (CT) scan. CT scans 
are relatively inexpensive, easily accessible and quick. A great deal of expertise exists in 
interpreting them.  
In a CT scan attenuation of x-rays is measured and used to determine the appearance of 
different tissues by differing electron density. Water is given a value of 0, air -1000, soft tissue 
100-300 and bone 700-3000. A series of cross sectional images (tomograms) are built up to 
give a complete scan. Composite images in coronal and sagittal planes can be created from 
the original axial images.  
The use of imaging as a pool of mineable data is termed radiomics (Gillies et al., 2016). 
Advanced image analysis has the potential to facilitate the extraction of large amounts of data 
from an image. It is being investigated in multiple types of cancer (Prestwich et al., 2015). One 
method of extracting extra data from an image is using Textural Analysis (TA). This uses 
mathematical descriptions of a region of interest to compare between different areas in the 
same image or between images.  
Different imaging modalities are used to investigate and assess patients with lung cancer. TA 
can be used in different imaging modalities. CT scans are the most widely used imaging tool 
in managing lung cancer. Other imaging modalities, particularly [(18)F]-2-fluoro-2-deoxy-D-
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glucose positron emission tomography/computed tomography (FDG PET-CT) are useful in 
providing more accurate staging of patients with lung cancer. For example PET-CT can greatly 
aid the identification of malignant lung nodules with a sensitivity of 95% and specificity of 
82% (Cronin et al., 2008). It is also useful in assessing treatment response and identifying 
tumour recurrence. FDG PET-CT super-imposes a functional assessment of tumour 
metabolism over a CT scan, which provides anatomical imaging. PET-CT is less widely available 
and considerably more expensive than standard CT imaging. Value-based care provides 
incentives to maximise information from standard investigations. Patients with lung cancer 
have a significant amount of imaging available that is potentially underused. 
The majority of published work has focused on the analysis of the tumour as the region of 
interest (Phillips et al., 2017). A range of techniques have been used to help characterise a 
range of clinical questions including: risk of malignancy of lung nodules, likely histological sub-
type of lung cancer and treatment response. The available published literature is discussed in 
detail in chapter 3. This chapter is a revised version of a published review article prepared by 
the author in the course of this study (see appendix 1). 
As well as focusing on the tumour, TA could be used to assess other tissues in the body. This 
could then be related to patient function. Table 1. Shows different ways that advanced CT 
analysis is being further investigated for non-malignant tissues.  
From the sources identified in table 2, it is possible to gain greater information from a CT scan 
regarding patient ‘health’ or ‘fitness’ as well as greater information about a disease state. This 
thesis will present the results of research into this area. Firstly in patients with small primary 
lung tumours, in understanding the effects of Stereotactic Ablative Body Radiotherapy (SABR) 
on the lung and seeing if it is possible to predict acute inflammation after SABR (Huang et al., 
2012), secondly in helping to predict patient fitness in 2 ways: showing that it is possible to 
predict lung fitness from a CT scan; and that measuring muscle mass can predict overall 
survival in NSCLC. These will be explored as 3 separate themes, however, they are united by 
the aim of gaining greater information from a patient’s CT scan.  
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Type of 
assessment 
Type of 
tissue 
Example References 
Perfusion  Blood 
vessels-
angiography 
CT angiography of pulmonary 
arteries is a standard investigation 
for pulmonary embolus. CT cardiac 
angiography is a newer technique, it 
is being investigated as an extra 
source of data including in oncology 
patients.  
 
(Girinsky et al., 2014, Group, 
2003) 
Pathological 
tissue 
density 
Heart Cardiac calcium scoring can predict 
the risk of coronary artery disease. 
CT can potentially predict cardiac 
function.  
(Pathan and Negishi, 2016, 
Rahaghi et al., 2017) 
 Lung Analysis of lung density has shown it 
is possible to differentiate benign 
lung diseases such as COPD and lung 
fibrosis from normal lung tissue.  
(Sorensen et al., 2012, Park et 
al., 2016) 
 Liver TA can be used to assess liver fibrosis (Daginawala et al., 2016) 
Biometrics Muscle Assessment of Sarcopenia (muscle 
loss) has been made in several types 
of cancer including gastric, renal cell, 
endometrial, pancreatic and bladder 
cancer surgery 
(Zhuang et al., 2016, Peyton et 
al., 2016, Kuroki et al., 2015, 
Smith et al., 2014, Pecorelli et 
al., 2016) 
Table 2: Previous studies that have investigated advanced CT analysis of non-malignant tissue.  
 
1.5 The potential benefits of getting more information from a CT scan 
In a resource-limited health setting, it is important to get as much value from investigations 
as possible. Despite being a source of significant data, CT scans are often only used to stage 
the patient or assess the response to treatment by measuring a lesion seen on an image.  
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Although the prevalence of smoking is decreasing, in the interim the incidence of lung cancer 
is increasing in the short term, particularly in older patients, as these patients were exposed 
to tobacco, before public health interventions such as a smoke free working environment 
were in place.   
In a frail population it is important to gain as much value from non-invasive investigations as 
possible. A single test such as a CT scan, which can assess patient fitness as well as staging the 
cancer is an attractive option.  
This thesis targets three main themes in extrapolating greater information from CT scans, one 
related to treatment response and two related to patient fitness. Assessing patients receiving 
SABR is the first major theme (theme 1). To understand the nature of the clinical problem a 
project was conducted in collaboration with Public Health England (PHE) to assess treatment 
of all stage 1 primary lung tumours diagnosed in 2015 in England. These results are discussed 
in chapter 2. Chapter 3 describes the background of TA in NSCLC. Chapter 4 is a technology 
assessment of the parameters of this TA tool, in terms of the variables in the image, variables 
in the TA tool and the potential for advanced analysis of the texture maps. Chapter 5 describes 
the initial analysis of the data generated from the TA of lung imaging from patients receiving 
SABR for NSCLC. Chapter 6 describes an initial study aiming to differentiate between tumour 
and Radiation Induced Lung Injury (RILI) after SABR.  
The second theme is investigating the relationship between unintentional weight loss and 
outcome in patients with Non-Small Cell Lung Cancer. Chapter 7 discusses the initial 
retrospective work evaluating whether it is possible to predict the outcome based on weight 
loss or the presence of sarcopenia. It then goes on to discuss the results of an early analysis 
of the first cohort of patients entered into the DAIL (Dietetic Assessment and Intervention in 
Lung cancer) trial. Chapter 8 discusses the third theme, which is showing how TA of a segment 
of a radiotherapy planning CT scan can differentiate between those who are fit or are not fit 
for radiotherapy. Chapter 9 brings together the results and provides and overall summary and 
conclusion of the work. A list of publications and presentations arising from this work are 
listed in Appendix 1. 
The novel research questions that this dissertation therefore aims to address may be listed as 
follows: 
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1. Can a methodology be generated in order to analyse a whole lung and identify the 
tumour within it using advanced image analysis? 
2. Is it possible to differentiate between early tumour recurrence and radiation induced 
lung injury after stereotactic radiotherapy to primary lung tumours using texture 
analysis? 
3. Can texture analysis differentiate between individuals who are fit and unfit for radical 
radiotherapy from imaging data generated from a radiotherapy planning CT scan? 
4. Is it possible to understand the relationship between malnutrition, sarcopenia, 
cachexia and changes in muscle appearance in advanced NSCLC? 
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Theme 1: CT Texture Analysis after SABR for Non-Small Cell Lung Cancer  
Chapter 2: Identification of patients with stage 1 Non-Small Cell Lung Cancer as an 
appropriate cohort for the further investigation of texture analysis. 
 
2.1 Background 
As previously discussed lung cancer is the second commonest cancer diagnosed in men and 
women in the UK and has a very poor prognosis, with 10% of patients living 5 years and 5% 
living 10 years after diagnosis. It is the commonest cause of cancer mortality in the UK and 
worldwide.  80% of patients with lung cancer have Non-Small Cell Lung Cancer (NSCLC) and 
20% of these present with early stage disease (UK, 2015). Other lung cancers such as Small 
Cell Lung Cancer rarely present with early stage disease. Therefore this chapter focuses on 
the patients with stage 1 NSCLC. The most common treatment options are surgical resection 
or radical radiotherapy. There is no current data on how frequently SABR (Stereotactic 
Ablative Body Radiotherapy) is used to treat stage 1 lung cancer. This chapter focuses on 
addressing this point.  
The aim of theme 1 of the thesis is to identify whether or not texture analysis (TA) is useful in 
identifying the presence of tumour after SABR for primary lung cancer. At present there are 
no statistics on how commonly SABR is used to treat early lung tumours in England. This 
project was developed and carried out in collaboration with the National Cancer Registration 
and Analysis Service (NCRAS) at Public Health England. This was the first project combining a 
unique set of databases that includes all patients diagnosed with cancer in England and all 
radiotherapy treatments delivered to patients in England. At that point in time, it was difficult 
to establish who received SABR, as SABR did not have a specific code. This chapter describes 
the development of the methodology used to identify patients with lung cancer who received 
SABR, followed by presentation of the results and subsequent discussion.  
From initial discussions with analysts from NCRAS it would be difficult to identify the absence 
of a treatment. Clinical data supports the use of SABR for stage 1 (T1a, T1b, T2a N0 M0) NSCLC. 
At this point in the process it was felt it would be easier to include all patients with stage 1 
NSCLC and identify the different treatment options. The use of the national Radiotherapy 
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Dataset (RTDS) would allow radiotherapy treatments to be sub-divided into SABR and other 
non-SABR treatments, something that was not previously possible. Analysing treatment of all 
patients with stage 1 NSCLC would provide a cohort of patients who received radiotherapy, 
which could then be further analysed.  
 2.1.1 Poor survival in lung cancer      
When compared to other common cancers, lung cancer survival is often very poor (Allemani 
et al., 2015), for example when comparing outcomes for 6 developed countries, 5 year 
survival for breast cancer is significantly higher (81-88.5%) than lung cancer (8.7-15.1%) 
(Coleman et al., 2011). Lung cancer survival rates in England are lower than in other 
developed countries such as Canada (8.7% vs 15.1%). This difference in outcome has been 
difficult to close over time, it is suggested that the difference is greater in older patients 
(taskforce, 2015). The Independent Cancer Task Force Report, ‘Achieving World Class Cancer 
Outcomes: A strategy for England 2015-2020’, has concluded that reasons for this include 
patients with lung cancer presenting at a more advanced stage and differences in treatment. 
One of the conclusions of this report was the need for greater access to cutting edge 
radiotherapy treatment, such as Stereotactic Ablative Body Radiotherapy (SABR). This would 
allow more patients to receive a radical treatment, when surgery is not suitable. 
Standard first line treatment for early stage NSCLC would be surgical excision in the form of a 
lobectomy (Ginsberg and Rubinstein, 1995). However, surgery is not suitable for all patients: 
some may be medically inoperable, surgery may not be technically feasible or the patient may 
opt not wish to pursue surgical treatment. SABR is an established alternative treatment, 
which delivers high dose, accurate radiotherapy to treat a small target volume in fewer doses 
than standard radical radiotherapy.  
 
SABR has shown a significant Overall Survival (OS) benefit from 10 months to 29 months 
(p=<0.001) when compared to Best supportive care (Nanda et al., 2015), and it has improved 
OS in patients aged over 75 years old (Palma et al., 2010).  SABR has also been shown to be 
an effective treatment in patients with severe Chronic Obstructive Pulmonary Disease (COPD)  
as less lung is irradiated (Palma et al., 2012) compared to conventional radiotherapy. SABR 
has fewer side effects than radical radiotherapy and potentially has a survival benefit (Nyman 
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et al., 2016, Ball et al., 2017). An analysis of 273 patients receiving lung SABR for medically 
inoperable early stage NSCLC treated in England, showed a median OS of 27.3 months, with 
a 3 year local control rate of 95.7% (Murray et al., 2016a). As well as being effective, SABR is 
well tolerated and more convenient. SABR does not cause a statistically or clinically significant 
deterioration in Health Related Quality of Life Measures (Lagerwaard et al., 2012), and fewer 
visits are required for treatment compared to fractionated radiotherapy. SABR has been 
traditionally used to treat peripheral tumours, however by increasing the number of fractions 
in which the treatment is delivered and respecting normal tissue constraints, toxicity does not 
increase (Chang et al., 2014, Senthi et al., 2013). Patients undergoing surgery would routinely 
undergo pathological staging of local lymph nodes, with the potential to upstage the tumour. 
Adjuvant chemotherapy can provide a 5% OS benefit at 5 years among patients with a larger 
than expected tumour or the presence of local and regional lymph node metastases (Pignon 
et al., 2008).  However, realistically the potential benefit of adjuvant chemotherapy in this 
cohort would be very small (Louie et al., 2015).   
 
The hypothesis within this work is therefore that fit patients would receive surgical resection 
of their primary tumour in the form of lobectomy, whereas less fit patients are more likely to 
receive SABR.  In terms of comparing the 2 modalities of treatment in operable patients, the 
only published randomised trial data comparing SABR with lobectomy is based on a pooled 
analysis of two trials that did not complete recruitment (Chang et al., 2015), and non-
randomised evidence is limited  (Mahmood et al., 2013).  Therefore, I aimed to understand 
the treatment of patients with stage 1 NSCLC tumours using national databases in 
collaboration with Public Health England, aiming to provide further evidence on the use of, 
and survival after, SABR in England.  The benefit of using a large clinical dataset such as RTDS 
is it can describe the actual clinical care being delivered to patients across a large geographical 
region. As a result, it includes sufficient patients that broad conclusions about oncological 
care can be drawn.  
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2.2 Materials and Methods 
2.2.1 Difficulties in identifying the absence of the delivery of SABR 
Data from national datasets (RTDS) and Hospital Episode Statistics (HES) were combined with 
cancer registration data extracted from PHE’s Cancer Analysis System (CAS) to identify 
patients with T1-T2a N0 M0 primary NSCLC.  
The Radiotherapy Dataset (RTDS) is a data standard that requires all NHS Acute Trust 
providers of radiotherapy services in England to collect and submit standardised data monthly 
against a nationally defined dataset. The purpose of the standard is to collect consistent and 
comparable data across all NHS Acute Trust providers of radiotherapy services in order to 
provide intelligence for service planning, commissioning, clinical practice and research and 
the operational provision of radiotherapy services.  Data collection began in 2009 and Public 
Health England (PHE) assumed responsibility for the dataset in 2016.  Its aim is to provide a 
comprehensive database of radiotherapy treatments delivered by acute trusts providing 
radiotherapy in England.  
Treatments performed 1 month before and 3 months after the date of diagnosis were 
included. These dates were chosen to only include treatments delivered in a timely manner. 
Surgery was recorded in both the cancer registration and inpatient (Admitted Patient Care, 
APC) Hospital Episode Statistic (HES) dataset.  A patient was identified as receiving surgery if 
they had a record for a procedure defined by the major resection tumour OPCS list within 3 
months from diagnosis. The list of procedures included in this list can be seen in table 1. The 
datasets were linked together by NHS number. 
Radiotherapy treatment was divided into three groups: SABR, radical radiotherapy and 
palliative radiotherapy. At the time of data collection, lung SABR did not have a specific code 
within RTDS.  
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Surgical 
code 
Surgical procedure 
E391 Open excision lesion trachea 
E398 Other specified partial excision trachea 
E399 Unspecified partial excision trachea 
E441 Excision carina 
E461 Sleeve resection bronchus & anastomosis HFQ 
E541 Total pneumonectomy 
E542 Bilobectomy lung 
E543 Lobectomy lung 
E544 Excision segment lung 
E545 Partial lobectomy lung NEC 
E548 Other specified excision lung 
E549 Unspecified excision lung 
E552 Open excision lesion lung 
E559 Unspecified open extirpation lesion lung 
T013 Excision lesion chest wall 
T023 Insertion prosthesis into chest wall NEC 
Table 1: Major resection surgical procedures included in the cohort as ‘radical surgery’ 
2.2.2 Methodological development for SABR patients 
An initial data set of patients treated in 2014 was investigated to see if it was possible to 
identify those patients receiving SABR based on dose and fractionation. UK SABR consortium 
guidelines suggest 3 different dose/fractionations for lung: 54Gy in 3 fractions for tumours 
not near the chest wall or the central chest, 55Gy in 5 fractions where PTV would overlap with 
chest wall and 60Gy in 8 fractions for tumours near central structures. As the SABR consortium 
guidelines were new, other potential dose/fractionation combinations were possible, for 
example 70Gy in 10 fractions (Chang et al., 2014).  
The first method was to identify patients who had received a dose consistent with consortium 
guidelines. A retrospective cohort analysis identified 555 patients who had received 
radiotherapy for lung cancer in 10 or fewer fractions. Of these 140 patients had received 55Gy 
in 5 fractions, 30 patients had received 54Gy in 3 fractions and 21 patients had received 60Gy 
in 8 fractions. These 3 treatment schedules made up 191 of 555 patients in the cohort (34%). 
Sub analysis of this revealed that 67% of the cohort (373 of 555 patients) received their 
treatment in 5 fractions. 370 patients had received more than 50Gy in 5 fractions and 365 
received 55Gy in 5 fractions or higher. This generated the hypothesis that the prescribed dose 
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was not being recorded, instead a maximum point dose was being recorded. Radiotherapy 
plans for SABR treatments have a higher dose in the centre of the treatment volume, which 
can be up to 140% of the prescribed dose. For example, if a patient receiving a prescribed 
dose of 55Gy in 5 fractions who had a maximum dose of 140% delivered in the centre, that 
maximum dose would be 77Gy. When this was checked by Public Health England, it was felt 
to be the cause of the range of doses seen in this analysis. Although recording data in this way 
has now been edited, the data was collected retrospectively and needed to take account of 
the maximum dose being recorded instead of the prescribed dose.  
As using only consortium guideline doses to identify patients receiving lung SABR was 
insufficiently broad it was decided to define SABR as 48 Gy or more delivered in 8 or fewer 
fractions. As well as taking account of treatments where a point dose was recorded, it would 
also take account of any patients receiving 48Gy in 4 fractions, which was a common 
dose/fractionation used in other countries such as Japan and USA (Murray et al., 2016b),  It 
would also include patients receiving 50Gy in 8 fractions, for central tumours or tumours close 
to the heart, which was a recognised alternative to 60Gy in 8 fractions.  
Radical radiotherapy was defined as 50Gy or more delivered in more than 10 fractions; this 
included standard fractionation and patients receiving hyperfractionated radiotherapy 
(Saunders et al., 1999). Palliative radiotherapy was defined as 50Gy or less in 15 or fewer 
fractions. Any patients who received more than one category of radiotherapy during the 
assessment period were excluded (less than 0.5% of the radiotherapy cohort). Patients 
receiving concurrent radiotherapy to a different primary tumour were included in this cohort.  
Patients identified as ‘no treatment recorded’ did not receive either radiotherapy, 
chemotherapy or major surgical treatment within the time period 1 month before and 3 
months after the date of diagnosis.  They may have received a minor surgical procedure, or 
less common treatment.   
2.3 Results 
2.3.1 Results for the whole cohort 
In total 5,826 patients with stage 1 NSCLC tumours were identified. Of these, 72% had a 
histological diagnosis and 28% (1,629) did not have a tissue diagnosis recorded. The 
commonest tissue type was adenocarcinoma (2,419 cases, 42%), the next largest cohort were 
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those with an unspecified or unrecorded tissue diagnosis (1,629, 28%) followed by squamous 
cell carcinomas (1129, 19%). The upper lobes were the commonest anatomical site, with 59% 
of tumours situated there. 47% of those identified were female and 53% male. The mean ages 
of patients who received radiotherapy and no recorded treatment were similar (76.1 years vs 
76.9 years); patients receiving chemotherapy were slightly younger and surgical patients were 
younger still (mean age 70.6 years and 68.6 years respectively).  
Table 2 includes the patient and tumour characteristics and treatments. The most common 
treatment for stage 1 NSCLC was surgical resection, with nearly half of patients (45%, 2802 
cases) undergoing surgery.  The next largest group of patients was the 32% (1878 cases) who 
did not have a treatment documented, reasons for this are discussed in section 2.4.3. The 
third largest group was those receiving radiotherapy.  
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Figure 1: Percentage of stage 1 tumours treated with SABR by Strategic Clinical Network. Error 
bars are 95% confidence intervals.   
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15% of patients (877 cases) received radiotherapy. Of the radiotherapy cohort, 514 (59%) had 
SABR, 248 (28%) had radical radiotherapy and 115 (13%) had palliative radiotherapy. The 
rates of SABR, radical and palliative radiotherapy by strategic clinical network are summarised 
in Figure 1.   
    No tx   SABR   
Radical 
RT   
Pall 
RT   Surgery   
  total total % total % total % 
tot
al % total % 
Stage                       
T1a 2,179 695 32% 223 10% 52 2% 22 1% 1,118 51% 
T1b 1,381 448 32% 147 11% 66 5% 25 2% 652 47% 
T2a 2,266 735 32% 144 6% 130 6% 68 3% 1,032 46% 
                        
Mean age - 76.9 - 75.7 - 75.5 - 77 - 68.6 - 
                        
Gender                       
Male 2,754 905 33% 236 9% 128 5% 62 2% 1,277 46% 
Female  3,072 973 32% 278 9% 120 4% 53 2% 1,525 50% 
                        
Histology                       
Adeno 2,419 327 14% 145 6% 74 3% 27 1% 1,707 71% 
Carcinoid 346 60 17% 0 0% 0 0% 1 0% 273 79% 
Large cell 67 10 15% 1 1% 1 1% 0 0% 44 66% 
Non-small 
cell 
237 82 35% 45 19% 24 
10
% 
9 4% 69 29% 
Other 0 0 - 0 - 0 - 0 - 0 - 
Squamous 1,128 200 18% 83 7% 67 6% 30 3% 675 60% 
Unspecified 1,629 
1,19
9 
74% 240 15% 82 5% 48 3% 34 2% 
 
Table 2: Patient characteristics of cohort of stage 1 primary lung tumours diagnosed in 2015 
in England. No tx = No treatment recorded within 3 months of diagnosis, SABR = Stereotactic 
Ablative Body Radiotherapy, Radical RT= Radical Radiotherapy, Pall RT= Palliative 
Radiotherapy and Surgery = Radical surgical resection of tumour.  
Patients (83 cases) received chemotherapy as a single modality first treatment within the 
search period (1 month before to 3 months after diagnosis). As the search period only 
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included 3 months after diagnosis, if it took more than 3 months to deliver the first day of the 
first chemotherapy treatment, any subsequent treatments would not have been recorded.  
Figure 1 shows the differing SABR rates by Strategic Clinical Network (SCN), these vary from 
just under 5% in Wessex to nearly 15% in Yorkshire and the Humber. The 3 highest SABR rates 
are in Northern England, North West/South London and Yorkshire. The rate of SABR 
treatment does not obviously correlate to the geographic size of the SCN or the population 
within it.  
A small number of patients (186 cases, 3%) received multi-modality treatment within the 
search period. The most common multi-modality treatment was surgery followed by 
chemotherapy. 107 of 186 patient receiving multi-modality treatment received this 
combination. This data suggests a very small number of patients (4% of the total surgical 
cohort) were upstaged and fit enough to receive chemotherapy.  
 
2.3.2 SABR cohort 
514 patients received SABR treatment at 24 radiotherapy centres.  
Treatment Type Alive at 6 
months 
Alive at 12 
months 
SABR only 97% 87% 
Radical only 94% 82% 
Palliative only 82% 67% 
Surgery only 98% 95% 
Chemotherapy only 94% 72% 
Chemo and Surgery 98% 91% 
Table 3: OS by treatment modality 
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Treatment 
Type 
Mean 
travel 
time 
(minutes) 
Median 
travel 
time 
(minutes) 
Min 
travel 
time 
(minutes) 
Max 
travel 
time 
(minutes) 
Inter 
quartile 
range 
Standard 
deviation 
 No. of pts 
travelling 
45 mins or 
less (%) 
No. of 
patients 
travelling > 
45 mins (%) 
SABR 39 30 1 379 29 37 378 (74) 136 (26) 
Radical 29 28 3 89 21 16 218 (88) 30 (12) 
Palliative 29 25 2 91 24 18 101 (88) 14(12) 
Table 4. Travelling time to receive radiotherapy  
 
The mean travelling time (illustrated in table 4) was slightly higher for patients travelling to 
attend a SABR treatment, compared to radical or palliative radiotherapy. The differences in 
median travelling time were less marked.  
 
2.4 Discussion 
2.4.1 Discussion of treatment of whole cohort 
The aim of this project was to understand the use and accessibility of SABR for primary lung 
tumours in England. This task is made more complex by the fact that referrals to surgical 
centres and radiotherapy centres do not overlap and the treatments may be delivered in 
different Strategic Clinical Networks, both to each other and to the referring hospital.  
 
From the results, it is clear that the most common treatment is surgical resection. It also has 
the best OS at 12 months: 95% of patients receiving a surgical resection were alive 1 year 
later.  It is important to bear in mind that the surgical cohort is likely to be fitter than those 
undergoing alternative treatment. SABR is a recognised treatment for stage 1 NSCLC and was 
delivered to 9% of patients (13% of those who received active treatment). With more 
radiotherapy sites being commissioned to deliver SABR for primary lung tumours, it is likely 
that the proportion of patients in this cohort receiving SABR number may increase over time.  
 
In terms of the patient population treated, the surgical cohort were 10 years younger on 
average than the SABR cohort. The mean ages of those receiving best supportive care and 
radiotherapy were similar.  
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98% of patients undergoing surgery had a histological diagnosis recorded; however, 2% did 
not, suggesting that there is likely to be a small cohort of patients whose data is incomplete. 
In the cohort overall, 28% of patients did not have a documented biopsy to prove the 
presence of NSCLC lung cancer. This equates with similar rates of microscopic examination 
confirmed lung cancer seen in other studies including data from the UK, where the rate of 
biopsy seen in patients with stage I-IV NSCLC was 26% (Walters et al., 2013). It is recognised 
practice that a significant proportion of patients with likely early stage lung cancer do not 
undergo biopsy before receiving SABR, principally because of concerns regarding a 
pneumothorax in patients who often have severe COPD. Previous data suggests a 
pneumothorax can occur in 15% of patients undergoing CT guided biopsy (Wiener et al., 2011, 
Vansteenkiste et al., 2014). Where no biopsy is obtained, international guidelines suggest that 
there should be 85% certainty or higher of a likely primary tumour before SABR is delivered 
(Vansteenkiste et al., 2014). Of the cohort receiving SABR, 53% had a documented tissue 
diagnosis. It would be expected that a higher proportion of patients undergoing SABR would 
be treated without histological confirmation of NSCLC compared to other treatment 
modalities. In a comparable cohort of 676 Dutch patients receiving SABR, histological 
confirmation was obtained in 35% of patients (Senthi et al., 2012).  However, it is important 
to note that in the Dutch SABR cohort the proportion of adenocarcinomas and squamous cell 
carcinomas (SCCs) were equivalent, whereas in the English cohort adenocarcinomas 
outnumbered SCCs approximately 2:1. Traditionally, adenocarcinomas tend to be more 
peripheral tumours, whereas SCCs are more central. The predominance of adenocarcinomas 
may suggest that more peripheral tumours are being treated. The risk of significant toxicity 
in treating peripheral lung tumours with SABR is small. Treating more central tumours has a 
higher risk of airway collapse and haemorrhage (Senthi et al., 2013). The different proportions 
of tissues types may suggest that lower risk peripheral tumours are being more commonly 
treated with SABR; however, it may be related simply to the rise in the proportion of 
adenocarcinomas being diagnosed (Song et al., 2017). 
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Figure 2 Kaplan Meier curve of different groups, SABR, surgery, radical RT, palliative RT, no 
recorded treatment. 
Patients receiving SABR had to travel for longer to receive their treatment than those 
receiving fractionated radical radiotherapy or palliative radiotherapy. This data is likely to be 
skewed by a small number of patients travelling for a long time to receive SABR treatment. 
 
2.4.2 Surgical cohort 
Surgery was the most common treatment delivered for stage 1 NSCLC. 99% of patients had a 
documented histological subtype of lung cancer documented suggesting this data set is near 
complete. Surgery had the highest one year survival rate. It is unsurprising that surgery is the 
most common treatment for stage 1 NSCLC, particularly if accessing radiotherapy is difficult. 
Surgery avoids the needs for multiple visits to a radiotherapy department.  
 
2.4.3 Cohort receiving no documented treatment 
There is a large cohort of patients that do not have a documented standard treatment within 
3 months of diagnosis. This could suggest that incidental tumours are found on imaging 
performed for other purposes, or that patients are not sufficiently fit for treatment, however 
over a third (36%) of those without a documented treatment had biopsy proven NSCLC, with 
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sufficient histological material to categorise the sub type of NSCLC. As these were early stage 
tumours it is likely that a malignant diagnosis would have had to be confirmed by CT guided 
biopsy or bronchoscopy. The early stage nature of these tumours means patients would not 
have been able to undergo less invasive diagnostic investigations such as a lymph node biopsy 
or aspiration of a pleural effusion, which are available for diagnosing more advanced disease. 
If patients were able to undergo an invasive biopsy, why did such a significant proportion not 
receive further treatment?  
In terms of SABR it is well tolerated in older, less fit patients with co-morbidities. One reason 
for this could be the availability of SABR. It would be interesting to explore whether, with a 
wider availability of SABR, more patients would have received treatment and potentially 
fewer patients would have received no treatment, particularly if increased provision meant 
they would have had to travel less far. Fewer patients were able to access SABR within 45 
minutes travelling time, compared to those receiving palliative or fractionated radical 
radiotherapy (74% vs 88% vs 88%). The Independent Cancer Taskforce have set out in 
‘Achieving World Class Cancer Outcomes: 2015-2020’ the importance in aiming to improve 
older patients’ cancer outcomes. Cancer registry data from the SEER database in the USA has 
shown that SABR improves OS when compared to best supportive care (29 months vs 10 
months) and improves outcomes in older patients (Nanda et al., 2015, Palma et al., 2011). It 
is also known that older patients with high co-morbidity scoring do worse after surgical 
resection of an early lung cancer (Wang et al., 2007). If more patients underwent SABR this 
would potentially improve the survival of the cohort as a whole.  
There may have been more than one cancer diagnosed in some of these patients. Figure 2 
shows that patients receiving chemotherapy alone or palliative radiotherapy had a worse 
outcome than those receiving no documented treatment. As these were early stage lung 
tumours, which were unlikely to be symptomatic it maybe that a different malignancy is being 
treated with chemotherapy or palliative radiotherapy. A concurrent malignancy would not 
have been identified using this methodology.  
The major limitation of this data set is the need for performance status and co-morbidity 
scoring. It is likely that this would explain why patients had neither a biopsy nor treatment for 
a stage 1 tumour. This was not available at the time of analysis.  
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2.5 Summary of findings 
This data suggests that SABR is an established treatment for early stage lung tumours, 
however, with the increase in the use of medical imaging, an ageing population and the 
potential for CT screening for lung cancer, the number of early stage tumours that are both 
detected and treated are likely to increase. More than 80% of new cases of lung cancer are 
diagnosed in the over 60s and more than 40% are diagnosed in those over 75 years. The 
number of cases of lung cancer in over 60’s is rising, particularly in those aged 81 or older, 
where cases have risen by nearly 1.5 times from 446 per 100,000 in 2004 to 666 per 100,000 
in 2012 . Many of these tumours are likely to occur in less fit individuals, which precludes 
surgery. SABR has the potential to be a very useful tool in this cohort and needs to be widely 
available. In England SABR is centrally commissioned by NHS England. This provides an 
opportunity to ensure that all patients have access to SABR without a prohibitive travelling 
time. It is vital that in a population of patients who are less likely to be fit, more likely to be 
older and have mutliple co-morbidities they can access treatment locally to them.  
 
The number of patients treated with SABR has the potential to increase. As discussed 
previously there appears to be a poplulation of patients who are sufficiently well to have a 
biopsy proven diagnosis of NSCLC, but have not had timely treatment. It may be that for these 
patients SABR treatment is difficult to access. As patients not receiving a documented 
treatment make up 36% of the cohort, it is likely that improving cancer treatment rates in this 
cohort would have a signiciant benefit on survival rates of the cohort as a whole. An analysis 
by Palma et al. has shown that in a cohort of elderly patients with early stage NSCLC, as SABR 
became a more established treatment,  the use of radiotherapy has increased, overall survival 
has increased and the proportion of patients receiving no treatment has decreased (Palma et 
al., 2010).   
 
At present only a small number of projects have used RTDS to investigate patterns of 
radiotherapy treatment for cancer. The first published study looked at the use of radiotherapy 
in rectal cancer (Morris et al., 2016). This methodology provides a way of identifying large 
cohorts of well characterised patients receiving radiotherapy and is particularly useful in 
identifying patients having radiotherapy as a single modality treatment (Phillips et al., 2018). 
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As follow up time from treatment increases, OS will become a more relevant indicator. The 
use of RTDS will be a very helpful tool in understanding prescription patterns, OS and access 
to radiotherapy. This has the potential to provide a large dataset for further research 
 
In identifying access issues this data set may identify regions of England that need better 
provision of SABR. Follow up of this cohort over a longer time period will also provide real 
world outcome data to compare to clinical trials.  
 
2.6 Future work: the appropriateness of Textural Analysis in patients receiving SABR for 
NSCLC 
Investigating the use of texture analysis in patients receiving SABR is appropriate because: it 
has the potential to be cost effective; it can be completed on existing imaging; can potentially 
be used to help define malignancy or recurrence when a patient cannot have a biopsy; and 
the use of SABR is likely to increase. 
The next chapter (chapter 3) focuses on different methods of TA to establish the context of 
TA in lung cancer. Chapters 4-6 establish and investigate a specific method of TA in patients 
who have received SABR for NSCLC. 
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Theme 1: CT Texture Analysis after SABR for Non-Small Cell Lung Cancer  
Chapter 3: Literature review of Clinical Applications of texture analysis in Non-Small Cell 
Lung cancer (NSCLC) 
3.1 Background 
The work generated for this thesis, described in chapter 2 has shown that surgery is the 
commonest treatment for Non-Small Cell Lung Cancer for stage 1 tumours in England. The 
second commonest active treatment is Stereotactic Ablative Body Radiotherapy. It showed 
that there was also a pool of patients who did not receive active treatment, which require 
further investigation. 
 
The aim of theme 1 of this thesis is to see if it is possible to differentiate between tumour and 
radiation-induced lung injury (RILI) after SABR (Stereotactic Ablative Body Radiotherapy), 
however, it is important to put this work in context, by reviewing previously published 
literature regarding TA being used in NSCLC. In terms of developing a novel TA tool, reviewing 
the literature will help to understand previous approaches to TA and the clinical questions 
that have been investigated. Previously published TA has been undertaken at different time 
points of diagnosis and treatment for Non-Small Cell Lung Cancer. Previously published data 
can be categorised into pre-treatment TA and assessing treatment response. Pre-treatment 
TA has several potential roles, in aiding diagnosis of lung nodules and assessing their 
malignant potential, predicting treatment response and prognostication for a tumour. This 
can be performed on differing imaging modalities including CT and PET-CT. 
 
When a patient has been diagnosed with lung cancer, during their treatment pathway they 
often undergo regular cross-sectional imaging to diagnose, stage, assess response and 
undertake surveillance after treatment, which leads to a pool of imaging data that potentially 
has significant value beyond accurate staging of the patient. Computed tomography (CT) is a 
central tool in managing lung cancer. It is relatively inexpensive, quick and widely available. 
[(18)F]-2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography 
(FDG PET-CT) superimposes a functional assessment of tumour metabolism. FDG PET-CT can 
greatly aid the identification of malignant lung nodules with a sensitivity of 95% and specificity 
of 82% (Cronin et al., 2008), but is less widely available and considerably more expensive. 
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Value-based care provides incentives to maximise information from standard investigations. 
Radiomics aims to extract and analyse large amounts of advanced quantitative data from 
medical imaging (Gillies et al., 2016). Textural Analysis (TA) is a subtype of radiomics, an 
example of an agnostic, rather than semantic, approach within this field, based on 
mathematical derivations rather than prior clinical concepts (Materka, 1998).  
 
TA can be used on existing data sets with no further dedicated or specialist imaging required. 
A considerable body of literature has accumulated in this field. TA has the potential to 
differentiate between benign and malignant lung nodules (Devan et al., 2014, Dilger et al., 
2015a, Froz et al., 2017, Lin et al., 2013, Hwang et al., 2015, Padma and Sukanesh, 2013a, 
Pires et al., 2013, Sun et al., 2013, Orozco et al., 2015, Son et al., 2014) prognosticate 
outcome(Ganeshan et al., 2010, Emaminejad et al., 2015, Hawkins et al., 2014a, Coroller et 
al., 2015, Fried et al., 2014, Grove et al., 2015, Song et al., 2016a, Kang et al., 2015, Cirujeda 
et al., 2016, Hunter et al., 2016, Fave et al., 2016, Parmar et al., 2015a, Kohutek et al., 2014), 
aid improved radiotherapy planning (Wu et al., 2016), predicting radiotherapy side 
effects(Cunliffe et al., 2013) and give a greater understanding of response assessment 
(Mattonen et al., 2014, Mattonen et al., 2015, Mattonen et al., 2016, Moore et al., 2015, 
Knollmann et al., 2014, Cook et al., 2015, van Gool et al., 2016, Ravanelli et al., 2013, Chong 
et al., 2014, Petrulli et al., 2015). The aim of this review is to explain how different TA methods 
have been investigated in non-small cell lung cancer, (NSCLC), and to describe their current 
applicability and future potential(Depeursinge et al., 2015). 
 
3.2 Methods 
In order to identify appropriate studies, 3 different search engines were interrogated, these 
were: Pubmed, Medline and Web of Science. I devised a search strategy in collaboration with 
the subject specific librarian at the University of Surrey library. I used the search terms 
“textural analysis”, “texture analysis” and “radiomics” with MeSH terms “lung neoplasms”, 
“non-small cell lung cancer” and “small cell lung cancer” to identify appropriate papers, 
abstracts and conference proceedings. The search period was limited to a period between 
January 2010 and December 2016. 341 references were identified, which were filtered using 
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the terms oncology, and English. Papers discussing other primary cancers and duplicates were 
excluded. This left 104 papers, all of which are included in this literature review.  
 
 
 
3.3 Background to textural analysis (TA) 
TA uses a range of mathematically calculated features to describe an image or region of an 
image. Often TA is used to describe a suspected or known tumour. The complexity of the 
analysis depends on the feature being described. Although different textural features have 
been generated from a wide range of sources, they can be broadly divided into three 
categories: first-order (least complex), second-order and higher-order (most complex). 
Different sub-categories of TA are summarised in table 1. First-order features are often 
calculated as a single figure describing the texture of the whole volume being analysed. 
Second-order features describe the relationship between 2 points, such as 2 pixels or voxels 
within the same image. Higher-order features describe the relationship between a pixel and 
more than one other pixel, i.e. a minimum of three points in space. 
First-order textural features use a range of basic statistical methods to express a single 
measure, including: energy, kurtosis, maximum and minimum intensity, average intensity 
(median and mean), range of intensities, skewness, standard deviation, uniformity, entropy 
(irregularity of intensity value distribution) and variance. Standard deviation, variance and 
mean absolute deviation express how the range of intensities are distributed. Skewness 
measures how much histogram asymmetry there is around the mean. Kurtosis measures the 
sharpness of the histogram. Randomness can be computed using uniformity and entropy. 
Entropy is a measure of disorder. The higher the entropy the greater the disorder or 
heterogeneity. The lower the entropy, the higher the homogeneity. First order features do 
not take account of any spatial relationship between different points in an image. Much of 
the published TA work, particularly related to lung nodules focuses on first order features of 
TA (Jacobs et al., 2015, Park et al., 2011, Elizabeth et al., 2012a, Dennie et al., 2016, Han et 
al., 2015, Lee et al., 2014b). 
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Feature Name of feature Definition 
First order  Mean Average intensity of values of an image 
 Variance Spread or variation around the mean 
 Skewness Symmetry of intensity values in an image. 
Skewness = 0 if histogram is symmetrical 
 Kurtosis Indication of histogram flatness, Leptokurtic 
curves are steeper and platykurtic curves are 
flatter/less peaked 
 Energy Uniformity of intensity values 
Second order 
local 
Contrast Measures amount of local variation in intensity 
values 
 Angular second 
moment (energy or 
uniformity) 
Measures homogeneity 
of intensity value distribution in 
an image 
 Homogeneity (inverse 
difference 
moment) 
Measures the homogeneity 
of the intensity values of the pixel 
pair 
 Correlation Measures the linear 
dependencies of intensity values 
in an image 
 Entropy Measure of randomness 
of intensity values in 
an image 
 Sum of 1st order 
features (squares, 
average, entropy, 
variance) 
 
Higher order 
(local) 
Complexity Measures amount of information in texture 
 Busyness Measures the rate of change in intensity values 
 Contrast Measures the variation of intensity values in an 
image 
 Coarseness Measures the density of edges in an image 
 Texture Strength Measures how definable (distinguishable) 
primitive texture is 
High order 
(regional) 
Grey-level non-
uniformity: 
Represents the similarity of 
intensity values in an image 
 Run length non-
uniformity: 
Measures the run length similarity 
 Run percentage Ratio of total number of runs to the total number 
of possible runs, measuring the homogeneity of 
runs. For images with most linear structure, the 
value of run percentage is lowest. 
Table 1: Categories of texture analysis. Adapted from Alobaidli et al. (Alobaidli et al., 2014) 
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Second-order textural features describe a relationship between two points within the same 
region of interest. It can describe the three-dimensional size and shape and a range of values 
within a tumour.  
By deriving a region of interest, measurements can be taken of variations across the tumour 
volume, including entropy, compactness, sphericity, surface area, and surface to volume 
ratio. Describing higher-order textural features is more complex than first or second-order 
features, as it involves identifying the relationship between 3 or more points.  
TA often requires complex interpretation. It is common to compare clinical interpretation 
with clinical interpretation combined with TA. The impact of TA can be assessed by various 
tools including Receiver Operating Characteristic Area under the Curve (ROC-AUC) and 
Concordance Index (CI). ROC-AUC is an explanation of the ‘usefulness’ of a test assessing 
sensitivity and specificity, assuming a test can be defined in a binary way, i.e. ‘positive’ or 
‘negative’. ROC-AUC gives a test four outcomes: true negative, true positive, false negative 
and false positive. The ROC-AUC analyses the true positive rate against the false positive rate, 
deriving values between 0.5-1.0. 0.5 shows a poor test as true positives = false positives, 1 is 
a perfect test with no false positives. Generally 0.6-0.7 = poor test, 0.7-0.8= a fair test, 0.8-
0.9= a good test, >0.9= an excellent test. A second measure is CI, which measures how well a 
prognostic test distinguishes individuals from a population with or without a particular 
outcome. Values range from 0.5 (no discrimination) to 1.0 (perfect discrimination)(Tripepi et 
al., 2010). To be significant a CI measurement should exclude 0.5 from its confidence interval.    
3.4 Pre-treatment textural analysis (TA) 
A wide range of studies have used TA to attempt to define different aspects of lung lesions 
seen on pre-treatment imaging. TA has been used to differentiate benign or minimally 
invasive lesions from malignant tissue (particularly lung nodules) using CT(Devan et al., 2014, 
Dilger et al., 2015b, Froz et al., 2017, Lin et al., 2013, Hwang et al., 2015, Padma and Sukanesh, 
2013b, Pires et al., 2013, Sun et al., 2013, Orozco et al., 2015, Son et al., 2014), FDG PET-CT 
(Orlhac et al., 2015) ultrasound (Nguyen et al., 2015), and different types of tumour histology 
(Basu, 2012, Wu, 2016, Chae et al., 2014), to aid assessment of the tumour and aid treatment 
decisions. These features can be combined to predict the likelihood of a nodule being 
malignant.  
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TA has also been employed to help classify histological subtypes. An automatic classifier of 
squamous cell and adenocarcinoma helped aid tissue classification(Wang and Yu, 2013) and 
TA of nucleus features has been shown to predict early recurrence of NSCLC (Wang et al., 
2016).  
 
3.4.1 Lung nodules 
TA has been used to differentiate between different tissues and determine the risk of 
malignancy of small pulmonary nodules. Pulmonary nodules are focal opacities appearing on 
imaging that are defined as less than 3 cm in axial diameter; they can be solid, semi-solid or 
non-solid in appearance (Callister et al., 2015). CT density [measured in Hounsfield units (HU)] 
and morphology can be used to assess pulmonary nodules.  Solid cancer, non-solid  lepidic 
adenocarcinoma, blood and inactive fibrous tissue all have different HU measurements 
(Sieren et al., 2011). However, it is still difficult to predict with certainty the pathology of small 
lung lesions, because up to 39% of lung nodules with a benign CT morphological  appearance 
can be malignant (Erasmus et al., 2000).  
As the use of medical imaging increases, more lung nodules are likely to be identified. Lung 
cancer screening using low dose CT has a relative risk reduction of 20% for lung cancer specific 
survival, when compared to chest radiography in a high risk population.  In each of the 3 years 
of screening, identification of a nodule occurred in 27.3%, 27.9% and 16.8% of the trial 
population in years 1-3 respectively. Individuals in whom a nodule was identified in years 1 
and 2 were not automatically excluded from continuing with screening. but more than 95% 
of these nodules would be benign (Aberle et al., 2011). TA may aid risk stratification of these 
lung nodules. This has significant potential to improve the predictive value of screening and 
reduce the morbidities rendered by biopsy and surgical resection.  
As stated, lung nodules can be broadly divided into solid, semi-solid and non-solid. Several 
studies have aimed to help classify lung nodules into broad categories before further analysis 
(Jacobs et al., 2015, Mukhopadhyay, 2016). Ground glass nodules (GGNs) are non-solid and 
can be difficult to extract from an image accurately (Park et al., 2011, Li et al., 2016). Three 
studies suggest TA can convincingly determine malignant from non-malignant nodules. The 
first study capitalised on potential differences in heterogeneity between the nodule edge and 
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centre. The difference was much greater in malignant nodules when compared to 
inflammatory nodules with ROC AUC of 0.836 (Suo et al., 2016). In a second study computer 
aided diagnosis of whether a lesion was benign or malignant achieved 94% accuracy in 
correctly identifying all non-cancerous lesions as benign using a single image slice (Elizabeth 
et al., 2012b).  
In a cohort of 55 patients, CT TA improved specificity from 38.5% to 100% when compared to 
a FDG PET-CT-CT in differentiating primary lung tumours from granulomatous lung lesions 
(Dennie et al., 2016). Sensitivity was similar in both groups (75% using 5 TA features vs 79 
with FDG PET-CT %). High entropy (high level of disorder) was more common in primary 
NSCLCs. Interestingly in this study, using a combination of 3 textural features generated from 
a contrast enhanced CT scan rather than a non-contrast CT scan reduced the sensitivity from 
88% to 38%. The reason for this is not clear, but the presence of contrast may obscure the 
texture of the region of interest. Contrast could potentially act as a marker of vascularity, but 
as this study suggests, it could obscure textural information. The effect of contrast is not 
necessarily binary, as the results using contrast could depend on contrast related factors such 
as: speed of infusion, contrast agent used, amount of infusion given; image related factors 
such as delay between contrast and image acquisition and patient related factors such as 
cardiac output and body habitus. These factors may require standardisation so that is does 
not unduly influence the TA. 
A combination of GGN and solid nodule have a higher malignant potential than GGO or solid 
nodules (62.5-89.6%)(Lee et al., 2014a, McWilliams et al., 2013), although at least half (49-
70%) of these Partial Solid Ground Glass Nodules (PSNs) disappear within 3 months.  Analysis 
was performed aiming to identify textural features that may predict persistent vs transient 
PSNs. When textural features were combined with clinical and CT features, differentiating 
performance significantly increased from 79% to 92.9% (p<0.05). As with the previous study 
Wang et al showed that TA can improve diagnostic certainty. In contrast to the previous study, 
this study analysed the whole tumour, instead of a single image slice. This technique improved 
sensitivity and specificity from 0.82 and 0.47 to 0.95 and 0.71 respectively (Wang et al., 2014). 
3D TA has also been used to differentiate between pre malignant adenocarcinomas and early 
invasive adenocarcinomas (Chae et al., 2014). It is not currently clear how large a region of 
interest needs to be analysed. There are 3 possible approaches, 2D analysis of a single slice, 
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2D analysis of multiple slices or 3D analysis of the whole region of interest.  If a single slice of 
an image identifying a lung nodule is being used, pragmatically the image showing the largest 
axial cross section of lesion is often chosen , but cross sectional area does not definitely 
correlate with the greatest amount of extractable information.  Han et al showed that 2D 
textural features generated on multiple slices from 3D data was better than generating it from 
a single 2D slice, although 3D data did not improve on multiple 2D slices, it can potentially 
analyse extra features not available in a 2D analysis. 2D analysis on a single plane on a single 
slice would not detect differences in other planes, for example if the axial plane was used, 
data regarding the coronal or sagittal plane of the tumour could not be generated. Analysing 
multiple 2D slices may help identify the most representative 2D slice, but does not overcome 
the limitations regarding information in 3D. 
FDG PET-CT is another type of imaging used to assess lung nodules. In many institutions 
worldwide FDG PET-CT is less available than CT, but is a very useful tool in identifying 
malignant lung nodules, with a sensitivity of 95% and specificity of 82% (Cronin et al., 2008). 
Tracer uptake can be heterogeneous within a tumour because of areas of necrosis, 
differences in blood flow, cellular activity, micro-vessel density or hypoxia. Whilst this review 
focuses on the exploitable TA features of standard CT scans, where PET-CT data sets are 
available, additional value can be extracted from these scans. Fractal analysis is a TA modality 
that has been studied in this setting.  
 
Fractal analysis is an example of higher order texture analysis. Fractals can be described as 
self-similar structures. The whole structure is made of up smaller repeating sub units that are 
identical to the overall structure, irrespective of the degree of magnification. A more fractal 
image or structure displays these properties. A less fractal structure does not display self 
similarity and would be regarded as more ordered as the structure/scale can be determined. 
Fractal analysis evaluates the spatial pattern of irregular objects, as a result morphological 
complexity and spatial heterogeneity can be given a specific value. Fractal analysis can take 
several forms giving different textural featues: fractal dimension is a measure of how an 
object fills space, fractal abundance is a measure of the volume of space filled and lacunarity 
is a measure of heterogeneity of the structure inside an object (Sanghera et al., 2012). As 
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these different forms of fractal analysis can be given a specific value, repeating this analysis 
could potentially give an agreement value or threshold can that be user independent. 
 
Morphological fractal dimension and density fractal dimension can be generated from CT and 
PET images of pulmonary images. Combining morphological fractal dimensions and FDG PET-
CT or density fractal dimensions improves diagnostic accuracy to above 90% when comparing 
benign nodules with a primary NSCLC(Miwa et al., 2014) using FDG-PET alone.  
 
MRI is not routinely used to assess lung tumours before treatment. However a small single 
institution series suggests that entropy derived from dynamic contrast enhanced MRI may 
predict progression free survival (PFS) (Yoon et al., 2016).  
 
3.4.2 Pre-treatment textural analysis (TA) of primary lung tumours using CT 
TA has been shown to have potential as an imaging biomarker to identify the histological 
subtype of NSCLC. Although many of these studies are relatively small, CT TA radio-genomics 
is a rapidly expanding field. CT TA has helped to  differentiate KRAS oncogene mutated 
tumours from pan-wild type tumours(Weiss et al., 2014), EGFR (Epidermal Growth Factor 
Receptor) mutant tumours from wild type tumours (Ozkan et al., 2015, Rizzo et al., 2016), 
EGFR mutated tumours from ALK (Anaplastic Lymphoma Kinase) rearranged tumours 
(Caramella et al., 2015), lepidic adenocarcinomas from non-lepidic adenocarcinomas(Wang 
et al., 2015) and ALK rearranged tumours from un-rearranged tumours (Bluthgen et al., 2015, 
Yoon et al., 2015). Work in progress has identified a correlation between kurtosis (a first-order 
textural feature) in NSCLC and the expression of a gene coding for a protein that regulates 
mucin production, Mucin5AC. The expression of this gene is considered a marker of the 
activation of the MAP kinase signalling pathway. Increased presence of mucin produces lower 
attenuation with x-rays than soft tissue. This begins to demonstrate the potential for radio-
pathologic correlation through advanced imaging analysis (Miles, 2016).   
Conventional predictors of outcome in NSCLC include TNM staging, AJCC stage, age, sex, 
histology, co-morbidities and performance status. The use of a biomarker from CT imaging to 
prognosticate patients’ outcomes, risk of distant metastases and overall survival is attractive. 
CT texture features have been correlated with PET-CT SUVmax, tumour staging and degree of 
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tumour hypoxia (Ganeshan and Miles, 2013, Ganeshan et al., 2010). A combination of TA 
features have been identified that predict recurrence in surgical patients (Emaminejad et al., 
2015) and overall survival in patients with adenocarcinoma (Hawkins et al., 2014b). 
 
TA can assess many different features and this presents a challengingly large experimental 
space. In 98 patients with stage I-III NSCLC receiving radical radiotherapy, the 15 most 
predictive textural features were chosen from over 600 features, from pre-treatment CT scans 
(Coroller et al., 2015). Risk of distant metastases were divided into high risk and low risk with 
a CI of 0.62. Use of simple radiomic features were able to predict risk of distant metastases in 
a discovery and validation set of patients. In a similar study in stage 3 patients, receiving 
chemo-radiotherapy, textural features extracted from the Gross Tumour Volume (GTV), 
patients could be divided into high and low risk based on traditional prognostic factors such 
as staging and features from TA(Fried et al., 2014), with a CI of 0.89 and 0.91 for overall 
survival and loco regional control respectively.  Grove et al showed that morphologically 
similar tumours could be divided into better and worse prognosis groups and validated this 
at a separate institution, using convexity and central tumour entropy. More irregular tumours 
conferred a worse prognosis (Grove et al., 2015). 
 
TA in combination with machine learning has been shown to predict recurrence with a high 
degree of accuracy (CI 0.81)(Depeursinge et al., 2015) and overall survival (Song et al., 2016b), 
using the pre-treatment image of a single CT slice of 101 patients who underwent resection 
of stage I primary lung adenocarcinoma. The TA used a second-order feature called Riesz 
wavelets, which were chosen to differentiate between solid component and ground glass 
opacities (GGO). SVM (Support Vector Machine, a form of machine learning) has been used 
to classify high risk and low risk lesions, as well as risk of recurrence (Kang et al., 2015, Cirujeda 
et al., 2016). The benefit is that SVM can separate non-linear data; it can separate data into 2 
groups that are not obviously distinct when plotted, when methods such as logistic regression 
are less useful. The more round the tumour (spherical disproportionality) and the greater the 
tumour heterogeneity, the less likely the response, in patients undergoing neo-adjuvant 
chemo-radiotherapy for NSCLC. The strength of this study was that treatment effect was 
assessed by pathological assessment of the surgically resected specimen. In a separate study 
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CT TA measures were able to predict tumour shrinkage after radical radiotherapy (Hunter et 
al., 2016).  
 
A range of TA studies have been performed with broadly similar methodology. A patient 
cohort with a known outcome measure is identified. A single slice or whole tumour is 
segmented out from the rest of the scan. A range of first, second and higher order textural 
features can then be extracted. In many cases a large number of TA features can be 
calculated. Features are chosen that correlate with outcome. The difficulty is that different 
TA features are significant in different studies, using different methods of analysis.An 
association between TA features and outcome could be statistically significant by chance, 
especially if very large numbers of parameters are analysed. Some TA features are dependent 
on pre-processing of the image before TA is performed, whereas others are independent(Fave 
et al., 2016), which means the independent features were more likely to be robust, as they 
are not prone to variations in pre-processing. These concerns limit the reproducibility of many 
studies and their applicability as a practical clinical tool. Large robust data sets may help to 
overcome some of these limitations. For example, Palmar et al were able to analyse lung 
tumours and head and neck tumours in 878 patients with training and validation sets for both 
tumour types.  In this study radiomic parameters were correlated with stage and prognosis 
(Parmar et al., 2015b). Reproducibility is a key element in using such a biomarker more widely. 
 
TA can potentially increase the accuracy of nodal staging as lymph nodes can be auto-mapped 
and identified (Liu et al., 2016). TA has been shown to predict whether a lymph node is 
malignant or not in biopsy proven nodes, with a sensitivity of 81% and specificity of 80% 
(AUC= 0.87, p<0.0001). This was achieved using a combination of three textural features: 
entropy, GLNU (Grey Level Non Uniformity) and RLNU (Run Length Non Uniformity) with three 
features of shape, which assessed the degree to which a lymph node was circular. Using this 
combination 84% of malignant nodes and 71% of benign nodes were correctly classified on a 
non-contrast CT (Bayanati et al., 2015). However, only half the patients (22 of 43 patients) 
received a staging PET-CT scan.  PET imaging shows a small improvement in diagnostic efficacy 
when compared to measuring nodal dimensions alone. A published study using commercially 
available software called TexRAD has shown that it is possible to differentiate malignant 
nodes from benign nodes with a low sensitivity of 53%, but much improved specificity of 97%, 
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with an ROC AUC of 83% (Andersen et al., 2016).TA based on endobronchial ultrasound has 
been shown to differentiate between benign and malignant nodes using fractal 
dimension(Nguyen et al., 2015).  
 
3.4.3 Pre-treatment textural analysis (TA) of primary lung tumours using PET-CT 
FDG PET-CT is used as standard to stage patients potentially suitable for radical treatment for 
NSCLC. It is becoming increasingly used in managing treatment in NSCLC. Using simple PET 
metrics such as mean and maximum SUV would not be defined as TA, but analysing tracer 
uptake can identify heterogeneity across the tumour.  
 
Extracting texture features is dependent on the size and FDG uptake seen on FDG PET-CT 
imaging (Brooks and Grigsby, 2015, Chicklore et al., 2013, Hatt et al., 2015). FDG-PET texture 
features have been found to be prognostic(Pyka et al., 2015, Cheng et al., 2016, Fried et al., 
2016, Desseroit et al., 2016a, Fried et al., 2014, Win et al., 2013)and provides more accurate 
prognostication than CT TA alone (Desseroit et al., 2015, Lovinfosse et al., 2016) . Simple 
measures such as SUVmax and Metabolically Active Tumour Volume have been associated 
with overall survival (OS) after radiotherapy and response rates after palliative chemotherapy 
in metastatic lung cancer(Borst et al., 2005, Lee et al., 2006, Hatt et al., 2015, Hayano et al., 
2016).In one study these metabolic measures have also been found to correlate with 1st order 
textural features (van Gómez López et al., 2014), however additional work has suggested that 
only second order features correlate with overall survival (Park et al., 2015). FDG PET-CT-CT 
has high test-retest and high inter observer stability. In contrast Cook et al showed that FDG 
PET parameters (such as SUVmax) did not predict outcome.(Cook et al., 2013). FDG PET-CT 
studies have also been shown to aid the diagnosis of mediastinal lymph nodes (Gao et al., 
2015).(Leijenaar et al., 2013). Although FDG is the commonest tracer used in clinical practice, 
other tracers such as F-fluromisonidazole (F-MISO), a marker of tumour hypoxia, are 
available. F-MISO uptake can vary across tumours and therefore it is possible to assess tracer 
uptake heterogeneity and to use TA to generate textural features  (Schwartz et al., 2017, 
Grkovski et al., 2015). FDG images take 15-20 minutes to acquire. As a result tumour 
movement caused by respiration during image acquisition appears to affect some, but not all 
textural measures (Yip et al., 2014), for example busyness (a measure of intensity change 
between a voxel and those around it) was 20% higher in the 4D scan, suggesting that as 
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possibly  expected blurring means these measures are sensitive to motion. Fried et al 
identified that a combination of histogram features, co-occurrence matrices (using 2D 
relationships), shape and volume correlated with OS and loco regional control, but was not 
externally validated. Further studies have shown that SUVmax and mean, total lesional 
glycolysis (TLG) and metabolic tumour volume correlated positively with entropy. Energy and 
contrast had an inverse relationship (Lopez et al., 2014) and that the FDG PET and CT 
heterogeneity assessments can separately predict OS. 
 
In a pilot study, Wu et al segmented sub-regions of tumour based on similarity of appearance, 
using CT and FDG PET-CT (Wu et al., 2016). Each tumour was over-segmented into multiple 
super pixels using K clustering of the FDG PET and CT images.  The volume of the metabolically 
active sub-region predicted overall survival in this patient cohort, with a CI 0.67 and Hazard 
Ratio of 2.79 (log rank p=0.004). These regions appear to be robust against a degree of mis-
registration, but the PET data does not appear to account for tumour movement. In 
supporting the use of TA in radiotherapy planning, some CT texture features are robust 
enough to be identified on linear accelerator based cone beam CT scans from on-treatment 
imaging during radiotherapy (Fave et al., 2015). Image quality and the ability to quantify an 
image is likely to improve as cone beam CT technology quality improves and optimisation of 
cone beam CT scan protocols becomes routine (Davies et al 2016). 
 
The majority of these studies are retrospective. Many studies also use a lot of clinical data 
alongside to stratify outcome, adding in TA then slightly improves prediction of outcome 
compared to clinical data alone, rather than the tumour textural features alone predicting 
outcome. These studies are heterogeneous. They utilise different standards, measurements, 
equipment and techniques. For this reason it is difficult to achieve accurate reproducibility. 
Some studies have heterogeneous cohorts receiving different treatment, either combining 
tumours that received radiotherapy alone with chemo-radiotherapy or different radiotherapy 
schedules. Accurate localisation and segmentation of tumours on CT imaging is easier to 
overcome using appropriate windowing, than differences on FDG PET-CT, particularly if 3D 
PET is used. Some studies have specifically looked at reproducibility and this is an important 
area of further research (Hunter et al., 2013, Balagurunathan et al., 2014). At present it is 
unlikely that TA assessment is sufficiently robust to act as a biomarker. 
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3.5 Assessing treatment response using TA 
Follow-up CT and PET-CT scans both provide additional opportunities for assessment of 
treatment response beyond simple visual interpretation. SUV intensity on FDG PET-CT 
imaging may give a faster response than decrease in tumour volume (Hicks, 2009). Early 
prediction of response to chemo-radiotherapy has been made using PET heterogeneity. In a 
study by Dong et al, patients undergoing a non-treatment FDG PET-CT scan (after receiving 
approximately 2/3 of total radiation dose), certain textural features indicated response to 
treatment with a higher sensitivity (92 vs 73%) and specificity (84 vs 80%) than baseline PET 
features (Dong et al., 2016). 
 
In advanced NSCLC tumours neither volumetric measurements on CT nor RECIST criteria 
predicted OS (Knollmann et al., 2014). PET SUVmax has been associated with response to 
chemotherapy and TKIs (Cook et al., 2015, van Gool et al., 2016), but not with overall survival 
(Lee et al., 2006, Ravanelli et al., 2013). TA could identify response of adenocarcinomas in the 
metastatic setting, but could not identify response in non-adenocarcinomas.(Ravanelli et al., 
2013). Different textural features have been identified in assessing response to chemo-
radiotherapy (found tumour volume, mass, kurtosis, and skewness)  or an EGFR tyrosine 
kinase inhibitor (heterogeneity) (Chong et al., 2014). 11-Cerlotinib PET requires further 
investigation, but has been shown to potentially identify TKI responders and non-responders 
in a murine model (Petrulli et al., 2015). Kurtosis after neoadjuvant chemotherapy and 
intensity variability after tyrosine kinase Inhibitor therapy have been shown to independently 
predict pathological response(Chong et al., 2014). Having a predictor of response is useful as 
non-responders could potentially avoid a toxic treatment, which would not benefit them and 
reduce costs of futile therapy.  
 
Texture analysis has been used in a range of situations in NSCLC. The majority of data has 
been generated from either CT or PET-CT imaging. It has the potential to be used to gain 
greater data from diagnostic imaging. This could be in terms of: diagnostic certainty of an 
indeterminate lung nodule, predicting clinical outcome or assessing treatment response. The 
limitation of much of this work is that it is limited to a single methodology or institution. It is 
difficult to apply this more widely unless there are textural techniques robust to different 
scanners, settings or interpretation. The rest of this chapter discusses textural analysis applied 
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to the specific diagnostic challenge of differentiating between tumour and radiation induced 
lung injury after hypofractionated radical radiotherapy for primary lung tumours.  
 
3.6 Defining the problem: differentiating between tumour and Radiation-Induced Lung 
Injury (RILI) after Stereotactic Ablative Body Radiotherapy (SABR) 
SABR describes a battery of methods that facilitate the highly targeted delivery of a high dose 
of radiotherapy in fewer, larger doses to an early stage lung tumour. The centre of the tumour 
often receives 2 or 3 times the biological equivalent dose compared to standard radiotherapy.  
 
3.6.1 Patterns of lung injury after SABR 
Identifying early recurrence after radical radiotherapy can be complex, particularly after 
Stereotactic Ablative Body Radiotherapy (SABR) (Huang et al., 2012). Patients are commonly 
followed up using CT imaging. Post treatment changes after SABR are often dynamic for a 
year or more (Huang et al., 2012) 
 
As the dose distribution for SABR is different to fractionated radical lung radiotherapy, it is 
unsurprising that the post-treatment changes seen on CT imaging are different (Trovo et al., 
2010, Bibault et al., 2013). Lung injury is broadly divided into: early lung injury, commonly 
defined as occurring at between 1 and 6 months after treatment; a fibrotic reaction occurs 
between 12 and 24 months. These early changes can include new areas of consolidation, 
ground glass opacification, appearance of lung nodules and the development of a new pleural 
effusion. These changes occur with or without the presence of vascular and bronchial lung 
markings. Pulmonary fibrosis can resemble an interstitial pneumonia, fibrotic changes which 
develop at 12-24 months include decrease in lung volume, linear scarring, septal thickening, 
opacities and possible bronchiectasis. As SABR is delivered either as a continuous arc or with 
multiple beams, it is more difficult to differentiate between irradiated and unirradiated lung 
tissue.  
 
Several studies have described changes to lung tissue after SABR and identified potential high 
risk features for recurrence, the difficulty being that these changes can occur in benign lung 
injury (Dahele et al., 2011, Nguyen and Palma, 2016, Nguyen et al., 2017). Bibault et al divided 
lung injury induced by SABR into 5 different patterns, these are: diffuse condensation, diffuse 
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ground glass opacity, patchy heterogeneous condensation with ground glass opacity, a 
mosaic of ground glass opacity and no reaction (Bibault et al., 2013). Diffuse condensation 
sees an increase in the attenuation of the lung parenchyma, which hides the vessels and 
bronchial walls. These changes fill the treated volume of lung. Ground glass opacity is defined 
as an area of increased density in the lung parenchyma, but does not obscure the bronchial 
and vascular markings seen in the lung.  
 
The 5 patterns of RILI are essentially one of, or a combination of, no reaction, GGO or solid 
consolidation.  
 
3.6.2 SABR and TA 
The lung reaction makes differentiating between tumour and RILI difficult after SABR. TA has 
a role in pre-treatment and post treatment assessment. Pre-treatment textural features can 
improve prediction of outcome, compared to SUVmax alone (Kohutek et al., 2014). Compared 
to other treatment response assessments, the evidence base for using radiomics and textural 
features in SABR response assessment is relatively advanced. Treatment-related toxicity is 
also amenable to assessment by TA. The texture of regions of lung injury were compared with 
recurrence from CT imaging, by comparing areas of ground glass opacity and consolidation. 
These analyses showed recurrences were denser and had different textural features when 
compared to areas of RILI, this could also aid in identifying an early response (Mattonen et 
al., 2014, Mattonen et al., 2015, Mattonen et al., 2016).  
 
Part of the reason that TA of CT images is attractive, is that FDG PET-CT has a limited role in 
identifying early tumour recurrence after SABR. This is partly because acute lung injury and 
inflammation can be PET avid. The 2 more proven markers of PET recurrence are FDG PET 
SUV >5 or a SUV value higher than the tumour on the diagnostic FDG PET-CT (Huang et al., 
2012). Radiomic features have been extracted, which predict early recurrence and are able to 
improve sensitivity when compared to physician assessment (AUC 0.85, false negative rate 
23% vs 99%) (Mattonen et al., 2016). Another study has suggested that perfusion 
characteristics of RILI and recurrence are different, with the areas of recurrence exhibiting 
changes in perfusion termed as wash-in and wash out phenomenon, not seen in areas of RILI 
(Moore et al., 2015). Lung CT TA changes can be identified in patients receiving radical 
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radiotherapy to the oesophagus, this technique not only identified patients who did, and did 
not, develop radiation pneumonitis, it also quantified it (Cunliffe et al., 2015). It achieved this 
by comparing randomly generated regions of interest in both pre and post treatment imaging.   
 
3.7 TA in context  
The use of TA and radiomics is rapidly evolving. It is attractive as it uses existing imaging data 
to gain greater information about a tumour or disease state. There has been sufficient work 
to establish that certain textural features can act as biomarkers. Indeed tumour kurtosis and 
entropy are entering real-world clinical evaluation as markers of poor prognosis (Miles, 2016). 
However to become more widespread a range of obstacles require attention. It is important 
to consider standardisation of each step in the process including: acquisition, segmentation 
(ideally auto-segmentation), analysis and interpretation of the data. TA techniques often 
require an expert to accurately delineate the tumour. TA requires a significant degree of 
computing power to generate the analysis, it is not currently integrated into current 
assessment of imaging in diagnosis and response assessment and TA potentially makes 
workflow with a radiology department more complex.  
Some of these challenges can be overcome. For example, extracting textural features 
automatically reduces or eliminates inter-observer error(Tixier et al., 2014), using an 
automated technique to delineate tumour volume is more robust than manual delineation 
(Parmar et al., 2014) and commercialisation and user interface optimisation may facilitate the 
incorporation of TA into radiology department workflows. Many studies have analysed the 
primary tumour and so at present are more likely to be useful for pre-treatment 
prognostication, rather than post treatment assessment.  
To gain the full benefit of textural features, identification and classification of features need 
to be sufficiently robust to overcome variables such as patient factors (including positioning, 
respiration phase and motion management and effects or lack of IV contrast), acquisition and 
processing variables such as image acquisition power, image slice thickness, image 
reconstruction algorithms, use of segmentation software and operator variability in tumour 
delineation. Some texture features are reproducible, while others are highly variable and do 
not generate the same results with repeat testing (Desseroit et al., 2016b, Orlhac et al., 2014). 
To minimise these variables and identify the changes related to tumours alone many studies 
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standardise their image acquisition process (Balagurunathan et al., 2014). Useful biomarkers 
need to overcome these features or have to be standardised to ensure accurate 
interpretation of this information.  
 
TA of routine imaging is likely to have a range of uses in the future both within and outside of 
oncology. With more robust measures of texture it may be helpful in differentiating between 
benign and malignant lesions, identifying sub-types of malignancy. It will aid surgical and 
radiotherapy planning and hopefully provide more accurate response assessment. Response 
assessment is becoming more important as treatment becomes increasingly complex. 
Standard RECIST size criteria are not adequate for assessing response in immunotherapy as 
standard RECIST criteria underestimate benefit (Hodi et al., 2016). Texture could potentially 
have a role in assessing how a lesion changes rather than just using size assessment. Assessing 
response after stereotactic radiotherapy is difficult because of the localised radiotherapy 
change induced by the treatment. Differentiating between inflammation and tumour is 
difficult, particularly if a biopsy is inconclusive.  
Outside of oncology TA has already been used to assess hepatic and pulmonary fibrosis 
(Alemzadeh et al., 2015) and to see if different lung pathologies can be diagnosed on imaging 
alone. It can potentially have a role in differentiating tissue anywhere in the body, potentially 
preventing the need for more invasive tests.  
For these reasons being able to extract more information for standard imaging is an attractive 
way of getting more ‘value’ from investigations and is likely to be more routinely introduced 
into clinical practice in the coming years. In the context of this thesis the majority of published 
TA studies use a first order method. In much of the published work a biological hypothesis 
behind the texture comparisons is not obvious.  
 
The aim of the work set out in this thesis is to develop a more complex TA tool, with the goal 
of analysing a whole lung and identifying sub-regions within it, to attempt to differentiate 
between tumour and post radiation lung injury after SABR. This work is described in chapters 
4-6 of this thesis. The same tool has also been applied to see if it is possible to make a 
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functional assessment using anatomical data generated from a CT scan. The literature behind 
assessing lung function and sarcopenia is discussed in those specific chapters.  
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THEME 1: CT Texture Analysis after SABR for Non Small Cell Lung Cancer  
Chapter 4: Summary of Development of a method for operator independent tumour 
recognition using GLCM bases textural analysis of a whole lung, generated from Computer 
Tomography data   
4.1 Background 
The aim of the work presented in this thesis, was to understand whether advanced image 
analysis in the form of texture analysis (TA) could be used to differentiate between a tumour 
and radiation induced lung injury (RILI) after SABR for primary lung cancer, which may be very 
difficult to do by assessing the appearance of post treatment images (Huang et al., 2012, 
Huang et al., 2015, Bibault et al., 2013, Nguyen et al., 2017, Ronden et al., 2018). This would 
be achieved by identifying a methodology that required limited assumptions regarding the 
spatial characteristics of the tissue, as well as being able to potentially analyse the whole lung 
and differentiate between tissues. By analysing more lung using an analysis that could take 
account of spatial variations, more complex interactions could be investigated, identified and 
understood. As well as understanding the spatial variations, analysing large volumes of lung 
tissue overcomes the difficulty in identifying the tumour bed after treatment. After SABR 
there can a lot of benign post treatment related lung injury, termed RILI (radiation induced 
lung injury), this can make it difficult to identify the precise tumour bed in post treatment 
imaging. Analysing large volumes of lung overcomes this.  
Choice of software 
TA can be undertaken using commercial software, such as TexRAD (TexRAD Ltd, Cambridge, 
UK). When using TexRAD the user identifies a region of interest on a single slice of a CT scan. 
This undergoes first order TA and the region of interest generates a single number to 
representing the whole region, for example skewness or kurtosis. This analysis can then be 
applied to clinical outcome, for example comparing patients with tumours that have relapsed 
early vs never relapsed to see if the texture measures are different.  
TexRAD was considered unsuitable for this project for a number of reasons. Firstly with a first 
order, single slice analysis, it would not be possible to take account of inhomogeneity both 
within a tumour and an area of RILI and between tumour and RILI. The analysis needed to 
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take account of sub regions within the lung as both a tumour and RILI could exist concurrently. 
Secondly, by not capturing all of the data regarding either tumour or RILI, it is more difficult 
to identify any patterns within tumour and RILI, which would allow the different ROIs (Regions 
of Interest) within the lung to be easily differentiated. This would not be possible with 
TexRAD. TexRAD is very user dependent and would require the user to have sufficient 
knowledge to identify the abnormality or region of interest.  
TexRAD was unable to compare sub-regions within a region of interest without repeatedly re-
drawing contours. Also as the source code was not available, it was more difficult to be sure 
of the exact method of analysis, as well as the fact the source code could not be manipulated 
to provide a more flexible TA tool. These limitations meant TexRAD was not suitable to pursue 
this project.  
As TexRAD was not thought to be suitable, alternative software that could use second order 
TA was investigated. FiniteRT is software used for TA, it was developed in a collaboration 
between the University of Surrey and the Royal Surrey County Hospital (Alobaidli, 2017). 
Before the work described in this thesis, finiteRT had been limited to analysing tumours. It 
was used to investigate and correlate intra-tumoural heterogeneity on CT imaging with FDG-
PET avidity, within the Gross Tumour Volume (GTV) of primary lung cancers, which were to 
be treated with radical radiotherapy (Alobaidli et al., 2017). This means that the previous 
study by Alobaidli et al focused on the analysis of the GTV as the region of interest.  The region 
of interest was extracted from single phase non-contrast images from the CT component of 
the PET-CT scan. Previous work did not have to contend with variables such at would need to 
have been taken account of, if larger post treatment ROIs were to be analysed.  
In order to develop as user independent a process as possible, the work outlined in this thesis 
had to take account of many more variables, when compared to the previous project e.g. the 
effect of IV contrast. New variables included understanding the effect of altering software 
parameters and the region of interest that was to be analysed. This summary covers the initial 
work on expanding the region of interest from the tumour to the whole lung, the work is laid 
out in more detail in appendix 4. The author devised and led the development of this 
methodology and process, which required active participation in developing the software as 
well as investigating the effects of different variables.  
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It became obvious that this tool had the potential to have wider applications in analysing CT 
data, other than in analysing post treatment response, such as analysing non-malignant 
tissue. Two examples of this are explored in themes 2 (muscle analysis) and 3 (lung 
parenchyma analysis) of this thesis.  
FiniteRT was chosen as software to pursue differentiating between tumour and RILI after 
SABR, principally because it can take account of spatial relationships between sub-regions of 
a texture plot. The final workflow can be seen in figure 1.  
FiniteRT uses a second order feature of TA called grey level co-occurrence matrices (GLCM), 
to create a map of heterogeneity. Essentially, the software divides the region of interest into 
voxels, before making a voxel by voxel comparison, assessing its similarity or dissimilarity to 
the 26 voxels immediately next to it in 3D space. The larger the structure the longer it takes 
the software to process the information. For comparison analysing a tumour volume would 
take several minutes and analysing an entire lung would take several hours. Each time a 
variable within the software is changed, the analysis needs to be re-run. 
The software characterises the image using the GLCM to identify how often pairs of pixels 
with a specific value appear as a function of the position of the voxel in space. FiniteRT assigns 
the voxel an entropy score. Entropy is a measure of disorder, the higher the entropy score, 
the more dissimilar a voxel is to voxels around it. The calculation used to measure entropy is 
shown below. Inversely, a low entropy score means a voxel is similar (more uniform) to the 
voxels around it.  
(Alobaidli, 2017) 
Where P(i,j,) is the probability that a voxel of intensity I has a voxel of intensity j immediately 
adjacent to it and the sum over i and j is over all intensity values in the image. 
The aim of the project was to differentiate between tumour and RILI. As in-house software, 
the system had a range of paremeters whose values need to be chosen.. It was important to 
understand how altering these variables might maximise the differences between tumour and 
RILI. Firstly the size of the filter can bevaried. The filter kernel/size is the size of the window 
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the software uses to analyse the GLCM. The software also sets the number of levels the data 
is divided or digitised into, which are the quantisation levels. The software makes a 
comparison between voxels by comparing data already divided into new quantisation levels, 
rather than by comparing the original values of the voxels in Hounsfield units, this reduces 
the calculation time and reduces the grey levels within the scan to a manageable number of 
levels. The initial version of software calculated the quantisation levels for each analysis using 
a Lloyd Max Quantiser (LMQ). Quantisation is described as the process of dividing up a 
continuous, or semi-continuous, range of values into a smaller range by group pixels with 
similar intensities. This means that similar HU values were often grouped together. A new 
value would then be given to each sub-region. The LMQ optimises the widths and values of 
the quantised bins to give the smallest RMS error from the original values (see equation 
below). The function to be minimised to achieve this was: 
(Alobaidli, 2017) 
Where: x is the original (unquantised) value, ri is the value this is quantised to for the ith 
output level, p is the probability distribution of the original data, t is the value at which the 
quantised intensity transitions from one output level to another and L is the number of output 
levels. 
This method of quantisation assigns thresholds based on the range of values within a region 
of interest. If the contents of ROIs are different, then the spread and quantity of specific 
density values are different, and the absolute density values at which the algorithm defines 
the quantisation levels will be different. For example if there are 2 ROI’s, one contains just 
lung tissue and one contains lung and bone, the actual values at which the quantisation levels 
are set are likely to be different. This type of quantisation has been termed individualised 
quantisation.  
It is also possible to standardise the quantisation levels, so that 2 or more structures are 
analysed using identical quantisation values for quantising the data. The comparison of two 
or more regions of interest using identical quantisation levels has been termed uniform 
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quantisation. The initial version of finiteRT used individualised quantisation. As more work 
was completed it became apparent that uniform quantisation would be more useful. Previous 
data has suggested that there are 2 methods to define quantisation levels, one by dividing 
the range of values into equally spaced levels (bins) where the bin size varies for each image 
and the second standardises the quantisation by maintaining a constant intensity resolution. 
The second method, which is comparable to uniform quantisation is more robust to intra- and 
inter-image assessment (Leijenaar et al., 2015).As part of this project finiteRT was developed 
so that it could use either uniform or individualised quantisation.  
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Figure 1: summary of workflow to identify the tumour within the elephant plot using finiteRT  
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FiniteRT needed to take account of many variables, which could affect the analysis of large 
ROIs. Understanding how the texture maps and entropy scoring changed when the variables 
were altered had two benefits. Firstly in understanding which variables alter the outcome of 
the TA and secondly, which variables could have helped maximise the ability to identify the 
tumour.  
 
figure 2. Overview of development of Texture Analysis methodology using finiteRT. 
Summarised in chapter 4, presented in more detail in appendix 3.  
These variables were divided into 2 groups, those image related and those analysis related. 
The analysis related variables related to understanding the effects of these variables in 
finiteRT on the results of the TA (e.g. number of quantisation levels), the image related 
variables related to  variables that might affect the pre-TA captured image e.g. presence or 
absence of IV contrast. An overview is given in figure 1. 
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The ROI analysed, filter size and number of quantisation levels analysed were TA variables, 
the first group as identified above. Exploring the effect of altering these variables formed the 
first part of the experimental work summarised in this chapter (section 4.2 & appendix 4).   
The second category of variables that may influence the analysis were the imaging variables. 
These were thought to include use of multi-phase radiotherapy planning scans, regions of 
interest containing tissues other than tumour or larger than the tumour, effects of intra-
venous contrast, breathing phase of the scan or the ability to interpret post treatment 
imaging. This work summarises the process of developing a model to understand the variables 
necessary to process and interpret a texture map of a whole lung, both before and after 
Stereotactic Ablative Body Radiotherapy (SABR). 
 
4.2 Defining the experimental space 1: Preliminary work on software related variables   
Early experimental work focused on understanding the effects of the software variables. The 
three software variables were the choice of ROI, size of filter and number of quantisation 
levels. 
The major principle of identifying the tumour, was that it had a central low entropy region 
appearing in black, surrounded by a rim of higher entropy voxels, appearing in grey or white 
as seen in figure 3b). Altering the size of the ROI and the filter size did not compromise the 
ability to see the low entropy region of tumour, whereas increasing the number of 
quantisation levels did affect this region, as more quantisation levels, perhaps expectedly, 
meant more heterogeneity. Simply increasing the size of the ROI, consequently increasing the 
proportion of lung vs tumour within the ROI, altered the absolute values of the quantisation 
levels. Altering the filter size gave a more blurred image  as filter size increased. 
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Figure 3. a) shows PET avid region of an FDG PET-CT scan, which represents tumour. b shows 
this region as a texture map, with heterogeneous and homogeneous images. c shows the same 
region of interest in terms of PET avidity.  
As these variables did affect the outcome of the analysis, even if only subtly, it was decided 
at this point to standardise these variables, by fixing the number of quantisation levels, the 
filter size and as far as possible, the ROI. 8 quantisation levels and a 5mm filter size were 
chosen for further work for two reasons, firstly these settings had previously been used to 
identify the homogeneous region of the tumour (Alobaidli et al., 2017). Secondly and most 
importantly, using 8 levels of quantisation appeared to maintain the central homogeneous 
region of the tumour more robustly than 16 or 32 levels. Although this decision was revisited 
at a later date, when much larger ROIs were analysed, the principle of maintaining intra-
tumoral homogeneity remained a central feature in the subsequent analysis, so the tumour 
centre could be easily identified. 
4.3 Defining the experimental space 2: Preliminary work on image related variables 
The next set of experiments investigated the imaging variables of the scans being analysed. 
The phase of the CT and the presence or absence of contrast appeared to affect the image, 
but did not affect the core aim of identifying the black central homogeneous region of the 
tumour.  
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Reviewing texture maps after SABR treatment suggested that the central region of 
homogeneity became less obvious after a successful treatment. This developed the 
hypothesis that a difference between tumour and RILI could possibly be identified.  
From the work outlined in appendix and discussed in this summary it can be concluded that 
all of the variables affect the appearance of the texture map, but mostly in subtle ways. In 
combination these could have a profound effect on the ability to compare similar structures 
between patients. The aim of this preliminary work was to understand, which variables were 
important. Perhaps unsurprisingly, all the identified variables were important, however 
although these factors influence the analysis, they do not appear to affect the architecture of 
the texture map and its appearance is grossly unchanged. In conclusion the appearance of 
the texture map generated from the analysis did not appear to risk the loss of the central 
homogenous region of the tumour. To maximise the accuracy of future analysis further work 
aimed at standardising the analysis needed to be completed, to minimise the effect of as 
many independent variables as possible.  
At this point it was felt that any future analysis would need to fix the filter size and number 
of quantisation levels and consider exploring uniform quantisation. Analysis would also aim 
to use scans with IV contrast in an identified breathing phase. 
It was felt that fixing the quantisation levels using uniform values would mean that differences 
in the texture maps were likely to be due to the tumour, not changes in software parameters. 
It offered two other benefits. Firstly, it would also allow the entropy (disorder) scores 
generated from the analysed structures to be directly compared between scans and between 
patients. Secondly, fixing quantisation levels means the quantisation levels are not 
determined by the content of the texture map. For example, by fixing the quantisation levels 
it does not matter whether a dense structure, such as bone or muscle, is inadvertently 
included in a ROI, which should only include lung and tumour. In a clinical context it reduces 
the need for specialist knowledge to volume a region of interest and minimises the effects of 
any errors in generating a region of interest.  
Going forward from this point, it was felt that further analyses should aim to include either 
large sections of lung or if possible the whole lung. Generating a contour of the lung requires 
less specialist knowledge than identifying the tumour bed (particularly in post treatment 
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imaging) and ensures that all post treatment inflammation would be included. To date all 
work had been completed on the GTV plus a margin of lung. If further analysis were to include 
large sections of lung tissue, then this would lead to a more complex analysis of the texture 
map, as the appearance of normal tissue as well as abnormal tissue would need to be 
accounted for. The texture analysis would also take a lot longer to process using finiteRT.  
4.4 Calibrating the texture map analysis 
The next step was to generate texture maps from large ROIs for large parts of the lung, or the 
whole lung. These analyses were completed using uniform quantisation using pre-determined 
levels, which allow more accurate comparisons to be made between regions of interest.  
Different analysis approaches were taken, including combining the texture map using entropy 
scores with the density data from the original CT scan, as a 2 dimensional feature plot. The 
author then wanted to see if an alternative visual presentation of the analysis would allow 
easy detection of the dense low entropy region, which was thought to correspond to tumour. 
As the low entropy region appeared in black, on a suitably windowed texture map, so that 
white was low entropy and increased density was white, potentially meant it was possible to 
easily identify dense regions with a low entropy score as the same colour. Although visually 
interesting, combining entropy scores and density did not add more information. 
Experimental work aimed to identify whether different tumours had similar combined 
entropy/density scores, as well as seeing if different organs had different combined scores. In 
summary this required artificial manipulation of the texture data and this was felt to introduce 
a possible source of error, as the way in which they were combined, could be easily 
manipulated.  
4.5 The ‘elephant plot’ An expression of combined CT and texture data as a hypothesis 
generating tool  
From the previous work described in more detail in appendix 4, it appeared that adding more 
complexity to the analysis did not obviously help differentiate between tumour and other 
structures. Each analysed voxel had 3 pieces of information: a density score, an entropy score 
and its position in space within the CT scan. The more complex analyses did not use these 
pieces of data to the greatest advantage.  
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As a result the data was plotted for with a density score on the x axis and the entropy score 
on the y axis. This was initially plotted for a whole lung containing tumour and as a separate 
analysis, the whole contra-lateral lung that did not contain tumour. These can be seen in 
figure 4. The data plot labelled a) shows the lung containing tumour and the data plot labelled 
b) shows the contra-lateral lung, which does not contain tumour.  
 
Figure 4: An ‘elephant plot’, a data plot of density (x axis) vs entropy score (y axis) for each 
data point from a whole lung segmented from a radiotherapy planning CT scan. a) is the lung 
ipsilateral to the tumour, b) is the contra-lateral lung. The absence of the ‘trunk’ of the 
elephant in b) suggests that this maybe a useful tool to identify the presence of tumour in a 
lung. X axis = density, Y axis = entropy score. 
In this example the tumour makes up approximately 1% of the lung volume and it corresponds 
to the ‘trunk’ of the elephant. The presence of tumour is very easy to identify when comparing 
figure 4 a) and b). At this point it was felt that the elephant plot may be a useful tool in 
determining the presence of tumour in a lung, following SABR for primary lung cancer. 
Chapter 5 explores the initial analysis using the elephant plot.  
The elephant plot illustrated in figure 4 shows how data points were distributed when a whole 
lung was identified and analysed. From the initial project concept the aim was to keep the 
ROI as simple as possible to identify. As a step on from identifying the whole lung, a whole 
scan was processed using both the LMQ quantisation method and the uniform quantisation, 
which is discussed in chapter 5.  
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The use and analysis of the elephant plot is discussed in more detail in chapters 5 and 6, 
however from the development of the methodology, it appears that the elephant plot is an 
experimental space, in which hypotheses can then be generated and tested.  
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Theme 1: CT Texture Analysis after SABR for Non Small Cell Lung Cancer  
Chapter 5: Preliminary Analysis of the texture maps, understanding the ‘elephant plot’ 
5.1 Preliminary analysis of the texture maps 
5.1.1 Experiment 12 Does plotting the texture map as a 2D and 3D feature plot (the 
‘elephant plot’) aid the analysis of tumour on pre-treatment imaging? 
Aim: As previously discussed in chapter 4 the elephant plot was a tool that could potentially 
help identify tumour within lung tissue. The author wanted to identify whether using a more 
advanced analysis method might help separate the data points relating to tumour from other 
data points more clearly. K mean clustering is a method to do this, it groups data around a 
pre-determined set number of clusters using means. K mean clustering aims to cluster 
unlabelled data, it is a form of unsupervised learning, i.e. data that is not in categories, such 
as all the voxels within a texture map. This means that groups/clusters are not pre-
determined and are clustered by features of the data, for example the ideal would be for the 
k mean clustering to separate tumour from the rest of the data points within the texture map. 
The clusters form around a ‘centroid’, using a set of feature values, which define the 
clusters/groups. The process of generating the Kmean plot is outlined in figure 1.  
The aim of this experiment was to see whether different clusters would obviously correspond 
to different tissues, particularly to see whether the tumour could be clustered separately to 
the rest of the lung.   
It was hypothesised at this point that if this was possible, it would be easier to identify the 
larger tumours using K mean clustering, compared to smaller tumour, as larger tumours have 
more data points and potentially could be more easily separated from the rest of data.  
Experiment 12 Methods: Large sections of lung involving at least 5cm above and below the 
tumour were analysed using finiteRT. In most cases this involved approximately 2/3 of the 
whole lung ipsilateral to the tumour. The aim was to group the data into 4 clusters. Texture 
analysis was performed on both the large section of lung and the primary tumour using 8 
quantisation levels and a 5x5mm filter.  
The data was then plotted using a 3D plot, using entropy, density and a combined metric of 
density and entropy.  
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Figure 1: An ‘elephant plot’, a data plot of density (x axis) vs entropy score (y axis) for each 
data point from a large section of lung segmented from a radiotherapy planning CT scan using 
4 cluster K mean clustering (coloured red, blue, cyan and magenta).The tumour appears at the 
tip of the elephant plot in the high density low entropy region, highlighted by the blue oval. 
The magenta cluster in the highlighted region of a) separates tumour from other tissues. This 
does not occur in figure 1a) or b). Left side of diagram shows process of producing plot.  
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Experiment 12 Results and Discussion: In this experiment, 10 large sections of the lung of 10 
patients with primary lung tumours were volumed and analysed. The region of interest 
included lung and primary tumour. This data was made up of a large number of data points, 
each representing a voxel, which had a density and an entropy score. K mean clustering is a 
method used to attempt to group uncategorised data. Figure 1 shows 3 examples using K 
mean clustering the texture map into 4 clusters. Of the 3 examples only the analysis in figure 
1c) clusters the tumour separately to the rest of the data. 
When reviewing the results of all 10 patients, it was noticed that In patients 9 and 6, that 
there wasn’t a low entropy high density region visible on the texture plot. Generating the 
hypothesis that for tumours to have a low entropy tip of the elephant trunk, the have to be 
above a minimum size. The size of the tumour in these 10 patients also suggested that the 
tumour was clustered differently, either not at all, with lung tissue or independently. Table 1 
shows the different size of tumour volume and how they were clustered. In patients 6 and 9 
(tumour volume 1.7 and 3.1 cm3), there was not obvious low entropy high entropy region, so 
there was no tumour cluster. In patients 1, 3 and 4 (range of tumour size 9.4cm3 to 13.1cm3) 
the tumour was clustered with lung tissue, which has a similarly low entropy, but very 
different density.  
In the 5 patients with the largest tumours in patients 5, 8, 2, 7 and 10 (tumour volume ranged 
from 26.5cm3 to 83.6cm3) the tumour was clustered separately, as seen in image c) figure 1. 
The k-mean clustering divided the data, but did not reveal any previously unsuspected 
conclusions about the elephant plot. The tip of the trunk that correlates with high density and 
low entropy as a different cluster did identify this as the region of the elephant plot that 
relates to tumour, but did not separate it in any additional way. As shown in figure 1, it did 
not consistently cluster the data points relating to tumour separately. 4 clusters were chosen 
as it was hoped that this would provide a workable number of clusters.  
To confirm that anatomical position of the tumour and the other clusters, the regions 
clustered in the K mean clustering were then replotted using the scan co-ordinates. Figure 2 
shows the results of 2 experiments. The same scan was analysed and has then undergone K 
mean clustering.  The difference between the upper and lower images are the number of 
quantisation levels used in the analysis. In figure 2a) the tumour region is clustered with the 
low density low entropy region representing lung in their original position. The red cluster is 
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plotted as the tumour and within the lung parenchyma. In figure 2b) the number of 
quantisation levels is increased from 8 to 16. This has 2 effects, firstly the low density lung 
tissue (seen in red in image b) is clustered together and can be seen to be separate from the 
tumour. At this point it was felt that using K mean  clustering could help identify the tumour, 
although, this did not occur in all cases, as a result it was used as an analysis technique for the 
next experiment.  
 
Tumour 
visible 
Tumour + low density lung 
separate to other clusters 
Tumour separate to 
low density lung 
Tumour 
volume 
Pt 9 No Just lung N/a 1.7 
Pt 6 No Just lung N/a 3.1 
Pt 3 Yes Yes No 9.4 
Pt 4 Yes Yes No 12.5 
Pt 1 Yes Yes No 13.1 
Pt 5 Yes Yes Yes 26.5 
Pt 8 Yes Yes Yes 26.8 
Pt 2 Yes Yes Yes 28.2 
Pt 7 Yes Yes Yes 38.1 
Pt 10 Yes Yes Yes 83.6 
Table 1: table showing the tumour volumes and a tumour cluster appeared and comparing 
whether it was clustered alone, or in the same group as a low density lung region.  
 
 
 
 98 
 
 
Figure 2: Feature space plot of K mean clustered data from a large section of lung tissue using 
the spatial co-ordinates from original CT image. The upper image labelled a) relates to an 
elephant plot clustered into 4 clusters. The upper image was created using a filter size of 5 x 
5mm and 8 quantisation levels. The lower image b) uses 16 quantisation levels with the same 
filter size. Plot a) shows that the magenta cluster corresponds to both tumour and low density 
lung. Plot b) shows that increasing the number of quantisation levels helps to isolate the 
tumour seen as magenta region.  
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5.1.2 Experiment 13 Does using a 3D feature plot aid the analysis of post treatment 
Radiation Induced Lung Injury (RILI) on post treatment scans? 
Aim: Experiment 12 showed that it is possible to cluster the tumour region separately from 
the rest of the lung. The aim of experiment 13 is to see whether the clusters in a post 
treatment scan correspond to obvious anatomical areas in a patient who hasn’t recurred after 
radiotherapy.  
Experiment 13 Methods: To repeat experiment 12 for pt 5 who hasn’t recurred on post 
treatment scans using a 5x5mm filter and both 8 and 16 quantisation levels, using a third 
metric, which was combined entropy and density. The texture map was inverted by 
subtracting the most positive value from zero. The entropy value was multiplied by 100 (as 
ITK-SNAP could not calculate decimal places. The resulting inverted entropy value was 
multiplied by the density in Hounsfield units.  
Experiment 13 Results and discussion:  
As in experiment 12, the aim of using K mean clustering was to see if an advanced analysis 
technique aided interpretation of the elephant plot. This experiment used a 3D ‘elephant plot’ 
to assess the data. The 3rd metric was a combination of density and entropy for each data 
point.  
Figure 3 shows a 3D elephant plot of the lung containing tumour, after the patient has 
received SABR. The red region in the middle image of figure 3 correlates with the opacity 
within the lung seen in the right hand CT image in figure 3.  
Figure 4 and 5 compare the changes in the 3D elephant plot before and after SABR. The major 
changes are that the cluster consistent with tumour, in the top right hand corner of the plot, 
becomes elongated, secondly the thin peak representing the rim of the tumour regresses 
away from zero entropy.  
Figures 4 used 8 quantisation levels, figure 5 used 16 quantisation levels. The major difference 
between 8 and 16 quantisation levels is that the tumour is separated from the rest of the plot 
when 16 levels are used. In both the 8 and 16 level analyses the plot has the same 
morphological appearance after treatment. The tumour becomes more elongated and 
smeared. The tip of peak of the upper plot in figure 4 and figure 5 represent the heterogeneic 
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tumour rim. This rims increases in entropy and the peak representing the tumour rim 
regresses from the zero entropy line. At this point it suggests that only tumour had a region 
of zero entropy as this disappeared after treatment. 
 
Figure 3: K mean clustering of post treatment scan, comparing K mean clustered plot and a 
plot using initial CT scan co-ordinates. On the left, central image shows the K mean clustering 
plotted using the original CT scan voxel co-ordinates. The right most image show the original 
CT image, the orange contour is the analysed region of interest.  
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Figure 4: comparing results of K mean clustering of a large section of lung ipsilateral to a 
primary lung tumour before and after SABR analysed using 8 quantisation levels  
The K mean plots in experiment 12 and experiment 13 appeared to show a pre-treatment 
cluster consistent with tumour that was separated in space from the rest of the plot. Figure 
18 in appendix 4 illustrates the morphology of the tumour, it shows a central region with an 
intensity value in the region of 4000 and the rim of the tumour with a negative intensity value 
of approximately -4000. This is also illustrated in the plots seen in figures 19-23 in appendix 
4.  
Although this analysis was promising, on reviewing the method of map inversion, it was 
realised that the inversion was not consistent and was dependent on the presence of the 
central zero entropy region seen in the centre of larger tumours. The method took the region 
of interest and set the central tumour homogeneity at 0. Then the maximum value of 
heterogeneity was identified and the whole map was subtracted from this. This meant there 
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were negative values. This method caused an aberration that the tumour should have been 
an extension of the heterogeneous tumour rim (seen in upper image in both fig 4 and 5) rather 
than in a separate position in the plot. This meant the separation was artificial and not a true 
result. When the whole texture map was inverted, rather than assigning specific values, the 
cluster was not separate. When the map was inverted so that all structures were inverted 
consistently the combined metric of density and entropy scoring did not appear to give any 
further information.  
 
Figure 5: Comparing results of K mean clustering of a large section of lung ipsilateral to a 
primary lung tumour before and after SABR analysed using 16 quantisation levels.  
At this point 2 important conclusions were made that would inform all future work. Firstly 
that as it was possible to volume large sections of lung, an effort should be made to volume 
the whole lung. Secondly that a 2D plot of density and entropy should form the basis of future 
analysis. The aim of this project was to keep the analysis as simple as possible.  A third axis 
using a combined metric of density and entropy was subject to manipulation and it was not 
possible to identify a fair and consistent way of combining entropy and density. K mean 
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clustering did not add any further information. It had helped in dividing up the feature plot 
so that visually it was easier to look at different parts of the plot, but did not add further 
information. As a result it was felt that future plots should not be clustered.  
 At this point it had been technically feasible to generate texture maps for large volumes of 
lung tissue. Generating a texture map for the whole lung had several advantages. Existing 
radiotherapy planning software is able to auto-contour lungs. Generating an accurate lung 
contour requires less specialist knowledge, compared to identifying a region of interest within 
a lung. Lung tumours often move geographical position after SABR. By including the whole 
lung, the whole tumour bed and treated area would be included in the analysis irrespective 
of the position of the tumour bed.  
The process of RILI after SABR is not well understood. Some patients develop significant 
opacification on lung imaging after SABR, whilst others develop very little change. By 
analysing the whole lung, this process may provide a method of tracking and understanding 
lung injury after SABR.  
Including the whole lung is likely to make for more reproducible results and potentially makes 
it easier to compare different patients. The negative effects of analysing the whole lung, 
increases the potential ‘noise’ from confounders, such as other anatomical structures e.g. 
bone/rib and contrast. For an analytic approach using texture to succeed, it would need to be 
as simple as possible, in terms of minimising the number of steps of human interaction. A 
more automatic and independent process is likely to be easier to introduce in a standard 
radiology workflow, rather than one that requires an assessment by a radiologist at multiple 
points in time. Using the whole lung makes generating the region of interest simple and would 
require little specialist knowledge. Outlining and/or checking a region of interest could be 
done with minimal training, then automated analysis could be completed and the results 
could be interpreted at a single time point. 
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5.1.3 Experiment 14: Texture analysis of whole lung using varying numbers of quantisation 
levels.  
Aim: The scans that had generated the structures analysed to date were revisited. A protocol 
was written to extend the large sections of lung to include the whole lung. The aim was to 
keep the localisation of the whole lung consistent between patients and between scans of the 
same patient. It was not clear whether it was possible to volume and analyse an entire lung.  
The second part of the experiment was to analyse the lung volumes using different 
quantisation levels to see the effect on the data plot.  
Experiment 14 Method: Broadly the lung volume aimed to exclude the left and right main 
bronchus, lobar bronchi, hilum and any large blood vessels. The guidelines were created as 
part of the TEXAS trial protocol, which can be seen in appendix 2.  
The whole lung was auto-contoured using eclipse radiotherapy planning software. The AVIP 
phase of the 4DCT scan was used for the volume. This volume was the edited back to avoid 
the trachea and 2 divisions of the bronchial tree, consistent with the structure volumed as an 
organ at risk in standard SABR planning for lung tumours. Using lung windows any liver was 
edited out of the volume.  
Experiment 14 Results and Discussion: This analysis was initially performed on 4 patients, 2 
who had recurred and 2 who were recurrence free. The combination of density and entropy 
score appeared to give a plot as seen in figure 6. Figure 6 shows how the pre-treatment plot 
changes after SABR. It also shows the effect of increasing the number of quantisation levels 
on these plots. Plots using 16 and 32 quantisation levels appeared to have a narrower curve, 
particularly in the high HU/low entropy region, which would correlate with tumour. In curve 
c) in figure 6 the use of 32 quantisation levels means the loss of the zero entropy high density 
region. This would potentially make it more difficult to identify the tumour within the data 
plot. As a result, 16 quantisation levels were chosen for future analysis, this was a compromise 
between the benefits of a greater spread of data than 8 levels and maintaining the zero 
tumour homogeneity previously identified in fig. 6, which was lost when using 32 levels.   
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Figure 6: Understanding how the appearance of the elephant plot is altered by increasing the 
number of quantisation levels used in the texture analysis. All these analyses are performed 
on the same region of interest from the same patient.  a)-c) plots of density (x axis) vs entropy 
(y axis) on a pre-treatment CT scan. d)-f) plots of HU vs entropy on a post treatment scan. a) 
and d) have 8 quantised levels, b) and e) have 16 quantised levels, c) and f) have 32 quantised 
levels. Colours represent automatic clustering as clusters 1-4 
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5.1.4 Experiment 15: generating texture analyses for whole lungs pre and post treatment 
Aim: The aim of this experiment was to see if it was possible to generate texture maps for the 
whole lung, for both pre-treatment scans and post treatment scans. 
Methods: The previous method explained in experiment 1 was used to segment a whole lung 
from the tumour, using guidelines from experiment 14. The analysis of each lung took several 
hours and successful analysis required some technical limitations to be overcome, to allow 
sufficient time for the analysis to be complete. Using the results from experiment 14, 16 
quantisation levels were chosen and a 5x5mm filter was used. 3 different patients were 
chosen, who had not recurred after a successful SABR treatment, these 3 patients all had 
available planning scans and post treatment scans at 3, 6, 12 and 18-20 months post 
treatment.  
Results and Discussion: Figure 7 shows that the plots of the whole lung ipsilateral to tumour 
for patients who received SABR for an early stage lung tumour, who had a successful 
treatment and the tumour did not recur. As a result these maps track the changes of RILI in 
the successful treatment of lung tumours, as the acute inflammation settles and becomes 
fibrosis. It shows that it is possible to plot the whole lung. It was felt that after this experiment, 
the K mean clustering did not add any further information to the 2D plots, as this analysis 
technique did not cluster the tumour separately from other tissues. As a result it was not used 
in further work and as per figure 7, all future plots were plotted in a single colour.  
The major observation is at the curved peak to the right of the plot (the elephants trunk) in 
each patient in fig 7 is dynamic over time. This suggests it changes as the acute lung injury 
develops, then subsides, and is then followed by the development of fibrosis. Figure 7 
generates the hypothesis that TA can potentially track these changes over time. From this 
work and experiment 12, it was felt the high density and low entropy region was likely to be 
tumour. However, it had not been proved conclusively. The current work meant that a region 
of interest could be identified on a CT scan, analysed and plotted, but a region of interest on 
the elephant plot could not be used to identify a region of interest in the scan. Two tools were 
developed, initially a region of interest analysis using a single point of interest, which is 
discussed in experiment 16. This tool was then used to generate a more complex region of 
interest analysis tool, which included multiple points. This tool is discussed in experiment 17.  
 107 
 
 
Figure 7: Comparison of planning scan and post treatment scans for 3 patients whose tumour 
did not recur after SABR. X axis= density, Y axis= entropy. Plan= radiotherapy planning scan. 
3, 6, 12 and 18-20 months= time after treatment 
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5.1.5 Experiment 16: Single point region of interest analysis 
Aim: The aim of this project was to see how single points in the texture map relate to different 
points in the plot of the texture map.  
Experiment 16 Method: Software was written to identify a specific point in the texture plot. 
The point was selected and then exported into matlab. This point was then replotted into the 
texture map in a different colour. Any point could be chosen within the texture plot. A variable 
was created for this point and it was transposed back into the texture map or original image 
using the original scan co-ordinates. The texture map was re-drawn with the single data point 
highlighted (an example of this can be seen in figure 8). The chosen data point could then be 
saved as a variable.  
Experiment 16 Results and Discussion: 
 
Figure 8: Localising data points related to tumour using original CT scan spatial co-ordinates. 
3 points extracted and plotted back in the texture map using the scan co-ordinates.  
Figure 8 shows 3 points from the high density, low entropy region of the texture analysis data 
plot. All 3 are in the tumour. Figure 9 shows the sub-analysis of a different region, which 
appears to relate to the edge of the liver.  
 109 
 
 
Figure 9, Localising data points related to liver edge using original CT scan spatial co-ordinates. 
texture analysis data plot, with 3 points extracted and plotted back in the texture map using 
the scan co-ordinates.  
Figure 8 and 9 suggest that this tool is helpful as it can generate hypotheses. It suggests that 
the high density, low entropy region of the texture analysis plot is consistent with the tumour, 
however unless all data points in the plot are included, it is difficult to prove this conclusively. 
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5.1.6 Experiment 17: Multiple point region of interest analysis 
Aim: This experiment aimed to investigate the regions of interest of the texture analysis data 
plot from the AVIP (Average Intensity Projection) phase of the pre-treatment radiotherapy 
planning CT scan of the ipsilateral lung to a primary lung tumour. The hypothesis for this 
experiment was that the majority of tumours contain a low entropy region, meaning the 
tumour is likely to be in the low entropy high density region of the texture analysis data plot.  
Methods: 15 patients who received SABR had the lung containing tumour segmented from 
the AVIP phase of the 4DCT scan. This was then analysed. The region of interest tool was 
then set to plot all points with a density of 900-1200 and an entropy score of 2 or less. This 
region was then converted into a Niftii file and overlaid with a Niftii file of the texture map 
of the whole lung in ITK-SNAP (Yushkevich et al., 2006). 
Results and Discussion: Image c) in figure 10 shows how the sub-region of the texture plot 
overlaps with the low entropy region of the tumour. The original CT image and texture map 
can be seen in a) and b) respectively. Figure 10 also shows the region of the data plot, which 
was analysed and overlaid with the original texture map.  Image c) shows that the sub 
region identified in red overlaps neatly with the original texture map.    
Figure 11 shows this comparison extended to 15 primary lung tumours overlap of the sub 
region (density 900-1200 and entropy 2 or less, seen in red). In 13 of 15 tumours this region 
overlaps with the tumour. This was a pictorial, rather than numerical analysis, but shows 
convincingly that the tumour sub region of the entire data plot can be predicted in the 
majority of tumours. What is not shown in figure 29, is that in some of the data plots other 
structures were included in the sub-region of the data plot, which were analysed. These 
were consistently larger blood vessels containing IV contrast.  
The results of this experiment are shown in figure 10. It shows that the central homogeneous 
region of the tumour consistently overlaps with the structure generated by segmenting the 
tip of the high density low entropy tip of the texture analysis data plot, as described in the 
methods of experiment 17.  
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Figure 10: Overlaying the tip of the trunk in the elephant plot with the original texture map 
of the whole lung for 1 patient before treatment. Image a) shows the original CT image 
containing a primary lung tumour, image b) illustrates the texture map generated from the 
CT data. Image c) shows a red region representing the sub region of the texture map 
including data points with an entropy score of 2 or less and a density score of 900-1200 
overlaid over the texture map. The data plots show the sub-region that was analysed.   
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Figure 11: Overlaying the tip of the trunk in the elephant plot with the original texture map 
of the whole lung for 15 patients from the AVIP phase of 4DCT planning scan before SABR 
treatment. The tip of trunk defined as points included with a density score of 900-1200 and 
entropy score of 2 or less, region of texture analysis data plot with texture map for 10 
primary lung tumours treated with SABR. The images were generated by overlaying 2 
texture maps, one from the whole texture map in white and the second in red as the sub-
region of interest. The 7th image did not contain data points within the sub-region os appears 
much brighter than the other images.  
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5.1.7 Experiment 18: Understanding use of different phases of pre-treatment analyses  
Aim: From previous experiments it was determined that it was possible to produce a texture 
analysis data plot for an entire lung. Experiment 17 showed it was possible to identify the 
tumour within the data plot. However, as the size of the analysed area had increased 
significantly since earlier experimental work, it was not clear what effect different phases of 
the 4DCT had on the texture analysis of an entire lung, as experiment 4 had only focused on 
the GTV. This was investigated to understand what effect movement had on the appearance 
of the pre-treatment elephant plot.  
Radiotherapy planning of lung tumours uses a multi-phase 4 dimensional CT scan. When a 
patient is scanned, the patient completes a breathing cycle for every 2cm scanned. The 
patient is breathing comfortably during the scan, they are not aiming to maximally inspire and 
expire. The scan software generates 10 phases, CT0, CT10, CT20 etc. to CT90. CT0 is end 
inspiration and CT50 is end expiration. Between CT0 to CT50 the patient is breathing out and 
between CT50 and CT0 the patient is breathing in. Two composite volumes are generated. 
The AVIP (Average Intensity Projection) is the average image, the MIP (Maximum Intensity 
Projection) is the maximum density experienced during the breathing cycle within each voxel. 
Standard practice is to outline all structures on the AVIP, but take account of tumour motion 
on the MIP. It is important to understand how different phases affect the texture plot of the 
whole lung so that any confounding variables can be adjusted for. Patients undergo different 
scans in different breathing phases. The CT of the PET-CT is a single image series performed 
with the patient in free breathing, for planning the CT is performed with multiple phases and 
most diagnostic and post treatment scans are performed in inspiration breath hold.  
Experiment 18 Methods: A single patient was used for this analysis. The radiotherapy 
planning structures had been drawn on the CT AVIP in Eclipse (Varian Medical Systems, Palo 
Alto). Eclipse contains a tool, which can auto-generate a structure from one phase of the 4DCT 
to other phases. A lung contour ipsilateral to the tumour and contra-lateral to the tumour 
was created for all phases of a scan of a single patient. These images were extracted and each 
volume was run twice, firstly standardised to itself using individualised quantisation and 
secondly standardised to the quantisation levels for the GTV for this patient (i.e. uniform 
quantisation).  
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Experiment 18 Results and discussion:   
Figure 12 shows the comparison all phases of the 4D CT for the contra-lateral lung. The most 
unexpected observation is that all phases except the AVIP have an obvious high density low 
entropy region in the contra-lateral lung. In the ipsilateral plots seen in figure 13, all plots 
including the AVIP have a high density low entropy region. The other observation is that for 
phases CT20-40 and CT60-90, they all have a split high density low entropy region. This is seen 
in both the plots containing tumour and the plots not containing tumour.  This raises the 
suspicion that the double plot is an effect of movement.    
 
Figure 12: Elephant plots from textural analysis of a whole lung contra-lateral to the tumour 
generated from all phases of a 4DCT. Analysis included 10 4DCT phases and 2 composite 
volumes for the contra-lung of a patient having a radiotherapy planning 4DCT for SABR. None 
of the analysed structures contained tumour.  
The elephant plots seen in figure 12 did not have standardised axes. The highest density point 
in the structure defines the X axis, this changes the relative shape of the data plots to each 
other making it difficult to compare different data plots. The high density low entropy region 
is an artefact due to how the structures for the different phases were generated. Eclipse has 
an auto-contouring tool that propagated the structure from the AVIP to the other phases. In 
these phases the structures were not reproduced faithfully, they included high density pixels 
related to rib and chest wall.  
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Figure 13: Elephant plots from textural analysis of a whole lung ipsilateral to the tumour 
generated from all phases of a 4DCT.  10 phases and 2 composite volumes for the ipsilateral-
lung of a patient having a radiotherapy planning 4DCT for SABR. All of the analysed structures 
contained tumour.  
The region of interest tool was used to transpose the data points of selected plots back into 
the original texture map using the co-ordinates of the original image. The results are seen in 
figure 14. The same definition as experiment 17 to analyse the high density low entropy 
region, i.e. density score of 900-1200 and entropy score of 2 or less. Figure 14 shows that the 
region of analysis from the high density low entropy region consistently overlaps with the 
position of the tumour in the original texture map, irrespective of the phase of the 4DCT used 
in the analysis.  
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Figure 14: Overlap of region of interest from data plot (density score 900-1200 and entropy 
score of 2 or less) with texture map from analysis of whole lung ipsilateral to tumour. a)= CT0, 
b)=CT20, c)=CT50, d)=CTAVIP and e)=CTMIP 
As part of this experiment, it was noted the contents of the analysed structures were similar. 
What was not clear was whether FiniteRT would set similar quantisation level boundaries for 
similar structures. Optimal quantisation sets the levels based on the data in the structure 
being analysed. The values of the quantisation levels were compared between the CT0 of 
ipsilateral lung and contra-lateral lung, as well as to the quantisation levels of the GTV. The 
results can be seen in figure 15. As the tumour makes up a small amount of the total lung, it 
was not clear whether the presence of tumour in the lung volume would affect quantisation.  
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Figure 15: morphology of the elephant plots and quantisation levels for similar Regions of 
Interest. a) + b) standardised to self = individualised quantisation using LMQ. c) standardised 
to GTV = uniform quantisation using quantisation levels from GTV texture analysis. 
Figure 15 shows that the individualised quantisation levels for the lung containing tumour and 
not containing tumour are broadly similar, but are different to the uniform quantisation levels 
set by the GTV. As a result this variability suggests that the values of the quantisation levels 
should be fixed to compare different structures. As the aim is to identify the presence of 
tumour, it was felt it would be reasonable to use tumour quantisation values to pre-dispose 
the plot to be able to identify tumour rather than other structures.  
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5.1.8 Experiment 19: Does uniform quantisation of texture maps affect data plot 
morphology? 
Aim: The aim was to understand the effects of using individualised and uniform quantisation 
levels, to see if standardising the quantisation of data allows comparison of different analysed 
volumes. This experiment used the data plots from experiment 18, to understand the effects 
of optimised quantisation vs uniform quantisation.  
Experiment 19 Methods: This experiment was made up of 2 parts. Firstly repeating the 
texture analysis as per experiment 18, however, in experiment 18 the quantisation levels 
were used individualised quantisation using the LMQ. In experiment 19, all structures to be 
analysed were standardised to the GTV of the same patient using uniform quantisation. The 
second part of the experiment was to take 2 lung structures containing tumour and 
standardise the quantisation to the tumour of the same patient and swap them, to 
standardise to the tumour of the other patient and compare the results.  
Experiment 19 Results and Discussion:  
 
Figure 16: comparing individualised quantisation standardised to each structure versus 
uniform quantisation using the GTV Textural analysis to set quantisation levels. Blue circle 
identifies a difference in plot morphology.  
 119 
 
Figure 16 takes 3 plots from the lung ipsilateral to the tumour, standardised to itself in the 
upper row and to the GTV in the lower row. It shows that there are subtle morphological 
differences between the plots, highlighted in CT20 between the 2 standardisations.  
 
 
Figure 17: Illustrating that altering the quantisation levels changes the appearance of the 
elephant plot. The top 2 data plots a) and b) show pt 3 and pt 18’s whole lung standardised 
to the tumour from the same patient. Plot c) shows pt 3 standardised to the GTV of pt 18, 
plot d) shows pt 18 standardised to the GTV of pt 3. The lower row shows the absolute 
values for the 16 quantisation levels of GTV for pt 3 and pt 18.  
Figure 17 shows that quantisation affects both the appearance of the texture map and the 
entropy scoring of the individual data points, although it doesn’t affect the density of a data 
point. In the lower part of figure 17, it shows that the quantisation levels are set at different 
levels. For example, if 2 adjacent voxels had a density level of 240 and 379, they would both 
be in the same quantisation level based on the values from the GTV of pt 18, but would be 4 
levels apart using the values set by the GTV of patient 3.  
These changes in scoring show that the absolute values selected by the quantisation levels 
are important. This affects any comparison between different patients. The outcome of 
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experiment 19 was to aim to understand the effect of uniform quantisation levels, which 
would be optimal for identifying the GTV/tumour within a texture plot.  
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5.1.9 Experiment 20: Generating uniform quantisation levels for further analysis.  
Aim: The aim is to generate uniform quantisation for lung tumours, which could be used for 
all future work.  
Methods: 16 primary lung tumours were analysed used by the original finiteRT code. The GTV 
of each tumour was extracted from AVIP phase of the 4D radiotherapy planning scan.  This 
allowed the software to select individualised quantisation levels for each tumour. The 
standardisations used for this experiment would then be used for all further work. As 16 
quantisation levels gave a greater spread of data than 8 levels, but was more likely to maintain 
the central homogeneous region of most tumours, this experiment used 16 quantisation 
levels and a filter size of 5 x 5mm. A mean was then generated for each level and fitted to a 
line of best fit. 
Results: 
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   Density scores for each quantisation level 
Table 2: Shows raw data for 16 quantisation levels for 16 different primary lung tumours.  
 
Q level 
              
Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
pt 3 133 192 241 291 347 407 466 526 591 660 737 816 891 960 1015 1049 
pt 4 138 201 260 322 383 441 506 570 640 718 789 859 934 997 1041 1069 
pt 5 214 260 305 356 407 459 516 575 636 693 750 807 864 920 976 1020 
pt 6 204 258 311 364 420 480 547 612 680 750 838 904 972 1029 1082 1169 
pt 7 250 342 432 523 615 711 808 896 970 1033 1081 1155 1279 1404 1544 1679 
pt 8 194 249 302 354 412 476 540 602 663 732 803 872 941 1007 1045 1075 
pt 9 233 281 320 361 402 449 506 570 624 680 729 776 820 874 925 971 
pt11 390 515 615 698 775 846 912 975 1033 1134 1259 1389 1525 1632 1743 1851 
pt 12 190 249 301 352 404 458 513 570 630 690 749 809 874 937 1006 1060 
pt 13 230 280 335 397 467 537 612 693 774 852 927 993 1046 1129 1207 1279 
pt 16 197 249 292 337 388 443 498 557 616 677 737 795 852 904 960 1011 
pt 17 210 265 317 371 425 478 536 596 660 717 779 839 904 972 1029 1060 
pt 18 380 445 500 550 592 640 694 745 800 850 894 932 969 1004 1109 1234 
pt 20 260 334 396 459 520 578 636 697 759 819 878 933 990 1048 1273 1403 
pt 21 143 219 281 330 386 446 506 564 626 687 745 809 886 964 1030 1078 
pt 22 281 334 383 426 476 530 581 633 687 752 807 866 921 978 1027 1058 
mean 228 292 349 406 464 524 586 649 712 778 844 910 979 1047 1125 1192 
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Figure 18: plotting the actual means of 16 quantisation levels (generated from textural 
analysis of 16 primary lung tumours) against a line of best fit. 
Discussion: 
Figure 18 shows the line of best fit plotted against the means of the 16 quantisation levels. As 
they are very similar a standard uniform quantisation file was created for further analysis. 
This would ensure that all future analyses would use the same quantisation, as a result, this 
would allow for a comparisons between ROIs, both at different time points for the same 
patient and between patients. It would meant that the contents of the ROI did not affect the 
quantisation.  
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5.1.10 Experiment 21: Understanding differences in phases of a 4DCT using uniform 
quantisation.  
Aim: In experiment 18, all phases of a 4DCT were examined. It was obvious that there were 
differences in the phases. The aim of this experiment was to understand the differences in 
phases of the 4DCT when the structures were analysed with uniform quantisation. I wanted 
to understand what effect tumour movement may have on the elephant plot. Because the 
4DCT is divided into phases, I felt this was a predictable way of investigating this, although 
this was less likely to affect  post treatment imaging, as most images are taken as a single 
phase in inspiration breath hold (if the patient can tolerate it). 
Method: The following phases were chosen: CT0 (end inspiration), CT20 (mid-expiration), 
CT50 (end expiration) and CT70 (mid inspiration) were chosen, as well as both composite 
volumes (CTAVIP and CTMIP).  
Results and Discussion: Figure 19 aids hypothesis generation. The most obvious finding is that 
all of the texture plots have a high entropy low density region except the AVIP of the contra-
lateral lung in patients 5 and 8. The data plot for patient 17 has a much thinner high density 
low entropy region in the contra-lateral lung when compared to the ipsilateral lung containing 
tumour. The obvious difference between the ipsilateral and contra-lateral plots in the AVIP 
phase for patients 5 and 8 suggest it would be relatively simple to detect whether or not there 
is tumour in the plot, but this does not explain why there is a high density low entropy region 
visible in all phases of the 4DCT of the contra-lateral lung, i.e. in the lung that does not contain 
tumour. 
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Figure 19: comparison of CT0, CT20, CT50, CT70, CTAVIP and CTMIP between ipsilateral lung 
containing tumour and contra-lateral lung, for 3 patients (pt5, pt 8 and pt 17) using uniform 
quantisation levels.  
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Figure 20: region of interest analysis of high density low entropy region of the AVIP phase of 
the lung contra-lateral to tumour from the 4DCT radiotherapy planning scan for pt 17.  
The second finding is the shape of the high density high entropy region. The AVIP plots are 
‘averages’ based on phases CT0-CT90. For phases CT0, CT20, CT50 and CT70 there is a visible 
extra region, which is not visible in the AVIP plots, this is most obvious in patient 8. This is 
illustrated in figure 21. The region of interest analysis shows this section relates to rib being 
included in the volume. The volumes for this experiment were generated using an auto-
contouring tool in eclipse from the AVIP volume. In patient 8, there appeared to be more 
movement and therefore the amount of rib moving in and out of the volume would be 
greater. As it is different parts of the rib, this is ‘smoothed’ out in the AVIP data plot.  
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Figure 21: region of interest analysis of high density low entropy region of CT0 for contralateral 
(image a) and ipsilateral lung (image b). The high density low entropy region in plot a) relates 
to contrast in a hilar blood vessel. In plot b) the same region of interest in the data plot relates 
to both a central blood vessel and the tumour.  
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Figure 22: Region of interest analysis of high entropy high density region of ipsilateral lung to 
tumour of CT0 for pt 8. The CT and texture map appearance can be seen and show that the 
high density high entropy region relates to rib being included in the volume.  
The choice of the AVIP for further analysis, is beneficial because it includes all planning 
information and the contoured structures. Secondly that from examining pt 5, 8 and 17, the 
AVIP excludes the high density low entropy region for 2 of the 3 patients analysed in the 
contralateral lung, which are seen in all other phases of the 4DCT analysed and illustrated in 
figure 18. The high density low entropy region in the AVIP phase of the contra-lateral lung to 
tumour for patient 17, is less obvious than for the ipsilateral lung from the same scan. Figure 
20 shows that this is related to IV contrast.  
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This difference in morphology between the AVIP and other series is likely to be related to 2 
factors, firstly the auto-contoured structures are generated from the AVIP. It appears that rib 
being included in the lung volume is an artefact of the auto-contouring algorithm. The 
movement in different phases of the 4DCT means that different areas of rib and contrast 
appear in different geographical regions in different phases, meaning they do not appear as 
an average structure in AVIP.  
 
Figure 23: comparing anatomical position of high density voxels from different phases of the 
same slice of a 4DCT in the lung contra-lateral to tumour, in patient 5. a) = CT0, b) = CT20, c) 
= CT50, d) = CTMIP.  
Figure 23 shows 4 different phases of the 4DCT, which contained a high density low entropy 
region on the data plot. CT0 shows a large blood vessel with contrast, CT20 and CT 50 shows 
the same blood vessel has been excluded from the volume by the auto-contouring algorithm 
in eclipse. CT20 shows some high density, low entropy data points on the rim of the medial 
side of the lung. These are not visible on CT0 or CT50. The areas of uptake are different in 
different phases of the original 4DCT. The CTMIP is a composite image, showing maximal 
movement and as a result shows uptake at both the rim of the lung and contrast related 
overlap in the large blood vessel.  
The AVIP phase of the contra-lateral lung does not have a high density low entropy region in 
the data plot. As the AVIP is a composite of the phases, it takes an average of all the phases, 
it appears that as the anatomical position of the high density low entropy region is different 
in each phase, this region of the plot gets smoothed out. As a result it is not visible in the AVIP. 
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The advantage of the absence of the high density low entropy region in the contra-lung 
suggests it could help guide whether or not there is tumour in a lung. To see if this was a 
consistent finding more AVIP phases were compared in the next experiment.  
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5.1.11 Experiment 22: Does excluding more of the hilum in the initial volume analysed in a 
texture plot reduce contrast as a confounder? 
Aim: The aim of this experiment was to see if removing the hilum from the region of interest 
would reduce contrast being a confounder in the high density low entropy region of the 
texture analysis data plot. This was chosen as a way of reducing the chance of large hilar 
vessels being included in the region of interest as both the bronchial tree and an airway 
avoidance structure are standard volumes generated in a radiotherapy plan. This structure 
would also be relatively simple to auto-contour. This approach maintains the aim that the 
region of interest should be kept very simple and require as little as possible specialist 
knowledge.  
Methods: The analysis of the AVIP of both lungs was undertaken, using the same method as 
in experiment 21. 2 examples of the elephant plot were chosen  for this experiment.  
In the contra-lateral plots with a high density low entropy region, these correspond to IV 
contrast. Contrast acts as a confounder for tumour. Figure 19 shows this in pt 17.  
 
Figure 24: shows a diagram and CT image of the airway avoidance structure, which forms the 
‘no fly zone’ for treating lung tumours with SABR. Adapted from SABR consortium guidelines 
It is standard practice to treat tumours 2cm or more from the bronchial tree. This is calculated 
by contouring a volume for the bronchial tree that includes all of the left and right main 
bronchi and the lobar bronchi. A margin of 2cm is added to this contour to create an airway 
avoidance structure, an example of this can be seen in figure 24 (Consortium, 2015). Standard 
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practice would be to not treat tumours within the airway avoidance structure. This structure 
would contain large vessels disseminating from the hilum. By excluding this volume the aim 
would be to remove large vessels containing tumour from the whole lung, whilst keeping the 
tumour within the lung/region of interest.  
Figure 25 shows the bronchial tree and the edited volume.  
 
Figure 25: Diagram of lung volumes used to exclude hilum from texture analysis of whole 
lung. Blue = bronchial tree, magenta = volume excluding tumour and bronchial tree + 1cm 
and cyan = volume excluding tumour and bronchial tree + 2cm. 
For 8 patients who had never recurred after SABR, the whole lung volume was edited to 
create 4 structures. Firstly the lung was edited to avoid bronchial tree + 1cm and + 2cm and 
exclude the tumour (seen in figure 25). Two further volumes were then generated from each 
structure, including the tumour and excluding the bronchial tree +1cm and +2cm. This process 
was repeated for each patient.  
The total list of volumes generated and analysed for each patient were as follows; whole lung, 
whole lung minus tumour, tumour, whole lung excluding bronchial tree +1cm, whole lung 
excluding bronchial tumour +2cm, whole lung excluding bronchial tree +1cm and tumour and 
finally, whole lung excluding bronchial tree + 2cm and tumour. 
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Results and Discussion: 
 
Figure 26: Summary of whether excluding the bronchial tree aids interpretation of the 
elephant plot. A comparison of data plots from the whole lung (planning CT) containing 
tumour, tumour alone, lung-tumour, then lung-tumour and exclusion of hilar structures from 
the ROI with a 1cm and 2 cm margin. Excluding the bronchial tree + 2cm does not alter the 
appearance of the elephant plot.  
Figure 26 shows 2 examples of the results for this experiment. It shows the data plot for the 
whole lung that contains tumour from the planning CT for pt’s 5 and 6.  
 
Figure 27: region of interest analysis for high density low entropy region of lung-minus tumour 
with bronchial tree +2cm excluded from the whole lung volume.  
When the tumour is excluded (lung-tumour) from the plot for pt 5, the high density low 
entropy region disappears, however, this is not the case in patient 6, figure 27 shows that the 
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residual high density low entropy region is related to the edge of liver inadvertently being 
included in the lung volume, this is why editing the structure away from the bronchial tree 
does not remove the high density low entropy region from the volume.  
From this experiment it shows that the interpretation of the elephant plot is sensitive to 
accurate contouring. This would be an area to be aware of for future experiments. It may be 
that some errors in contouring are more important than others. Those that would be more 
important are those that could appear in the high density low entropy region of the elephant 
plot.  
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5.2 Conclusion of preliminary experimental work 
Before this part of the project was completed, previous work had used finiteRT to overlap 
PET-avidity with intra-tumoural CT based texture analysis. The experiments described in this 
chapter expanded the region of analysis to include whole lung.  
In order to achieve this the following variables of texture analysis using finiteRT have been 
explored: the effect of the tissues included in the region of interest, the filter size, the number 
of quantisation levels, whether individualised or uniform quantisation is used, the role of 
contrast, the role of breathing motion and the differences related to the different phases of 
the 4DCT, alternative analysis tools, including both single point and region of interest analysis, 
K mean clustering and the effects of these factors in relation to the tumour and the whole 
lung.  
Understanding the effects of these variables aids the interpretation of the texture image and 
the subsequent data plot. From this work, it is important to standardise as many variables as 
possible, using a set filter size and number of quantisation levels. Standardising the absolute 
quantisation levels allows different regions of interest to be compared equally.   
Preliminary work has generated the research question: is it possible to identify the difference 
between tumour and fibrosis in patients who have undergone Stereotactic Ablative Body 
Radiotherapy (SABR) for NSCLC? This will be explored in the next chapter.  
Lung tumours treated with SABR are often straight forward to delineate on a radiotherapy 
planning scan, however, it can be difficult to identify the tumour bed on post treatment scans 
as there can be significant inflammation and this inflammation can cause a change in 
anatomical position of the tumour bed, relative to the lung. Differentiating between tumour 
and RILI can also be difficult. The aim of the next chapter is to use as objective a process to 
identify the differences between RILI and tumour, which requires minimal specialist 
knowledge and avoiding assessment by a clinician at multiple time points.  
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THEME 1: Theme 1: CT Texture Analysis after SABR for Non-Small Cell Lung Cancer  
Chapter 6: The TEXAS trial, differentiating between tumour and Radiation Induced Lung 
Injury (RILI) after Stereotactic Ablative Body Radiotherapy (SABR) 
6.1 Background 
The previous experimental work described in chapters 4 and 5 outlined the investigative 
process used to provide an analysis of the texture of a whole lung, meaning each voxel within 
an image had both a density score and an entropy score. The aim of this chapter is to describe 
a 2 step process to differentiate between tumour and Radiation Induced Lung Injury (RILI) 
after SABR.  
In the previous chapter, the standard data plot was a 2 axis plot termed the elephant plot, 
the x axis representing a density score and the y axis representing an entropy score, based on 
how similar or dissimilar a voxel was to the 26 voxels around it. The data points relating to 
the tumour were found in a region relating to high density and low entropy, the tip of the 
‘trunk’ in the elephant plot. The initial analysis defined this region as including any data points 
with a density score of 900-1200 and an entropy score of 2 or less. This region co-incided with 
the tumour in 13 of 15 patients. When the data points were plotted in the texture map, using 
the original scan co-ordinates, this region of interest did not exclusively include tumour, other 
structures particularly blood vessels containing intra-venous contrast and the edge of the liver 
were included in the ROI.  
The first part of the work described in this chapter, was to understand what confounding 
structures appeared in the tip of trunk, as well as tumour. The second part of this chapter was 
to review the appearance of RILI within the data plot and finally, the third part was to 
understand whether it is possible to differentiate between tumour and RILI after SABR using 
TA. The first experiment in this chapter (experiment 24) aimed to confirm that the tumour 
appeared in the ‘trunk’ of the elephant plot.  
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6.2 Experiment 24: Is it possible to define a sub region of the data plot that relates to 
tumour? 
Aim: The aim of this experiment was to see if it was possible to ensure that the tumour 
appeared in the ROI defined in the methods.   
Methods: 8 patients were selected for this experiment. These were patients who did not 
recur within the first year after having a primary lung tumour treated with SABR. These 
patients all had a post treatment CT scan with IV contrast at 6 or 7 months.  
Inclusion criteria: 
1. Patients previously treated with Stereotactic Ablative Lung Radiotherapy (SABR) for 
Non-Small Cell Lung Cancer (NSCLC).  
2. Patients either had biopsy confirmed NSCLC or a clinical decision has been made that 
there is a high probability of NSCLC suitable for SABR.  
3. Patients had a pre-treatment pet available, with a minimum of 12 months follow up 
with a minimum of 2 CT scans.  
4. Patient had not recurred after SABR 
5. Patient had CT planning scan available 
Exclusion criteria 
1. Patients not had SABR for primary lung cancer or did not receive the full dose/course 
of radiotherapy  
2. Were treated for a lung metastasis from a different primary cancer.  
3. Patients had less than 1 years follow up, less than 2 scans available or no pre-
treatment PET-CT scan  
4. Patients had recurred after SABR 
The first step was to plot the high density low entropy sub-region (trunk) of the elephant plot, 
defined as a density score of 900-1200 and an entropy score of 2 or less. It was suspected that 
some of these sub regions would contain more than 1 data cluster. These were then plotted 
individually. 
Results: Table 1 shows all of the data plots from the whole lung analysis of 8 patients. It also 
shows the feature plot for the tumour and a sub-region relating to the tip of the trunk, from 
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the whole lung elephant plot discussed in the methods (density 900-1200 and entropy 2 or 
less). The right hand column of table 1 shows the sub-region (tip of the elephant’s trunk) that 
contains tumour. When analysing this region of interest, data points correlating to tumour 
appeared in 7 of the 8 sub-region analyses. Figures 1-4 show the different data clusters within 
the high density, low entropy region of the elephant plotted back into the image.   
Discussion: This experiment aimed to understand what structures appear in the ROI where 
tumour appears, within the elephant plot. 7 of the 8 patients analysed had data points relating 
to the tumour, within the defined ROI. Only pt 16 did not appear to have the typical 
appearance of other tumours, seen in table 1, as there is no data cluster in the tip of the trunk, 
which represents the high density, low entropy region consistent with tumour. The data plot 
for the tumour of patient 16 does not contain these data points. It does appear to have data 
points with an entropy score of 3 or less (seen in table 1). It may be that future analyses may 
need to include voxels with an entropy score of 3 or less, rather than 2 or less.  
 
Figure 1: sub region analysis, replotting data points within the high density low entropy region 
(tip of the trunk of the elephant plot) using CT spatial co-ordinates. All of the tip of the trunk 
of the elephant plot is plotted within the tumour. 
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Table 1: data plots for 8 patients, for whole lung containing tumour, tumour and a sub region 
analysis of tip of elephant trunk (region of interest including data points with a density of 900-
1200 and entropy of 2 or less). X axis= density score. Y axis= entropy score.   
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Figure 2: Sub region analysis for patients 7 + 8. For patient 7 left sided data cluster is consistent 
with contrast and the larger right sided cluster is consistent with the tumour. For patient 8, 
the larger left sided data cluster includes both tumour and contrast, the smaller right sided 
cluster includes contrast.  
 
Figure 3: sub-region analysis for patients 16, 18 and 22. The region analysed containing data 
points relating to tumour in 2 of the 3 patients analysed in this figure and 7 out of 8 overall. 
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Figure 4: sub region analysis for patient 6. The sub region shows the 3 peaks relate to regions 
of interest in the texture map. Left peak = liver edge, middle peak = tumour and right peak = 
IV contrast in a blood vessel 
Of the 8 patients 7 contained more than one data cluster within the ROI. Patient 5 had a single 
obvious data cluster in the ROI. Figure 1 shows the data points within the ROI for patient 5. 
When these data points are replotted back into the scan, it shows that all of the data points 
are within the tumour. Patients 7, 8, 16, 18 and 22 had 2 data clusters. Patients 6 and 17 had 
3 data clusters.  
Figures 2 and 3 show 5 different patients, who each have 2 data clusters in the ROI 
representing the tip of the trunk. It shows the 2 separate data clusters replotted back into the 
original image. Of the 5 different patients illustrated in these analyses, different regions 
consistently relate to tumour and contrast. The dominant data cluster that represents tumour 
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appears to consistently have a density score (on the x axis) of between 1000-1150. The density 
score = Hounsfield Units plus 1000.  
Other sub regions show multiple clusters of data. Figure 4 shows that the sub region for 
patient 6 has 3 obvious clusters of data. These correspond to tumour, a vessel containing IV 
contrast and the edge of the liver. This suggests that the density range used in the sub-region 
could potentially be further narrowed.  
In summary for the majority of tumours analysed in this small data set, the tumour lies within 
the set boundaries of the ROI. This would need to be confirmed in larger data sets. In Figures 
2-4 it can be seen that the initial contouring is can affect the analysis of the sub region of 
interest. It shows that confounders such as blurred diaphragm/liver edge or IV contrast can 
potentially impact on elephant plot analysis. 
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6.3 Experiment 25: Does the tumour volume correlate with the volume of Radiation Induced 
Lung Injury (RILI)? 
Aims: To differentiate between tumour and RILI, more needed to be understand about the 
natural history of RILI. The hypothesis for this experiment was to see if the volume of post 
treatment lung injury at a single time point (6 months) increased as treatment volume 
increased. The aim being to see if there were guiding principles in how RILI develops after 
SABR.  
Methods: Patterns of Radiation induced Lung Injury (RILI) are discussed in chapter 3 (section 
3.5.1). 5 patterns of lung injury are known to occur, however, there are a combination of 
either no visible change in the lung parenchyma, the appearance of Ground Glass Opacities 
(GGO) or the appearance of areas of solid opacification. Areas of GGO are characterised by 
an increase in the background density of the lung parenchyma, however, airways and blood 
vessels are still visible. In areas of solid opacification these obscure the appearance of small 
airways and blood vessels.  
The 8 patients whose pre-treatment scans were analysed in experiment 1 were used for 
experiment 2. These were patients who had at least 2 CT scans in the first year after treatment 
with SABR for primary lung cancer. These patients did not have recurrence at 12 months. The 
diagnostic scan 6-8 months after treatment was obtained for each of these patients. Each 
patient had the following volumes localised: the whole lung ipsilateral to tumour, GGO, solid 
RILI, total fibrosis and lung minus fibrosis. This was based on the 5 patterns of lung injury 
identified by Bibault et al (Bibault et al., 2013). The contours of the first 4 patients were edited 
by and agreed with a Consultant Radiologist.  
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Results: 
Patient 
number 
iGTV 
volume 
(cm3) 
PTV 
volume 
(cm3) 
Dose/fraction 
(Gy) 
Max dose (%) Mean 
dose to 
PTV (%) 
Min 
dose to 
PTV (%) 
Pt 6 3.1 12.6 54 in 3 125.5 109.3 93.7 
Pt22 6.2 20.3 55 in 5 133 110 93 
Pt 16 11.2 31.2 54 in 3 130 112 93 
Pt 17 12.1 31.6 55 in 5 128 112 93 
Pt 18 14.6 39.7 55 in 5 121 111 90 
Pt 5 26.4 59.2 55 in 5 129 110 85 
Pt 8 26.8 59.2 55 in 5 130 114 92 
Pt 7 38.1 77.3 55 in 5 127 82 112 
Table 2: Doses/fraction schedules and % doses to GTV+ PTV for patients included in this 
analysis. Doses are consistent irrespective of GTV and PTV size, suggesting treatment plans 
and delivered doses are similar across the cohort.  
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Patient 
number 
iGTV 
volume 
(cm3) 
Whole lung 
post 
treatment 
volume(cm3) 
Volume 
total 
RILI 
(cm3) 
Volume 
GGO 
(cm3) 
Volume 
solid RILI 
(cm3) 
Volume 
of total 
RILI as a 
% of lung 
volume.  
Pt 6 3.1 1630 5.2 4.9 0.2 0.3 
Pt22 6.2 1563.7 47.4 39.2 7.5 3.0 
Pt 16 11.2 3844.1 309.7 283.6 14.2 8.1 
Pt 17 12.1 2472.8 278.5 275.2 3.2 11.3 
Pt 18 14.6 2189.6 529.5 493.1 30.1 24.2 
Pt 5 26.4 2609.2 119.5 101.8 14.6 4.6 
Pt 8 26.8 2055.4 139.1 128.9 9.1 6.8 
Pt 7 38.1 1797.8 129.9 112.0 13.3 7.2 
Table 3, analysis of post treatment volumes of total Radiation Induced Lung Injury (RILI), SABR 
induced ground glass opacities (GGOs) and solid RILI.  
Two sets of correlation coefficients were calculated. The first was a correlation coefficient 
generated for the absolute volume of total RILLI, GGO RILI and solid RILI. These results are 
seen in table 4. It was noted that the volume of the post treatment whole lung ipsilateral to 
tumour, varied very significantly between patients (range 1563.7cm3 to 3844.1cm3). The 
coefficients were re-analysed, by comparing the GTV to total RILI, GGO RILI and solid RILI as a 
percentage of the lung volumes. Neither of these approaches showed a likely correlation 
between the size of the GTV and volume of RILI after SABR. The correlation co-efficients are 
seen in table 4. 
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Comparison Correlation co-
efficient 
GTV vs total RILI -0.019 
GTV vs GGO RILI -0.04 
GTV vs solid RILI 0.293 
GTV vs % total RILI 0.072 
GTV vs %GGO RILI 0.049 
GTV vs % solid RILI 0.357 
Table 4: correlating GTV with RILI following SABR. Analysis was performed in 2 ways, 
correlating GTV with absolute volume of total RILI, GGO RILI and solid RILI. The second method 
was to correlate the volume of fibrosis for total RILI, GGO RILI and solid RILI as a % of the total 
lung volume from the post-treatment volume.  
Discussion: Table 2 shows that the SABR dose statistics were similar for the treated tumours, 
however there was a large variation between the smallest and largest PTV volumes (12.6 cm3 
to 77.3 cm3). The iGTV was generated as a volume, which included the gross tumour volume 
in all positions of the breathing cycle using a 4DCT.  
This experiment suggests that tumour size did not obviously correlate with the scale of post 
treatment lung injury after SABR. It supports the clinical observation that it is difficult to 
predict the post treatment reaction as other factors may be important, however this cannot 
be definitively deduced from this analysis, as there are many variables that need to be 
considered, as well as the very small size of the cohort. As the total lung volumes vary greatly, 
standardising the volume of RILI to the total volume of the irradiated lung does not improve 
the correlation. It may be that the volume of lung injury correlates to another technical 
radiotherapy or dose distribution factor such as: volume of lung receiving a low dose of 
radiotherapy, length of treatment volume in superior-inferior direction, tumour motion, or 
whether treatment was delivered in half or full arcs. To conclude definitively that the size of 
the treatment volume does not correlate with post treatment lung injury would require a 
much larger cohort to be analysed, this data set was also limited by the fact that there was 
some variability in the time points of the scans being analysed.  
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Previously published work has suggested that increased CT density after radiotherapy is 
associated with a higher dose, increased planning target volume size and increasing time after 
SABR (Palma et al., 2011). Density increases were more significant in areas of tissue receiving 
more than 6Gy and plateaued at 40Gy. Understanding the dose of radiotherapy received by 
different parts of the lung is more difficult to calculate as RILI also causes traction on the lung 
meaning the tumour bed can be in a different geometric position, in relation to its position in 
the lung. It is interesting to note that in the results of experiment 25 the only positive weak 
correlation was between the volume of GTV and volume of solid RILI, when compared to both 
absolute volume of solid RILI (correlation coefficient 0.29) and when solid RILI is expressed as 
a percentage of total lung volume (correlation coefficient 0.357).  
As SABR is used in patients who are likely to have co-morbidities specifically COPD, defining 
normal lung tissue compared to acute lung injury may be more complex. This may further 
complicate understanding RILI after SABR. In this study, 4 initial volumes were reviewed and 
agreed by a Consultant Radiologist and the volumes were completed by an Oncology Registrar 
who was experienced outlining lung tumours and had completed Fellowship exams for the 
Royal College of Radiology. It may be that tighter definitions of RILI are required to ensure 
only localised inflammation, rather than pre-existing GGO or solid consolidation changes are 
included.  
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6.4 Experiment 26: can tumour and RILI be differentiated in patients who have received 
SABR 6 months previously.  
Aim: Using the elephant plot, was it possible to differentiate between tumour and RILI after 
SABR. The hypothesis was that the distribution of data points in the low entropy high density 
region around the tip of the trunk in the elephant plot, would be different for tumour 
compared to RILI.  
Methods: 8 patients who were selected and whose scans were analysed in experiment 24 
and 25 were compared to 3 patients who had a local recurrence 6 months after lung SABR. 
Recurrence was confirmed on PET-CT. These were patients who did not recur within the first 
year after having a primary lung tumour treated with SABR. These patients all had a post 
treatment CT scan with IV contrast at 6 or 7 months. The first step was to plot the high density 
low entropy sub-region, defined as a density score of 900-1200 and an entropy score of 2 or 
less. The data points included in the sub region of the plot were then analysed and returned 
to the scan image.  
Results: Figure 5 shows the ROI post treatment, for the 8 patients who underwent pre-
treatment analysis in table 1 and figures 1-4. Figure 6 shows the same region of interest for 3 
patients who had tumour recurrence 6 months after SABR for primary lung cancer.  
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Figure 5a: Comparing the trunk region of the elephant plot before and after treatment. Region 
of interest defined as region containing data points with a density score of 900-1200 and an 
entropy score of 2 or less, from 8 patients who received SABR for primary lung cancer and had 
not recurred at 6 months post treatment. The scale of these plots are the same as in 
experiments 24 and 25. X axis = density, Y axis = entropy score. 
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Figure 5b: Comparing the trunk region of the elephant plot before and after treatment. Region 
of interest defined as region containing data points with a density score of 900-1200 and an 
entropy score of 2 or less, from 8 patients who received SABR for primary lung cancer and had 
not recurred at 6 months post treatment. The scale of these plots are the same as in 
experiments 24 and 25. X axis = density, Y axis = entropy score. 
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Figure 6: illustrating the sub-region of interest (density 900-1200 and entropy 2 or less) of 3 
patients who had FDG-PET CT proven recurrence 6 months after SABR for a primary lung 
tumour. Patient 11 and 20 show a high density of data points within the region consistent with 
the tip of the trunk in the elephant plot. The analysed CT scans were taken 6 months after 
treatment.  
Discussion: 
The post treatment sub-regions of interest illustrated in the right hand column of figure 5, 
when compared to those in table 1 (section 6.2) and figure 1-4, shows the spread of data 
appears different. The sub-regions do not have a pre-dominant trunk in the same position as 
pre-treatment imaging. None of the post treatment data plots have a high density zero 
entropy region in the trunk of the elephant plot, whereas 6 of the 8 tumours analysed have a 
zero entropy region relating to tumour in the pre-treatment imaging.  
By comparison 2 of the 3 recurrences (patients 11 and 20) show different patterns to the non-
recurrent sub region analyses seen in table 5. Interestingly patient 11 did not have IV contrast 
due to  poor renal function, so the differences in appearance of the 3 patients in figure 6 are 
not due to contrast, as patients 11 and 20 appear similar.  
Comparing the post treatment sub region analyses of recurrers and non-recurrers allows for 
the generation of hypotheses, but is difficult to produce conclusive results in such a small data 
set, but it does suggest that the morphology of the data plots may be different.  
These data plots do not take into account the spatial relationship between the data points 
that are similar to each other in terms of entropy and density scores, but not necessarily 
geometrically close. The sub region analysis of patient 5 who never recurred vs patient 11 
who recurred at 6 months are similar. The post treatment reaction in patient 5 appears to be 
denser than other patients who have not recurred. This would explain the similarity of the 
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appearance of the tip of the elephant trunk, for patient 11 who recurred and patient 5 who 
didn’t.  
The post treatment analyses of patients 11 and 20 are similar to the appearance of pre-
treatment tumour, this technique may be suitable to help differentiate between tumour and 
RILI after SABR for primary lung cancer, however definitive conclusions cannot be drawn from 
such a small data set.  
 
Conclusion Future work 
SABR is an effective treatment for primary lung cancer, with local control rates above 90% 
(Murray et al., 2016). One of the major clinical difficulties is differentiating tumour recurrence 
from the significant lung inflammation that can occur as a result of SABR (Huang et al., 2012). 
From the experimental work in theme 1 of this thesis it is possible to identify a sub-region of 
interest (the tip of the trunk in the elephant plot) in which the tumour lies before treatment. 
In a small data set it is possible to generate some hypotheses regarding the differences 
between tumour recurrence and RILI after SABR. Overall there appear to be fewer data points 
in the tip of the trunk, when compared to the recurrences. The other major difference 
between tumour and RILI for data plots 6 months after SABR is that when the data points are 
replotted in the original image, the data points relating to RILI are much more likely to be 
spread out across a wider region, whereas those representing tumour are more likely to be 
clustered together. These observations need to be proven in a larger dataset. Identifying 
patients who have not recurred is technically challenging when looking at the CT image. TA 
may make this process more straight forward. Identifying a larger cohort of patients who have 
local or ipsilateral lung recurrence is more difficult as SABR treatment is effective. In this 
cohort that the data was extracted from, the 1 year control rate is 97% (Phillips et al., 2017).  
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Figure 7: comparing different regions of interest within the elephant plot for patient 16 before 
receiving treatment. The voxels from the data plot are highlighted in red on the texture map. 
Figure a) shows no tumour, but the presence of contrast when density range is 900-1200 and 
entropy range is 2 or less. Figure b) shows tumour and contrast when density range is 900-
1200 and entropy 3 or less. Figure c) shows less tumour and contrast when density is 1000-
1150 and entropy is 3 or less.  
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The region of the elephant plot, which could be included as the sub-region could be adjusted.  
For example in the pre-treatment data plot for patient 16 the standard values for the ROI 
means tumour is not included (figure 8a). By increasing the range of entropy scores from 0 - 
2 to 0 - 3, adjusting the entropy score means tumour is included in the sub region (figure 8b). 
Narrowing the density range from 900-1200 to 1000-1150 reduces the number of voxels in 
the region representing contrast, but also reduces the region representing tumour. This form 
of analysis needs to be repeated in a larger data set for both pre-treatment and post-
treatment imaging.  
Further work is required to analyse these ROIs using an assessment of how the data points 
relate to each other in space.  
Other types of advanced analysis could also add to this. The elephant plot was deliberately 
kept as a 2D analysis, but a 3rd dimension could be added, other factors could be the spatial 
relationship as detailed above, or an analysis of the density of data points on the 2D plots. 
Kernel density estimation would help achieve this. 
As a minimum this analysis helps localise ROIs within the lung, which could be areas of 
interest, and have similar appearance to tumour in terms of density and entropy. Taking 
patient 20 as an example of a recurrence, It is possible to identify the tumour (15.3cm3) in a 
whole lung (2777.9cm3), which contains areas of RILI (155.6cm3) ten times the volume of the 
tumour. Larger data sets need to be analysed to better narrow down the way that RILI and 
tumour are arranged in space and to identify differences between the two, but this is a very 
promising early result.   
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Theme 2: CT based sarcopenia assessment and NSCLC 
Chapter 7: Assessing weight loss in Non-Small Cell Lung Cancer 
7.1. Background to theme 2 
 
As discussed previously lung cancer occurs in a vulnerable and frail population. The previous 
texture analysis (TA) work in this thesis was applied to an entire lung, aiming to identify 
tumour and differentiate it from other tissue in the lung. Theme 2 and theme 3 in this thesis 
involve using TA for a different process. The work completed in theme 1 of this thesis was 
aiming in particular to differentiate between tumour and lung injury. Themes 2 and 3 are 
aiming to examine a normal tissue and see if a functional assessment can be extracted from 
a standard CT scan, by analysing normal tissue. CT scans are commonly used to measure 
anatomical features such as the dimensions of a tumour, or the site of a tumour or 
metastases. Simple conclusions can be drawn from imaging, to categorise organ function, for 
example the presence of bullae in the lung, which are essentially holes in the lung caused by 
the destruction of elastic tissue in the lung. This means that qualitative statements can be 
made about organ function, but it is difficult to make quantitative statements, that are quick 
in implementation and could be incorporated in the standard workflow of a radiology 
department.  
 
The aims of themes 2 and 3 are to show how texture analysis (TA) can be used to provide a 
quantitative analysis of organ function from a CT scan. Theme 2 focuses on the investigation 
of weight loss in metastatic Non-Small Cell Lung Cancer (NSCLC). Theme 3 focuses on 
identifying lung function and differentiating between fit and unfit patients undergoing radical 
radiotherapy.  
 
This section focuses on weight loss in lung cancer. Assessing weight loss in NSCLC could have 
several potential benefits. Firstly to see if assessing muscle loss (sarcopenia) could predict 
outcome, either using radiological measurements of muscle or TA. Secondly to assess the 
symptom burden of patients with newly diagnosed NSCLC and finally to see if there was a 
need for dietetic intervention for malnutrition in patients with NSCLC. No obvious previous 
literature was found, which incorporated an assessment of malnutrition, cachexia and 
sarcopenia in advanced NSCLC.  
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This work was completed in collaboration with the specialist Macmillan Oncology Dietetic 
service at St Luke’s Cancer Centre, Royal Surrey County Hospital. It includes retrospective 
analysis of weight loss of patients assessed by the dietetic service for advanced NSCLC, a 
retrospective analysis of sarcopenia in a cohort of patients with NSCLC and an analysis of the 
initial cohort of a prospective trial investigating rates of malnutrition, cachexia and sarcopenia 
in patients with advanced NSCLC. During the experimental work for this trial (DAIL trial, 
Dietetic Assessment and Intervention in Lung cancer) was set up. I wrote the first draft of the 
protocol, obtained trust sponsorship, completed the IRAS form, gained funding and achieved 
ethical approval for the trial. The trialopened at the Royal Surrey County Hospital. The trial is 
on the NIHR portfolio and reports regularly to the National Cancer Research Institute (NCRI) 
Lung Cancer Clinical Studies Group.  
 
In summary this chapter illustrates that cachexia (5% or greater weight loss) at the time of 
dietitian review leads to a significantly poorer overall survival (7.4.1, experiment 1), it shows 
that the presence of sarcopenia at diagnosis leads to a poorer outcome in lung cancer (7.4.2, 
experiment 2) and that sarcopenia is assessable in a prospective trial and that a TA measure 
is statistically significantly associated with sarcopenia in advanced lung cancer (7.5.2).  
 
7.2 Understanding weight loss: Malnutrition, Sarcopenia and Cachexia 
This section focuses on weight loss in advanced, i.e. incurable, NSCLC. Lung cancer is the 
second commonest cancer diagnosed in the UK in both men and women. Lung cancer is 
caused by smoking and occurs in a vulnerable population. Smoking and lung cancer are a 
disease of poverty (Li et al., 2015, Cooley and Jennings-Dozier, 1998, Gadgeel and 
Kalemkerian, 2003, Gadgeel et al., 2001) and the risk of lung cancer is inversely proportional 
to socio-economic status. As well as greater active smoking behaviour, this population is more 
likely to be exposed to other risk factors such as higher passive smoking rates, occupational 
exposure, less healthy diets and occupational/environmental carcinogens (Cooley and 
Jennings-Dozier, 1998). An example of this can be seen in the UK, where it is estimated there 
would be 9,900 fewer cases of lung cancer if those worst off had the same incidence of lung 
cancer as the least deprived section of society (taskforce, 2015). As the majority of patients 
with NSCLC were smokers, many will also have multiple co-morbidities also caused by 
smoking. These conditions include Ischaemic Heart Disease, Chronic Obstructive Pulmonary 
159 
 
Disease (COPD) and other primary cancers such as bladder cancer. Recent data suggests that 
nearly a fifth (18%) of patients had 4 or more co-morbidities (Gould et al., 2017). Lung cancer 
is more common in older patients and the numbers of cases are rising in this population. More 
than 80% of new cases of lung cancer are diagnosed in the over 60s and more than 40% are 
diagnosed in men and women over 75 years. The number of cases of lung cancer in over 60’s 
is rising (Foundation, 2017), particularly in those aged 81 or older, where cases have risen by 
nearly 1.5 times from 446 per 100,000 in 2004 to 666 per 100,000 in 2012 (Foundation, 2017). 
 
All of the risk factors identified in the paragraph above show that patients with incurable 
NSCLC have a lot of risk factors for being less fit and frailer. Patient fitness for systemic anti-
cancer treatment is made up of many factors, many of these e.g. stage of cancer, the patient 
is not able to directly influence. Ensuring adequate nutrition is one element that patients can 
directly influence in the management of their cancer. Others potentially include exercise, 
physical fitness and psychological factors.  
 
The work in this chapter relates to investigating weight loss in NSCLC and its effects. Weight 
loss is a broad term that encompasses three different entities. In clinical practice these terms 
may be used interchangeably, however, in this context it is important to understand where 
these syndromes overlap and where they are distinct. Malnutrition is weight loss due to 
inadequate calorific intake, cachexia is an inflammatory metabolic syndrome leading to loss 
of muscle and possibly fat despite adequate nutrition and sarcopenia is specifically the loss of 
muscle bulk, muscle function and overall function. These syndromes can occur in other non-
malignant medical conditions and sarcopenia can occur as a physiological process as part of 
aging.  
 
Malnutrition can be defined as a state of nutritional imbalance leading to negative effects on 
weight and function (Fearon et al., 2011). Cancer cachexia differs from malnutrition as it 
occurs despite adequate nutrition. Cachexia is defined as 5% or greater weight loss from usual 
body weight (in absence of starvation) within 6 months, or 2% weight loss with either 
sarcopenia or a body mass index (BMI) of less than 20 (Fearon et al., 2011, Blum et al., 2014). 
Refractory (irreversible) cachexia is a marker of poor prognosis and is defined as a survival of 
less than 90 days. Cachexia is a progressive disorder, leading to decreased physical activity, 
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adverse psychological side effects, poor performance status and higher mortality rates. The 
stages of cachexia are illustrated in figure 1. Pre-cachexia is defined as weight loss of 5% or 
less with accompanying anorexia and metabolic change. Patients with sarcopenia can also 
have cachexia, depending on the degree of muscle loss. Sarcopenia is defined as a loss of 
muscle mass and function, leading to the risk of adverse outcomes (Cruz-Jentoft et al., 2010, 
Muscaritoli et al., 2010, Fielding et al., 2011). 
 
 
Figure 1. Diagram showing the 3 stages of cachexia, from Fearon et al (Fearon et al., 2011) 
 
7.3 Current understanding of weight loss in NSCLC  
Patients with NSCLC have co-morbidities, which before a diagnosis of NSCLC can influence 
their nutritional state. These conditions can cause nutritional deficits independent of a 
diagnosis of cancer. Malnutrition is common in COPD (Collins et al., 2016, Vermeeren et al., 
2006) and is associated with decreased physical work load (Budweiser et al., 2008). A recent 
study suggests 22% are malnourished. Symptoms associated with COPD include a dry mouth, 
pain and constipation and all can impact on nutritional status. Patients with more significant 
fat free mass depletion are more likely to have these symptoms (Norden et al., 2015) and 
lower muscle mass has been correlated with poor respiratory function (Jeon et al., 2015). 
Malnutrition has also been associated with poorer outcome in patients with Coronary Artery 
Disease (Kunimura et al., 2017).  
 
Patients may have a nutritional deficit before being diagnosed with cancer, however, in 
addition weight loss is common in patients with cancer. In a study of 1,000 patients with 
locally advanced or metastatic cancer, more than a third had significant weight loss (defined 
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as greater than 10% weight loss) (Bozzetti and Group, 2009). Twelve percent of patients in 
this study had lung cancer with a median rate of significant weight loss of 6.6%. As stage of 
cancer and performance status worsened, so did percentage weight loss.  
 
There are relatively few studies assessing malnutrition in lung cancer [62]. Pre-treatment 
nutritional assessment has shown that malnutrition is common in lung cancer patients, with 
an incidence of between 35% and 65% (Kiss et al., 2014a, Percival et al., 2013, Li et al., 2011). 
There are a number of assessment tools that have been used to identify malnutrition. One is 
the Mini-Nutritional Assessment (MNA), which has identified that two thirds of patients with 
metastatic lung cancer are either at risk of malnutrition or are malnourished (Gioulbasanis et 
al., 2011). The MNA outcome correlated with overall survival.  The Subjective Global 
Assessment is another recognised tool for assessing nutritional status (Detsky et al., 1987), 
which has been adapted to form the Patient Generated Subjective Global Assessment (PG-
SGA) for use in patients with cancer (Jager-Wittenaar and Ottery, 2017). The PG-SGA is useful 
as it is a multi faceted tool, it aids determination of weight loss, changes in food intake, 
symptoms of nutrition alterations, limitations of function, presence of metabolic stress and a 
physical examination. In a study using the PG-SGA 40% of patients with metastatic lung cancer 
were malnourished and a further 40% were at risk of malnutrition(Li et al., 2011). Patients 
who were defined as malnourished had an overall survival of 9 months vs 17 months in well-
nourished patients in advanced NSCLC. A range of studies have shown that malnutrition is 
associated with negative clinical outcomes in patients with cancer in general, including poorer 
quality of life, decreased functional status, increased utilisation of health care services and 
poorer survival (Kiss et al., 2014a).  
 
A series of studies have assessed nutritional status in surgical patients with NSCLC suitable for 
radical treatment. Malnutrition was found to be a significant risk factor for early death, in 
patients’ aged 70 years or older undergoing resection of a primary lung tumour. The cohort 
was divided into two groups, those that were underweight (BMI <18.5kg/m2, Group A, 21 
patients) and those that were not underweight (BMI 18.5kg/m2 or greater, Group B, 96 
patients). BMI and weight loss of 5% or greater before surgery were independent risk factors 
for 1 year mortality (Fiorelli et al., 2014). In patients undergoing pneumonectomy for lung 
cancer, 33 of 86 patients were found to have malnutrition. This was assessed using biological 
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markers of nutrition including albumin and transthyretin (Bagan et al., 2013). In contrast, a 
study enrolling 146 patients irrespective of age suggested that BMI and surgical outcome did 
not obviously correlate, however only 109 of 146 patients underwent surgery, patients not 
undergoing surgery were not included in the analysis (Win et al., 2007). Poor nutritional status 
and increased mortality has been associated with non-oncological thoracic surgery, such as 
lung transplantation (Shah and Orens, 2013). As well as assessment tools, functional and 
imaging measures can assess nutritional status. The correlation between decreased handgrip 
status and malnutrition has been established in patients with potentially operable NSCLC [67]. 
In terms of sarcopenia, patients with sufficient muscle loss to be sarcopenic, had a poorer 
survival when undergoing surgery for stage 1 NSCLC (Tsukioka et al., 2017). In this study, 
sarcopenia was assessed by measuring the anterior-posterior and medial-lateral diameters of 
the psoas muscle. These were then multiplied by each other to calculate the surface area and 
standardised for height. This technique has approved thresholds. If the muscle surface area 
standardised for height is below the threshold the patient would be regarded as sarcopenic 
(<55cm2 for males and 39cm2 for females).  
 
In patients receiving radiotherapy for lung cancer, a retrospective review of 96 patients has 
shown that 31% lost 5% or more of their usual total body weight (Kiss et al., 2014a). This was 
more likely if the patients had more advanced disease, or radiotherapy was given with 
chemotherapy. The dose of radiotherapy to the oesophagus during high dose palliative or 
radical lung radiotherapy predicted for weight loss. The maximum dose to the oesophagus 
predicted for weight loss of 5% of greater. A recent study has found that in patients 
undergoing chemo-radiotherapy for NSCLC, poor performance, low BMI and low muscle 
attenuation predicted for adverse outcomes (Bowden et al., 2017). BMI is a relatively 
insensitive marker of weight loss, as a result for many patients it would require a substantial 
loss of weight to alter their BMI. Of note, this study had a 90 day mortality rate of 11%, which 
could be regarded as high and could influence their results.  
 
The study by Bowden et al specifically looked at muscle appearance on CT scan. It was found 
that low muscle attenuation was an independent prognosticator for overall survival. Low 
muscle attenuation was thought to be myosteatosis, which was the infiltration of muscle 
tissue by fat (Bowden et al., 2017). This is associated with skeletal muscle wasting, but as with 
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sarcopenia can be associated with older age, obesity and non-malignant disease. Sarcopenia 
has been associated with poorer outcome in metastatic renal cell cancer and patients 
undergoing radical surgery for oesophageal cancer (Nakashima et al., 2017). 
  
In terms of intervening to improve outcomes in lung cancer, randomising patients to dietary 
advice +/- nutritional supplements did not show a significant benefit, however compliance 
with the nutritional supplements and completing food diaries was low (Baldwin et al., 2011). 
A systematic review of dietetic intervention in advanced cancer suggests that intervening can 
have a positive effect on weight and calorific intake, but study heterogeneity makes it difficult 
to prove this conclusively (Balstad et al., 2014). Chemotherapy may improve muscle mass in 
advanced lung cancer (Stene et al., 2015). The lack of definitive benefit in some studies may 
be in part due to short follow up, analysis of patients with lung cancer along with other 
tumour types and difficulties in patients reaching adequate calorific intake (Kiss et al., 2014b). 
A systematic review of exercise and nutrition strategies published in 2013, suggests that they 
are not harmful and may have beneficial effects on unintentional weight loss for patients with 
advanced lung cancer. Only 203 patients from 5 studies were included in this analysis, of 
which only 3 were assessing nutrition. All 3 studies investigated use of a specific supplement 
rather than the impact of a nutritional assessment (Payne et al., 2013). 
 
Early intervention in metastatic lung cancer shows improved outcomes, a pre-treatment 
palliative care assessment has been shown to improve overall survival (11.6 months vs 8.9 
months) in advanced lung cancer when compared to standard intervention (Temel et al., 
2010). This includes identifying malnutrition and addressing nutritional deficits, which can 
affect a patient’s fitness for treatment. It is interesting to note that the use of dietary 
supplements did not improve outcome. For example in the trial by Baldwin et al compliance 
with supplements was 31% in the first week and had declined to 19% in week 6 (Baldwin et 
al., 2011). This suggests that simply prescribing supplements is ineffective as a simple 
intervention. As previously discussed patients with advanced NSCLC are likely to have 
complex symptomatology, this may be why an early palliative care review improves survival. 
For example a palliative care review for a patient in pain rather than simply providing 
analgesia allows a nuanced approach that can be individually tailored to the patient, where 
as providing a strong analgesic lacks any of that subtlety. The limitations of prescribing a drug 
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without reviewing the patient may include not being educated adequately on how to take it 
appropriately, may not tolerate it or find its application difficult. The same can be argued for 
patients who have lost weight. Food intake is one of the few interventions under the control 
of the patient, they may be intolerant of the supplement, may struggle to eat/swallow it, may 
have dietary restrictions contra-indicating its use or simply not like the taste. Health beliefs 
around food may also be complex. A dietetic review can provide the same subtlety for a 
patient’s calorific intake, as a palliative care review can for pain. Many of the studies have 
used a supplement, rather than a more complex approach.  
 
Although malnutrition, cachexia and sarcopenia inter-relate these are distinct entities. The 
aim of this experimental work was to identify how commonly these occur in patients with 
advanced NSCLC and explain the relationship between them. Whilst screening assessment 
and prophylactic nutritional support is standard practice for patients with primary cancers of 
the head and neck and upper GI tract region, this is not the case for those with lung cancer, 
despite often being a vulnerable, frail patient group with multiple co-morbidities, as well as 
the fact that exposure to alcohol and tobacco may be similar to those with primary head and 
neck cancers. Recent ESPEN guidelines have suggested that nutritional screening should be 
performed at the time of a cancer diagnosis, however, there is a low level of evidence to 
support this recommendation (Arends et al., 2016). My work aims to add to this knowledge 
base. I also wanted to understand certain factors including the proportion of patients 
presenting malnourished, cachectic and sarcopenic with advanced NSCLC. I wanted to identify 
the proportion of patients who need to see a dietitian pre-treatment, to consider whether 
this should be standard practice. Overall the key aim of this project was to understand 
whether sarcopenia identifies those at risk of cachexia and refractory cachexia much earlier, 
meaning intervention can happen earlier.   
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7.4 Preliminary experimental work in patients with NSCLC 
 
7.4.1 Experiment 1: Does more than 5% weight loss from usual body weight lead to a poorer 
outcome? A retrospective review of patients seen by specialist Oncology dietetics service 
at Royal Surrey County 
 
Aim: To identify whether weight loss at time of dietetic review was associated with poorer 
survival in patients with metastatic NSCLC? Standard practice at St Luke’s Cancer Centre is for 
health care professional-guided referrals to a Macmillan Oncology Dietitian, this can occur at 
any time during a patient’s cancer pathway, potentially before, during or after radical or 
palliative treatment.  
  
Methods: As part of the dietetic service, a large database of weight change in patients 
reviewed by the dietetic team is collected prospectively. In collaboration with the dietitians, 
the oncology outcome database was interrogated, only patients with metastatic NSCLC were 
included, any patients with other types of cancer and those with early stage or locally 
advanced NSCLC were excluded. Percentage weight change was calculated. This data only 
included patients who had been assessed in person by a Macmillan Oncology Dietitian and so 
needed to be well enough to attend the hospital for that assessment. Patients were defined 
as (per the international definition) cachectic if they had lost more than 5% from their usual 
body weight in the last six months, as recorded on the database (Fearon et al., 2011). The 
NHS spine was used to identify those patients who had died. Overall survival for cachectic and 
non-cachectic patients was identified.  
 
Results and Discussion: This cohort study showed that cachexia is a significant problem in 
advanced lung cancer and has an impact on overall survival. It is important to recognize that 
there maybe a selection bias as only patients seen by the dietetic service were included in this 
analysis. The vast majority of patients (76%) lost more than 5% of their usual total body weight 
at the time they were first seen by a Dietitian. Overall survival from time of dietitian review 
was significantly worse in patients with cachexia vs patients without cachexia (188 days vs 
299 days, p=0.0078) (Hug, 2017). In a cohort whose median survival is 6-12 months, the 
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difference of more than 3 months is significant, however, there may be other factors such as 
time to dietitan review, performance status, previous anti-cancer treatment and stage of 
disease. Figure 2 shows % weight change in this cohort, patient by patient, it shows that some 
patients lost very noteworthy amounts of weight. In this cohort, the median weight change 
was -9.4% (range 7.3% to -35.8%).  
 
This study also showed that percentage loss of total body weight is more sensitive than BMI. 
In our study, we saw mean BMI decrease from 26.9kg/m2 to 23.2 kg/m2 (BMI range at time of 
review 13.3-62 kg/m2) which is still within the healthy range of 20.0kg/m2 – 25.0kg/m2. 
Therefore using BMI to determine malnutrition and cachexia in lung cancer patients would 
not be a true reflection of this population. Other studies have shown that high BMI correlates 
with survival, but this means a patient would need to lose a large amount of weight to lower 
their BMI, data for the thesis supports the fact that change in BMI is relatively insensitive to 
weight loss (Bowden et al., 2017).  
 
 
    Patients 
Figure 2: Graph showing a waterfall plot of % weight change by patient Patients to the left of 
the red line have lost more than 5% of usual body weight and were defined as cachectic. 76% 
of patients were cachectic in this cohort.  
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All patients were well enough to attend the cancer centre. 85% (264) of patients were 
receiving chemotherapy when referred to the dietitian. This data suggests that cachexia is a 
significant issue in patients receiving active palliative anti-cancer treatment.  
 
Although Performance Status (PS) was not routinely recorded, the fact that patients were 
receiving chemotherapy with palliative intent suggests their PS was 2 or fitter when treatment 
was initiated. 
This study shows that many patients with metastatic NSCLC lose a lot of weight and the 
majority are cachectic at the time they are reviewed by an oncology dietitian, it suggests how 
major weight loss in terms of refractory cachexia impacts on survival. This study was a very 
helpful starting point in identifying there was a need to further investigate weight loss in this 
population. The retrospective nature of this project illustrated its major limitation, which was 
that the time point of dietetic assessment was not consistent in the patient’s journey through 
diagnosis and treatment. The patients were reviewed when a health professional felt the 
patient needed to be seen by a dietitian. This lack of consistency would need to be remedied 
in future work. From this data, it was also not clear whether patients would have been 
cachectic at diagnosis, or whether this was a phenomenon that developed during treatment, 
or whether both scenarios could have occurred.  
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Figure 3: Kaplan-Meier curve showing overall survival for patients with NSCLC classed as those 
with cachexia or without cachexia. Median survival for cachectic patients was 188 days and 
299 days for non-cachectic patients. X= axis time in days.  
This cohort data is limited by the fact that TNM staging and tissue type were not routinely 
recorded, and that usual body weight was self-reported by patients. It did not record the date 
of diagnosis and so there is likely to be variability in time between date of diagnosis and date 
of referral to the dietitian. This has the potential to introduce a source of lead time bias, if 
more weight is lost as more time passes since diagnosis, it could suggest an artificial 
relationship between weight loss and survival in advanced NSCLC. Although the time point 
may have been inconsistent, cachexia could have been under-estimated in this cohort as it 
did not include patients who had lost 2-5% of usual body weight and had co-existing 
sarcopenia or a BMI below 20. It may underestimate the rate of cachexia in this population, 
as sarcopenia is common in lung cancer (Stene et al., 2015). 
 
In summary, it was felt that this work highlighted an important area of further investigation. 
Future work would assess patients at the same time point, the most consistent time point 
was felt to be diagnosis.  
 
169 
 
7.4.2 Experiment 2: Is sarcopenia associated in a poorer outcome in NSCLC? 
  
Aim: Sarcopenia is a loss of muscle mass and function, in combination with an overall 
decrease in function. There are multiple ways to assess sarcopenia, this can be radiological or 
functional in nature. Previous published data has shown that sarcopenia occurred in 14% of 
patients with stage 1 NSCLC (Tsukioka et al., 2017), when it was assessed by calculating the 
surface area of the psoas muscle (standardised for height), although in this study sarcopenia 
did not predict for post-operative complications, it did predict for grade 3 or greater toxicities 
in patient undergoing surgery for bowel cancer (Jones et al., 2015) 
 
Methods: All patients from a lung MDT from July 2012-December 2013 with biopsy proven 
NSCLC were included. Patients were categorised by age and treatment, the overall data was 
presented separately (Ezhil, 2016). From this cohort all patients were included who met 2 
criteria, firstly patients who had available imaging on the electronic PACS system, which 
included the transverse processes of the third lumbar vertebra and secondly a formally 
documented height measurement, available either from chemotherapy records or formal 
lung function testing.  
 
Figure 4, example anterior-posterior and medial-lateral measurement of the left and right 
psoas muscle. The left psoas muscle is outlined in green and the right psoas muscle is outlined 
in magenta.   
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This methodology had been previously tested in peer reviewed literature in early stage lung 
cancer and colo-rectal cancer (Tsukioka et al., 2017, Jones et al., 2015). The psoas muscle was 
measured in cm at the widest point anterior-posteriorly (AP) and medial-laterally (ML), at the 
level of L3 transverse process. The measurements were taken with the measuring line vertical 
for AP measurements and horizontal for the ML measurements. These measurements were 
multiplied by each other and divided by the patient’s height (metres). An average was then 
generated from the left and right psoas muscle. A man with a standardised measurement of 
less than 55cm2/m2 and a women with a measurement of less than 39cm2/m2 were 
considered sarcopenic. An example measurement is seen in figure 4.  
 
Experiment 2 Results and Discussion:  
 
Figure 5: Survival curve of sarcopenic vs non sarcopenic patients with Non Small Cell Lung 
Cancer. P=0.22, there was not a statistically significant difference between the 2 groups. X axis 
= time in months. 
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90 patients were identified who met the criteria for this study. 56% were male and 44% 
female. The mean age was 73 (range 41-88). The median survival of the non-sarcopenic cohort 
was 15 months vs 12 months (p=0.22) for the sarcopenic cohort, the survival curve is shown 
in figure 5. Nearly half (47%) of patients were sarcopenic at the time of their diagnostic scan 
(Phillips et al., 2016).  
Although it did not meet statistical significance, sarcopenia is common in NSCLC and appears 
to be a biomarker of poorer survival. This cohort did include patients with a range of stages 
of NSCLC. This study did not standardize for stage of disease, age or treatment received, but 
was aimed to be hypothesis generating in terms of whether assessing patients with lung 
cancer was possible and practical. The cohort was standardised by time of assessment of 
sarcopenia, all patients had the assessment on pre-treatment CT imaging either from a 
diagnostic CT scan or the CT component of the PET-CT scan. The only major difference 
between the 2 scans was the use of either IV contrast or IV FDG radioactive tracer. This was 
not felt to have an effect on the sarcopenia assessment as it was measuring muscle 
dimension.  
 
This study suggests that sarcopenia could be a biomarker for poor outcome in NSCLC cancer 
and requires further investigation. As an assessment, measuring the psoas muscle is simple, 
quick, but requires time for trained staff to measure the psoas muscle accurately in a 
reproducible way. This study shows that it is possible for sarcopenia to be performed on 
multiple patients (Phillips et al., 2016).  
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7.5 Conclusions from retrospective work on weight loss in NSCLC 
The two experiments on cachexia (defined by weight loss) and sarcopenia both show that 
weight loss in lung cancer influences outcome. It appears that sarcopenia is a potential 
biomarker for decreased overall survival. This work also shows that many patients 
experience weight loss by the time they are reviewed by a dietitan after a diagnosis of 
NSCLC.  
 
Treating cachexia is difficult, although appetite stimulation or nutritional support can help 
slow the loss of muscle mass, improve quality of life and reduce malnutrition. Treating 
symptoms such as nausea and pain can also help improve nutritional status as can graded 
physical activity. New agents such as ghrelin analogues offer a glimpse of more innovative 
treatments of cachexia (Temel et al., 2016). 
 
There is some evidence that dietary counseling and nutritional supplements may ameliorate 
the effects of radiotherapy and chemotherapy, although the exact benefit is not clear. The 
lack of definitive benefit in these studies may be in part due to short follow up, analysis of 
patients with lung cancer with other tumour types and difficulties in patients reaching 
adequate calorific intake (Kiss et al., 2014b). Other studies including patients with advanced 
lung cancer have not found a benefit in early nutritional advice or use of supplements 
(Baldwin et al., 2011). 
 
Whilst screening, assessment and prophylactic nutrition support is standard practice for 
patients with primary cancers of the head and neck region, this is not the case for those with 
lung cancer. More research is needed to identify the rate of pre-treatment cachexia in NSCLC 
and then how to implement tools that may improve outcome 
 
This study shows that cachexia in patients with advanced lung cancer is very common. Many 
patients with lung cancer are older and can have multiple co-morbidities. As a result, they are 
a more vulnerable and less fit population and require significant multi-disciplinary support.  
 
This retrospective work aimed to identify potential problems and pitfalls, before considering 
a prospective cohort study. The high cachexia rate is a compelling argument for further 
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investigation of nutritional support in lung cancer As it was difficult to know when weight loss 
occurred, it was felt that a prospective study including patients at diagnosis would be helpful, 
to answer the question of whether malnutrition, cachexia or sarcopenia were present at 
diagnosis or develop later in the disease pathway. In terms of the effect of possible 
interventions, it was felt it was difficult to predict the proportion of patients who may present 
with weight loss. This meant it was difficult to complete any sample size calculations. It was 
also not clear how easy it would be to complete a range of assessments within normal clinical 
practice. For these reasons it was felt that a pilot study would answer many of these questions 
and help frame a more accurate clinical question for a randomised control trial. 
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7.6 DAIL trial (Dietetic Assessment and Intervention in Lung cancer)  
7.6.1 Development of the DAIL trial 
The trial idea was developed in collaboration with specialist oncology dietitians at the Royal 
Surrey County Hospital. I presented the trial concept at 2 national oncology clinical trials 
meetings. Firstly at the National Cancer Research Institute (NCRI) and British Thoracic 
Oncology Group (BTOG) meeting Clinical trials day in 2016, then to gain patient input it was 
presented at the NCRI conference ‘Dragons Den’. The idea received support at these 
meetings. A small amount of funding was obtained in open competition from Chugai. The trial 
had a successful application to be entered to the National Institute for Health Research (NIHR) 
clinical trials portfolio.  
 
The final design was a cohort study of patients with incurable NSCLC (defined as stage IIIB or 
IV). Patients would have a single visit where they undergo a range of assessments. More detail 
can be found in appendix 3 which includes both the trial protocol and the Patient Information 
Sheet (PIS).  
 
7.6.2 DAIL trial methodology 
The aim of the DAIL (Dietetic Assessment and Intervention in Lung cancer) is to recruit 100 
patients according to the inclusion and exclusion criteria below, to complete a range of 
assessments of weight loss, malnutrition, cachexia and sarcopenia detailed in table 1.  
 
DAIL trial objectives and inclusion/exclusion criteria 
Primary Objectives 
 To identify the proportion of patients diagnosed with advanced Non-Small Cell Lung 
Cancer who are malnourished, cachectic and have sarcopenia before anti-cancer 
treatment. 
 To identify the proportion of lung cancer patients who would require dietetic review 
before anti-cancer treatment. 
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Secondary Objectives 
 To identify whether malnutrition, cachexia and sarcopenia affect overall survival in 
advanced NSCLC. 
 To identify whether sarcopenia predicts for a poor outcome in NSCLC 
 
Inclusion Criteria 
 Patients >18 years old who are able to consent to entry into a clinical trial 
 Biopsy confirmed Advanced Non Small Cell Lung Cancer (stage IIIb and IV). 
 Patient receiving first line anti-cancer treatment 
Exclusion Criteria 
 Patient declines anti-cancer treatment 
 Inability to consent to treatment 
The following assessments would be completed by each participant in the trial: 
 PG-SGA (malnutrition assessment) 
 Charlson Co-morbidity Index (assessment of other medical conditions that the patient 
has) 
 EORTC QLQ C30 core module and LC13 lung cancer module (comprehensive quality of 
life assessment) 
 ECOG performance Status (simple assessment of a patient’s activity level) 
 SPARC assessment (2nd comprehensive quality of life assessment) 
 Spirometry (respiratory function assessment) 
 Hand grip strength (physical function assessment) 
 Weight and BMI (based on standard weight and height measurements) 
 Routine blood tests (FBC, U+E, LFT) 
 Advanced analysis of patients standard diagnostic CT imaging.  
 
 
 
 
7.6.3 Initial analysis of the first 11 patients from the DAIL trial 
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This analysis is an initial analysis of the DAIL trial. It had 2 aims. Firstly to ensure that 
completing the assessments outlined in section 7.6.2 was practicable and did not raise any 
obvious concerns. It includes the first 11 patients included in the DAIL trial. As a result a lot of 
the statistics are descriptive in nature as it is difficult to draw conclusions on a small 
proportion of the total trial.  
 
All patients had all of the standard assessments, with the exception of 1 patient not 
completing hand grip strength. Patients did not obviously object to any of the paper based 
questionnaires or physical assessments. The co-investigators carrying out data collection felt 
that the assessments were completed in approximately 30 minutes and this was manageable. 
If the PG-SGA assessment indicated that the patient required dietetic review, this was 
completed after the trial assessments were complete. This increased the contact time with 
each patient to 45 minutes.  
 
1 of 11 patients required review by the dietitian. Imaging was available for all 11 patients. 
Mean age was 66.3 years (range 53-75 years). 5 patients (45%) were male and 6 (55%) were 
female. 8 of 11 (73%) were sarcopenic on their diagnostic imaging. 2 patients had a low BMI 
(defined as under 20.0) and both of those patients were sarcopenic. None of the patients felt 
they had lost a noteworthy amount of weight in the previous 6 months.  
 
7.6.3.1 Functional assessments 
It is difficult to generate conclusions from such a small cohort, however, some initial 
comparisons were made. Standardised psoas muscle surface area was compared to both 
hand grip strength (Pearons correlation co-efficient = 0.27, t-test sarcopenic vs non-
sarcopenic p=0.47) and FEV1 (correlation co-efficient =-0.55, t-test sarcopenic vs non-
sarcopenic p=0.41).  
 
7.6.3.2 Co-morbidities 
8 of 11 patients scored 0 in the Charlson Co-morbidity index, meaning that other than the 
NSCLC, patients do not have any co-morbidities. The index I used was used in a previous 
study I contributed to(Okonji et al., 2017). Of the 3 patients that identified co-morbidities, 2 
had both COPD and a non-lung malignant tumour, the other patient had diabetes. Of note 8 
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of 11 met the gold criteria for at least mild COPD (FEV1 <80% predicted), despite the fact 
that only 2 of the 11 reported they had COPD (Luize et al., 2014). Under-diagnosis of COPD 
fits with previously published data (Hill et al., 2010). In this study 1003 patients over 40 with 
more than a 20 pack year smoking history were screened for COPD with spirometry, defined 
as a FEV1/FVC ratio of <0.7 and an FEV1 of less than 80% predicted. 205 participants had 
COPD and only 67 (32%) of those with COPD were aware of their diagnosis.  
 
7.6.3.3 Assessing sarcopenia by measuring psoas muscle surface area standardized to 
height 
Aim: To see whether patients with advanced NSCLC were sarcopenic at diagnosis by 
assessing the surface area of the psoas muscle.  
 
Methods: This method had been previously used in assessing sarcopenia as described in 
section 7.4.2 (Jones et al., 2015, Tsukioka et al., 2017, Phillips et al., 2016). The anterior-
posterior and medial-lateral measurements were multiplied by each other and divided by 
the patients height. The result was then compared to the international definition 
established by Fearon et al, sarcopenia value for males was 55cm2 and for females 39cm2. 
 
Results: All 11 patients had suitable, available imaging in order to measure the dimensions 
of the psoas muscle. Psoas surface measurements ranged from 23.0cm2 to 72.3cm2. 8 
patients were sarcopenic, 3 were not.  
 
Discussion: This experiment showed that sarcopenia is prevalent in patients with advanced 
NSCLC before treatment starts. Further follow up within the DAIL trial will indicate whether 
it has the potential to be a useful biomarker.  
 
7.6.3.4 Texture analysis of the psoas muscle 
Aim: The aim of this preliminary analysis was to see if it was possible to differentiate 
between sarcopenic patients and non-sarcopenic patients using texture analysis rather than 
by measuring the standardized surface area of the muscle.  
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Methods: The psoas muscle was identified and a volume generated to include all of the 
psoas muscle from the superior to the inferior borders of the third lumbar vertebrae in 
Eclipse radiotherapy planning software. This scan was exported from eclipse into CERR 
(Computational Environment for Radiotherapy Research). Left and right psoas muscle 
regions of interest were segmented from the image in Matlab. The segmented region of 
interest underwent analysis using finiteRT, using the method identified in experiment 1 
chapter 4. The TA is a voxel by voxel comparison of the Region of Interest (ROI) by assessing 
the Grey Level Co-Occurrence Matrices (GLCM) of the 26 voxels around the voxel of interest.   
For each patient the left and right psoas were analysed as separate structures. 
 
From previous work highlighted in theme 1 and subsequently in theme 3, three types of 
analysis were to be carried out. Firstly to compare the mean, median and mode of density 
and entropy for each patient. Secondly to compare the appearance of the data plots for 
sarcopenic and non-sarcopenic patients. Thirdly to further interpret the data plots using a 
measure of density of the data points, in this case using kernel density estimation.  
 
Results: 9 patients had available imaging for assessment. 7 patients had the L3 vertebra 
imaged on a diagnostic CT scan and 2 had the imaging on the CT of an FDG PET-CT. Where 
possible the diagnostic CT was chosen in preference to the CT from the PET-CT as it would 
not be routine for patients with advanced NSCLC to have a FDG PET-CT scan.  
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Left psoas 
muscle         
Right psoas 
muscle     
 
    
 HU     
entrop
y     HU     
entro
py 
 
    
Pt no.  Mean median mode mean median mode mean median mode mean  median mode 
1 1051 1054 1058 4.023 4.03 2.776 1050 1053 1052 3.787  3.789 2.032 
2 1031 1036 1045 4.381 4.388 3.201 1034 1040 1051 4.307  4.313 2.622 
3 1037 1041 1042 4.387 4.399 1.558 1031 1035 1039 4.476  4.479 2.59 
4 1026 1031 1029 4.325 4.353 1.098 1017 1027 1033 4.063  4.122 1.039 
5 1033 1035 1035 4.231 4.246 3.256 1030 1034 1041 4.095  4.107 3.38 
6 1055 1061 1065 4.1 4.125 2.556 1059 1063 1067 4.233  4.256 1.135 
           
 
  
          
 
  
7 1013 1015 1019 4.598 4.609 3.935 1023 1024 1016 4.804  4.815 4.223 
8 1038 1043 1047 4.392 4.398 3.548 1039 1045 1046 4.255  4.24 3.526 
9 1043 1044 1047 3.94 3.905 3.06 1036 1038 1034 4.059  4.032 3.163 
           
 
  
T test 0.522 0.459 
0.507
8 0.763 0.846 0.041 0.614 0.477 0.218 0.451 
 
0.524 0.019 
 
Table 1: Textural analysis of a segment of left and right psoas muscle in sarcopenic and non-
sarcopenic patients. Patients 1-6 are sarcopenic, patients 7-9 are not sarcopenic. Entropy 
mode is statistically significant different between sarcopenic and non-sarcopenic patients 
with advanced NSCLC.  
Of these 9 patients, 3 were sarcopenic based on the surface area of the psoas muscle at the 
level of L3.  The results are presented in table 1.  
 
Discussion: Texture analysis on psoas muscle is possible. This analysis used individualised 
quantisation. In the analysis of each structure the LMQ was used to aid quantisation, 
meaning the absolute values of the quantisation levels are different. For uniform 
quantisation it is not clear whether it should be based on an analysis of non-sarcopenic 
patients with or without cancer, or from a PET-CT or diagnostic CT.  
 
It is interesting that the T-test comparing texture markers of sarcopenic and non-sarcopenic 
muscle reaches statistical significance, seen in table 1, however these results are purely for 
generating a hypothesis. It is essential that statistical tests are completed on the whole DAIL 
cohort. Table 1 shows that the values obtained from the left and right psoas muscle act as 
an internal control for the process and are broadly similar. This experiment aimed to see if 
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TA was feasible, rather than to identify specific outcomes with such a small cohort of 
patients. It will potentially be further tested when the DAIL trial has completed recruitment.  
 
7.7 Summary 
This work has shown that cachexia is common in patients with NSCLC and that sarcopenia is 
common at diagnosis in NSCLC. Sarcopenia was present on diagnostic imaging in 47% 
(irrespective of stage) in experiment 2 and in 73% of those with advanced (stage IIIb and IV) 
NSCLC in the early analysis of the DAIL trial(Phillips et al., 2016). The fact that all patients in 
the DAIL trial had incurable NSCLC is likely to account for the higher rate of sarcopenia. It will 
be important to see if sarcopenia is a marker of poor outcome in advanced NSCLC.  
 
The DAIL trial will continue to recruit and the aim is to produce a final analysis to assess the 
primary and secondary outcomes as detailed above.  
 
Weight loss is becoming more important in cancers. Dietetic intervention is established in 
cancers of the upper GI tract and primary head and neck cancers. Tools to assess whether a 
patient has malnutrition exist, such as the PG-SGA. This study will help to identify whether a 
PG-SGA should become part of the standard pre-treatment assessment of patients with 
advanced NSCLC.  
The presence of cachexia and sarcopenia is likely to become substantially more relevant with 
the development of novel therapeutic options. In the same way that growth factor stimulating 
medications and bisphosphonates have changed the way neutropenia and bone metastases 
are managed, the development of systemic therapies for cachexia is likely to change the 
landscape in terms of how we approach weight loss. Reversing cachexia and sarcopenia 
cannot be done by nutritional intervention alone.  
 
The trial published by Temel et al.  has shown that in patients with cachexia defined as more 
than 5% weight loss or BMI<20kg/m2 in patients with NSCLC, anemorelin can increase lean 
muscle mass in the short term, however it does not appear to improve handgrip strength 
(Temel et al., 2016). Anamorelin is a ghrelin analogue of the ghrelin ligand. It stimulates the 
ghrelin receptor, which stimulates appetite and has anabolic effects. It achieved this with 
minimal toxicity, in comparison with previously tested therapies including progestins such as 
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megestrol acetate. Megestrol improved appetite, but not weight and had a risk of significant 
side effects including oedema, thrombo-embolic events and an increased risk of death (Ruiz 
Garcia et al., 2013).  
 
The most striking feature of the sub-group analysis in the anamorelin trial is that the 
treatment caused statistically significant weight change in patients with a BMI above 18.5 
rather below 18.5, PS 0-1 rather than PS 2, in younger patients and in those who did not 
receive anti-cancer treatment in the form of chemotherapy or radiotherapy. This may suggest 
that intervening with anamorelin to treat cachexia may be most effective earlier in younger, 
fitter patients. Other new agents are also potentially available to treat cachexia, enobosarm 
is a non-steroidal selective androgen receptor modulator (SARM), which in phase 2 trials has 
shown increase in lean body mass and physical function, this is being tested in phase 3 clinical 
trials (Dobs et al., 2013, Crawford et al., 2016).  
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7.8 Future work 
As data for systemic therapies matures it is likely that biomarkers such as muscle surface area 
assessment or texture analysis of the muscle be used maybe able to triage patients with 
weight loss. Defining cachexia using weight loss from usual body weight is subjective and may 
be inaccurate. Defining weight loss by BMI is an insensitive assessment of weight loss as 
shown previously in this chapter. Both muscle surface area assessment and texture analysis 
require further testing, to see if these assessments may help identify suitable patients for 
systemic therapy for cachexia. It is not clear how closely sarcopenia and weight loss are and 
whether dietetic intervention may aid both conditions. The DAIL trial will attempt to establish 
to what degree those with sarcopenia overlap with those who have lost weight with NSCLC.  
It is also not clear how these conditions change during treatment.  
 
It is likely that new systemic therapies to treat cachexia, if efficacious, will mean that cachexia 
becomes more relevant, in terms  of routinely assessing a wider range of patients for cancer 
related weight loss. It is likely to change how oncologists perceive cachexia, as it becomes 
more treatable, in the same way that 5HT3 antagonists have affected chemotherapy induced 
nausea, or bisphosphonates have affected malignant bone disease.  
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Theme 3: Lung function and predicting fitness for radiotherapy from a CT scan 
Chapter 8: TEAL (TExtural Analysis and Lung function) study: Predicting lung fitness for 
radiotherapy from a CT scan.  
8.1 Background 
The third theme of this thesis is to explore a method used to differentiate between ‘fit’ and 
‘unfit’ patients receiving radical radiotherapy for a lung tumour, using data from a standard 
radiotherapy 4DCT scan of the lungs. This is a novel approach, which does not require extra 
data and uses standard images generated for radiotherapy planning.  
This chapter outlines the background, methodology and results of analysing a small cylinder 
of lung tissue and correlating it with lung fitness for radiotherapy. It shows that when 
comparing density and entropy scores for a cohort of fit and unfit patients, there are 
statistically significant differences. This means that TA could be used as a screening test for 
fitness for radiotherapy, it may help identify lung fitness in a resource limited setting  or a 
setting where accessing more complex lung function tests, such as gas transfer may be 
difficult. It could become part of a minimum data set of assessments of fitness, for example 
assessing lung function using the method below and assessing for sarcopenia through psoas 
muscle surface area assessment.  
CT scans are ubiquitous in managing patients with lung cancer. They are important in staging, 
radiotherapy planning and assessing treatment response. The major advantages of CT 
imaging are that it is accessible, relatively inexpensive, quick and there is a great deal of 
expertise in CT interpretation. CT imaging is quicker and often more tolerable than MRI and 
PET-CT. It delivers a smaller dose of radiation to the patient, when compared to a PET-CT scan 
and does not require normoglycaemia. A single CT scan may be the only imaging a patient 
with metastatic lung cancer would receive before starting treatment.  
Within the management of lung cancer, CT scans are commonly used in a relatively simple 
assessment of measuring tumour size or site, for staging or to determine a treatment 
response. A patient with lung cancer may have a large number of CT scans during the 
management of their disease. This imaging represents a pool of potential information that 
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could be extracted and interpreted, extracting extra data from imaging is termed radiomics. 
Textural Analysis (TA) is a subtype of radiomics, based on mathematical derivations rather 
than prior clinical concepts (Materka, 1998). TA uses a range of mathematically calculated 
features to describe an image or region of an image (often a tumour (Phillips et al., 2017)).  
The vast majority of TA used to assess images from patients with lung cancer has been used 
to assess malignant tissue, however CT data can used to assess normal tissue. For example 
cardiac CT is able to detect global left ventricular function and was able to assess cardiac wall 
motion abnormalities with a sensitivity of 90% and specificity of 97% (Kaniewska et al., 2017).  
The aim of this project was to see if more advanced analysis of the CT could separate those 
with adequate from those with inadequate lung function to receive radical radiotherapy. A 
previous study in correlating lung function with CT appearance, has shown that Forced 
Expiratory Volume in one second (FEV1) correlated with mean lung density (Moloney et al., 
2012).  To achieve this, the study required analysis of the whole lung. Other studies have been 
able to show that TLCO (transfer factor for the lung for carbon monoxide) and FEV1 were able 
to correlate with volume of emphysema (Sashidhar et al., 2002, Desai et al., 2007, Cerveri et 
al., 2004, Sanders et al., 1988, Gu et al., 2014). However, none have been used to assess 
fitness for radiotherapy.  
8.2 Assessing lung function 
Chronic Obstructive Pulmonary Disease (COPD) is common in patients with lung cancer, as 
both conditions are most commonly associated with smoking exposure (Gould et al., 2017). 
COPD is defined as airflow obstruction that is usually progressive, not fully reversible and does 
not improve significantly over several months. Patients with COPD are a vulnerable 
population, often with poorer social backgrounds and multiple co-morbidities (Li et al., 2015, 
Gadgeel and Kalemkerian, 2003, Gadgeel et al., 2001, Gould et al., 2017).  
Lung function tests measure many different respiratory parameters. Simple tests such as 
spirometry measure the volume of air that a patient is able to expel from their lungs after 
maximal inspiration. One of the markers used is the FEV1, which measures the volume of air 
expelled in the first second of forceful expiration. FEV1 cannot alone can be used to diagnose 
COPD using the GOLD criteria, it requires an FEV1/FVC or less than 70% and a clinical history 
to suggest COPD (Global and Disease, 2017). A predicted value is calculated standardised by 
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the patient’s height, age and gender. The value obtained by an individual is expressed as a 
percentage of the predicted value. The lower the % predicted value, the more severe the 
COPD (Luize et al., 2014).  
Spirometry is a simple bedside investigation, however more extensive lung function tests such 
as measuring gas transfer can give greater information. TLCO measures the diffusion of 
Carbon Monoxide between alveoli in the lung and blood. It is a marker of the ability of the 
lung to perform efficient gas exchange and provides a marker of lung fitness.  
The majority of available data correlating lung function with radical treatment outcome has 
been identified in surgical patients, rather than patients receiving radical radiotherapy. 
Previous studies have suggested that low FEV1 correlates with higher post-operative 
mortality, for example an FEV1 of below 40% predicts a higher mortality rate (16-50%). The 
mortality rate rises to 60% or greater if patients have a % predicted FEV1 of less than 30% 
(Brunelli et al., 2009).  
As well as a higher post-operative mortality rate, low TLCO has been associated with an 
increased risk of readmission to hospital and poorer quality of life (Brunelli et al., 2009). TLCO 
is an independent prognostic factor for long term survival after curative lung surgery (Liptay 
et al., 2009). As a result of this data, European guidelines suggest that TLCO should be 
routinely used to assess for pre-operative assessment of lung function.  
In contrast to surgical data, there is little evidence in relation to what level to set a threshold 
using lung function tests, to decide who is fit for radical radiotherapy. Most data relates to 
the design of the radiotherapy treatment, instead of whether or not to treat. Low oxygen 
tension, TLCO and FEV1 have been associated with increased toxicity and morbidity, in some, 
but not all studies (Brunelli et al., 2009). Factors that need to be taken into account are pre-
treatment lung function, size of the irradiated volume, radiotherapy technique, prescribed 
dose to the tumour, whether concurrent chemotherapy is given and the choice of appropriate 
markers of lung toxicity such as V20 (volume of normal lung receiving 20 Gray or more). All 
these factors could affect risk of short and long term toxicity and potentially mortality. The 
major established predictors of toxicity are treatment related rather than patient related. 
Using treatment markers such as V20 and mean dose received by the lung predict lung toxicity 
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in relation to population studies, but don’t take into account how individual patients might 
respond to the dose of radiotherapy (Marks et al., 2010).   
In this study we test the hypothesis that TA of the lung parenchyma in a standard radiotherapy 
planning CT scan correlates with lung fitness for radiotherapy, using a novel assessment of an 
apical segment of lung, by calculating a density and entropy score for each volume. 
8.3 Methods 
8.3.1 Patient selection 
Local ethics approval was gained for this study. Sequential patients who had a 4DCT 
radiotherapy planning scan with IV contrast and available lung function tests at a single 
institution were screened for the study.   This included patients who were to receive either 
fractionated radical radiotherapy or Stereotactic Ablative Body Radiotherapy (SABR). By 
including these patients it was thought it would include patients with a range of lung function, 
as many patients receive SABR because they are not medically fit for surgical resection of an 
early stage lung cancer.  
Patients were divided into those who were defined as ‘fit’ and those who were ‘not fit’ based 
on their lung function. For these patients, rather than actual values for FEV1 and TLCO, the % 
of predicted TLCO and FEV1 were standardised individually for gender, height and age. This 
means for each patient in the study a % predicted value was generated. As a result it was felt 
it was not necessary to collect individual data on height, age and gender as the predicted 
value took account of these variables. 
A fit patient was defined as a patient who had both a TLCO and FEV1 of 50% predicted or 
greater. Unfit patients had either TLCO or FEV1 below 50% predicted. Although there may be 
patients who would receive treatment below these thresholds, the reasons we chose these 
values was that it was felt all patients above these thresholds would receive radical treatment 
assuming they were otherwise fit with an appropriate performance status. To some degree 
these values were arbitrary, but it was important to identify an appropriate threshold. 
Patients were excluded if they had previous lung surgery or previous radiotherapy, or did not 
have both a TLCO and FEV1 % predicted available. 
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8.3.2 Data Extraction 
All patients had undergone the same scanning protocol for a standard 4DCT performed on a 
GE CT scanner (General Electric, California) scanner. The entire thorax was imaged and the 
scan was divided into 10 breathing phases. From this scan an Average Intensity Projection 
(AVIP) scan was generated. The AVIP image set was standardly used for planning. As a result 
it contained all of the planning data and radiotherapy structures and was used for this 
analysis. Identical regions of interest were generated on each CT scan using the Eclipse 
treatment planning system (Varian Medical Systems, Palo Alto, Ca.).  A volume of interest 
(VOI) measuring 4cm by 2.5cm was generated in the apex of the lung contralateral to the 
tumour. The VOI did not overlap with the PTV in any patient. A 4cm circle was used to draw 
the structure on 10 consecutive 2.5mm slices, ensuring that chest wall and rib was excluded 
superiorly and circumferentially, as well as the aortic arch being excluded inferiorly. Figure 1 
illustrates the lung volume generated.  
 
 Figure 1. An illustration of the lung volume identified for a patient within the TEAL study. 
Volume of interest was 4cm in diameter and 2.5cm long in as apical position as possible when 
not including chest wall or rib superiorly or aortic arch inferiorly.  
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The CT scan was then exported and anonymised within CERR (Computational Environment 
for Radiotherapy Research). The cylindrical structure was then extracted and analysed using 
finiteRT software developed in house, as a collaboration between the Royal Surrey County 
Hospital and the University of Surrey.  
The Hounsfield units were quantised into 16 levels and then each voxel in turn was compared 
to the 26 voxels around it using a Grey Level Co-occurrence Matrix. Each voxel was then 
assigned an entropy score based on how similar it was to the voxels around it. As previously 
discussed in chapter 4, standardising the quantisation levels allows structures from different 
patients to be compared, as it removes the error related to differences in quantisation. This 
analysis used uniform quantisation, standardised to a patient defined as fit, and had to meet 
3 criteria as the ‘gold standard patient’. These were to be a non-smoker, someone who could 
be defined as fit (FEV1 50% or above predicted value and TLCO 50% or above predicted value) 
and finally had a standard 4DCT that imaged the whole of their lungs. Only one patient 
obviously met these criteria and they were used as the gold standard comparison for all the 
analyses.  
8.3.3 Data analysis 
The initial analysis involved looking at the data plots used previously in analysing the whole 
lung. A density score based on the original CT scan was generated and plotted on the X axis, 
entropy score was plotted on the Y axis. Initial analysis of a small number of patients 
suggested that patients with poor lung function had a greater proportion of data points in the 
low density and low entropy region of the plot, when compared to analysis of a volume from 
a patient with better lung function. Figure 2 shows a typical ‘boomerang’ plot from a ‘fit’ 
patient with good lung function and an ‘unfit’ patient with poor lung function showing a 
‘bonfire in the wind’ plot.   
 
a) b) 
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Figure 2 shows a ‘boomerang shaped plot’ (plot a) of a fit patient and a ‘bonfire in the wind’ 
(plot b) of an unfit patient plot. Density is on x axis, entropy is on y axis.  
As one of the observed differences between fit and unfit patients was the distribution of data 
points in the low entropy, low density region of the plot, the first analysis only included points 
with a density of 200 or less. A second analysis included all data points with a density score 
of 400 or less and a third and final analysis was performed on  the whole volume. Mean, 
median and mode of both the density and entropy scores were generated for the 2 sub 
regions and the whole volume analysis. The patients were divided into fit and unfit and 
compared mean, median and mode density and entropy using a 2 sided unpaired t-test with 
a significance value of 0.05. 
8.4 Results 
Analysis  Density   Entropy   
  Mean Median  Mode Mean Median Mode 
Density 0-
200 
Fit 164.72 166.33 168 1.69 1.58 0.45 
 Unfit 134.57 133.97 135.88 1.21 1.05 0.12 
 P value 0.00034 0.00049 0.00872 0.01570 0.01528 0.12582 
        
Density 0-
400 
Fit 223.12 213.77 197.03 2.38 2.31 0.34 
 Unfit 172.61 160.72 146.66 1.84 1.67 0.10 
 P value 0.00089 0.00111 0.00471 0.03280 0.03240 0.08448 
        
Whole 
Volume 
Fit 252.05 224.69 199.03 2.51 2.43 0.33 
 Unfit 193.53 166.28 146.66 1.97 1.78 0.10 
 P value  0.00211 0.001888 0.00494 0.03574 0.03633 0.08663 
Table 2. P values of unpaired 2 tail T-test when comparing fit versus unfit patients.  
33 fit and 33 unfit patients were included in this analysis. In the lowest density assessment 
(0-200) 2 patients did not have any data points below 200, so were excluded from that part 
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of the analysis. The three analyses shown in table 2 show that mean, mode and median 
density, as well as mean and median entropy all have highly statistically significant p values.  
This suggests that these results are unlikely to be due to chance. The 2 patients not included 
in the analyses did not affect the overall results.  
 
 
Figure 3. Kernel density estimation plots of 3 patients with adequate lung function versus 3 
patients whose lung function would be inadequate for radical radiotherapy. It shows that the 
area of high probability (in yellow) is in a different part of the data plot in fit and unfit patients.  
Figure 3 shows kernel density estimation, which is another way of presenting the distributions 
of the data. It is discussed further in the future work section of this chapter.  
 
8.5 Discussion 
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This study has shown that it is possible to differentiate between patients who are fit for radical 
radiotherapy with good lung function from patients with poorer lung function from data from 
a CT scan. Comparing fit versus unfit patients using mean, median, mode density score and 
mean and median entropy score met statistical significance.  
The relationship between lung function and fitness for radiotherapy with density and entropy 
scores is potentially more complex than a correlation with one marker of lung function. It 
appears that TA helps explain this relationship, as correlations with FEV1 or TLCO individually 
were low, however separating patients into fit and unfit lead to highly significant p values.  
Using FEV1 or TLCO alone does not take account of this complexity and it is important to note 
individual lung function tests are not recommended to be used as a single value to assess 
patient fitness for radical anti-cancer treatment (Brunelli et al., 2009). 
The explanation for this finding in relation to density is likely to be related to the bullae seen 
in COPD. For patients with worse COPD, they will likely have poorer lung function and be more 
likely to be categorised into the unfit group. More severe COPD would manifest itself as 
greater destruction of the elastic lung tissue of the lung, which leads to the formation of 
‘holes’ in the lung known as bullae. These bullae would have a lower density than lung tissue, 
this data suggests that unfit patients are potentially more likely to have more bullae than fit 
patients, meaning a lower density score.  
In relation to entropy, it is not surprising that a higher entropy score is related to lung fitness. 
Entropy is a measure of disorder. The higher the entropy, the greater the disorder and 
inversely the lower the uniformity. A section of healthy peripheral lung tissue would contain 
a variety of tissues, including small airways, blood vessels and alveoli. It would be expected 
that a range of different densities would be seen in the section of healthy lung parenchyma, 
which had undergone analysis. The interaction of these different tissues means it is likely that 
a voxel has a different density to other voxels around it as they contain different tissue. This 
is likely to explain the reason that the mean entropy is consistently higher in patients with 
better lung function. Patients with a greater degree of COPD would be more likely to have 
more lung damage and potentially more bullae, which would appear as low density 
homogeneous areas in the texture map, meaning the voxels are more uniform i.e. would have 
lower entropy.  
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This study used one non smoker as the ‘gold standard’ patient. This then set the uniform 
quantisation levels. It is likely it is more important to have uniform quantisation, than the 
exact levels at which they are set, to allow inter-patient comparisons. As this data was 
generated from the AVIP of a 4DCT, only patients having radiotherapy were eligible for the 
study. If this work was repeated on diagnostic CTs, then a cohort of non-smokers could be 
used to define more generalizable quantisation levels.  
Part of the difficulty in integrating advanced analysis of CT images using textural analysis or 
other radiomic approaches is the interruption of a radiology department’s work flow (Phillips 
et al., 2017). This limits a lot of analyses as they are either time consuming or require review 
by a clinician with specialist knowledge before the completion of the analysis. A technique 
that analyses part of the lung rather than the whole lung is attractive in the interests of time. 
Using this technique, analysis of the whole lung would take several hours compared to less 
than 10 minutes for the analysis of a cylinder of lung. The analysis would be automated and 
it may be possible to automate the generation of the ROI, meaning the analysis does not 
requie a radiographer or radiologist to generate the analysis. Although less detailed than 
formal pulmonary function tests, this CT analysis is quick and its second major benefit is that 
it does not require any specialist expertise to identify/contour the region of interest. In this 
study the regions of interest were drawn by hand, but this process could easily be automated 
in the future. The speed of analysis and the lack of specialist knowledge needed to complete 
the analysis means it could easily be incorporated into the standard radiology work flow, 
before the scan is reviewed by a radiologist for formal reporting. 
CT scans are ubiquitous in the management of many common cancers. Toxicities can be 
difficult to predict. At present there is no straight forward tool to model or predict the effects 
of SABR on lung function.  
If this technique could be used to differentiate fit and unfit patients for radical radiotherapy, 
it could also be used to screen patients to assess their lung function. From a single CT scan it 
may be possible to obtain a marker of cardio-pulmonary function. Gaining greater 
information regarding lung function may also help to develop understand lung injury after 
radiotherapy. There is not a current effective tool to predict the effects of radiotherapy on 
lung parenchyma. This work in chapter 8 is hypothesis generating. To achieve these aims 
outlined above, it would need to be re-confirmed on a larger cohort of patients. The potential 
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to generate a cardiac assessment from CT data would need to be repeated and assessment 
of cardio-resipiratory function has not yet been attempted on the same cohort of patients.   
This work on lung function has helped to inform the experimental work described in theme 
1. In theme 1 the whole lung was analysed and volumed. By understanding the appearance 
of the data plot in patients with good or poor lung function this has the potential to help 
understand the likely lung function of patients whose whole lung has been analysed using 
finiteRT.  
8.6 Future work 
The next step would be to perform a prospective study and to further understand the 
relationship between image texture and lung function. The likelihood that in this experiment 
differentiating between fit and unfit patients is due to chance is low, which is illustrated by 
the low p values identified in section 8.4. However, the correlation coefficients between 
individual parameters such as FEV1 or TLCO with the results of TA (either density or entropy) 
are low. This means the relationship is more complex. The data in this work shows that the 
region of interest has lower density and entropy in those who are unfit, when compared to 
the values from fit patients. More advanced techniques need to be investigated to help 
differentiate between the two cohorts. Two options to help further classify this data are the 
use of kernel density estimation to assess the density of data points and a moment analysis 
to use a series of statistical assessments to help differentiate between the 2 groups.  
Figure 2 shows a 2D plot of density vs entropy, but does not take account of the density of 
the data points. Figure 3 shows 6 data plots, which plot density on the x axis and entropy on 
the y axis. A third metric is used called the kernel density estimation. This shows where there 
is an increased density of data points. In kernel density estimation the density of data points 
calculates the probability of a data point being in a certain region. The probability is higher in 
a region where there is a greater density of data points, compared to a region with a lower 
density of data points.  
This approach is not limited to lung function and is being expanded in a prospective trial to 
look at muscle function and muscle bulk in patients with metastatic lung cancer (as described 
in theme 2). There is established data in predicting cardiac function from CT (Rahaghi et al., 
2017). Potentially these techniques could be combined to achieve two aims. Firstly to more 
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accurately define treatment risk and fitness for treatment. Secondly they could form part of 
a screening assessment of patient fitness. It is possible that a simple staging investigation 
could predict or screen for cardiac function, lung function and muscle bulk assessment. This 
could then predict clinical outcome and treatment toxicity.  
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Chapter 9: Conclusion  
9.1 Summary 
As part of the work presented in this thesis I set up 2 clinical trials. The first was the DAIL 
(Dietetic Assessment and Intervention in Lung cancer) trial, a prospective cohort study 
investigating cancer related weight loss in advanced lung cancer. The second was the TEXAS 
(TEXtural Analysis after Stereotactic radiotherapy) trial investigating whether it was possible 
to differentiate between early tumour recurrence and radiation induced lung injury after 
Stereotactic radiotherapy to a primary lung tumour. These trials helped to answer 4 novel 
research questions set out in the introduction in chapter 1. In summary these were answered 
as followed: 
1. A robust methodology was generated, which meant an entire lung could be 
segmented from a CT scan and analysed. This analysis produced the ‘elephant plot’. 
The elephant plot was an effective tool to detect the presence of tumour in a lung.  
2. Initial work from the TEXAS trial has shown that by analysing a sub-region of the 
elephant plot, it is possible to distinguish between early tumour recurrence and 
radiation induced lung injury after SABR to a primary lung tumour. 
3. The TEAL sub-study showed that using texture analysis meant CT data could be used 
to distinguish between patients who are fit or unfit for radical radiotherapy  
4. Early results from the DAIL trial have shown that it has been possible to recruit patients 
and complete the appropriate assessments for malnutrition, sarcopenia and cachexia. 
Texture analysis has the potential to differentiate between sarcopenic and non-
sarcopenic muscle.  
Advanced image analysis can generate more information from a standard CT scan, than 
simple oncological staging. In the work presented in this thesis it has been shown that image 
analysis in the form of Textural Analysis (TA)can differentiate between tumour and radiation 
induced lung injury (RILI) after SABR (Stereotactic Ablative Body Radiotherapy), as well as 
having a role in the analysis of non-malignant tissue. It has established statistically significant 
differences between sarcopenic and non- sarcopenic patients and patients who are fit for 
radiotherapy and those who are not, based on two markers of lung function. These 
approaches are exciting and novel approaches to the use of CT data in patients with cancer. 
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For TA to become useful in a real time clinical environment the process of ROI identification 
and analysis needs to be as uncomplicated as possible. One way of simplifying this is to use 
an ROI that is straight forward to draw, does not require specialist knowledge, is reproducible 
and could potentially be automated. As this project developed it became clear that TA would 
be most useful if the ROI could be easily reproducible, as whilst still able to establish 
differences between 2 groups of patients,  e.g. for lung function, those fit and not fit for 
radiotherapy. By maintaining its simplicity, this means that a ROI has the potential to be either 
generated by a radiographer at the time of image acquisition, or automatically generated and 
confirmed by a radiographer on completion of the scan. The aim being that a radiologist could 
interpret the TA at the same time that they formally report the CT scan. This means that a 
radiologist would not need to interact with the analysis before it has been completed. By 
comparison other previously published analyses have required specialist knowledge to 
identify the specific ROI (Mattonen et al., 2013, Mattonen et al., 2014). Requiring specialist 
knowledge at multiple time points makes integrating TA techniques into a radiology 
department and standard work flow more complex. Ideally if TA can present complete data 
at the first time a radiologist reviews the images, this causes minimal interruption to the work 
flow. 
 
Generating the analysis for lung function and muscle takes a few minutes. Generating the TA 
for the whole lung can take several hours, but this could be done overnight, before the scan 
is formally reported and would not disrupt standard reporting of images.  As the TA would be 
performed on standard staging scans, rather than emergency imaging such as a CTPA 
(Computer Tomography Pulmonary Angiogram) the time taken for analysis could still be 
incorporated without disruption. 
 
9.2 Developing the current models 
9.2.1 Theme 1: Identifying recurrence after Stereotactic Ablative Body Radiotherapy 
The methodology generated for the experimental work discussed in chapters 4-6 shows that 
TA has the potential to differentiate between tumour and post treatment radiation induced 
lung injury (RILI) after SABR. This methodology needs expanding to a larger data set. Figure 1 
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shows plots of the tips of the elephant trunk for patient 8 and patient 20 (figure 1 a and b). 
Figure 1c) shows the same patient who recurred 6 months later, compared to 1d) when the 
patient did not recur The 2 plots are very different, figure 1d) shows very few data points, 
where as there are a lot of data points in the plot illustrated in figure 1c).  It is likely that 
further assessment of the tip of the elephant trunk could differentiate between tumour and 
RILI. Possible further analysis could include kernel density estimation or an analysis of the 
spatial relationship of the data points within the tip of the elephant trunk.  
 
Figure 1: Analysis of the tip of the elephant trunk for 2 patients before and after treatment, 
patient 8 who did not recur compared to patient  20 who recurred after SABR.  
Kernel density estimation is a measure of probability of where a data point will appear, the 
probability rises in areas where there are more data points. It is possible there could be a 
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difference in the density of distribution of data points between RILI and recurrence. The data 
points in the tip of the trunk of the elephant plot are likely to be spread more diffusely when 
they represent RILI, whereas data points related to tumour are likely to be clustered together 
in space. Both these techniques potentially give a third dimension to the elephant plot.  
Analysing the whole lung means that different regions of the lung could be compared to each 
other, it has the potential to quantify RILI after SABR and could provide a model for helping 
to predict or track the degree of RILI after SABR.  
 
9.2.2 Theme 2: Assessing weight loss in lung cancer 
Sarcopenia and muscle TA are being assessed prospectively in the DAIL trial. This will tell us 
whether both methods have the potential to act as a biomarker for outcome. New therapies 
are emerging for the treatment of cachexia, specifically anamorelin (Temel et al., 2016). The 
major clinical trials that assessed anamorelin did not take sarcopenia into account as part of 
the definition of cachexia. It defined cachexia as low BMI or greater than 5% weight loss. None 
of the 11 patients analysed in the DAIL trial, as the initial cohort, had lost this amount of 
weight, but 8 of 11 were sarcopenic, suggesting sarcopenia is an early phenomenon and 
develops before the patient has lost weight, or notices they have lost weight. Weight loss in 
the DAIL study has been self-reported. From previous observational data, 75% of patients had 
significant weight loss (defined as >5%) at the time the patient first saw the dietitian (Hug, 
2017). In combination this data suggests that weight loss in a population who are fit for 
treatment, is a late, rather than early phenomenon. In contrast sarcopenia is an early 
phenomenon and has been associated with poorer outcome in Non-Small Cell Lung Cancer 
(Phillips et al., 2016). 
 
In the DAIL trial protocol overall survival will be assessed at 6 and 12 months. The patients 
who are non-sarcopenic and sarcopenic, as well as cachectic or not can be compared to see 
if sarcopenia or cachexia is a biomarker for overall survival.  
 
9.2.3 Theme 3: Assessing lung function from a CT scan 
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Data generated for this study from the radiotherapy planning scan needs repeating on 
diagnostic CT scans, ideally in a prospective study. It also needs further analysis in terms of 
defining entropy and density values which are likely to indicate poor lung function. A larger 
data set is likely to give more accuracy in terms of calculating the sensitivity and specificity of 
this test. Further analysis such as with Kernel Density Estimation as described may also help 
to improve the sensitivity and specificity. 
 
Establishing lung function from CT imaging is a novel intervention. Although it would be 
unlikely to replace formal lung function testing, it would provide a useful screening test at an 
earlier time point. As discussed in more detail below, it could form part of a fitness assessment 
based on a CT scan.  
9.3 Incorporating TA into clinical practice  
9.3.1 Understanding treatment delays in lung cancer 
It is possible to get more data from a CT scan, with existing standard imaging. This could 
potentially mean that treatment decisions could be made more quickly, shortening the time 
from presentation with NSCLC to starting treatment. 
Assessing ability to shorten time from presentation to starting treatment and the effects on 
outcome in NSCLC is a complex relationship between a range of variables. NSCLC often 
presents late as it may have minimal symptoms in the early stages of the disease. In terms of 
delays associated with time to treatment in NSCLC, the majority of studies have found that 
quicker treatment is associated with poorer survival. Three studies have shown that those 
with a shorter treatment delay were associated with a poorer survival, factors associated with 
quicker treatment included more advanced stage of cancer, in older patients with poorer 
general health, suggesting those who are more unwell receive more prompt treatment 
(Gonzalez-Barcala et al., 2014, Myrdal et al., 2004, Diaconescu et al., 2011). Another study 
found that patients who were treated with palliative intent had shorter times from first 
symptom to first abnormal test and from first symptom to pathological diagnosis of NSCLC 
(Wai et al., 2012). The use of PET-CT has been shown to increase the proportion of patients 
who received delays in diagnosis to treatment in NSCLC, as an additional test is required 
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(Gomez et al., 2015). It is perhaps unsurprising that patients being considered for radical 
treatment take longer to start treatment. This may be in part because they have to undergo 
extra investigations compared to those being considered for palliative treatment. Patients 
with metastatic NSCLC would undergo a biopsy and a staging CT scan. Those being considered 
for radical treatment may require a more invasive biopsy, as well as formal lung function 
testing, PET-CT imaging and pre surgical anaesthetic risk assessment. Inevitably the need for 
more investigations can delay treatment. Interestingly surgical data suggests that patients 
with stage I and II NSCLC had a significantly shorter time from first symptom to surgery 
(p=0.037) and first contact with healthcare to surgery (p=0.017), when compared to patients 
with stage III and IV NSCLC (Christensen et al., 1997). Potential delays have been found to 
affect treatment effectiveness in other types of cancer, specifically in treating breast cancer 
(Gagliato et al., 2014, Bleicher et al., 2016, Chavez-MacGregor et al., 2016). Fewer delays and 
attending for fewer tests, as well as more efficient treatment delivery is likely to benefit 
patients in terms of less anxiety and attending the hospital on fewer occasions.  
 
9.3.2 A minimum data set, incorporating organ function assessment into TA analysis of a 
single CT scan  
Gaining more information from existing imaging has 3 potential advantages: firstly it may be 
cost effective in screening for poor organ function and could prevent the use of more detailed 
tests; secondly it may provide more comprehensive information about an individual that 
could contribute to a patient fitness assessment in terms of suitability for anti-cancer 
treatment; third and finally it means clinical decisions could potentially be made more quickly 
as a CT scan is usually one of the first investigations a patient with suspected lung cancer 
undergoes.  
In this thesis it has been shown that assessing a small region of interest within the lung 
generates the hypothesis, it may be possible to differentiate between good and poor 
respiratory function on a CT scan. Recent published data suggests it is possible to extrapolate 
cardiac function from non-contrast CT data (Rahaghi et al., 2017). In current UK practice, all 
NSCLC patients being considered for radical treatment undergo a PET-CT scan. This means 
non-contrast CT imaging would be available for this cohort. From pre-treatment imaging it 
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would be possible to identify cardiac function, lung function and a sarcopenia assessment. At 
present this information requires multiple investigations for cardiac and respiratory 
assessment, a sarcopenia assessment is not standardly used in clinical practice. It may be 
possible to assess other organ function from standard imaging with further work. There is 
published data on MRI TA predicting renal function (Kline et al., 2017) and on investigating 
kidney function using CT TA in a murine model (Gleason et al., 2002). TA has been used to 
assess liver haemodynamics, in a small cohort of patients. Differences could be identified on 
apparently normal imaging, which predicted survival (Ganeshan et al., 2007). It is likely that 
this forms a screening assessment, rather than a definitive assessment of organ function, 
however it could also be used to generate a risk score for radical and palliative treatment.  
 
9.3.3 Using existing imaging data to deliver more efficient decision making in Multi-
Disciplinary Team Meetings 
In England all patients with a diagnosis of cancer must be discussed at a site-specific multi-
disciplinary team (MDT) meeting (tumour board). Each MDT will have core members essential 
for the treatment of that cancer. Core members of a lung MDT are likely to include respiratory 
physicians, thoracic surgeons, radiologists, pathologist, oncologists and clinical nurse 
specialists. In these meetings vital investigation results are reviewed and treatment decisions 
are made. These meetings often happen weekly, so if an investigation is not ready for one 
meeting, waiting for the next meeting immediately adds a delay to deciding on the 
management plan for a patient.  
In some cancers such as breast cancer, it is standard practice that pathology reports are 
reported using a proforma, which forms a minimum number of pieces of information, for 
example the size of a tumour, its oestrogen receptor status or HER2 receptor status. It has 
been shown that a standard proforma to collect data on histology of tumours causing early 
breast cancer significantly improved the completeness of histo-pathology reports (Mathers 
et al., 2001, Srigley et al., 2009). This meant that the data needed to make clinical decisions 
was more complete clinicians can make appropriate treatment decisions more quickly. This 
improves a patient’s care as definitive management decisions can be made more quickly and 
this may potentially improve outcome. From the work described in this thesis, this principle 
could be extended to markers of function on fitness in a standard CT imaging. Much of the 
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published data on TA has been predicting outcome based on tumour assessment (Phillips et 
al., 2017). This could also be added to a minimum dataset, giving a more complete picture of 
tumour assessment and patient fitness.  
A minimum data set for CT image reporting does not currently exist. Some guidelines exist for 
CT screening. These guidelines define follow up or investigation of lung lesions identified 
during screening for lung cancer, based on the risk of malignancy of the lesion. There are 6 
levels, level 1 means no lesions are seen, whereas level 5 are frankly malignant lesions and 
level 6 lesions are biopsy proven cancer. By defining the level the lesion falls into this provides 
an appropriate follow up schedule (Manos et al., 2014).  Something similar could be done 
using TA to assess patient fitness from a CT scan. As previously described it is possible to 
extract lung function, muscle bulk and cardiac function from CT imaging. The DAIL trial will 
help to establish whether sarcopenia correlates with poorer outcome, as well as whether 
there is an association between muscle bulk, nutritional status, lung function and hand grip 
strength in advanced NSCLC.  
9.4 Future work: Identifying SABR recurrence 
The data presented in chapter 2 shows that at present approximately 10% of patients with 
stage 1 NSCLC receive SABR. However, a third of patients did not receive a documented timely 
treatment. Previous Dutch data has shown that as the proportion of non-surgical patients 
receiving SABR increases, the overall survival as a whole increases (Palma et al., 2010). 
As the rate of lung cancer in older patients increases, the use of SABR is likely to increase. Its 
use is also likely to increase in the treatment of oligometastatic cancer. It has shown benefit 
in oligometastatic lung cancer and randomised trials are under way in other tumour sites such 
as breast cancer and prostate cancer (Gomez et al., 2016).  
Patients undergoing SABR for metastatic disease are likely to be younger and fitter than those 
receiving SABR for primary lung cancer. This makes overcoming the difficulties in interpreting 
post treatment imaging more important, particularly in determining recurrence.  
The TA identified in theme 1 of this thesis requires a bigger data set to help understand the 
post treatment effects of SABR on the lung and to identify recurrence. But it does show that 
TA has the potential to generate significantly more data from standard imaging than is 
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currently extracted. It also suggests that functional data can be generated from a standard CT 
scan. This could potentially have a significant impact on stratifying risk and identifying 
recurrence in patients with lung cancer.  
 
9.5 A grand vision of the future of texture analysis in improving care for patients with lung 
cancer 
This thesis has illustrated that TA can be applied to imaging at 3 major time points in the 
management of patients with lung cancer. These are diagnosis, treatment and response 
assessment. These principles are illustrated in figure 2. Previous published studies have 
suggested TA can be applied to a diagnostic scan to provide a greater certainty of a diagnosis 
of lung cancer and give information on possible tissue type of the tumour. This thesis has 
established that a screening patient fitness assessment is possible. It is known that patients 
with lung cancer have multiple co-morbidities. Functional data generated from these scans 
could then stimulate earlier referrals to respiratory physicians, cardiologists and allied health 
care professionals such as dietitians and physiotherapists. This may then allow for 
prehabilitation while a patient is undergoing diagnostic tests, which can improve functional 
outcome, cardio-pulmonary fitness and health related quality of life in patients undergoing 
oncological surgery (Hijazi et al., 2017).  
 
Figure 2: Potential role of TA in managing patients with lung cancer.  
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TA could provide radiological biomarkers to predict response to radiotherapy or systemic 
treatment. It could also help prognosticate outcome. As shown in this thesis TA could improve 
the assessment of treatment response. By understanding radiotherapy reactions after SABR, 
it could be the first step in building a model to understand and predict respiratory outcome 
after radical radiotherapy. As imaging becomes more integral to delivering anti-cancer 
therapy, particularly in planning and delivering radiotherapy, the quantity of imaging data and 
potential to extract increasing amounts of additional data is likely to increase significantly in 
the next few years.  
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AbstrAct
Lung cancer is the leading cause of cancer mortality worldwide. Treatment pathways include regular cross-sectional 
imaging, generating large data sets which present intriguing possibilities for exploitation beyond standard visual inter-
pretation. This additional data mining has been termed “radiomics” and includes semantic and agnostic approaches. 
Textural analysis (TA) is an example of the latter, and uses a range of mathematically derived features to describe an 
image or region of an image. Often TA is used to describe a suspected or known tumour. TA is an attractive tool as 
large existing image sets can be submitted to diverse techniques for data processing, presentation, interpretation and 
hypothesis testing with annotated clinical outcomes. There is a growing anthology of published data using different TA 
techniques to differentiate between benign and malignant lung nodules, differentiate tissue subtypes of lung cancer, 
prognosticate and predict outcome and treatment response, as well as predict treatment side effects and potentially 
aid radiotherapy planning. The aim of this systematic review is to summarize the current published data and understand 
the potential future role of TA in managing lung cancer.
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introduction
Lung cancer is the second commonest cancer diagnosed in 
the UK after prostate cancer in males and breast cancer in 
females. It has a very poor prognosis.1,2 Patients undergo 
regular cross-section imaging to diagnose, stage, assess 
response and undertake surveillance after treatment for 
lung cancer, which leads to a pool of imaging data that 
potentially has significant value beyond accurate staging of 
the patient. CT is a central tool in managing lung cancer. It is 
relatively inexpensive, quick and widely available. [18F]−2-
fluoro-2-deoxy-D-glucose positron emission tomography/
computed tomography (FDG PET-CT) superposes a func-
tional assessment of tumour metabolism. It can greatly aid 
in, e.g. the identification of malignant lung nodules with a 
sensitivity of 95% and specificity of 82%,3 but is less widely 
available and considerably more expensive. Value-based 
care provides incentives to maximize information from 
standard investigations. Radiomics aims to extract and 
analyse large amounts of advanced quantitative data from 
medical imaging.4 Textural analysis (TA) is a subtype of 
radiomics, an example of an agnostic, rather than semantic, 
approach within this field, based on mathematical deriva-
tions rather than prior clinical concepts.5
TA can be used on existing data sets with no further 
dedicated or specialist imaging required. A considerable 
body of literature has accumulated in this field. TA has 
the potential to differentiate between benign and malig-
nant lung nodules6–15 prognosticate outcome,16–28 aid 
improved radiotherapy planning,29 predicting radiotherapy 
side effects30 and give a greater understanding of response 
assessment.31–40 The aim of this review is to explain how 
different TA methods have been investigated in non-small 
cell lung cancer (NSCLC), and to describe their current 
applicability and future potential.41
Methods And MAteriAls
PubMed, Medline and Web of Science were searched 
using the search terms “textural analysis”, “texture anal-
ysis” and “radiomics” with MeSH terms “lung neoplasms”, 
“non-small cell lung cancer” and “small cell lung cancer”. 
The search period was January 2010 to December 2016. 
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Table 1. Categories of textural analysis. Adapted from Alobaidli et al48
Feature Name of feature Definition
First-order Mean Average intensity of values of an image
Variance Spread or variation around the mean
Skewness Symmetry of intensity values in an image. Skewness = 0 if 
histogram is symmetrical
Kurtosis Indication of histogram flatness, Leptokurtic curves are steeper 
and platykurtic curves are flatter/less peaked
Energy Uniformity of intensity values
Second-order local Contrast Measures amount of local variation in intensity values
Angular second moment (energy or uniformity) Measures homogeneity of intensity value distribution in an image
Homogeneity (inverse difference moment) Measures the homogeneity of the intensity values of the pixel pair
Correlation Measures the linear dependencies of intensity values in an image
Entropy Measure of randomness of intensity values in an image
Sum of first-order features (squares, average, entropy, 
variance)
Higher-order (local) Complexity Measures amount of information in texture
Busyness Measures the rate of change in intensity values
Contrast Measures the variation of intensity values in an image
Coarseness Measures the density of edges in an image
Texture Strength Measures how definable (distinguishable) primitive texture is
High-order (regional) Grey-level non-uniformity: Represents the similarity of intensity values in an image
Run length non-uniformity: Measures the run length similarity
Run percentage Ratio of total number of runs to the total number of possible 
runs, measuring the homogeneity of runs. For images with most 
linear structure, the value of run percentage is lowest.
341 papers were identified, which were filtered using the terms 
oncology and English. Papers discussing other primary cancers 
and duplicates were excluded. This left 104 papers.
What is textural analysis (TA)?
TA uses a range of mathematically calculated features to 
describe an image or region of an image. Often TA is used to 
describe a suspected or known tumour. The complexity of the 
analysis depends on the feature being described. Although 
different textural features have been generated from a wide 
range of sources, they can be broadly divided into three catego-
ries: first-order (least complex), second-order and higher-order 
(most complex). Different subcategories of TA are summarized 
in Table  1. First-order features are often calculated as a single 
figure describing the texture of the whole volume being anal-
ysed. Second-order features describe the relationship between 
two points, such as two pixels or voxels within the same image. 
Higher-order features describe the relationship between a pixel 
and more than one other pixel, i.e. a minimum of three points 
in space.
First-order textural features use a range of basic statistical 
methods to express a single measure, including: energy, kurtosis, 
maximum and minimum intensity, average intensity (median 
and mean), range of intensities, skewness, SD, uniformity, 
entropy (irregularity of intensity value distribution) and vari-
ance. SD, variance and mean absolute deviation express how 
the range of intensities are distributed. Skewness measures how 
much histogram asymmetry there is around the mean. Kurtosis 
measures the sharpness of the histogram. Randomness can be 
computed using uniformity and entropy. Entropy is a measure 
of disorder. The higher the entropy the greater the disorder or 
heterogeneity. The lower the entropy, the higher the homo-
geneity. First-order features do not take account of any spatial 
relationship between different points in an image. Much of the 
published TA work, particularly related to lung nodules focuses 
on first-order features of TA.42–47
Second-order textural features describe a relationship between 
two points within the same region of interest. It can describe the 
three-dimensional size and shape and a range of values within a 
tumour. By deriving a region of interest, measurements can be 
taken of variations across the tumour volume, including entropy, 
compactness, sphericity, surface area and surface to volume 
ratio. Describing higher-order textural features is more complex 
than first- or second-order features, as it involves identifying the 
relationship between 3 or more points.
TA often requires complex interpretation. It is common to 
compare clinical interpretation with clinical interpretation 
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combined with TA. The impact of TA can be assessed by various 
tools including receiver operating characteristic area under the 
curve (ROC-AUC) and concordance index (CI). ROC-AUC is 
an explanation of the “usefulness” of a test assessing sensitivity 
and specificity, assuming a test can be defined in a binary way, 
i.e. “positive” or “negative”. ROC-AUC gives a test four outcomes: 
true negative, true positive, false negative and false positive. The 
ROC-AUC analyses the true positive rate against the false posi-
tive rate, deriving values between 0.5 and 1.0. 0.5 shows a poor 
test as true positives = false positives, 1 is a perfect test with no 
false positives. Generally 0.6–0.7 = poor test, 0.7–0.8 = a fair 
test, 0.8–0.9 = a good test,  >0.9  = an excellent test. A second 
measure is CI, which measures how well a prognostic test distin-
guishes individuals from a population with or without a partic-
ular outcome. Values range from 0.5 (no discrimination) to 1.0 
(perfect discrimination).49 To be significant, a CI measurement 
should exclude 0.5 from its confidence interval.
Pre-treatment textural analysis (TA)
A wide range of studies have used TA to attempt to define 
different aspects of lung lesions seen on pre-treatment imaging. 
TA has been used to differentiate benign or minimally invasive 
lesions from malignant tissue (particularly lung nodules) using 
CT,6,8–10,12–15,50,51 FDG PET-CT52 ultrasound53 and different 
types of tumour histology,54–56 to aid assessment of the tumour 
and aid treatment decisions. These features can be combined to 
predict the likelihood of a nodule being malignant.
TA has also been employed to help classify histological images. 
An automatic classifier of squamous cell and adenocarcinoma 
helped aid tissue classification57 and TA of nucleus features has 
been shown to predict early recurrence of NSCLC.58
Lung nodules
TA has been used to differentiate between different tissues and 
determine the risk of malignancy of small pulmonary nodules. 
Pulmonary nodules are focal opacities appearing on imaging that 
are defined as less than 3 cm in axial diameter; they can be solid, 
semi-solid or non-solid in appearance.59 CT density [measured 
in Hounsfield units (HU)] and morphology can be used to assess 
pulmonary nodules. Solid cancer, non-solid lepidic adenocar-
cinoma, blood and inactive fibrous tissue all have different HU 
measurements.60 However, it is still difficult to predict with 
certainty the pathology of small lung lesions, because up to 39% 
of lung nodules with a benign CT morphological appearance can 
be malignant.61
As the use of medical imaging increases, more lung nodules are 
likely to be identified. Lung cancer screening using low-dose CT 
has a relative risk reduction of 20% for lung cancer specific survival, 
when compared with chest radiography in a high risk popula-
tion. In each of the 3 years of screening, identification of a nodule 
occurred in 27.3%, 27.9% and 16.8% of the trial population in years 
1–3, respectively. Individuals in whom a nodule was identified in 
years 1 and 2 were not automatically excluded from continuing with 
screening, but more than 95% of these nodules would be benign.62 
TA may aid risk stratification of these lung nodules. This has signif-
icant potential to improve the predictivity of screening and reduce 
the morbidities rendered by biopsy and surgical resection
As stated, lung nodules can be broadly divided into solid, semi-
solid and non-solid. Several studies have aimed to help classify 
lung nodules into broad categories before further analysis.43,63 
Ground glass nodules (GGNs) are non-solid and can be difficult 
to extract from an image accurately.44,64 Three studies suggest 
TA can convincingly determine malignant from non-malignant 
nodules. The first study capitalized on potential differences in 
heterogeneity between the nodule edge and centre. The differ-
ence was much greater in malignant nodules when compared 
with inflammatory nodules with ROC-AUC of 0.836.65 In a 
second study, computer-aided diagnosis of whether a lesion 
was benign or malignant achieved 94% accuracy in correctly 
identifying all non-cancerous lesions as benign using a single 
image slice.66 These results were achieved using all slices of the 
abnormal lesion.47
In a cohort of 55 patients, CT TA improved specificity from 38.5 to 
100% when compared with a FDG PET-CT-CT in differentiating 
primary lung tumours from granulomatous lung lesions.46 Sensi-
tivity was similar in both groups (75% using five TA features  vs 
79 with FDG PET-CT %). High entropy (high level of disorder) 
was more common in primary NSCLCs. Interestingly in this 
study, using a combination of three textural features generated 
from a contrast-enhanced CT scan rather than a non-contrast CT 
scan reduced the sensitivity from 88 to 38%. The reason for this is 
not clear, but the presence of contrast may obscure the texture of 
the region of interest. Contrast could potentially act as a marker 
of vascularity, but as this study suggests, it could obscure textural 
information. The effect of contrast is not necessarily binary, as 
the results using contrast could depend on contrast-related 
factors such as speed of infusion, contrast agent used, amount 
of infusion given; image-related factors such as delay between 
contrast and image acquisition and patient-related factors such 
as cardiac output and body habitus. These factors may require 
standardization so that they do not unduly influence the TA.
GGNs have a higher malignant probability than solid nodules, 
while a combination of GGN and solid nodule have an even 
higher malignant potential (62.5–89.6%),67 although at least 
half (49–70%) of these partial solid ground glass nodules disap-
pear within 3 months. Analysis was performed aiming to iden-
tify textural features that may predict persistent  vs  transient 
partial solid ground glass nodules. When textural features were 
combined with clinical and CT features, differentiating perfor-
mance significantly increased from 79 to 92.9% (p < 0.05). 
As with the previous study, Wang et al68  showed that TA can 
improve diagnostic certainty. In contrast to the previous study, 
this study analysed the whole tumour, instead of a single image 
slice. This technique improved sensitivity and specificity from 
0.82 and 0.47 to 0.95 and 0.71, respectively.68 3D TA has also 
been used to differentiate between pre malignant adenocarci-
nomas and early invasive adenocarcinomas.56 It is not currently 
clear how large a region of interest needs to be analysed. There 
are three possible approaches, 2D analysis of a single slice, 2D 
analysis of multiple slices or 3D analysis of the whole region of 
interest. If a single slice is being used, then often this is the largest 
slice, but cross-sectional area does not definitely correlate with 
the greatest amount of extractable information. Han et al showed 
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that generating 2D textural features on multiple slices from 3D 
data was better than generating them from a single 2D slice. 
Although 3D data did not improve on multiple 2D slices, it can 
potentially analyse extra features not available in a 2D analysis. 
2D analysis on a single plan on a single slice would not detect 
differences in other planes, e.g. if the axial plane was used, data 
regarding the coronal or sagittal plane of the tumour could not 
be generated. Analysing multiple 2D slices may help identify the 
most representative 2D slice, but does not overcome the limita-
tions regarding information in 3D.
FDG PET-CT is another type of imaging used to assess lung 
nodules. In many institutions worldwide FDG PET-CT is less 
available than CT, but is a very useful tool in identifying malignant 
lung nodules, with a sensitivity of 95% and specificity of 82%.3 
Tracer uptake can be heterogeneous within a tumour because 
of areas of necrosis, differences in blood flow, cellular activity, 
microvessel density or hypoxia. Whilst this review focuses on the 
exploitable TA features of standard CT scans, where PET-CT data 
sets are available, additional value can be extracted from these 
scans. Fractal analysis is a TA modality that has been studied in 
this setting. Morphological fractal dimension and density fractal 
dimension can be generated from CT and PET images of pulmo-
nary images. Combining morphological fractal dimensions and 
FDG PET-CT or density fractal dimensions improves diagnostic 
accuracy to above 90% when comparing benign nodules with a 
primary NSCLC69 using FDG-PET alone.
MRI is not routinely used to assess lung tumours before treat-
ment. However, a small single institution series suggests that 
entropy derived from dynamic contrast enhanced MRI may 
predict progression free survival (PFS).70
Pre-treatment textural analysis (TA) of primary lung 
tumours using CT
TA has been shown to have potential as an imaging biomarker 
to identify the histological subtype of NSCLC. Although many 
of these studies are relatively small, CT TA radio-genomics is a 
rapidly expanding field. CT TA has helped to differentiate KRAS 
oncogene-mutated tumours from pan-wild type tumours,71 
epidermal growth factor receptor (EGFR)  mutant tumours from 
wild type tumours,72,73 EGFR-mutated tumours from anaplastic 
lymphoma kinase (ALK) () rearranged tumours,74 lepidic adeno-
carcinomas from non-lepidic adenocarcinomas75 and ALK 
rearranged tumours from unrearranged tumours.76,77 Work in 
progress has identified a correlation between kurtosis (a first-
order textural feature) in NSCLC and the expression of a gene 
coding for a protein that regulates mucin production, Mucin5AC. 
The expression of this gene is considered a marker of the activa-
tion of the MAP kinase signalling pathway. Increased presence of 
mucin produces lower attenuation with X-rays than soft tissue. 
This begins to demonstrate the potential for radio-pathological 
correlation through advanced imaging analysis.78
Conventional predictors of outcome in NSCLC include TNM 
staging, AJCC stage, age, sex, histology, comorbidities and 
performance status. The use of a biomarker from CT imaging to 
prognosticate patients’ outcomes, risk of distant metastases and 
overall survival (OS) is attractive. CT texture features have been 
correlated with PET-CT SUVmax, tumour staging and degree of 
tumour hypoxia.16,79 A combination of TA features have been 
identified that predict recurrence in surgical patients17 and 
overall survival in patients with adenocarcinoma.80
TA can assess many different features and this presents a chal-
lengingly large experimental space. In 98 patients with stage 
I-III NSCLC receiving radical radiotherapy, the 15 most predic-
tive textural features were chosen from over 600 features, from 
pre-treatment CT scans.19 Risk of distant metastases were 
divided into high risk and low risk with a CI of 0.62. Use of 
simple radiomic features were able to predict risk of distant 
metastases in a discovery and validation set of patients. In a 
similar study in Stage 3 patients, receiving chemo-radiotherapy, 
textural features extracted from the gross tumour volume, 
patients could be divided into high and low risk based on tradi-
tional prognostic factors such as staging and features from TA,20 
with a CI of 0.89 and 0.91 for overall survival and locoregional 
control, respectively. Grove et al showed that morphologically 
similar tumours could be divided into better and worse prog-
nosis groups and validated this at a separate institution, using 
convexity and central tumour entropy. More irregular tumours 
conferred a worse prognosis.21
TA in combination with machine learning has been shown to 
predict recurrence with a high degree of accuracy (CI 0.81)41 
and OS,81 using the pre-treatment image of a single CT slice of 
101 patients who underwent resection of Stage I primary lung 
adenocarcinoma. The TA used a second-order feature called 
Riesz wavelets, which were chosen to differentiate between solid 
component and ground glass opacities. Support vector machine 
(SVM, a form of machine learning) has been used to classify high 
risk and low risk lesions, as well as risk of recurrence.23,24 The 
benefit is that SVM can separate non-linear data; it can sepa-
rate data into two groups that are not obviously distinct when 
plotted, when methods such as logistic regression are less useful. 
The more round the tumour (spherical disproportionality) and 
the greater the tumour heterogeneity, the less likely the response, 
in patients undergoing neo-adjuvant chemo-radiotherapy for 
NSCLC. The strength of this study was that treatment effect was 
assessed by pathological assessment of the surgically resected 
specimen. In a separate study, CT TA measures were able to 
predict tumour shrinkage after radical radiotherapy.25
A range of TA studies have been performed with broadly similar 
methodology. A patient cohort with a known outcome measure 
is identified. A single slice or whole tumour is segmented out 
from the rest of the scan. A range of first-, second- and high-
er-order textural features can then be extracted. In many cases, 
a large number of TA features can be calculated. Features are 
chosen that correlate with outcome. The difficulty is that different 
TA features are significant in different studies, using different 
methods of analyses. An association between TA features and 
outcome could be statistically significant by chance, if very 
large numbers of parameters are analysed. Some TA features are 
dependent on preprocessing of the image before TA is performed, 
whereas others are independent,26 which means the independent 
features were more likely to be robust, as they are not prone to 
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variations in preprocessing. These concerns limit the reproduc-
ibility of many studies and their applicability as a practical clin-
ical tool. Large robust data sets may help to overcome some of 
these limitations. For example, Palmar et al were able to analyse 
lung tumours and head and neck tumours in 878 patients with 
training and validation sets for both tumour types. In this study, 
radiomic parameters were correlated with stage and prognosis.82 
Reproducibility is a key element in using such a biomarker more 
widely.
TA can potentially increase the accuracy of nodal staging as 
lymph nodes can be auto-mapped and identified.83 TA has been 
shown to predict whether a lymph node is malignant or not in 
biopsy proven nodes, with a sensitivity of 81% and specificity of 
80% (AUC = 0.87, p < 0.0001). This was achieved using a combi-
nation of three textural features: entropy, grey level non-uni-
formity and run length non-uniformity with three features of 
shape, which assessed the degree to which a lymph node was 
circular. Using this combination, 84% of malignant nodes and 
71% of benign nodes were correctly classified on a non-contrast 
CT.84 However, only half the patients (22 of 43 patients) received 
a staging PET-CT scan. PET imaging shows a small improve-
ment in diagnostic efficacy when compared with measuring 
nodal dimensions alone. A published study using commercially 
available software called TexRAD has shown that it is possible 
to differentiate malignant nodes from benign nodes with a low 
sensitivity of 53%, but much improved specificity of 97%, with 
an ROC-AUC of 83%.85 TA based on endobronchial ultrasound 
has been shown to differentiate between benign and malignant 
nodes using fractal dimension.53
Pre-treatment textural analysis (TA) of primary lung 
tumours using PET-CT
FDG PET-CT is used as standard to stage patients potentially 
suitable for radical treatment for NSCLC. It is becoming increas-
ingly used in managing treatment in NSCLC. Using simple PET 
metrics such as mean and maximum SUV would not be defined 
as TA, but analysing tracer uptake can identify heterogeneity 
across the tumour.
Extracting texture features is dependent on the size and FDG 
uptake seen on FDG PET-CT imaging.86–88 FDG-PET texture 
features have been found to be prognostic20,89–93 and provides 
more accurate prognostication than CT TA alone.94,95 Simple 
measures such as SUVmax and metabolically active tumour 
volume have been associated with OS after radiotherapy and 
response rates after palliative chemotherapy in metastatic lung 
cancer.88,96–98  In one study, these metabolic measures have 
also been found to correlate with first-order textural features,99 
however additional work has suggested that only second-order 
features correlate with OS.100 FDG PET-CT-CT has high test-re-
test and high interobserver stability. In contrast, Cook et al101 
showed that FDG PET parameters (such as SUVmax) did not 
predict the outcome.FDG PET-CT studies have also been shown 
to aid the diagnosis of mediastinal lymph nodes.102,103Although 
FDG is the commonest tracer used in clinical practice, other 
tracers such as F-fluromisonidazole, a marker of tumour 
hypoxia, are available. F-fluromisonidazole uptake can vary 
across tumours and therefore, it is possible to assess tracer uptake 
heterogeneity and to use TA to generate textural features.104,105 
FDG images take 15–20 min to acquire. As a result, tumour move-
ment caused by respiration during image acquisition appears to 
affect some, but not all textural measures,106 e.g. busyness (a 
measure of intensity change between a voxel and those around 
it) was 20% higher in the 4D scan, suggesting that as possibly 
expected blurring means these measures are sensitive to motion. 
Fried et al identified that a combination of histogram features, 
co-occurrence matrices (using 2D relationships), shape and 
volume correlated with OS and locoregional control, but was not 
externally validated. Further studies have shown that SUVmax 
and mean, total lesional glycolysis (TLG) and metabolic tumour 
volume correlated positively with entropy. Energy and contrast 
had an inverse relationship107 and that the FDG PET and CT 
heterogeneity assessments can separately predict OS.
In a pilot study, Wu et al29 segmented subregions of tumour 
based on similarity of appearance, using CT and FDG PET-CT.
Each tumour was over-segmented into multiple super pixels 
using K clustering of the FDG PET and CT images. The volume 
of the metabolically active subregion predicted OS in this 
patient cohort, with a CI 0.67 and hazard ratio of 2.79 (log rank 
p = 0.004). These regions appear to be robust against a degree of 
misregistration, but the PET data does not appear to account for 
tumour movement. In supporting the use of TA in radiotherapy 
planning, some CT texture features are robust enough to be iden-
tified on linear accelerator based cone beam CT scans from on 
treatment imaging during radiotherapy.108 Image quality and the 
ability to quantify an image is likely to improve as cone beam CT 
technology quality improves.
The majority of these studies are retrospective. Many studies also 
use a lot of clinical data alongside to stratify outcome, adding 
in TA then slightly improves prediction of outcome compared 
with clinical data alone, rather than the tumour textural features 
alone predicting outcome. These studies are heterogeneous. They 
utilize different standards, measurements, equipment and tech-
niques. For this reason, it is difficult to achieve accurate repro-
ducibility. Some studies have heterogeneous cohorts receiving 
different treatment, either combining tumours that received 
radiotherapy alone with chemo-radiotherapy or different radio-
therapy schedules. Accurate localization and segmentation of 
tumours on CT imaging is easier to overcome using appropriate 
windowing, than differences on FDG PET-CT, particularly if 3D 
PET is used. Some studies have specifically looked at reproduc-
ibility and this is an important area of further research.109,110 At 
present, it is unlikely that TA assessment is sufficiently robust to 
act as a biomarker.
Assessing treatment response
Follow-up CT and PET-CT scans both provide additional oppor-
tunities for assessment of treatment response beyond simple visual 
interpretation. SUV intensity on FDG PET-CT imaging may give a 
faster response than decrease in tumour volume.111 Early predic-
tion of response to chemo-radiotherapy has been made using 
PET heterogeneity. In a study by Dong et al, patients undergoing 
an on treatment FDG PET-CT scan (after receiving approxi-
mately two-thirds of total radiation dose), certain textural features 
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indicated response to treatment with a higher sensitivity (92 vs 
73%) and specificity (84 vs 80%) than baseline PET features.112
Identifying early recurrence after radical radiotherapy can be 
complex, particularly after stereotactic ablative body radiotherapy 
(SABR).113 SABR describes a battery of methods that facilitate 
the highly targeted delivery of a high dose of radiotherapy in 
fewer larger doses to an early stage lung tumour. The centre of the 
tumour often receives two or three times the biological equiva-
lent dose compared with standard radiotherapy. Pre-treatment 
textural features can improve prediction of outcome, compared 
with SUVmax alone.28 Compared with other treatment response 
assessments, the evidence base for using radiomics and textural 
features in SABR response assessment is relatively advanced. 
Treatment-related toxicity is also amenable to assessment by TA. 
Radiation induced lung injury (RILI) consolidation commonly 
occur after SABR.114 Differentiating RILI and tumour recur-
rence is difficult. When comparing areas of ground glass opacity 
and consolidation, recurrences were denser and had different 
textural features than areas of RILI and early response could be 
predicted.31–33 FDG PET SUV >5 or SUV higher than the diag-
nostic FDG PET-CT suggest recurrence.113 Radiomic features 
have been extracted, which predict early recurrence and are able 
to improve sensitivity when compared with physician assessment 
(AUC 0.85, false negative rate 23% vs 99%).33 Another study has 
suggested that perfusion characteristics of RILI and recurrence 
are different, with the areas of recurrence exhibiting changes in 
perfusion termed as wash-in and wash out phenomenon, not 
seen in areas of RILI.34 Lung CT TA changes can be identified 
in patients receiving radical radiotherapy to the oesophagus, 
this technique not only identified patients who did, and did not, 
develop radiation pneumonitis, it also quantified it.115 It achieved 
this by comparing randomly generated regions of interest in both 
pre and post treatment imaging.
In advanced NSCLC tumours, neither volumetric measurements 
on CT nor RECIST criteria predicted OS.35 PET SUVmax has 
been associated with response to chemotherapy and TKIs,36,37 
but not with OS.38,97 TA could identify response of adenocarci-
nomas in the metastatic setting but could not identify response 
in non-adenocarcinomas..38 Different textural features have been 
identified in assessing response to chemo-radiotherapy (found 
tumour volume, mass, kurtosis and skewness) or an EGFR 
tyrosine kinase inhibitor (heterogeneity).39 11 C erlotinib PET 
requires further investigation but has been shown to poten-
tially identify TKI responders and non-responders in a murine 
model.40 Kurtosis after neoadjuvant chemotherapy and inten-
sity variability after tyrosine kinase Inhibitor therapy have been 
shown to independently predict pathological response.39 Having 
a predictor of response is useful as non-responders could poten-
tially avoid a toxic treatment, which would not benefit them and 
reduce costs of futile therapy.
Future perspective
The use of TA and radiomics is rapidly evolving. It is attractive as 
it uses existing imaging data to gain greater information about a 
tumour or disease state. There has been sufficient work to establish 
that certain textural features can act as biomarkers. Indeed tumour 
kurtosis and entropy are entering real-world clinical evaluation as 
markers of poor prognosis.78 However, to become more widespread 
a range of obstacles require attention. It is important to consider 
standardization of each step in the process including: acquisition, 
segmentation (ideally auto-segmentation), analysis and interpreta-
tion of the data. TA techniques often require an expert to accurately 
delineate the tumour. TA requires a significant degree of computing 
power to generate the analysis, it is not currently integrated into 
current assessment of imaging in diagnosis and response assess-
ment and TA potentially makes workflow with a radiology depart-
ment more complex.
Some of these challenges can be overcome. For example, 
extracting textural features automatically reduces or eliminates 
interobserver error,116 using an automated technique to delineate 
tumour volume is more robust than manual delineation117 and 
commercialization and user interface optimization may facili-
tate the incorporation of TA into radiology department work-
flows. Many studies have analysed the primary tumour and so at 
present are more likely to be useful for pre-treatment prognosti-
cation, rather than post treatment assessment.
To gain the full benefit of textural features, identification and 
classification of features need to be sufficiently robust to over-
come variables such as patient factors (including positioning, 
respiration phase and motion management and effects or lack of 
IV contrast), acquisition and processing variables such as image 
acquisition power, image slice thickness, image reconstruction 
algorithms, use of segmentation software and operator variability 
in tumour delineation. Some texture features are reproducible, 
while others are highly variable and do not generate the same 
results with repeat testing.118,119 To minimize these variables and 
identify the changes related to tumours alone many studies stan-
dardize their image acquisition process.110 Useful biomarkers 
need to overcome these features or have to be standardized to 
ensure accurate interpretation of this information.
TA of routine imaging is likely to have a range of uses in the future 
both within and outside of oncology. With more robust measures 
of texture it may be helpful in differentiating between benign and 
malignant lesions, identifying subtypes of malignancy. It will aid 
surgical and radiotherapy planning and hopefully provide more 
accurate response assessment. Response assessment is becoming 
more important as treatment becomes increasingly complex. 
Standard RECIST size criteria are not adequate for assessing 
response in immunotherapy as standard RECIST criteria under-
estimate benefit.120 Texture could potentially have a role in 
assessing how a lesion changes rather than just using size assess-
ment. Assessing response after stereotactic radiotherapy is diffi-
cult because of the localized radiotherapy change induced by the 
treatment. Differentiating between inflammation and tumour is 
difficult, particularly if a biopsy is inconclusive.
Outside of oncology, TA has already been used to assess hepatic 
and pulmonary fibrosis121 and to see if different lung patholo-
gies can be diagnosed on imaging alone. It can potentially have 
a role in differentiating tissue anywhere in the body, potentially 
preventing the need for more invasive tests.
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Letter
Beneﬁts of Stereotactic Radiotherapy Fellowships to Clinical Oncology
Trainees
Madam e As Clinical Research Fellows in stereotactic
radiotherapy, we recognise the growing beneﬁt of acquiring
greater technical skills in advanced radiotherapy during our
clinical oncology training.
Our involvement in the development of new stereotactic
radiotherapy services has helped us to understand the
background process in delivering a new treatment tech-
nique. This includes the commissioning process, designing
treatment protocols and departmental pathways for
implementing a new radiotherapy technique and the
importance of multidisciplinary working.
In the radiotherapy planning pathway we have hadmore
exposure to imaging in both the selection of suitable pa-
tients and tumour localisation. We have also had more time
to devote to radiotherapy planning [1]. Beneﬁts include
gaining familiarity with new positron emission tomography
tracers, potential extension of magnetic resonance imaging
and the role of rigid and deformable registration in radio-
therapy planning.
We now have a greater understanding of volumetric and
ﬁducial-based image guidance, motion management stra-
tegies and online/real-time veriﬁcation. These speciﬁc skills
are generally notwell developed in our training [2].Weneed
to be able to act on changes seen at planning and treatment
delivery to know when it is appropriate to treat and when
there may be a need for an urgent re-plan. Our fellowships
have helped to develop our clinical judgement, giving
us more conﬁdence to act independently as consultants.
Frequent discussions and presentations on stereotactic
radiotherapy to specialist and non-specialist audiences,
including current literature reviews, have helped us to un-
derstand the techniques better and also improved our
communication skills.
Use of advanced radiotherapy techniques, such as ste-
reotactic radiotherapy, image-guided radiotherapy and
volumetric-modulated arc therapy, is increasing. We are
now more familiar with these techniques, which are
essential for clinical oncologists. We think it is important
that a developing clinical oncology curriculum should
include more exposure to stereotactic radiotherapy.
We would like to acknowledge our supervisors Dr V.
Ezhil, Dr K. Franks, Dr R. Shaffer and Dr M. Ajaz for their
support during our fellowships.
I. Phillips*y, K. Thippu Jayaprakash*y, P. Murrayz
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were PIRADS 5. In the extended Tofts model, the mean Ktrans value of
PIRADS 3, 4 and 5 lesions were 0.35 min1, 0.55 min1and
0.57 min1, respectively (p value ¼ 0.041). However, in the Tofts & Ker-
mode model, the mean Ktrans value of PIRADS 3, 4 and 5 are 1.0329,
1.0776 and 1.065 min1 (p value ¼ 0.380), respectively. In addition, kep
of both models, PE% and SER% were not correlated with PIRADS score,
when assessed using a quantitative method rather than shape of the curves.
Conclusion: Ktrans using extended Tofts model, positively correlates
with the PIRADS scores but other quantitative methods, assessing wash
in and out did not correlate with the PIRADS scoring. Further analysis
of histopathology and Gleason score is needed to confirm these findings.
http://dx.doi.org/10.1016/j.ejso.2016.07.049
82. Rate of cachexia in lung cancer
Adele Hug, Iain Phillips, Lindsey Allan, Veni Ezhil
Royal Surrey County Hospital, UK
Background: Lung cancer is the second most common cancer diag-
nosed in men and women in the UK with a very poor 5 year survival
(10%). There is a lack of robust data on the stage of cachexia in which pa-
tients with lung cancer present. The severity of cachexia can influence
overall outcome. Refractory (irreversible) cachexia indicates a poor prog-
nosis of usually less than 3 months.
Method: We reviewed all patients diagnosed with primary lung cancer
that were reviewed by the Macmillan Oncology Dietitians over a 4 year
period at the Royal Surrey County Hospital. Reasons for referral
commonly included: weight loss, glycaemic control in diabetes, decreased
oral intake and food texture modification. Patients were defined as
cachectic if weight loss was >5%.
Results: 458 patients were reviewed by the dietitian. 43% were female,
57% were male. Mean and median weight loss of total body weight at re-
ferrals was 9.5% and 13% respectively. Mean pre-cancer body mass index
(BMI) was 26.9 (kg/m2), mean BMI at referral was 23.0 (kg/m2). 359 pa-
tients (78%) were treated with palliative intent. 99 were treated with
radical/adjuvant intent. 341 (76%) of this cohort had >5% weight loss
from their usual body weight prior to diagnosis.
Conclusion: This data suggests cachexia is very common in lung can-
cer. It is known that early symptom control improves survival in lung can-
cer. It is not known whether early dietetic intervention may improve lung
cancer outcomes. Further research is needed. These patients have a BMI
within the healthy range of 20e25 kg/m2 before and after their cancer
diagnosis in spite of significant weight loss. We are seeking ethical
approval to prospectively assess the rate of cachexia in lung cancer and
its correlation with other simple nutrition assessment tools. We aim to
assess clinical outcomes categorised by % weight loss in advanced lung
cancer.
http://dx.doi.org/10.1016/j.ejso.2016.07.050
85. Building a weight of evidence to prevent cancer in later life
Gillian Rosenberg, Lucie Hooper, Jyotsna Vorhra
Policy Research Centre for Cancer Prevention, Cancer Research, UK
Background: Obesity is the largest preventable risk factor for cancer
after smoking. Being overweight as an adult is linked to 10 cancer types,
and overweight children are more likely to become overweight adults.
Recent data shows that around one in three children leave primary school
overweight or obese, with the most deprived children twice as likely to be
so. A comprehensive evidence-based childhood obesity strategy is vital in
order to prevent obesity related cancers later in life.
Method: A multidisciplinary research strategy was developed at Can-
cer Research UK to build a body of evidence that can directly influence
government policy making in obesity. This included a quantitative study
to investigate obesity and cancer awareness in the general population; a
modelling study to predict future obesity related cancer cases; and qualita-
tive studies to explore obesity-linked behaviours in children.
Results: Cancer was not at the forefront of people’s minds when
thinking about obesity, with only 26% showing an unprompted awareness
of the link. However the projected impact of obesity on cancer is high: if
current trends continue it will lead to a further 670,000 cases over the next
20 years. When looking specifically at childhood obesity, it was found that
junk food marketing was associated with parental pester power and can
override nutritional knowledge.
Conclusion: These research studies formed an integral part of the cur-
rent Cancer Research UK campaign on obesity. The first stage addressed
the poor knowledge of obesity and cancer in the general population. The
modelling results were a key part of this, alongside existing data on the
mechanisms behind the causal relationship of obesity and cancer.
Following this, during the development of the government’s childhood
obesity strategy, the childhood obesity studies demonstrated to policy
makers the importance of taking action to limit advertising exposure in
children.
http://dx.doi.org/10.1016/j.ejso.2016.07.051
92. Interest of radiochemotherapy in the rectal cancer
Messaoud Ayad1, Naima Haoui2
1 EHS Centre Anti Cancer, UK
2Centre Anti Cancer, UK
Background: We propose the study of treating patients with locally
advanced rectal cancer by radiochemotherapy followed by surgery with
TME. The objective is to make inoperable patients, operable after the radio
chemotherapy and get a pathologic complete response at the maximum of
the patients and decrease the rate of local recurrence and distant.
Method: During 2008e2011, we have recruited 80 patients in our
radiotherapy oncology department of Blida; age is between 18 and 70
years. Radiotherapy (RT) is made at a dose of 45 Gy in the pelvis; the pa-
tient received three courses of CT (FOLFOX) for all the radiation therapy.
All patients were assigned to surgeons for surgery (TME).
Results: Rectal bleeding was found in 89% of patients. 70% of our pa-
tients had a low rectal cancer 98% of our patients are classes T3, T4. 78 %
N+, and only 21% N. The RTCT was well tolerated by patients, no side
effects Grade 4.77 had surgery 55% of our patients had a conservative sur-
gery. 41% had an abdomino perineal resection. The downstaging affects
more 45% of tumors after the RTCT and we have 12% complete patholog-
ical response, 61% of objective response. The local recurrence rate is (4%)
relapse distance is 22.9%. The average time of relapse was 14 months
away. The survival rate at 5 years was 64%. Relapse distance during
follow-up of patients operated is 22.9%.
Conclusion: Our result of 12% complete response is less than the re-
sults of others studies (16% to 21%). Our result of local relapse is similar
to international studies. Every patient should have a personalized treatment
for all steps (radiochemotherapy, surgery, adjuvant chemotherapy).
http://dx.doi.org/10.1016/j.ejso.2016.07.052
93. Breast cancer in woman younger than 35 years
Messaoud Ayad1, Naouel Aksil2
1 EHS Centre Anti Cancer, UK
2Centre Anti Cancer, UK
Background: Our aim was to report the epidemiological and clinical
characteristics of breast cancer in young women and to evaluate the ther-
apeutic Results in Radiotherapy Oncology department of Blida.
Method: We report the Results of a retrospective study including 64
patients less than 35 years old treated for breast cancer between January
2010 and December 2014 in our department.
ABSTRACTS S227
living in an island community [OR 1.32; CI 1.09e1.59] predicted timely
treatment (treatment within 62 days of GP referral). Increased travelling
time to treatment centre >30 minutes on the mainland was associated
with reduced survival to one year (30e59 minutes [OR 0.70; 95%CI
0.59e0.86], >60 minutes [OR 0.80; 95%CI 0.67e0.96]). Living in an is-
land community did not have an association with survival.
Conclusion: Living in an island community or having travelling time
on the mainland of greater than 60 minutes to a cancer treatment centre is
associated with timely treatment. However, survival at one year is less
likely in those on the mainland with a travelling time greater than 30 mi-
nutes.
http://dx.doi.org/10.1016/j.ejso.2016.07.084
229. Sarcopenia in lung cancer
Iain Phillips1, John Tenny1, LucindaGunn1, Kofi Nimako2, Adele Hug1,
Lindsey Allan1, Veni Ezhil1
1 Royal Surrey County Hospital, UK
2East Surrey Hospital, UK
Background: Cancer cachexia (loss of muscle mass) is an adverse ef-
fect of many common cancers. The presence of refractory (irreversible)
cachexia is associated with a very poor overall survival. Sarcopenia (mus-
cle loss) is a feature of cachexia and can be assessed on CT imaging. Cross
sectional measurement of the psoas muscle is an accurate, quick and inex-
pensive assessment of sarcopenia. Sarcopenia is associated with a poor
prognosis in Small Cell Lung Cancer. This has not been previously shown
in Non Small Cell Lung Cancer (NSCLC). We show the relationship be-
tween sarcopenia and overall survival in NSCLC.
Method: Data was collected from an MDT between July 2012 and
December 2013. Anterior-posterior and lateral measurements of greatest
diameter of psoas muscle was made at level of L3 through the transverse
processes from the diagnostic CT. Left and right psoas muscle measure-
ments were taken and standardised for height. Psoas area (in mm)/height
(m). Sarcopenia defined as <385mm/m2 in females and <585mm/m2 in
males.
Results: 90 patients were identified retrospectively with appropriate
imaging. Cohort was 54% male and 46% female. Mean age 67 years
(range 46e85). Of 56 patients with radically treatable cancer (stage
IeIIIa + T4N2M0), 24 patients (43%) had sarcopenia at diagnosis. Of
31 patients with incurable lung cancer (stage IIIb + IVexcludingT4N2M0),
15 had sarcopenia at diagnosis.
Median survival of non-sarcopenic patients was 14 months. Median
survival of sarcopenic patients was 12 months (p ¼ 0.2218).
Conclusion: Sarcopenia is common in patients with NSCLC. Sarcope-
nia assessment using cross sectional measurements of psoas muscle is
quick and easy. The presence of radiological sarcopenia may correlate
with a poorer overall survival in NSCLC, but did not reach statistical sig-
nificance. Sarcopenia requires further investigation and will be investigated
in a prospective clinical trial, the NAIL trial (Nutrition Assessment and
Intervention in Lung Cancer).
http://dx.doi.org/10.1016/j.ejso.2016.07.085
255. Cancer stigma among ethnic minority women
Laura Marlow, Charlotte Vrinten, Jo Waller
University College of London, UK
Background: Qualitative research with ethnic minority groups often
finds that participants feel cancer is stigmatised or ‘taboo’. Cancer stigma
has also been shown to influence engagement with cancer prevention/early
detection behaviours particularly in some ethnic minority groups. To date
there have been few studies attempting to quantify perceptions of stigma in
ethnic minority populations. We aimed to explore differences in cancer
stigma in a sample of ethnic minority women and the association between
cancer stigma and attendance at cervical screening.
Method: Women aged 30e60 years were recruited from Indian, Pak-
istani, Bangladeshi, Caribbean, African and white British backgrounds
(n ¼ 720, response rate ¼ 65%). Participants completed face-to-face inter-
views with a multi-lingual interviewer. We assessed socio-demographics,
self-reported cervical screening attendance, and four dimensions of cancer
stigma: personal responsibility, awkwardness, avoidance and community-
level stigma.
Results: There were significant differences by ethnic group for each of
the four stigma dimensions (p < .001 for each), with White British women
scoring lowest on each. Differences on individual items were striking, for
example <5% of Bangladeshi and Pakistani women believed cancer was
talked about openly in their community compared to 97% of White British
women. Across all ethnic groups, personal responsibility, awkwardness
and avoidance scores were significantly lower among those born in the
UK, but there were no differences in community stigma. Cancer stigma
was significantly associated with increased odds of non-attendance for cer-
vical screening. This was the case for community stigma (OR ¼ 1.09), per-
sonal responsibility (OR ¼ 1.12), awkwardness (OR ¼ 1.12) and
avoidance (OR ¼ 1.15). Odds ratios were small but highly significant
(p < .001).
Conclusion: While low in the general population, cancer stigma is
prevalent in ethnic minority groups, even among the younger generation,
and is associated with cervical screening status. Interventions to tackle
stigma in ethnic minority populations could be a first step to addressing
ethnic inequalities in cancer awareness and preventive behaviours.
http://dx.doi.org/10.1016/j.ejso.2016.07.086
264. The meaning of the term ‘breast cancer survivor’ for young
women living with a history of breast cancer in the UK
Sophie Rees
University of Warwick, UK
Background: Despite its usage, ‘cancer survivor’ remains a contested
term as not only is there is a lack of consensus over the exact definition and
meaning, but there have been strong critiques of ‘survivorship’ by scholars
and activists. A recent turn to researching how individuals who have or
have had cancer perceive the term ‘cancer survivor’ has had mixed find-
ings. Some people embrace the term, but there are many who do not
feel it fits with their own experience, and who resist it. Most existing
research has been conducted outside of the UK.
Method: Twenty women diagnosed with breast cancer under the age of
45 took part in semi-structured interviews, and, among other topics, their
perceptions of the term ‘breast cancer survivor’ were explored. Social
constructionist grounded theory methods were used in order to develop
an understanding grounded in the worldviews of the participants.
Results: Only 3 of the twenty women interviewed said they would use
‘survivor’ to describe themselves and many held negative views about the
identity in relation to themselves. Reasons for rejecting it included not
feeling close enough to death, the fear of recurrence, and the obfuscating
of cancer’s ongoing presence in their lives. At the end of curative breast
cancer treatment, most young women found themselves in a ‘liminal’ state
e neither patients nor survivors e and, therefore, found that the term did
not resonate with their experiences.
Conclusion: The term ‘cancer survivor’ may not be appropriate for
many young women living with a history of breast cancer for a number
of reasons, including that it obscures the long-term and uncertain impact
on their lives. Being labelled a ‘survivor’ can be a disempowering experi-
ence. Further research is needed but this small study troubles the use of the
term in everyday usage to refer to this population.
http://dx.doi.org/10.1016/j.ejso.2016.07.087
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laterally. Maximum discrepancy: 1.4 cm,1.3 cm and 2.3 cm respectively, that
is, larger than current PTV margins. Mean treatment time 15.56 minutes.
1st action plan: Advise undertaking daily KV clip matching as protocol for all
photon boost treatments on patients with clips. Reduce PTV margins to
0.5 cm; discount ﬁeld border and distance measurements as not a true
marker of treatment accuracy. Audit time taken after new protocol
implemented.
Results of 2nd audit round:Mean treatment time with new protocol: 10.17
minutes; implementation improves treatment accuracy without reducing
capacity.
2nd action plan: Continue protocol.
References:
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Audit of radiotherapy plan quality for stereotactic ablative radiotherapy
(SABR) for stage 1 non-small cell lung cancer
A.C. Pascoe, K. Foweraker, C. Esler, S. Morgan, A. Wallace, D. Launders,
E. Harron
Oncology, Nottingham University Hospitals NHS Trust, Nottingham,
United Kingdom
Background to the audit: 101 patients with non-small cell lung cancer
(NSCLC) have been treated with SABR since December 2012. The aim of this
audit was to assess SABR plan quality and correlate with clinical outcomes.
Standard, indicator and target: UK SABR consortium guidelines for treat-
ment planning in lung SABR.1
Methodology: Radiotherapy planning parameters are prospectively
collected for each SABR patient, thesewere collatedwith clinical data and the
information analysed.
Results of 1st audit round: 98% of SABR plans achieved coverage of 99% of
the planned target volume (PTV) with 90% of the prescription dose. 68%
achieved 95% coverage of PTV with 100% dose; however, 84% of plans ach-
ieved99% to 95% of PTV, likely within error of dose calculation. Only 2% had
a major deviation for target conformity and 1% for intermediate dose con-
formity. No plans hadmajor deviations for Dmax, organs at risk (OAR) or dose
at 2 cm.
Biologically equivalent dose (BED) the dose received by 95% of the PTV was
calculated, as it is established that BED 100 Gy (assuming a/b of 10 for
tumour) is associated with better local control.2 Nine patients did not receive
a BED of 100 Gy; eight due to conservative fractionation and only one due
to poor coverage.
With median follow up of 12 months there have been four local relapses, one
of these received BED <100 Gy due to conservative fractionation.
1st action plan: Conclusions: For the majority of patients we meet planning
guidelines for lung SABR. The 95% PTV coverage can be challenging; however,
this rarely compromises PTV receiving BED of 100 Gy.
Action plan: Share audit results with multi-professional SABR team.
Review plans not meeting guidelines or requiring conservative fractionation
in weekly SABR meeting; treatment may go ahead if no other treatment
options.
Re-audit following introduction of ﬂattening-ﬁlter free mode to check
impact on plan quality.
References:
1. Stereotactic ablative body radiation therapy (SABR): a resource. UK SABR
consortium. Version 5.0, January 2015. Endorsed by the Faculty of Clinical
Oncology of The Royal College of Radiologists.
2. Onishi H, Shirato H, Nagata Y et al. Hypofractionated stereotactic radio-
therapy (HypoFXSRT) for stage 1 non-small cell lung cancer: updated results
of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007;
2(Suppl3), S94eS100.
Orchestrating timely check cystoscopy after radical radiotherapy to the
bladder
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Background to the audit: Patients treated radically for muscle invasive
bladder cancer have a high risk of recurrence.
For those who have undergone radical radiotherapy (RT), post-RT cystoscopy
facilitates prompt surgical salvage if appropriate. Appropriate timing of post-
RT cystoscopy requires careful and timely communication between centre
providing RT and peripheral urology services.
Standard, indicator and target: National Institute of Health and Care
Excellence (NICE) guidelines advocate rigid cystoscopy within three months
of completion of RT.1
All our patients should:
e Undergo cystoscopy within three months of end of RT, unless evident why
not indicated or unable to be performed within this time
e Have end-of-treatment letters sent to peripheral urology services,
generated within 14 days of completion of RT.
Methodology: Patients who underwent radical RT to bladder from
2011e2013 identiﬁed. Radiotherapy and end-of- treatment letter dates ob-
tained from local records. Peripheral urology clinics contacted for date of ﬁrst
cystoscopy post-RT or reason for not having cystoscopy if appropriate.
Results of 1st audit round: 100 patients who completed RT were identiﬁed.
96 patients (96%) either underwent cystoscopy or had a valid reason for not
undergoing cystoscopy documented (87% and 9% patients, respectively).
Among patients who underwent cystoscopy, seven (8%) and 37 (43%) had
procedure within three and four months, respectively.
98 patients (98%) had end-of-treatment letters. 48 (48%) had letter typed
within 14 days.
1st action plan: Automatic letter to referring urologist indicating likely time
of cystoscopy generated at time of RT booking; check this letter has been
done at time of RT planning.
Standard agreed end-of-treatment letter to be sent at completion of RT.
Further discussion planned by peripheral urology services regarding dedi-
cated uro-oncology cystoscopy lists. Re-audit 18 months.
References:
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Audit of treatment of older patients with lung cancer
V. Ezhil *, I.D. Phillips *, L. Gunn *, K. Nimako y
*Clinical Oncology, Royal Surrey County Hospital, Guildford, Surrey,
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y East Surrey Hospital, Redhill, United Kingdom
Background to the audit: Older cancer patients receive less treatment than
younger patients.1e6 Detrimental physiological changes occur from age 70.7
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Patients were audited as over 70 and under 70 to see if older patients
received less treatment.
Standard, indicator and target: No standard exists for the proportion of
older patients with lung cancer receiving active anti-cancer treatment. We
generated our standard from the proportion of under 70s receiving active
treatment. Our target was 80% of the proportion of under 70’s receiving
treatment.
Methodology: Data for patients with biopsy proven lung cancer discussed at
the multidisciplinary team (MDT) between 01/07/12 and 31/12/13 was
collected and patients were divided into four groups. Under 70 years old
radical (stage I-IIIa and T4N2), under 70 palliative (other IIIb and stage IV),
70þ radical and 70þ palliative.
Results of 1st audit round: Data was available for 197 new patients. 13%
stage I, 7% stage II, 29% stage III (18% IIIa, 11% IIIb) and 51% stage IV. Median
age was 70 (range 41e95 years). Overall survival was 22 vs 11 months for
radical patients under 70 and over 70. Overall survival for palliative patients
was four months irrespective of treatment.
Radical treatment in over 70s and under 70s was similar (57% vs 52%). Best
supportive care as ﬁrst treatment was 3% and 7% in radical patients under
and over 70. It was 5% in palliative patients under 70 and 50% in over 70s.
Chemotherapy rates for under 70 vs over 70 was 75% vs 34%. One-third of
palliative patients over 70 were too unwell to attend an oncology clinic. 50%
of palliative patients over 70 who attended clinic received palliative
chemotherapy. The target of 80% of 75% of younger patients (60%) was not
reached.
1st action plan: Implement a geriatric screening tool (G8) before attending
clinic to identify those ﬁt for chemotherapy, aiming to prevent unnecessary
clinic attendance.
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Stereotactic body radiotherapy (SBRT) for metastatic breast cancer: an
audit of the Royal Marsden experience
D.R. Henderson, A. Kirby, I. Locke, G. Ross, D. Tait, V. Khoo, N. van As
Radiotherapy, Royal Marsden Hospital, London, United Kingdom
Background to the audit: There is little data speciﬁc to breast cancer for
SBRT. Case series indicate that SBRT to metastatic disease can be delivered
safely with high local control.1
Standard, indicator and target: Common terminology criteria for adverse
events (CTCAE) Grade 3 toxicity  5% Local control (LC) at one year 80%.
Methodology: A review of all patients having SBRT for metastatic breast
cancer from 2011 to present. A three fraction schedule was given on alternate
days, typically prescribed to the 80% isodose. LC and progression-free sur-
vival (PFS) were assessed with cross sectional imaging. All patients but one
had imaging within six months of most recent follow-up.
Results of 1st audit round: Nineteen sites were treated in 17 patients.
Median dosewas 27 Gray (Gy) (biologically equivalent dose [BED]3.5¼96 Gy).
Sites treated: spine (12), other bone (4), sternum (2) and liver (1). Median
follow-up was 22 months (inter-quartile range [IQR] 6.9e32.6).
Treatment settings were: metachronous (13) and synchronous (2) oligome-
tastatic disease, and widespread metastatic disease for local control (4).
Two patients experienced grade 2 toxicity (nausea; dysphasia). One patient
(5.3%) developed grade 3 toxicity due to worsening of a pre-existing verte-
bral fracture following disease shrinkage, which was treated successfully
with surgical stabilisation.
Three patients experienced local failure on imaging (at 3.2e13.2 months).
Estimated LC at one and two years was 82% and 76%, respectively. Estimated
PFS in patients with 1e3 sites of disease at one and two years was 79% and
39%, respectively (n¼14).
1st action plan: Early results from this ongoing audit are reassuring with
respect to LC and toxicity. This audit will continue to monitor toxicity asso-
ciated with this novel treatment. The phase III Conventional care Or Radio-
ablation in the treatment of Extracranial metastases (CORE) trial will open
shortly, and will determine the beneﬁt of adding SBRT to standard care in the
oligometastatic setting.2
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Salvage radiotherapy for relapsed non-small cell lung cancer (NSCLC). Is
it worth it?
P. Calisaya *, R. Johnston *, J. McAleese *, R. Eakin *, G. Hanna y
* Belfast City Hospital, Belfast, United Kingdom
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Background to the audit: Effective surgical salvage for recurrent and second
primary NSCLC is possible, with reported ﬁve-year survival rates between 8%
and 40% and 25% to 53%, respectively.1,2
Although large surgical series have consistently shown that treating re-
currences improves survival, this is only feasible in 1 to 4% of patients with
isolated local recurrence.1,3 This is not the case with computed tomography
(CT) detected second primary NSCLC, which are typically small and detected
asymptomatically more than 90% of the time.
Consequently, such tumors can be resected more than 50% of the time.4
For patients who are unﬁt for surgery, stereotactic ablative radiotherapy
(SABR) enables a curative treatment option, achieving ﬁve-year local control
rates of approximately 90%, without decreasing patient-reported quality of
life.5
Standard, indicator and target:
To assess the effectiveness of salvage irradiation.
Standards aim paper from Seabag-Monteﬁore et al.6
Methodology: Retrospective review of records of patients receiving salvage
treatment in Northern Ireland radiotherapy database
Results of 1st audit round: 47 patients were treated with salvage radio-
therapy between 2006 and 2015.
The median age was 71 years (54 to 86). 56% were male.
23% had clinical lung cancer; 43% squamous and 34% adenocarcinoma. 59%
were performance status (PS) 0e1, 57% were stage IeII.
83% had relapsed after prior surgery, 15% post radiotherapy and one patient
post radiofrequency ablation (RFA). The median time from ﬁrst treatment
was 24 months.
10% died within 90 days of therapy and 16% within six months.
The median survival was 22 months, two-year overall survival (OS) 47%. At
two years 74% had local control and 48% distant control.
1st action plan: Salvage radiotherapy is an effective and safe treatment in a
selected population.
Follow-up protocols should be designed to detect those suitable for salvage
therapy.
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Determining Optimal Array Layouts for
Delivering TTFields to the Lungs Using
Computer Simulations
Topic: Advanced General
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Switzerland
Background: Tumor Treating Fields (TTFields) are low
intensity, alternating electric ﬁelds in the intermediate
frequency range. TTFields disrupt mitosis by interfering
with formation of the mitotic spindle. The therapy is FDA
approved for the treatment of glioblastoma (GB). A study
to assess the efﬁcacy of TTFields in combination with
chemotherapy for the treatment of mesothelioma is un-
derway, and a pivotal study testing the efﬁcacy of TTFields
in NSCLC is planned. TTFields are delivered through two
pairs of transducer arrays applied to the patient’s skin. In-
vivo and In-vitro studies suggest that treatment efﬁcacy
increases with ﬁeld intensity. Therefore personalizing the
array placement to deliver optimal ﬁeld distributions is
important and is a prerequisite when treating GB patients.
However, optimal array layouts for lung cancer patients
have not yet been determined. Here we present a ﬁnite
element simulations-based study investigating optimal
array layouts in male and female anatomic models.
Methods: The study was performed using the Sim4Life
software package and the DUKE and ELLA computational
models (ZMT, Zurich, Switzerland). To represent in-
dividuals with a variety of body dimensions, the models
were linearly scaled. The distribution of TTFields within
the thorax of these models was calculated for a set of
array layouts. The layouts were ranked with highest
scores for those that conformed well to body contours
and delivered uniform high intensity ﬁelds to the lungs.
Results: Uniform ﬁeld distributions within the lungs are
obtained when the arrays are axially-aligned with the
parenchyma as much as anatomically possible. Generally,
the layouts that received the highest scores were those in
which one pair of arrays delivered an electric ﬁeld from
the anterolateral to the posterior-contralateral aspect of
the patient, with the second pair inducing the ﬁeld from
the antero-contralateral to the posterolateral aspect of
the patient. However, due to body contours, this type of
layout does not adhere well to smaller females, poten-
tially hampering the efﬁcient delivery of TTFields.
Therefore, for smaller females, a layout in which one pair
of arrays is placed on the lateral and contralateral aspects
of the patients, and a second set of arrays is placed on the
anterior and posterior aspects of the patient is preferred.
Conclusion: This study provides important insights into
how TTFields distribution in the lungs is inﬂuenced by
the array layout. These results should be accounted for
when developing guidelines for transducer array place-
ment on the thorax.
Keywords: Novel Therapies, Tumor Treating Fields,
NSCLC, TTFields
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Analysis of the Incidence of Cancer
Cachexia in Patients with Advanced
Lung Cancer at Referral to a Dietitian
Topic: Advanced General
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Background: Lung cancer is the second most common
cancer diagnosed in men and women in the UK with a
very poor 5 year survival (10%). There is a lack of robust
data on the stage of cachexia in which patients with lung
cancer present. The severity of cachexia can inﬂuence
overall outcomes and a patient’s quality of life. Re-
fractory (irreversible) cachexia indicates a poor
prognosis.
Methods: We reviewed all patients diagnosed with
metastatic primary lung cancer that were referred to
the Macmillan Oncology Dietitians over a 4 year period
at the Royal Surrey County Hospital. Reasons for
referral commonly included: weight loss, glycemic
control in diabetes, decreased oral intake and food
texture modiﬁcation. We compared self-reported usual
body weight (UBW) to weight at referral. Patients were
deﬁned as cachectic if weight loss was >5% and re-
fractory cachexia if survival was <90 days from dieti-
tian review.
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Results: 310 patients with incurable lung cancer were
reviewed by the dietitian. Mean age was 68.8 (range
36-89). 42% were female, 58% were male. Mean
weight loss was 10%. 76% of patients had lost >5% of
usual body weight. Mean pre-cancer body mass index
(BMI) was 26.9 (kg/m2), mean BMI at referral was
23.0 (kg/m2). Median survival of non-cachectic and
cachectic cohorts were different (299 vs 188 days
respectively, p¼0.0078). 24% (73 patients) had re-
fractory cachexia.
Conclusion: Our study shows cachexia is very common
(76%) in lung cancer and affects survival. A quarter of
patients had refractory cachexia. BMI is an insensitive
measure of weight loss. Early symptom control improves
survival in lung cancer and this data suggests patients
are routinely being referred too late to a dietitian.
Cachexia in lung cancer is a signiﬁcant clinical problem.
Could upfront assessment of cachexia improve outcome
in patients with advanced lung cancer? We propose to
investigate this further.
Keywords: cachexia, metastatic, dietitian, nutrition
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Loss in Advanced Non-Small Cell
Lung Cancer
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Background: Assessment of body composition,
including fat mass and fat%, is a useful measure of
nutritional status in cancer and may help guide nutri-
tional interventions. However, these abnormalities have
not been well documented in lung cancer. We aimed to
study alterations in parameters of body composition in
non-small cell lung cancer (NSCLC).
Methods: A retrospective chart review was conducted of
all newly diagnosed patients with NSCLC. Age and sex
matched healthy controls were recruited prospectively.
Disease staging was done according to the American
Joint Committee on Cancer (7th edition). Performance
status was assessed using the Karnofsky performance
Scale(KPS), and the Eastern Cooperative Oncology Group
(ECOG). Details of body composition including basal
Metabolic Rate (BMR), total body water (TBW), fat mass,
and Fat-free mass (FFM) were calculated by bioelectric
impedance method using TANITA TBF 300 body
composition analyzer.
Results: A total of 256 patients (83.6% males) and 211
controls (81.5% males) were studied. The mean (SD) age
of patients was 54.5(9.0) years, median smoking index
was 598 (range, 0-2500) and mean duration of symp-
toms was 158.3(91.7) days. Median KPS was 80 (range,
40-100). Majority had Stage IV disease (54.7%), followed
by Stage III (41.4%) and Stage II (3.9%). All measured
components of body composition were signiﬁcantly
lower in NSCLC compared to controls (Table).Among
patients with normal body weight (BMI 18.5 e 25 kg/
m2), the TBW and FFM were signiﬁcantly lower
compared to their healthy counterparts.
Conclusion: NSCLC is associated with signiﬁcant
malnutrition and altered body composition, especially
reduction in the percentage of body fat. Nutritional in-
terventions must, therefore, be tailored accordingly for
these patients.
Keywords: bioimpedence, lung cancer, body composi-
tion
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Timing and Predilection for Distant
Metastasis
Topic: Advanced General
Thomas Klikovits,1 Zoltan Lohinai,1 Katalin Fabian,2
Márton Gyulai,3 Andrea Fodor,4 Judit Varga,5
January 2017 Abstracts S671
2% had documented driving advice.
First action plan: 15% nominally suitable to aggressive local therapy did not
proceed but reason clearly documented. Most not suitable; uncontrolled
disease.
Driving advice poorly documented.
Prospective audit of stereotactic radiotherapy cases proposed in NI.
12 Gy/2# rarely used.
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Docetaxol in metastatic prostate cancer
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Category: Prostate
Background to the audit: Docetaxol is used in the management of meta-
static prostate cancer. Six cycles are given upfront in hormone sensitive
prostate cancer and ten cycles are recommended in castrate resistant disease.
ASCO recommends using colony stimulating factors prophylactically when
the febrile neutropenia risk is greater than 20%. The dose is 75 mg/m[2] given
every three weeks. Many older men at NMUH were given a dose of 65 mg/
m[2] to ensure tolerability.
Standard: As per the TAX 327 trial[2], rates of febrile neutropenia rates were
3% and in Stampede[3], the rates were 12%.
Indicator:
1. Primary aim of audit is to establish rates of febrile neutropenia and
neutropenia in patients receiving Docetaxol.
2. We also explored the rates of response and toxicities between men
receiving 65mg/m[2] versus 75mg/m[2] of Docetaxol.
Target: Less than 12% of patients receiving Docetaxol develop febrile
neutropenia.
Methodology: Audit was performed retrospectively. Patients with meta-
static prostate cancer who were prescribed Docetaxol between January 2014
and 2016 were identiﬁed using the chemotherapy prescribing system, Che-
mocare. Further information about admissions was obtained from the hos-
pital computer database and notes.
Results of ﬁrst audit round:
- 21 patients identiﬁed, aged between 54 and 86 years old.
- 8 patients received a dose of 60mg/m2 and 13 received a dose of 75mg/
m[2].
- 15 patients had castrate resistant disease and six patients had hormone
sensitive disease.
- Rate of neutropenia sepsis was 25% and rate of grade 3e4 neutropenia was
15%. Rate of febrile neutropeniawas higher than expected and rate of grade
3e4 neutropenia was in keeping with the trials.
- Rates of response were similar in the 60mg/m[2] and the 75mg/m[2] group.
The toxicities seemed largely similar in both groups, and the number of
hospital admissions was overall less in the 60mg/m[2] group.
First action plan:
1. Add in a ﬁve-day course of prophylactic granulocyte-colony stimulating
factor (G-CSF) for patients receiving Docetaxol chemotherapy in meta-
static prostate cancer as per ASCO guidelines.
2. The number of patients included in the 2nd part of the audit is small
therefore further data is required.
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Survival outcomes after whole-brain radiotherapy for metastatic
melanoma
D. Yang, K. Yip, J. Adlam, H. Laidley, M. Mashar, W. Ye
Department of Clinical Oncology, Ipswich Hospital NHS Trust, Suffolk,
United Kingdom
Category: Radiotherapy
Background to the audit: 60% of melanoma patients develop brain metas-
tases (BMs).[1] Whole brain radiotherapy (WBRT) is a commonly used
treatment option at our local centre, although it is unclear if patients gain
signiﬁcant improvements in quantity or quality of life. An analysis of overall
survival (OS) following WBRT may help determine whether it is being used
appropriately. Analysis of 30-day and 90-day mortality after radiotherapy is
recommended in the Cancer Reform Strategy.[2]
Standard: Survival outcomes were benchmarked against the expected value
for each melanoma disease-speciﬁc Graded Prognostic Assessment (DS-GPA)
score as published by Sperduto et al.[3]
Indicator: Percentage of DS-GPA subgroups within our cohort meeting or
exceeding the standard.
Target: 100%.
Methodology: Data on diagnosis, treatment, and death were collected from
the electronic records of all patients withmetastatic melanomawho received
WBRT at Ipswich Hospital between January 2011 and December 2016.
DS-GPA scores were calculated fromKarnofsky performance status (KPS) and
number of BMs. OS of the cohort was estimated using the Kaplan-Meier
method.
Results of ﬁrst audit round: 23 patients with a mean age of 65 years were
audited. 30-day mortality was 9%, 90-day mortality was 43%. The median
survival for the whole cohort was 3.29 months, signiﬁcantly less than the
6.74 months suggested by Sperduto et al. Further analysis of the survival of
subgroups on the basis of DS-GPA score was not possible because perfor-
mance status (PS) was documented in only 52% of patients. Of those with a
documented PS, 50% had a KPS of <70, and 21% had a KPS of >90. Earlier
death was noted in those with more than one brainmetastasis: a single brain
metastasis was associated with a mean survival of 62 weeks, 2e3 brain
metastases with 14 weeks, and four brain metastases with ten weeks.
First action plan: Improve assessment and documentation of PS to allow
calculation of DS-GPA, and facilitate targeting of more aggressive manage-
ment of intracranial metastases to patients with fewer BMs and better PS, as
they may derive greater beneﬁt from alternative treatments such as ste-
reotactic radiosurgery or neurosurgery.
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Stereotactic radiotherapy for primary lung cancer
I. Phillips, R. Flint, B. Hin, V. Ezhil
Royal Surrey County Hospital, Guildford, United Kingdom
Category: Radiotherapy
Background to the audit: Stereotactic ablative body radiotherapy (SABR) is
now a standard treatment for non small cell lung cancer. It has an established
role in patients who are medically inoperable and randomised trial data
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suggests there is signiﬁcantly less short-term mortality than surgical
intervention.[1]
As an established centre for SABR for primary lung cancer and oligometastatic
disease we wanted to audit the outcomes of our initial cohort of patients.
Standard: For our standard we compared our results to two recent publi-
cations. Firstly a meta analysis of early stage primary lung cancer that has
compiled clinical outcomes for published randomised control trials and
secondly to the ﬁrst UK case series, both published by St James Institute of
Oncology, Leeds.[2],[3]
Indicator: One-year local control rate.
Target: Local control rate of over 90% at one year.
Methodology: We reviewed all patients with available imaging treated be-
tween January 2012 and November 2016.
More than 50% of patients have been treated since June 2015.
All patients with at least one post-treatment scan, or those who had died
before a ﬁrst scan were included.
Results of ﬁrst audit round: 116 patients had been treated with SABR. They
were followed up at seven different district general hospitals. Mean age was
66.5 years (range 56e90). 55% of patients had a biopsy proven lung cancer,
45% were radiologically diagnosed with a formal MDT decision of likely
primary lung cancer.
Local control rate at one year was 97%. Median survival is 713 days (95% CI
578e848 days).
First action plan: To establish accurate three-year survival data.
To maintain database of SABR patients.
Continue to follow-up SABR patients to see if median survival increases as
cohort matures.
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Regional audit of timing of surgery in patients receiving short course
pre-operative radiotherapy (SCPRT) for rectal cancer
L. Davidson *, N. Alam *, C. Arthur *, C. McBain *, V. Misra *,
M. Saunders *, S. Duff y
*Christie NHS Foundation Trust, Manchester, United Kingdom
yUniversity Hospital of South Manchester NHS Foundation Trust,
Manchester, United Kingdom
Category: Rectal and colon
Background to the audit: SCPRT should be considered to reduce local
recurrence risk for some rectal cancers where the circumferential resection
margin is clear.[1],[2],[3] SCPRT acute toxicity occurs two weeks from the start
of treatment. This may impact on surgical outcomes.[4] However, there is no
clear consensus regarding the timing of surgery following SCPRT.[2],[3]
Standard: 95% of patients operated within ten days from start of SCPRT.
Primary aim: to assess timing of surgery in relation to SCPRT for patients in
Greater Manchester and Cheshire.
Secondary aim: to improve the regional pathway.
Indicator: The number of days from commencement of SCPRT to surgery, for
patients in Greater Manchester and Cheshire.
Target: 95% of patients operated within ten days from start of SCPRT.
Methodology: Retrospective audit of patients treated with SCPRT 1/1/14 -
31/3/14 (1st audit) and 1/1/16 e 31/3/16 (re-audit).
Data collected: SCPRT start date and surgical date.
Results of ﬁrst audit round:
43 patients (30 males: 13 females) received SCPRT.
The range of days was 5e25 days.
13 out of the 43 (30.2%) patients underwent surgery within ten days from
start of SCPRT.
First action plan:
The above results were discussed at the Manchester Cancer Colorectal
Pathway Board (MCCPB). Due to inconsistency, it was recommended that
patients should receive surgery within 12 total days from the start of SCPRT.
Essentially patients would have SCPRT one week and surgery the following
week. To improve the clinical pathway, referrals would include a surgical
date to aid SCPRT.
To re-audit patients treatedwith SCPRT between 1/1/16 and 31/3/16 to assess
the implementation of the recommendations.
Results of second audit round: 20 patients (12 males: 8 females) received
SCPRT.
The range of days was 7e18 days.
19 out of the 20 (95%) patients underwent surgery within 12 days from start
of SCPRT.
Second action plan: 95% of patients operated within 12 days from start of
SCPRT was achieved. These results were re-discussed at the MCCPB. The one
outlier was discussed to improve the patient pathway.
To re-audit in ﬁve years or as deemed clinically appropriate.
Conclusion: This simple pathway change has led to a dramatic improvement
in time to surgery, in turn improving patient outcomes.
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An audit of neoadjuvant radiotherapy in soft tissue sarcoma at Not-
tingham City Hospital, 2011e2016
J. Price, C. Esler
Nottingham University Hospitals NHS Trust, Nottingham, United
Kingdom
Category: Sarcoma
Background to the audit: There is increasing use of neoadjuvant radio-
therapy (RT) prior to curative surgery in soft tissue sarcoma. This involves a
lower dose, smaller margins and can improve patients’ functional outcomes
when compared to postoperative RT, but at the expense of an increased risk
of acute wound complications.[1]
We audited our clinical outcomes, RT technique and patient treatment
pathways at Nottingham City Hospital. Indications for RT, planning margins,
doses, treatment duration and timelines for surgery were all compared to
published standards. Clinical outcomes analysed were acute toxicity, local
control and time to metastases.
Standard: UK guidelines for the management of soft tissue sarcomas e
British Sarcoma Group, 2016[2]
Indicator:
1. Patients should receive 50 Gray (Gy) in 25 fractions over ﬁve weeks.
2. Post-RT magnetic resonance imaging (MRI) should be performed around
three weeks post radiotherapy.
3. Surgery should take place 4e6 weeks post radiotherapy.
Target: 100% compliance to above indicators
Methodology: Patients were identiﬁed from Mosaic RT database. De-
mographics and clinical data collated from NOTIS (clinical database). RT
margins, dose, duration, acute toxicity and use of bolus collated from Pros-
oma RT software.
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Conclusion  
The use of IMRT for SIB in right breast has to be limited to 
those patients for which electron boost or brachytherapy 
is not adequate as the mean dose to heart is significantly 
higher. The use of DIBH in left-sided breast considerably 
reduces mean and V25 heart doses. IMRT in left-sided 
breast shows an increase in Dmean and a decrease in V25, 
which leads to significant differences in dose distribution 
over the heart. Heart toxicity could, therefore, have 
different patterns depending on the technique, being Dmean 
a poor surrogate for heart toxicity.  
Skin toxicity has to be followed-up carefully in patients 
with high breast volumes.  
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Purpose or Objective  
Intratumoural heterogeneity has been reported in the 
literature to correlate to treatment outcome and overall 
survival. In this study, a volumetric voxel based map of 
intratumoural heterogeneity measured from CT images 
was used to guide dose painting. This approach was 
compared against dose painting based on FDG PET uptake 
distributions in regards to the overlap between the boost 
volumes and the delivered dose to target volumes and 
organs at risk (OAR).  
Material and Methods  
PET/CT and planning CT images for ten patients diagnosed 
with advanced inoperable non-small cell lung cancer 
(NSCLC) were retrieved retrospectively. The gross tumour 
volume (GTV) contour was used to segment the primary 
tumour from the CT and PET images. A volumetric voxel 
based map of intratumoural heterogeneity was generated 
from tumour CT image using a second-order statistical 
texture analysis method of grey level co-occurrence 
matrices. The FDG PET image was converted to SUV map. 
The low CT intratumoural heterogeneity regions within the 
generated texture map overlapped with high FDG uptake 
regions within the PET image (overlap of 65±11%). Hence, 
two boost volumes were identified, the low CT 
intratumoural heterogeneity region (BoostHeterogeneity) and 
the high FDG uptake region of >50% SUVmax (BoostFDG). A 
3mm margin was added to the boost volumes to account 
for physical uncertainties and these volumes were labelled 
PTVHeterogeneity and PTVFDG. Two volumetric arc therapy plans 
(VMAT) were created for each patient, with a prescribed 
dose of 84Gy in 32 fractions to PTVHeterogeneity or PTVFDG and 
64Gy in 32 fractions to the remainder of the clinical PTV. 
The dose to the boost volumes and OARs (spinal cord, 
oesophagus, normal lung and heart) was measured and 
compared between the two plans.         
Results  
The dose escalation to the boost volumes in the created 
plans were shown to be clinically feasible with the dose to 
OARs  within tolerance limits and 95% of the target volume 
receiving ≥95% of the prescribed dose. When boosting 
based on PTVHeterogeneity, the dose to 95% of PTVFDG received 
≥95% of the prescribed dose for 3 patients while the other 
seven patients received 80-92% of the prescribed dose. 
However, 95% of the BoostFDG volume received ≥95% of the 
prescribed dose for 9 of the 10 patients.   
Conclusion  
The results show the feasibility of dose escalation in 
advanced NSCLC while keeping to normal tissue 
constraints. Moreover, the preliminary results suggest that 
boosting based on intratumoural heterogeneity measured 
from CT images,  results in the high 18F-FDG regions 
receiving a high dose, indicating the potential of using CT 
intratumoural heterogeneity generated from standard CT 
images as a surrogate for functional imaging in dose 
painting. 
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Purpose or Objective  
Synchrotron microbeam radiation therapy (MRT) is a novel 
radiotherapy modality with significant clinical potential. 
We have produced a simple dose calculation algorithm for 
MRT using the Eclipse Treatment Planning System (TPS), 
by Varian Medical Systems. 
Material and Methods  
The calculation engine in Eclipse was configured to 
directly evaluate ‘peak’ doses.  Monte Carlo-simulated 
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G8 assessment for patients with lung cancer 
I Phillips, K Webb, S Cabral, S Quirin, K Nimako and V Ezhil 
Introduction 
The aim of this project was to see whether a G8 assessment correlates with an intention to give anti-
cancer treatment.  
Method  
We prospectively assessed all patients attending a respiratory clinic with a new diagnosis of lung 
cancer using a G8 questionnaire. This information was collected as part of completing an audit cycle 
approved by East Surrey Hospital audit committee. ‘Fit’ was defined as a G8 score of 15 or higher, 
‘unfit’ as lower than 15. Statistical analyses performed were chi-squared and Mann-Whitney tests; p-
values were two-tailed with a significant level set at <0.05.  
Results 
55 assessments were completed between October 2016 and May 2017. Mean age was 61 (range 55-
87). 13 patients (24%) presented with stage 1 disease, 6 (11%) with stage 2, 10 (18%) with stage 3 
and 26 (42%) with stage 4 disease.  28 had stage 1-3a, 27 patients had stage 3B or 4. 12 patients 
were fit, and 43 were unfit.  Overall 12 out of 12 (100%) of fit patients were intended for at least one 
kind of treatment, and 37 of 43 (86%) unfit patients were intended for treatment (p=0.3206).  20 
patients were considered for radical treatment, and 35 patients were considered for palliative 
treatment. The mean G8 score for radical patients was 13.4, and the mean score for palliative 
patients was 10.7 (p=0.00158). Overall, those intended for treatment had a mean score of 12.1, and 
those who were not intended for treatment had a mean score of 7.9 (p=0.0028). Of the 35 palliative 
patients, 26 were deemed fit for chemotherapy (mean score 11.5), and nine patients as not fit for 
chemotherapy (mean score 8.2, p=0.0053). 
Discussion 
Our results show that the G8 assessment may be a useful tool for assessing fitness to treat in lung 
cancer and is worth further evaluation in larger studies.  
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OBJECTIVES 
MATERIALS and METHODS 
CONCLUSIONS 
PET/CT and planning CT images for ten patients diagnosed with advanced 
inoperable NSCLC were collected, the gross tumour volume (GTV) contour was 
used to segment the primary tumour from the CT and PET images. 
 A volumetric voxel based map of intratumoural heterogeneity was generated 
from tumour CT image using a second-order statistical texture analysis method 
of grey level co-occurrence matrices.  
The FDG PET image was converted to an SUV map. 
 The low CT-derived intratumoural heterogeneity regions within the generated 
texture map overlapped with high FDG uptake regions within the PET image 
(overlap of 65±11% 1SD). Hence, two boost volumes were identified, the low 
CT-derived intratumoural heterogeneity region (BoostHeterogeneity) and the high 
FDG uptake region of >50% SUVmax (BoostFDG).  
A 3mm margin was added to the boost volumes to account for physical 
uncertainties and these volumes were labelled PTVHeterogeneity and PTVFDG.  
Two volumetric arc therapy plans (VMAT) were created for each patient, with 
a prescribed dose of 84Gy in 32 fractions to PTVHeterogeneity or PTVFDG and 64Gy 
in 32 fractions to the remainder of the clinical PTV.  
The dose to the boost volumes and OARs (spinal cord, oesophagus, normal 
lung and heart) was measured and compared between the two plans. 
 
The results show the feasibility of dose 
escalation in locally advanced NSCLC while 
keeping to normal tissue constraints.  
The preliminary results suggest that boosting 
based on intratumoural heterogeneity measured 
from CT images, results in the high 18F-FDG 
regions receiving a high dose, indicating the 
potential of using CT intratumoural heterogeneity 
generated from standard CT images as a 
surrogate for functional imaging in dose painting. 
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Results 
Figure1: An example of the GTV, BoostHeterogeneity and 
BoostFDG for a patient from our investigated cohort. 
The dose escalation to the boost volumes in the 
created plans were shown to be clinically feasible 
with the dose to OARs within tolerance limits and 
95% of the target volume receiving ≥95% of the 
prescribed dose. 
 When boosting based on PTVHeterogeneity, the dose 
to 95% of PTVFDG received ≥95% of the prescribed 
dose for 3 patients while the other seven patients 
received 80-92% of the prescribed dose. However, 
95% of the BoostFDG volume received ≥95% of the 
prescribed dose for 9 of the 10 patients. 
Figure 2: The dose received by 95% of the BoostFDG volume in the boost plans based  
on PTVHeterogeneity labelled VMATHeterogeneity and PTVFDG labelled VMATFDG. The dashed  
line is 95% of the prescribed dose and the solid line is 100% of the prescribed dose. 
Radical radiotherapy ± chemotherapy is the standard of care for treatment of locally advanced Non-Small Cell Lung Cancer 
(NSCLC). Standard dose escalation of external beam radiotherapy has not led to better treatment outcomes1. CT intratumoural 
heterogeneity has been shown to correlate with patient survival in NSCLC2,3. We pursued a novel approach to guide dose painting, 
using volumetric voxel based mapping of intratumoural heterogeneity captured from CT images. This approach was compared against 
dose painting based on FDG-PET uptake distributions; in regards to the overlap between the boost volumes and the delivered dose to 
target volumes and organs at risk (OAR). 
Weight loss in lung cancer at referral to the dietitian
Adele Hug, Iain Phillips, Lindsey Allan, Veni Ezhil
St Luke’s Cancer Centre – Royal Surrey County Hospital
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Conclusion
• It is known that early symptom control improves
survival in lung cancer3.
• Cancer cachexia is very common (75%) in patients
with advanced lung cancer at time of dietitian review.
• BMI is a poor marker of weight loss. These patients
have a BMI within the healthy range of 20-25 kg/m²
before and after their cancer diagnosis in spite of
significant weight loss.
• It is not clear how common malnutrition, cachexia or
sarcopenia is at presentation in lung cancer.
• Could up front dietetic assessment and counselling
improve patient experience and outcome in patients
with advanced lung cancer?
• Ethical approval is being sought to prospectively assess
the rate of cancer cachexia in lung cancer and its
correlation with other simple nutrition assessment
tools in the NAIL trial (Nutrition Assessment and
Intervention in Lung Cancer).
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Results
• 314 patients were included
• Mean age = 68.8 years (36 to 89 years)
• 42% were female, 58% were male
• Mean weight change at referral: -10% (-35.8% to +7.3%)
• 76% of patients had lost >5% of pre diagnosis weight.
• Mean pre-diagnosis BMI: 26.9kg/m²
• Mean BMI at referral: 23.0kg/m².
Background
Lung cancer is the second most common cancer diagnosed
in men and women in the UK with a very poor 5 year
survival (10%)1.
Cancer cachexia is a progressive disorder, leading to
decreased physical activity, adverse psychological side
effects, poor performance status and higher mortality rates.
The severity of cancer cachexia can influence overall
outcome; refractory (irreversible) cachexia indicates a poor
prognosis of usually less than 3 months2. Cancer cachexia
has previously been defined by percentage weight loss from
usual body weight, ‘weight loss greater than 5%, or weight
loss greater than 2% in individuals already showing
depletion according to current bodyweight and height (BMI
<20 kg/m2) or skeletal muscle mass loss (sarcopenia)’2.
There is a lack of robust data in advanced lung cancer on the
stage of cancer cachexia and whilst screening, assessment
and prophylactic nutrition support is standard practice for
patients with primary cancers of the head and neck region,
this is not the case for those with lung cancer.
% weight change at referral to the dietitian
Adapted from Fearon et al. 2011, Lancet Oncology 12(5):489-495
Characteristic
Cachectic (>5% 
weight loss)
Non cachectic (< 
5% weight loss)
% weight loss at 
referral
-12.9 -2.1
Mean pre-treatment 
BMI (kg/m2)
25.7 25.1
Mean post treatment 
BMI kg/m2)
22.4 24.5
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Methods
• All patients with advanced lung cancer referred to the 
oncology dietitian  from July 2011 to April 2014 were 
included
• Height, weight at referral, patient reported usual body 
weight was collected, and Body mass index (BMI) was 
calculated.
Introduction
Cancer cachexia is a multifactorial syndrome characterised
by a loss of muscle mass and function and is an adverse
effect of many common cancers. The presence of refractory
(irreversible) cachexia is associated with a very poor overall
survival. Radiological sarcopenia is a feature of cancer
cachexia and can be assessed on CT imaging. Sarcopenia
refers to the loss of muscle mass, power and function (1).
Cross sectional measurement of the psoas muscle is one
method of assessing radiological sarcopenia. It is an
accurate, quick and inexpensive assessment of sarcopenia
as the imaging forms part of a patient’s standard staging
investigations.
Methods
This was a feasibility study to assess how manageable it
was to measure sarcopenia. Data was collected from an
MDT between July 2012 and December 2013. All patients
with biopsy proven lung cancer from this period were
eligible. Patients were included if they had a formal
recorded height measurement as part of lung function
testing or the electronic chemotherapy record. Anterior-
posterior and lateral measurements of greatest diameter of
psoas muscle was made at level of L3 through the
transverse processes from the diagnostic CT. Left and right
psoas muscle measurements were taken and standardised
for height. As per figure 1. This measure had previously
been found to be equivalent to more complex methods (2).
The cut off value for men was 390mm/m2 and 550mm/m2
for women. These are from internationally agreed
consensus guidelines (3).
Results
• 90 patients were identified retrospectively with 
appropriate imaging and recorded height data 
• 56% were male, 44% female 
• Mean age was 73 (range 41-88)
• 47% of patients with lung cancer were sarcopenic
• Median survival of non-sarcopenic patients was 15 
months. Median survival of sarcopenic patients was 12 
months (p= 0.22).
Discussion and future 
recommendations
• Sarcopenia is common in patients with lung cancer. 
• Sarcopenia assessment using cross sectional 
measurements of psoas muscle is quick, easy, 
inexpensive and reproducible. 
• Combining this assessment with weight loss could 
measure cancer cachexia.
• There is an association between sarcopenia and 
survival. 
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Audit of treatment received by older patients with lung 
cancer between July 2012 – December 2013 
Philips I, Gunn L,  Nimako K, Ezhil V 
St Lukes Cancer Centre – Royal Surrey County Hospital 
Background 
40% of lung cancer cases occur in over 70’s. It is perceived that older patients with other common cancers are under 
treated and less likely to enter clinical trials [1-6]. We completed an audit to review our management of patients over 70 
versus under 70  in both the radical and palliative setting.  
Standards, Indicators and Targets 
 
No standard exists for the management of older patients 
with lung cancer. We generated our standard from the 
number of patients treated in the under 70 group. Our 
target was that 80% of the proportion of under 70's, 
receiving treatment in the over 70’s. 
Methodology 
 
Data was collected for patients with biopsy proven lung 
cancer discussed at the MDT between 01/07/12 and 
31/12/13 . Patients were divided into 4 groups based on 
their suitability for treatment as per the MDT.  
 
• Under 70 years old radical (stage I-IIIa and T4N2) 
• Under 70 palliative (other IIIb and stage IV) 
• Over 70 years radical  
• Over 70 years palliative 
Results 
 
Data was available for 197 new patients. 13% stage I, 7% 
stage II, 29% stage III (18% IIIa, 11% IIIb) and 51% stage IV. 
Median age was 70 (range 41-95 years).  
 
Overall survival  for radical patients under 70 was 22 
months versus 11 months in the over 70’s group. 
Irrespective of age, overall survival for all palliative 
patients, including those who had best supportive care 
alone,  was 4 months. 
 
Radical treatment rates in over 70’s and under 70’s were 
similar (57% vs 52%). For those with disease amenable to 
radical treatment, similar rates were referred for best 
supportive care irrespective of age (3% and 7%).  For those 
with metastatic lung cancer 5% of under 70’s were referred 
for best supportive care compared with 50% in over 70’s.   
 
For those with metastatic disease, 75% of under 70’s 
received palliative chemotherapy. 1/3 of patients over 70 
were too unwell to attend clinic, a further 1/3 attended but 
were unfit for treatment following clinic assessment. 
Therefore 34% over 70’s received palliative chemotherapy. 
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Actions 
To implement a geriatric screening tool (G8) before 
attending clinic and correlate with those identified as fit 
for chemotherapy. 
 
 
Conclusion 
 
• Radical treatment rates for the patients >70y are 
equivalent to younger patients. 
 
• Patients >70y with metastatic lung cancer are less likely 
to receive palliative chemotherapy. 
 
• Patients >70y with metastatic disease are 10 times 
more likely to be referred for best supportive care. 
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Introduction 
As a Commissioning Through Evaluation (CTE) centre we 
wanted to formalise our Cone Beam CT (CBCT) protocol for 
treating patients with abdominal level oligometastases. 
We wanted to compare different imaging modes when 
treating patients eligible for Stereotactic Ablative Body 
Radiotherapy (SABR) through CTE using VMAT. Patients 
receive 3 CBCTs during each treatment. Abdominal CBCTs 
are often limited by bowel gas obstructing soft tissue 
visualisation, leading to difficulties in target matching 
Methods 
 
Patients undergo a ‘day 0’ dry run of their radiotherapy. 
The treatment is delivered in 2 arcs as VMAT. For each 
fraction of treatment a patient received a pre-, mid and 
post-treatnebt CBCT. They had at least 1 pelvic mode and 1 
spotlight mode CBCT with the same slice thickness (usually 
2mm) during each fraction of treatment.  
 
We used the standard deviation as a metric to determine 
whether Pelvis or Spotlight mode was better at abdominal 
soft tissue visualisation. An area of bowel gas artefact, fat 
and other tissue were chosen on each Spotlight and pelvis 
modes 
 
Power standard deviations would reflect better image 
reconstruction of homogenous regions, leading to greater 
confidence in soft tissue matching.  
 
 
Results 
CBCTs were matched to the planning CT via 
bony registration for 18 separate fractions 
over 9 patients. Pelvis and Spotlight CBCTs 
were taken within 20 minutes of each 
other giving a near simultaneous 
comparison of on-treatment image 
acquisition. Once registered, a 2x2cm ROI 
was positioned within areas of related 
tissue in the same space on both CBCTs 
and CT to measure the mean and standard 
deviation in the HU numbers.  
 
Discussion and future 
recommendation 
• there was no statistical significance between the 
Spotlight and Pelvis mode 
• the average standard deviation was marginally lower 
for the Pelvis mode in all three regions.  
• Due to the faster acquisition time and overall lower 
dose the spotlight mode has been favoured for soft 
tissue matching.  
• Radiographers have also commented their preference 
for the mode 
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Choosing the appropriate Cone Beam CT mode for treating 
abdominal metastases with SABR on a Linear Accelerator 
Phillips, I. Earley, J. Julian, R. Kelly, M. Lamont, K. & Ezhil, V.  
Royal Surrey County Hospital, Guildford. 
ROI 
Standard Deviation 
in ROI T-test 
Spotlight Pelvis 
Tissue 43 39 0.2 
Fat 41 38 0.2 
Artefact 73 69 0.4 
Introduction 
As a designated Commissioning Through Evaluation (CTE) Stereotactic Ablative Body Radiotherapy (SABR) 
centre, we evaluated the service given to patients who have received SABR for primary lung cancer or to 
oligometastases within CTE. 
Methods 
We surveyed a random sample of patients who received 
their treatment under the care of 1 consultant. Patients 
were eligible if they were 4 weeks from completion of 
treatment. Patients were given the feedback form after 
their clinic appointment. 
 
Patients were asked the following:  
1. Did they receive enough information about the 
treatment?  
2. Did they receive enough information about medication 
needed for the treatment?  
3. Was the treatment delivered in a timely manner?  
4. Would they have the treatment again?    
 
All answers were graded 1 to 5. 1=strongly disagree, 3= 
neither agree or disagree, 5=strongly agree. We also asked 
patients for specific comments to improve the service. 
Patient Comments 
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Results 
We surveyed 33 patients. 28 patients had treatment 
to a primary lung tumour. 5 patients were treated 
within CTE. Average age was 77.9 (range 55-91).  
 
100% of patients agreed/strongly agreed that they 
received sufficient information about the treatment, 
felt it was delivered in a timely manner and would 
have it again. 97% of patients agreed/strongly 
agreed that they had been well informed regarding 
the treatment.  88% of patients felt they had been 
well informed about medications required. 
 
Mean travelling distance between home and hospital 
was 17 miles (range 2.8-44.7) and mean travelling 
time was 28 minutes (range 7-53).  
Discussion 
• Our patients had a positive experience receiving 
SABR treatment under our care.  
• We have developed specific patient information 
for patients attending the clinic for Lung SABR. 
• The comments directly informed our patient 
information sheet now given to patients to further 
improve their experience. 
• To minimise delays and as some patients travel a 
significant distance for SABR we aim to perform a 
radiotherapy planning CT scan on the day of the 
new patient appointment.  
 Treatment experience of patients receiving SABR at a regional cancer 
centre 
 
Phillips, I. Chan, K. Kelly, M. Lamont, K. Ezhil, V  
St Lukes Cancer Centre – Royal Surrey County Hospital  
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Analysis of the Incidence of Cancer Cachexia in Patients  
with Advanced Lung Cancer at Referral to a Dietitian 
Hug, A, Phillips I, Allan, L, Mendis, A & Ezhil, V. 
St Luke’s Cancer Centre – Royal Surrey County Hospital, Guildford, Surrey, United Kingdom 
Background 
Lung cancer is the second most common cancer diagnosed in men 
and women in the UK with a very poor 5 year survival (10%) 1. 
Cancer cachexia is a progressive, multifactorial syndrome, leading to 
decreased physical activity, adverse psychological side effects, poor 
performance status and higher mortality rates. The severity of cancer 
cachexia can influence overall outcome; refractory (irreversible) 
cachexia indicates a poor prognosis of usually less than 3 months 2. 
Cancer cachexia has previously been defined by percentage weight 
loss from usual body weight, ‘weight loss greater than 5%, or weight 
loss greater than 2% in individuals already showing depletion 
according to current bodyweight and height (BMI <20 kg/m2) or 
skeletal muscle mass loss (sarcopenia)’2. There is a lack of robust 
data in advanced lung cancer on the stage of cancer cachexia and 
whilst screening assessment and prophylactic nutrition support is 
standard practice for patients with primary cancers of the head and 
neck region, this is not the case for those with lung cancer. 
Results 
• 314 patients with advanced lung cancer were reviewed by the dietitian; 
average 94 each year.  
• Mean age was 68.8 (range 36 to 89). 42% were female, 58% were male.  
• Mean weight loss was -10% (range -35.8% to +7.3%). 76% of patients had 
lost >5% of pre diagnosis weight.  
• Mean pre-diagnosis BMI was 26.9kg/m², mean BMI at referral was 
23.0kg/m².  
• Reasons for referral commonly included: weight loss, glycaemic control in 
diabetes, decreased oral intake and food texture modification.  
• Median survival of non-cachectic and cachectic cohorts were different 
(299 vs 188 days respectively, p=0.0078) 
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Conclusion 
• It is known that early symptom control improves survival in lung 
cancer 3.  
• Cancer cachexia is very common (75%) in patients with 
advanced lung cancer at time of dietitian review . 
• BMI is poor indicator of weight loss. These patients have a BMI 
within the healthy range of 20-25 kg/m² before and after their 
cancer diagnosis in spite of significant weight loss.  
• It is not clear how common malnutrition, cachexia or sarcopenia 
is at presentation in lung cancer.  
• Could up front dietetic assessment and counselling improve 
patient experience and outcome in patients with advanced lung 
cancer?  
• We are seeking ethical approval to prospectively assess the 
rate of cancer  cachexia in lung cancer and its correlation with 
other simple nutrition assessment tools in the DAIL trial (Dietetic 
Assessment and Intervention in Lung Cancer). 
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Methods 
• Data was collected prospectively from June 2011 until July 2015. 
• On referral to the dietitian date of birth, sex, treatment, actual 
weight, height, self reported usual body weight (UBW) were 
recorded. 
• Age at referral was calculated and date of death was obtained 
from the NHS Spine and used to calculate overall survival from 
referral to the dietitian. 
• Weight loss was calculated from UBW and body mass index  
(BMI) calculated. 
% weight loss at referral to the Registered Dietitian 
Visually identifying poor lung function
‘Boomerang’ plot=                      ‘Bonfire in the wind’  
Good lung function                     lot = poor lung function
Comparing good lung 
Function with high 
entropy (left) with poor 
lung function (right)
Green = high entropy
Introduction
Lung cancer is commonest cause of cancer death worldwide. It is the second commonest cancer diagnosed 
in both men and women in the UK. CT scans are ubiquitous in assessing and managing lung cancer in the 
developed world. CT scans show anatomical information using density measured in Hounsfield Units (HU). 
Texture analysis (TA) can provide greater information about an image. The aim of this project was to see if 
TA outcome measures correlated with lung function using a region of interest from a patient’s CT scan.
Methods
Patients were included if they had a diagnosis of lung
cancer, and had both pre-treatment formal lung
function tests and the radiotherapy planning CT scan
available. A 4 x 2.5cm segment of lung from planning
CT scan was extract and analysed as seen in figure 1.
The entropy score was derived software using a
GLCM (Grey Level Co-Occurrence Matrix) developed
in house. Average (mean, median and mode) entropy
score and density score (in HU) were derived for each
volume. These scores were compared to % predicted
FEV1 (volume of air expelled in 1 second) and TLCO
(lung gas transfer function). Pearson correlation co-
efficient was used to analyse associations between
different measures of texture and lung function
(both FEV1 and TLCO).
Results
20 patients were included. When lung function is
tested is it is calculated by comparing to a %
predicted value standardized using height,
gender and age. Range of % predicted value
FEV1 ranged from 25-100%, TLCO from 43-112%.
Highest correlation was between mode density
and TLCO (0.81)
Discussion
1. Lung function appears to correlate with
scan appearance.
2. Extracting extra data from routine medical
imaging is possible
3. It may be possible how is fit for radiotherapy
based on scan appearance.
Predicting lung function and fitness for radiotherapy from a CT scan
Phillips, I. Hussein, M., Ezhil V. Ajaz, M. South, C. Nisbet, A. Evans, P.  
St Lukes Cancer Centre – Royal Surrey County Hospital 
Centre for Vision, Speech and Signal Processing, Univ of Surrey
Mean
HU
Median 
HU
Mode 
HU
Mean 
entropy 
Median 
entropy
Mode 
entropy
FEV1 0.49 0.50 0.55 0.62 0.65 0.68
TLCO 0.7 0.72 0.81 0.60 0.64 0.59
Table 1 shows Peason correlation co-efficients between 
measure of lung function (either TLCO or FEV1) and a 
measure of density of entropy.
Figure 1, diagram illustrating the lung sections 
analysed in this study. 
How do you analyse texture?
Texture analysis (TA) is a way of getting data from an
image or region of interest within an image. There
are a range of ways of achieving this, in this study a
voxel in an image was compared to the 26 other
voxels around it, to see if they were similar or
different. This built a map of similarity and difference
rather than of density, as seen in a normal CT scan.
Stereotactic Ablative Body Radiotherapy (SABR) for 
oligometastatic cancer
Methodology
Descriptive statistics have been used to present the nominal
data collected. The sample group included all patients who
have received SABR for oligometastases treated by the
SABR team at RSCH, through the CTE (Commissioning
Through Evaluation) programme.
Clinical outcomes measured were; Local control rate, distant
control rate and the relapse free rate.
Introduction
Royal Surrey County Hospital (RSCH) has been designated
as a national centre able to treat oligometastases using
Stereotactic Ablative Body Radiotherapy (SABR). SABR is a
form of highly targeted radiotherapy, giving a radical
treatment in fewer, larger doses, when compared to normal
radical radiotherapy1. Oligometastases are 1-3 areas of
cancer that have metastasized from the original tumour2.
The hypothesis for treating oligometastases is that by
controlling clinically apparent disease, this can prevent the
need for systemic treatment and possibly improve overall
survival3. Recent data suggests that SABR treatment after
chemotherapy in Non-Small Cell Lung Cancer significantly
improves progression free survival (12 months vs 4 months)
when compared to maintenance chemotherapy3.
Results
We have treated 51 lesions in 41 patients. Mean age at
treatment 72 years old (range 36-90). 27% female and 73%
male. Of the lesions treated 37% were lymph node
metastases, 35% lung metastases, 25% bone metastases,
and 2% adrenal metastases. The commonest primary
tumour was prostate cancer (24%), melanoma (15%), colo-
rectal (15%), lung (12%), breast (12%) and renal cell
(10%). Mean follow up to date is 169 days, with local and
distant control rates of 90% and 85% respectively. Relapse
free rate at 6 months of follow up was 75%.
Conclusions
Although the follow up for this cohort is immature, our data 
suggests the majority of patients (75%) with incurable 
cancer, do not need further anti-cancer therapy within 6 
months of treatment.
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Stereotactic Radiotherapy for Primary Lung Cancer
Methodology
All patients treated with SABR between January 2012 and
November 2016, with available imaging, and a diagnosis of
primary lung cancer (biopsy or radiologically confirmed) were
reviewed.
All patients with at least 1 post treatment scan, or those who
had died before a first scan were included.
Imaging reports were obtained from 7 referral hospitals.
Introduction
Stereotactic Ablative Body Radiotherapy is now a standard
treatment for Non Small Cell Lung Cancer. It has an
established role in patients who are medically inoperable due
to co-morbidities or poor lung function, or patient choice.
A pooled analysis of 2 randomised trials that recruited fewer
patients than anticipated by Chang et al. suggests there is
significantly less short term mortality than surgical
intervention.
Improved 3 year overall survival SABR vs surgery of 95%
(95% C.I 85–100) vs 79% (64–97) (1). Grade 3 toxicities 10%
in the SABR vs Grade 3-4 toxicities 44% in the surgery group.
The Royal Surrey County Hospital is a commissioned centre
for SABR for primary lung cancer and oligometastatic disease
within the Commissioning Through Evaluation (CTE)
programme.
As part of our commitment to improve patient care and quality
improvement, we carried out an audit to review the outcomes
of our initial cohort of patients treated with lung SBRT.
Results
Local control rate at 1 year was 97%. 
116 patients were treated with SABR.
Follow-up occurred at 7 different district general hospitals.
More than 50% of patients have been treated since June
2015.
Mean age was 66.5 years (range 56-90).
55% of patients had a biopsy proven lung cancer, 45%
were radiologically diagnosed with a formal MDT decision
of likely primary lung cancer.
Median survival is 713 days (95% CI 578-848 days).
All patients were staged with a PET-CT
Action Plan
To establish accurate 3 year survival data.
To maintain database of SABR patients.
Continue to follow up SABR patients to see if median
survival increases as cohort matures.
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Standard
For our standard we compared our results to two recent
publications.
Firstly a meta analysis of early stage primary lung cancer that
has compiled clinical outcomes for published randomised
control trials
secondly to the first UK case series, both published by St James
Institute of Oncology, Leeds (2,3). 1 year local control from
meta-analysis was and 98% in the published case series. From
15 published studies the mean 1 year local control rate was
87% (range 78-100%).
Indicator: 1 year local control rate.
Target: Local control rate of over 90% at 1 year
Conclusions
Our data shows that we achieved the 1 year local control
rate for SABR or NSCLC which was above the target of
90% at 97%.
Local control  following 
SABR for primary lung 
cancer
Local Control
Local Recurrence
Method of diagnosis
Biopsy proven NSCLC
Radiologically diagnosed lung
cancer
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Appendix 2 
 
 
TEXAS trial: TEXtural Analysis after Stereotactic 
radiotherapy  
 
Understanding the Relationship between PET-CT and CT textural 
analysis before and after radical radiotherapy in Non-Small Cell Lung 
Cancer.  
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Glossary 
AE  Adverse Event 
BMI                   Body Mass Index 
CBCT                Cone Beam Computer Tomography Scan 
CT                      Computer Tomography 
CTE                   Commissioning through evaluation 
CVSSP              Centre for Vision, Speech and Signal Processing, Univ of Surrey 
EBRT                External Beam Radiotherapy 
Gy                      Gray (unit of radiotherapy dose) 
GTV                   Gross Tumour Volume 
HR                     Hazard Ratio 
IMRT                 Intensity Modulated Radiotherapy 
ITV               Internal Target Volume 
NSCLC  Non-Small Cell Lung Cancer 
PET-CT scan Positron Emission Tomography-Computer Tomography Scan 
PTV              Planning Target Volume 
RSCH  Royal Surrey County Hospital 
SABR  Stereotactic Ablative Radiotherapy 
VMAT               Volumetric Modulated Arc Therapy
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1. Protocol Summary 
 
TITLE:  
TEXAS trial: TEXtural Analysis after 
Stereotactic radiotherapy  
 
SHORT TITLE TEXAS trial 
SPONSOR   Royal Surrey County Hospital 
FUNDER REFERENCE  
CLINICAL TRIALS GOV   
DESIGN: Pilot study, retrospective cohort study 
OVERALL AIM: To understand textural changes of the tumour and 
surrounding lung tissue, when primary lung tumours 
receive Stereotactic Ablative Body Radiotherapy (SABR). 
PRIMARY 
OBJECTIVES; 
 To identify whether it is possible to predict 
recurrence of primary lung tumours using textural 
analysis of post treatment CT scans of patients 
previously treated with Stereotactic Ablative Body 
Radiotherapy (SABR). 
SECONDARY 
OBJECTIVES: 
 To identify whether it is possible to predict a pattern 
of radiation induced lung injury after SABR 
 To see if textural analysis can predict lung function 
in patients having radical radiotherapy using the 
4DCT scan (TEAL sub-study) 
Target Accrual 30 patients for TEXAS study 
60 patients for TEAL (Textural Analysis and Lung 
Function) sub study.  
Inclusion criteria  TEXAS study 
 Patients previously treated with Stereotactic Ablative 
Lung Radiotherapy (SABR) for Non-Small Cell Lung 
Cancer (NSCLC). 
  Patients either had biopsy confirmed NSCLC or a 
clinical decision has been made that there is a high 
probability of NSCLC suitable for SABR. Cohort 1: No 
recurrence of cancer after SABR, 
 Patients have pre-treatment pet available, with a 
minimum of 12 months follow up with a minimum 
of 2 CT scans, unless they have recurred within 12 
months. 
 Cohort 2: Recurrent lung cancer after SABR (either 
ipsilateral recurrence or local recurrence)  
 Patient needs pre-treatment and recurrence PET-CT 
available.  
 TEAL sub-study 
 Patients had a 4DCT planning scan at Royal Surrey 
County Hospital 
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 Patient have lung function test results available 
including FEV1 and TLCO.  
Exclusion criteria  TEXAS study 
 Patients not had SABR for primary lung cancer or 
did not receive the full dose/course of radiotherapy 
 Were treated for a lung metastasis from a different 
primary cancer.  
 No recurrence cohort, have less than 1 years follow 
up, less than 2 scans available or no pre-treatment 
PET-CT scan 
 Recurrence cohort, no PET-CT pre-treatment or on 
recurrence  
 Did not receive the full dose of radiotherapy 
 
 TEAL sub study 
 
 Lung function tests not available 
 
Number of sites 2 
Duration of 
recruitment 
This is a retrospective study so patients will be identified 
from an existing SABR database.  
Duration of patient 
follow-up 
N/A 
Definition of end of 
trial 
 
Background 
Lung cancer is the second commonest cancer diagnosed in the UK in both men and 
women. Overall survival for all comers for Non-Small Cell Lung Cancer (NSCLC) is 
10% at 5 years.  
 
Lung cancer is caused by smoking and is more common in older patients. Forty 
percent of cases are diagnosed in patients aged 75 or over. These patients are 
more likely to have multiple co-morbidities also caused by smoking. Because of 
these many patients with early stage lung cancer are likely to be less fit and so not 
suitable for surgical treatment. In this population radical (curative) external beam 
radiotherapy (EBRT) is an important treatment in managing lung cancer.  
 
Stereotactic Ablative Body Radiotherapy (SABR) is a method of delivering radical 
radiotherapy to patients not fit for/or who decline surgical resection or standard 
radical radiotherapy of early stage (T1-T2a N0 M0) lung tumours [1]. 
Radiotherapy for NSCLC (Non-Small Cell Lung Cancer) is usually given in small 
daily fractions (2 Gray per treatment) over 4 or 6 weeks. SABR is given in 3-8 
fractions over 1-3 weeks [1]. Each fraction is 7.5Gy-18Gy. The larger fraction size 
means a higher biologically effective dose is given to the tumour, in a fewer 
number of fractions over a much shorter period of time. The dose distribution 
across the tumour is different in SABR compared to standardly fractionated 
radiotherapy. Standard radical radiotherapy aims to cover the tumour with a 
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homogenous dose, which is mandated to be 95-107% of the prescribed dose [2]. 
In SABR the dose varies across the tumour with a high peak in the middle. This 
means the dose outside the tumour has a very steep fall off, so less lung is 
irradiated. As a result patients whose lungs could not tolerate surgery or 
standardly fractionated radical radiotherapy are suitable for SABR.  In 
retrospective series SABR appears to have outcomes similar to surgery [3, 4], 
although clinical trials have struggled to recruit patients for a direct head to head 
comparison [5]. The dose of radiotherapy is targeted using Intensity Modulated 
Radiotherapy (IMRT) or Volumetric Modulated Arc Therapy (VMAT), this means 
the dose of radiotherapy can be varied across the radiotherapy field through 
movement of multi-leaf collimators (MLCs). This shapes the radiotherapy beam 
during treatment. IMRT radiotherapy plans often have 7 or 9 fields delivered from 
different directions. VMAT is delivered with the linear accelerator moving in an 
arc as the treatment is delivered. This spreads the low dose level of radiotherapy 
across the patient in an arc. 
 
Radiotherapy is planned on a CT (Computer Tomography) scan. For SABR 
planning a patient undergoes a 4D-CT scan. This divides the CT scan into 10 
respiratory phases and accounts for tumour movement during the breathing 
cycle. Two composite volumes are created using the 4DCT. These are the CT 
average, which is an average across the breathing cycle and the CT-Maximum 
Intensity Projection (MIP). Organs at risk are volumed on the average scan and the 
tumour is volumed using the MIP, to account for all positions of the tumour during 
the breathing cycle. As this Gross Tumour Volume (GTV) is a composite of all 
breathing phases it can also be described as an Internal Target Volume (ITV) as it 
accounts for tumour movement. A margin is added to the ITV to account for set up 
error and is termed the Planning Target Volume (PTV).  
 
Textural analysis has the potential to gain more prognostic information about a 
tumour or its response to treatment, such as after radiotherapy. It is a technique 
of advanced imaging analysis to gain extra information from a standard diagnostic 
image, such as a CT or PET-CT scan. The aim of this study is to understand whether 
textural analysis can elicit more information for CT scans as a prognostic marker 
before treatment and a more complex analysis after a patient has received SABR, 
particularly whether textural analysis can predict recurrence of primary NSCLC 
tumours.  
Literature review 
Efficacy of SABR 
A comparison from the SEER database in America suggests that SABR has a 
definite role in treatment of early stage NSCLC. In a review of over 10,000 patients, 
5 treatment modalities were explored [6]. These were surgery (lobar resection 
and sub-lobar resection), conventionally fractionated radiotherapy and 
stereotactic radiotherapy. The commonest treatment was lobar resection (59%), 
followed by conventional radiotherapy (14.85%), then sub lobar resection 
(11.7%), then observation (12.6%) and finally SABR (1.1%). In this analysis the 
median age was 75 years and old nearly a third of patients (29%) had severe co-
morbidities. Using Cox regression SABR was associated with the lowest risk of 
death within 6 months (HR 0.48 95% C.I 0.38-0.63) when compared to lobectomy. 
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After 6 months lobectomy had the best disease specific survival. With a median 
follow up of 3 years lobectomy had a similar outcome when compared to SABR 
(HR 0.71, 0.45-1.12). Conventional radiotherapy (HR 1.97, 1.31-2.96, p=0.001) 
and observation (HR 2.10, 1.37-3.08, p=<0.001) were both significantly poorer 
when compared to SABR. This analysis is limited by the small numbers of patients 
who received SABR, particularly compared to surgery. A subsequent analysis has 
suggested that lobectomy is better than sub lobar resection or SABR, but SABR 
remains a beneficial treatment for those not suitable for surgical resection [7].  It 
also establishes that SABR is a better treatment when compared to conventionally 
fractionated radiotherapy for smaller lung tumours [8]. In older patients 
retrospective data suggests SABR improves overall survival compared to 
observation in patients who would not be fit for surgical treatment [9].  
 
There is little published work regarding SABR and textural analysis. Textural 
analysis uses a range of mathematical features to describe a region of an image. In 
this context it is used to describe a tumour. Standard imaging such as a CT scan 
shows differences in density. Other measures such as heterogeneity can be 
calculated. Heterogeneity measures the level of disorder or dis-similarity, which 
can occur at a genetic and a supra-cellular level, as well as on an image. Tumours 
can vary in their blood supply and vascularity, cell density, level of oxygen 
delivery, hypoxia or in the rate of proliferation. These radiobiological changes 
confer greater sensitivity or resistance to radiotherapy. The difference in biology 
across the same tumour and between different tumours means there is a range of 
radio-sensitivity and therefore a range of responses to treatment.  
 
Two standard imaging modalities that are used to assess lung tumours are CT and 
PET-CT (Positron Emission Tomography-Computer Tomography). The benefit of 
performing a PET-CT scan is that it gives functional information. The commonest 
tracer used in PET-CT scans in clinical practice is FDG (Fludeoxyglucose). For this 
trial CT scans will be used for the analysis in the form of stand-alone CT imaging 
and the CT of PET-CT scans.  
 
The complexity of a textural analysis technique depends on the feature being 
described.  Although different textural features have been generated from a wide 
range of sources, they can be broadly divided into three categories: first-order 
(least complex), second-order and higher-order (most complex). First-order 
features are simplest and can often be described as a single figure and describe 
the whole volume being analysed. Second order features describe the relationship 
between 2 points, such as 2 pixels or voxels. Higher order features describe the 
relationship between a pixel and more than one other pixel, i.e. a minimum of 
three points in space. 
 
First-order textural features use a range of basic statistical methods to express 
different measures. Commonly used textural features include energy, entropy, 
kurtosis, maximum and minimum intensity, average intensity (median and mean) 
and range of intensities, skewness, standard deviation, uniformity, entropy 
(irregularity of intensity value distribution) and variance. Standard deviation, 
variance and mean absolute deviation measure how the range of intensities in a 
histogram are dispersed. Skewness measures how much histogram asymmetry 
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there is around the mean. Kurtosis measures the sharpness of the histogram. 
Randomness can be computed using uniformity and entropy. Entropy is a measure 
of disorder. The higher the entropy the greater the disorder or heterogeneity. The 
lower the entropy, the higher the homogeneity. The majority of published textural 
analysis work focuses on first order features of textural analysis.  
 
Second-order textural features describe a relationship between two points. By 
taking each point in turn and comparing it to all points around it, a three 
dimensional comparison can be built up. It can then describe the three-
dimensional size and shape and a range of values within a tumour. By deriving a 
tumour volume, measurements can be taken of variations across this volume, 
these include entropy (measure of randomness of values within an image), 
compactness, sphericity, surface area, and surface to volume ratio. 
 
A wide range of studies have used textural analysis to attempt to define different 
aspects of lung lesions seen on pre-treatment imaging. Textural analysis has been 
used to differentiate benign from malignant tissue (particularly lung nodules), 
different types of tumour histology [13, 14], to aid assessment of the tumour and 
aid treatment decisions. Textural differences have been identified in images from 
PET-CT scans. They suggest that non-malignant tissue is more homogeneous than 
malignant tissue and adenocarcinoma is more homogeneous than squamous cell 
carcinoma [15].  
 
Conventional predictors of outcome in NSCLC include TNM staging, AJCC stage, 
age, sex, histology, co-morbidities and performance status. The use of a biomarker 
from CT imaging to prognosticate patients’ outcomes, risk of distant metastases 
and overall survival is attractive because CT imaging is ubiquitous within the 
management of NSCLC.  
 
A common way of analysing tumours for textural analysis is to delineate the 
tumour and segment it out of the scan. The segmented structure (which is 
analogous with the primary tumour) can then be analysed. Statistical features of 
the tumour can be identified and plotted against an outcome measure such as 
disease free survival or overall survival. Features that give a strong correlation 
could potentially act as biomarkers for those with poorer survival[16]. CT texture 
features have been correlated with PET-CT SUVmax, tumour staging and degree 
of tumour hypoxia [17, 18]. 
 
A range of studies have been performed with a broadly similar method. A patient 
cohort is identified with a known outcome such as overall survival or progression 
free survival. Either a single slice or the whole tumour is identified and segmented 
out from the rest of the scan. A range of different commercially available software 
such as TexRAD and MaZda is available. Other studies have used in house 
software. A range of first, second and higher order textural features can then be 
extracted. In many cases a large number of textural/mathematical features can be 
calculated. Features are chosen that correlate with outcome. The difficulty is that 
different textural features are significant in different studies, using different 
methods of analyses. In some studies hundreds of features are analysed and 
compared. This means that statistically significant textural features could be 
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identified by chance, despite there not being any actual correlation. The 
consequence is that this limits the reproducibility of many studies.  
 
Many studies use clinical data alongside textural analysis to stratify outcome. 
Many are retrospective. In many cases textural analysis improves prediction of 
outcome compared to clinical data alone, rather than the tumour textural features 
alone predicting outcome.  These studies often utilise different standards, 
measurements, imaging equipment and techniques. As a result it is difficult to 
achieve accurate reproducibility. It is also difficult to identify sufficiently large 
cohorts, some studies have heterogeneous cohorts receiving different treatment, 
either combining tumours that received radiotherapy alone with chemo-
radiotherapy or different radiotherapy schedules.  
 
At present it is unlikely that a prognostic measure would affect a treatment 
decision. A ‘good’ or ‘bad’ prediction of response to radical treatment would 
change not currently alter a management plan, but it is important to have as many 
robust biomarkers as possible as clinical trials and treatment strategies could be 
stratified according to these biomarkers.  
 
In the UK CT imaging is the standard follow up tool for lung cancer. PET-CT maybe 
used following radical treatment to identify recurrence. SUV intensity on PET-CT 
imaging may give a faster response than decrease in tumour volume [19]. 
Identifying early recurrence after radical radiotherapy can be complex, 
particularly after stereotactic radiotherapy [20]. 
 
In order to be of benefit textural features, identification and classification of 
features needs to be sufficiently robust to overcome features including patient 
variables (including positioning, respiration phase and motion management and 
effects of contrast or lack of contrast), acquisition and processing variables such 
as image acquisition power, image slice thickness, image reconstruction 
algorithms, use of segmentation software and operator variability in tumour 
delineation. To minimise these variables and identify the changes related to 
tumours alone many studies standardise their image acquisition process [21]. 
Useful biomarkers need to overcome these features or have to be standardised to 
ensure accurate interpretation of this information.  
 
Robust textural features have the potential to give the clinician significantly more 
information in the clinic. As so many features can be extracted, the challenge is to 
extract useful information, which is, reproducible, prognostic and predictive. This 
is likely to require prospective data collection. At present large numbers of 
textural features are often analysed. This has two consequences, firstly a large 
number of variables means that it is possible that some features may correlate 
with outcome by chance. Secondly it is easy to become overwhelmed by the level 
of information and number of textural features that can be derived. Establishing 
robust biomarkers, means they can then be incorporated into appropriate clinical 
trials.  
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For these reasons, being able to extract more information for standard imaging is 
an attractive way of getting more ‘value’ from investigations and is likely to be 
more routinely introduced into clinical practice in the coming years.  
 
SABR and Textural Analysis 
Pre-treatment textural features can improve prediction of outcome, compared to 
SUVmax alone [22]. Compared to other treatment response assessments, there is 
an evidence base for using radiomics and textural features in SABR response 
assessment. This is perhaps unsurprising given the technological and imaging 
requirements needed to deliver SABR. The lung reacts to SABR differently to 
standardly fractionated radiotherapy.  
 
After SABR significant local inflammation can occur. An example is Radiation 
Induced Lung Injury (RILI). This is difficult to differentiate from tumour 
recurrence by appearance alone (illustrated in figure 1). Manual and automatic 
delineation of the areas of ground glass opacity and consolidation showed that 
early recurrences were denser and had different textural features than areas of 
RILI and can predict early response [23-25]. PET SUV >5 or SUV higher than the 
diagnostic PET-CT suggests recurrence [20]. Radiomic features have been 
extracted, which predict early recurrence and are able to improve sensitivity 
when compared to physician assessment (AUC 0.85, False negative rate 23% vs 
99%) [25]. 
 
A textural analysis tool has been developed in collaboration with the Centre for 
Vision, Speech and Signal Processing at the University of Surrey. It has been shown 
that FDG-PET uptake correlates with areas of homogeneity in the tumour. Each 
voxel is compared to the voxel next to it in all directions, this allows a map of 
entropy (disorder) to be built up. The analysis can potentially be used across 
whatever structure is segmented (extracted) from a CT scan.  
 
 
Figure 1. adapted from Mattonen et al. [26] Solid black line represents tumour in 
1st image of both recurrence and benign lung injury. Dotted line represents area 
of interest and ground glass opacification.  
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This baseline use of tumour specific textural analysis formed the basis of this 
study. The aim of the experiments so far and future work is to identify whether 
textural analysis using this method can distinguish patients with good and poor 
lung function and between tumour and fibrosis in CT scans of patients who have 
received SABR. 
Rationale for study 
The aim of this study is part of an overarching project to extract more information 
from CT scans, which are part of standard imaging for patients with lung cancer. 
The TEAL sub study aims to identify more information from a patient’s pre-
treatment imaging.  
 
The TEXAS study is using this concept to extract more post treatment information 
from routine CT scans. In patients who have received SABR for early stage NSCLC, 
it is difficult to identify areas of recurrence and differentiate this from an acute 
lung injury or inflammation after SABR. This is more common where radiologists 
are not commonly reviewing post SABR imaging. CT textural analysis provides a 
potentially useful tool in identifying early recurrence. Traditionally patients who 
would undergo SABR would not be suitable for salvage treatment, however SABR 
is now being used for the treatment of oligometastatic disease in a wider group of 
patients who are often fitter than those with primary NSCLC. It is becoming more 
important to be able to identify when local recurrence/progression occurs. 
 
Standard follow up of patients who have undergone radical treatment for NSCLC 
involves routine CT scans. Textural analysis of CT scans is an attractive tool 
because of the widespread availability of CT imaging compared to PET-CT 
imaging. If prognostic factors for CT texture can be established, this may give 
greater information to clinical oncologists managing NSCLC.  
 
Textural analysis is a broad field using a range of imaging analysis techniques. This 
is a pilot study to explore the applications of texture analysis before and after 
SABR to the lung. This study will use 2 methods to assess the benefits of using CT 
textural analysis in pre-treatment imaging to assess lung function and post 
treatment imaging to assess response to SABR.  
 
The software is able to compare like for like image voxels in all directions. Each 
voxel in an image has a relationship with 26 voxels around it (as illustrated in 
figure 2). This builds up a second order map of entropy. This means that it is 
possible to build a map of the relative intensities of the tumour and the 
surrounding lung. The advantage of using this is that a map can be derived for the 
whole lung. In SABR the position of the ablated area of the lung, which previously 
contained tumour often alters its anatomical position within the lung, due to the 
inflammatory and fibrotic reaction of the lung.  
 
The aim of using the post treatment tool is to improve diagnostic certainty in 
identifying recurrence on a standard staging CT scan. Being able to identify 
recurrence in previously treated primary lung tumours after stereotactic 
radiotherapy has several advantages. It could mean that fewer PET-CTs are 
Protocol [version 1.2 May 2017]  257 
required to confirm recurrence; it may provide more information where PET-CT 
access is limited or not available; it may potentially reduce the need for 
unnecessary biopsy; particularly in a population that are much more likely to 
experience complications of a biopsy such as pneumothorax. 
 
 
 
 
Figure 2. Central white sphere has a relationship with 26 voxels around it.  
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3. Trial Objectives 
Primary 
To identify whether it is possible to predict recurrence of primary lung tumours 
using textural analysis of post treatment CT scans of patients previously treated 
with Stereotactic Ablative Body Radiotherapy (SABR). 
Secondary 
 To identify whether it is possible to predict a pattern of radiation induce 
lung injury after SABR 
 To see if textural analysis can predict lung function in patients having 
radical radiotherapy using the 4DCT scan (TEAL sub-study) 
 
4. Trial design 
The trial will be a retrospective analysis of patients who have completed 
Stereotactic Ablative Body Radiotherapy (SABR) for primary NSCLC or presumed 
NSCLC.  
 
Three cohorts of patients will be identified.  
 
TEXAS Cohort 1: Patients treated with SABR for NSCLC who have a minimum of 1 
years follow up and have at least 2 diagnostic post treatment CT scans, where 
there is no evidence of local tumour recurrence.  
 
TEXAS Cohort 2: Patients treated with SABR for NSCLC who have a PET proven 
local recurrence.  
 
TEAL sub-study cohort (including patients from TEXAS cohort 1 and 2). Patients 
who have undergone a planning 4DCT at Royal Surrey County Hospital of their 
whole lungs and have pre-radiotherapy formal lung function available.  
 
5. Patient Population  
All patients who have been treated for localized primary NSCLC at the Royal 
Surrey County Hospital will be eligible for entry into this study.  
Inclusion 
 TEXAS study 
 Patients previously treated with Stereotactic Ablative Lung Radiotherapy 
(SABR) for Non Small Cell Lung Cancer (NSCLC). 
 Patients either had biopsy confirmed NSCLC or a clinical decision has been 
made that there is a high probability of NSCLC suitable for SABR. 
 Cohort 1: No recurrence of cancer after SABR, 
 Patients have pre-treatment pet available, with a minimum of 12 months 
follow up with a minimum of 2 CT scans, unless they have recurred within 
12 months. 
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 Cohort 2: Recurrent lung cancer after SABR (either ipsilateral recurrence or 
local recurrence)  
 Patient needs pre-treatment and recurrence PET-CT available.  
 TEAL sub-study 
 Patients had a 4DCT planning scan at Royal Surrey County Hospital 
 Patient have lung function test results available including FEV1 and TLCO. 
Exclusion 
 TEXAS study 
 Patients not had SABR for primary lung cancer or did not receive the full 
dose/course of radiotherapy 
 Were treated for a lung metastasis from a different primary cancer.  
 No recurrence cohort, have less than 1 years follow up, less than 2 scans 
available or no pre-treatment pet-ct scan 
 Recurrence cohort, no pet-ct pre-treatment or on recurrence  
 Did not receive the full dose of radiotherapy 
 
 TEAL sub study 
 Lung function tests not available 
 
6. Patient Recruitment  
Consent  
Consent will not be sought from patients to participate in the study.  
 
The study involves retrospective analysis from patients who have received SABR 
treatment for Lung cancer.  As a result of their disease many of the patients who 
are eligible for this study would no longer be alive to provide consent. For those 
who are still alive many would suffer from a number of comorbidities and it is not 
felt appropriate to invite them back to the hospital to consent to a study that is not 
going to change their future treatment.  
 
To maintain patient anonymity data will be collected from eligible patients by the 
clinical team and provided to the research team in an anonymised form for 
analysis. No patient identifiable data will be available to the research team.  
 
The initial stage of the TEXAS trial will be to identify 10 patients for the non-
recurrence cohort. The first step will be to identify a ‘normal’ pattern of 
fibrosis.  
 
The second stage will be to increase the non-recurrence control cohort to 
20-30 patients. They will then be compared to 5-10 local or ispsilateral lung 
recurrences. Local recurrences are rare following SABR.  
 
60 patients who are eligible for the TEAL sub-study will be identified from 
an internal RSCH database of patients who have received radical 
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radiotherapy (including both SABR and standardly fractionated 
radiotherapy) at RSCH. 
 
7. Trial Treatment 
The treatment that patients received was standard SABR for primary lung 
tumours as documented in Royal Surrey County Hospital Clinical Protocol for 
Stereotactic Ablative Body Radiotherapy (SABR). The document number is RT-
PT56v1. It is available on QPulse at RSCH and is in appendix 1.  
 
Patients were given a prescription for 4mg of dexamethasone to be taken before 
radiotherapy on each day of treatment. This is standard management at RSCH. If 
there is concern regarding lung inflammation a steroid inhaler was given to the 
patient to take during their treatment.  
 
Standard post treatment staging CT scans will be used for this analysis. The trial 
does not ask for any additional or different imaging. All patients underwent 
standard treatment and standard clinical and imaging follow up. Neither the 
TEXAS study nor the TEAL sub-study ask for any additional investigations or 
changes in treatment or follow up.  
 
8. Assessments 
For the TEXAS study each patient will have a duplicate pseudo anonymised copy 
of their radiotherapy plan created within Eclipse (radiotherapy planning 
computer system) at RSCH. All appropriate scans will be requested through the 
Information Exchange Portal (IEP). Post treatment diagnostic scans will be 
imported electronically from the PACS system at RSCH into Eclipse. Importing 
scans from PACS into the anonymised radiotherapy plan, automatically 
anonymises the imported scan. The whole lung will then be volume (see 
guidelines below). Importing these scans into an anonymised patient record 
anonymises the patient name. The scans will exported from the radiotherapy 
system and anonymised to ensure that all identifiable information has been 
removed. The anonymised scan will then be exported from Eclipse into Matlab on 
a password protected and encrypted University of Surrey computer. The lung 
volume will be extracted from the CT scan using CERR (Computational 
Environment for Radiotherapy Research) software (ref). A textural map will be 
processed to create a map of relative entropy using software developed in 
collaboration withthe Centre for Vision, Speech and Signal Processing, University 
of Surrey.  
 
For the TEAL sub-study, a region of interest will be drawn on a duplicate structure 
set within the radiotherapy planning system. This structure will then be 
anonymised and exported. It will be analysed in the same manner as patients in 
the TEXAS trial. This anonymised texture map will then be analysed. 
 
 
Lung localisation guidelines.  
The aim is to keep the localisation of the whole lung consistent between patients 
and between scans of the same patient. Broadly the lung volume aims to exclude 
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the left and right main bronchus, lobar bronchi, hilum and any large blood vessels 
over >1cm. Superiorly and laterally the lung volume is bordered by ribs. The lung 
volume should not include any rib. Medially the lung is borded by mediastinum, 
hilum and heart. Inferiorly the lung is bordered by diaphragm and liver or spleen. 
The proximal bronchial tree should be excluded from the lung volume. UK SABR 
consortium guidelines define the bronchial tree as: “The most inferior distal 2cm 
trachea, carina, right and left mainstem bronchi, right and left upper lobe bronchi, 
the bronchus intermedius, right middle lobe bronchus, lingular bronchus, and the 
right and left lower lobe bronchi. Contouring of the lobar bronchi will end 
immediately at the site of a segmental bifurcation.” The hilum that would be 
defined as hilar lymph node (station 11) will be excluded.  
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Figure 3. Adapted from Chapet et al, definition of station 11 lymph node 
[28].  
 
TEAL sub-study voluming guidelines 
A 4 cm circle is selected from eclipse drawing functions. The aim is to volume a 
cylinder of lung tissue 4cm in diameter including continuous 10 slices of the CT-
AVERAGE phase of the 4DCT. The structure should be drawn superior to inferior. 
The first slice should be as apical as possible, but the volume should not include 
any tissue other than lung tissue. See figure 4. for an example structure. For left 
sided tumours, if the inferior part of the left sided structures includes the aortic 
arch, the structure should start 1-2 slices lower with the volume started as 
laterally as possible to avoid the aortic arch. 
 
 
Figure 4. Cyclinder of lung tissue which will be analysed in the TEAL study.   
 
9. Data Management  
Patients will have a range of characteristics of the patient and tumour staging 
collected, as well as date of relapse and date of death. This information will be 
collated and kept confidentially at St Lukes Cancer Centre, Royal Surrey County 
Hospital.  
 
Cases will be identified on the SABR database, created by the scientific computing 
department at Royal Surrey County Hospital. The database is made up of a 
relational database which resides on a dedicated database server and a web portal 
(which accesses the database server) which resides on a dedicated web server. 
Protocol [version 1.2 May 2017]  263 
Both servers are only accessible within the hospital network. No external access 
is possible. The database server is secured behind a dedicated firewall which only 
allows communication specific IP addresses on specific ports within the hospital 
network. Both servers are fully patched CentOS servers with all standard security. 
Access to root accounts is available to a small number of Scientific Computing 
staff. Both servers reside on a virtualisation platform which is cloned to ensure 
uptime. Access to the web portal is restricted by username/passwords over an SSL 
connection. Timeouts for connectivity are currently set at 15 minutes. All activity 
on the web portal is logged for auditing purposes. The database server storage is 
an NFS mounted NAS server which is setup in a high availability structure. The 
database server is backed up twice a day to an encrypted gzip file which is stored 
on a separate NAS high availability cluster in a separate location within the 
hospital site. Delete procedures exist which are capable of removing a patients 
data from the database, backups and logs.  
 
Patients for recurrence and non-recurrence cohort will be identified by a Clinical 
Oncologist who treats NSCLC with SABR.  
 
Unanonymised scans will be stored on RSCH PACS or Eclipse computer systems. 
Both the computers on which the systems are accessible are password protected. 
The anonymised scans and texture maps will be stored on a password protected 
University of Surrey computer.  
 
Patients will be selected and pseudo-anonymised within eclipse (radiotherapy 
planning system) by creating a ‘phantom’ anonymised copy of the patients 
planning CT scan and a copy of the structures drawn on the original planning CT. 
Post treatment CT scans will then be imported from Royal Surrey County Hospital 
electronic imaging (PACS) system. Where multiple series of images exist, the key 
images to import are axial 5mm slices. Importing the scans into the phantom 
radiotherapy scan anonymises any patient identifiable information. The scans will 
then be exported as DICOM data with an associated radiotherapy structure set. 
These anonymous files can then be imported into either matlab for 3D textural 
analysis or TexRAD.  
Data Analysis 
This study will comprise 2 cohorts of patients for the TEXAS study, those whose 
tumour locally recurs and those where there is no evidence of recurrence.  
 
The data points created by the texture map give an entropy score. Entropy is a 
measure of disorder. High entropy is equivalent to more disorder, which can also 
be described as more heterogeneity. This means that low entropy is equivalent to 
high homogeneity or uniformity.  
The entropy score for each voxel will be plotted against the Hounsfield Unit (HU) 
for that voxel. This will give a plot of data points. The aim is to use these plots to 
see if it is possible to identify features of recurrence by plotting all the data, when 
compared to a control group where the tumour hasn’t recurred. This analysis will 
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aim to match a number of patients who haven’t recurred (to act as a control) with 
a patient who has recurred 
10. Adverse Events 
 This study is a retrospective analysis of post treatment CT scans, adverse 
events will not be collected. 
 
Reporting procedures 
11. Trial monitoring 
 
The CI will facilitate any local monitoring by the R&D quality manager, REC review 
and provide access to source data as required.  
 
Following any monitoring a report will be provided which will summarise the visit 
and documents, along with any findings. The CI will be responsible for ensuring 
that all findings are addressed appropriately. 
 
Additional monitoring will be scheduled where there is evidence of suspicion of 
non-compliance with the Trial protocol. 
 
 
12. Trial closure 
End of Trial 
Upon the end of trial a “declaration of end of trial” form will be submitted to REC, 
as required. 
 
Archiving trial documents 
Following the end of trial arrangements for non-essential confidential documents 
will be destroyed. Essential documents will be securely archived for 5 years. 
 
Early closure of the trial 
The trail may be stopped early upon recommendation. 
13. Sponsorship 
The trial will be sponsored by Royal Surrey County Hospital 
14. Indemnity 
 
Royal Surrey County Hospital Foundation Trust holds professional liability 
insurance to meet the potential legal liability of the sponsor and employees for 
harm to participants arising from the design and management of the research. 
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Indemnity to meet the potential legal liability of the investigators/collaborators 
for the harm of participants arising from the conduct of the research is provided 
by the NHS Indemnity scheme or through professional indemnity. 
 
15. Publication 
The results of this study will be published by peer-reviewed journals and 
presented at national and international oncology and radiology conferences. 
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Glossary 
AE  Adverse Event 
ASPH                Ashford and St Peters Hospital 
BMI                   Body Mass Index 
BTS  British Thoracic Society 
CI  Chief Investigator 
CCI   Charlson Co-morbidity Index   
FBC  Full Blood Count 
IHD  Ischaemic Heart Disease 
LFT  Liver Function Test 
MNA  Mini-Nutritional Assessment 
NSCLC  Non-Small Cell Lung Cancer 
PG-SGA Patient Generated Subjective Global Assessment 
RSCH  Royal Surrey County Hospital NHS Foundation Trust 
SGA  Subjective Global Assessment 
SLCC  St Luke’s Cancer Centre 
U+E  Urea and Electrolytes 
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1. Protocol Summary 
 
TITLE: DieteticAssessment and Intervention in Lung 
cancer (DAIL) study 
SHORT TITLE DAIL study 
SPONSOR  Royal Surrey County Hospital 
FUNDER 
REFERENCE 
 
DESIGN: Prospective cohort study 
OVERALL AIM: To quantify the number of patients with Non-
Small Cell Lung Cancer (NSCLC) who present with 
malnutrition, cachexia and/or sarcopenia before 
starting anti-cancer treatment.  
PRIMARY 
OBJECTIVES; 
 To identify the proportion of patients diagnosed 
with NSCLC who are malnourished, cachectic 
and have sarcopenia before anti-cancer 
treatment. 
 To identify the proportion of lung cancer 
patients who would require dietetic review 
before anti-cancer treatment. 
SECONDARY 
OBJECTIVES: 
 To identify whether malnutrition, cachexia or 
sarcopenia affects overall survival in metastatic 
NSCLC. 
 To identify whether sarcopenia predicts for a 
poor outcome in NSCLC 
Target Accrual 100 patients 
Inclusion criteria  Patients >18 years old who are able to consent 
to entry into a clinical trial 
 All patients should have biopsy confirmed 
Advanced NSCLC (stage IIIb and IV). 
 Patient receiving first line systemic palliative 
anti-cancer treatment. 
Exclusion criteria  Inability to consent to treatment 
 Patient declines anti-cancer treatment 
Number of sites 2 
Duration of 
recruitment 
October 2016-February 2017 
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Duration of patient 
follow-up 
Patients involvement in the study will be 
complete once patients have completed their pre-
treatment assessment 
Definition of end of 
trial 
When the last patient completes their pre-
treatment assessment 
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2. Background 
Lung cancer is the second commonest cancer diagnosed in the UK in both men and 
women. Over 43,000 cases are diagnosed a year, over 35,000 deaths occur a year 
and there is a 5 year survival of 10% and 10 year survival of only 5% [1].  It is the 
commonest cancer worldwide in terms of both incidence and mortality.  
 
Lung cancer is caused by smoking and is more common in older patients. It is a 
disease of poverty [2]. It has been associated with a higher incidence in areas with 
higher unemployment, lower socioeconomic position and a less educated 
population.  
 
As the majority of lung cancer is associated with tobacco exposure, these patients 
are more likely to have multiple co-morbidities also caused by smoking. Exposure 
to tobacco is associated with numerous co-morbidities including Ischemic Heart 
Disease (IHD), Chronic Obstructive Pulmonary Disease (COPD) and other cancers 
including bladder cancer. Evidence shows that being a smoker at 25 years old 
means a patient is 50% less likely to live to 79 years old excluding all factors. 
Smokers on average live 10 years less than non-smokers, with a mortality rate 
three times higher than non-smokers [3].  
 
More than 80% of new cases of lung cancer are diagnosed in the over 60’s and 
more than 40% are diagnosed in men and women over 75 years. 
 
In the current healthcare environment it is important to use all available resources 
to maximize outcomes in lung cancer. This includes addressing malnutrition, 
cachexia and nutritional deficit, as this can affect fitness for treatment.  
 
2.1 Literature review 
 
2.1.1 Nutrition and COPD 
Malnutrition can be defined as a state of nutritional imbalance leading to negative 
effects on weight and function and is common in COPD [4]. Poor respiratory 
function has been correlated with poor muscle mass [5]. Symptoms associated 
with COPD include a dry mouth, pain and constipation and all can impact on 
nutritional status. Patients with more significant fat free mass depletion are more 
likely to have these symptoms [6]. Malnutrition is also associated with decreased 
physical workload in this patient group [7]. Oral nutrition supplements have been 
shown to improve body weight and handgrip strength, as well as decrease airflow 
limitation in patients with COPD [8]. The most recent Cochrane Review on stable 
COPD and nutrition suggests that malnourished patients with COPD can improve 
respiratory muscle strength and overall health related quality of life with 
nutritional support [9]. British Thoracic Society (BTS) guidelines suggest that 
patients with a low Body Mass Index (BMI) (<20 kg/m2) should be offered 
nutritional support. Many patients with lung cancer will have underlying COPD 
and will need to cope with the additional burden of managing their COPD as well 
as lung cancer.  
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2.1.2 Nutritional status in cancer 
Cachexia is a progressive disorder, leading to decreased physical activity, adverse 
psychological side effects, poor performance status and higher mortality rates. 
The model of cachexia can be divided into three phases, pre-cachexia, cachexia and 
refractory (likely irreversible) cachexia [10, 11]. Refractory cachexia is 
characterized by poor overall survival (less than 3 months). Cachexia has 
previously been defined by percentage weight loss from usual body weight, 
‘weight loss greater than 5%, or weight loss greater than 2% in individuals already 
showing depletion according to current bodyweight and height (BMI <20 kg/m2) 
or skeletal muscle mass loss (sarcopenia)’ [10]. 
 
Pre-treatment nutritional assessment has shown that malnutrition is common in 
lung cancer patients, with an incidence of between 35% and 65% [12, 13]. A range 
of studies have shown that malnutrition is associated with negative clinical 
outcomes in patients with cancer in general, including poorer quality of life, 
decreased functional status, increased utilisation of health care services and 
poorer survival [12].  
In a study of 1,000 patients with locally advanced or metastatic cancer, more than 
a third had significant weight loss (defined as greater than 10% weight loss) [14]. 
Twelve percent of patients in this study had lung cancer. Median rate of significant 
weight loss was 6.6%. Overall weight loss percentage increased as performance 
status worsened. Weight loss was more significant with more advanced cancers 
compared to stage 1 cancers.  
 
In view of the fact that many patients with lung cancer are likely to be older, have 
co-morbidities and come from a lower socio-economic background, we 
investigated the proportion of patients who presented with cachexia and 
refractory cachexia in advanced lung cancer at the time of referral to the dietitian, 
73% of patients were cachectic and 25% had refractory cachexia.  
 
In a prospective series of patients aged 70 years or older undergoing resection of 
a primary lung tumour, malnutrition was found to be a significant risk factor for 
early death. The cohort was divided into two groups, those that were underweight 
(BMI <18.5kg/m2, Group A, 21 patients) and those that were not underweight 
(BMI 18.5kg/m2 or greater, Group B, 96 patients). BMI and weight loss of 5% or 
greater before surgery were independent risk factors for 1 year mortality [15].  
 
In patients undergoing pneumonectomy for lung cancer 33 of 86 patients were 
found to have malnutrition. This was assessed using biological markers of 
nutrition including albumin and transthyretin [16]. Malnutrition did predict for 
increased morbidity and mortality in patients undergoing pneumonectomy. A 
study enrolling 146 patients irrespective of age by Win et al suggested that BMI 
and surgical outcome did not obviously correlate, however only 109 of 146 
patients underwent surgery, patients not undergoing surgery were not included 
in the analysis [17]. Poor nutritional status and increased mortality has been 
associated with non-oncological thoracic surgery, such as lung transplantation 
[18].  
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There is some evidence that dietary counseling and nutritional supplements may 
ameliorate the effects of radiotherapy and chemotherapy, although the exact 
benefit is not clear. The lack of definitive benefit in these studies may be in part 
due to short follow up, analysis of patients with lung cancer with other tumour 
types and difficulties in patients reaching adequate calorific intake [19].  
 
Whilst screening assessment and prophylactic nutrition support is standard 
practice for patients with primary cancers of the head and neck region, this is not 
the case for those with lung cancer. Radical lung radiotherapy (with or without 
chemotherapy) for lung cancer is associated with acute toxicities that can 
adversely affect nutritional intake. A retrospective review of 96 patients has 
shown that 31% lost 5% or more of their usual total body weight [12]. This was 
more likely if the patients had more advanced disease, or radiotherapy was given 
with chemotherapy. The dose of radiotherapy to the oesophagus during high dose 
palliative or radical lung radiotherapy predicts for weight loss. The maximum 
dose to the oesophagus as well as absolute length of oesophagus receiving 40Gy 
or higher did predict for weight loss of 5% of greater.  
 
A systematic review of exercise and nutrition strategies published in 2013, 
suggests that they are not harmful and may have beneficial effects on 
unintentional weight loss for patients with advanced lung cancer. Only 203 
patients from 5 studies were included in this analysis, of which only 3 were 
assessing nutrition. All 3 studies investigated use of a specific supplement rather 
than the impact of a nutritional assessment [20]. 
 
2.1.3 Evidence in other cancers  
Nutrition support is more established in other tumour sites such as upper 
gastrointestinal and head and neck cancers. For this reason all patients 
undergoing radical treatment for a primary head and neck or oesophageal cancers 
are routinely screened for nutritional deficit.  
 
Oesophageal cancer is less common than lung cancer. It is the 13th commonest 
cancer in the UK with a 5 year survival rate of 15% with 80% of cases occurring in 
people aged 60 years or older [21].  
 
As with lung cancer, multi-modality treatment is better than surgery or 
radiotherapy alone. These patients are likely to experience significant barriers to 
maintaining their nutritional status such as dysphagia and cachexia induced by 
the cancer. Weight loss is associated with a poorer outcome in oesophageal cancer 
[22]. Up to 79% of patients experience weight loss.  
 
Obesity is a risk factor for developing adenocarcinoma of the oesophagus; many 
patients present as obese, but have ongoing weight loss. These patients have 
mechanical factors preventing adequate nutrition, which could include pain, 
reflux, dysphagia and fatigue. Patients may have altered their diet with the onset 
of symptoms, which may be several months before diagnosis. These symptoms 
may worsen with anti-cancer therapy. Pre diagnosis weight loss has also been 
identified with poorer survival [23]. Treatment with neo-adjuvant chemotherapy 
potentially improves survival. It can have a positive effect on symptoms by 
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shrinking the tumour, but the side effects of the tumour and toxicities of the 
treatment have the potential to negatively affect nutritional status. 
 
2.1.4 Nutrition screening tools 
Ranges of physical assessments have been used to attempt to gain insight into 
clinical outcomes in lung cancer [24]. 
 
The Mini-Nutritional Assessment (MNA) was initially used to screen for 
malnutrition in older patients. In lung cancer it has been shown that two thirds of 
patients are either at risk of malnutrition or are malnourished [25]. The MNA 
outcome correlated with overall survival. It also correlated with depression and 
low mood, but not with anxiety.  
 
Subjective Global Assessment (SGA) has been used in patients with lung cancer. 
Patients who were defined as malnourished had an overall survival of 9 months 
vs 17 months in well-nourished patients in advanced NSCLC [26].  
 
The SGA was adapted to form the Patient Generated Subjective Global Assessment 
(PG-SGA) which is validated for use with oncology patients [27]. It includes a 
range of factors including determining weight loss, changes in food intake, 
symptoms of nutrition alterations, limitations of function, presence of metabolic 
stress and a physical examination. Li et al. established that 40% of patients with 
advanced lung cancer were malnourished and another 40% were at risk of 
malnutrition [28].  
 
Functional measures can assess nutritional status. Decreased handgrip status and 
malnutrition has been established in patients with potentially operable lung 
cancer [29].  Other methods such as Bioelectrical Impedance Analysis can be used 
to estimate body composition.  
 
2.1.5 Sarcopenia 
Sarcopenia is defined as a loss of muscle mass [10]. It has been associated with 
poorer outcome in metastatic renal cell cancer. It can be measured quickly and 
simply by calculating the area of the psoas muscle [30]. A small study has 
suggested that maintaining or improving weight with chemotherapy is a positive 
predictor in lung cancer. It did not show that sarcopenia predicted outcome.  
2.1.6 Machine Learning in lung cancer 
Machine learning is a way of using a computer programme to identify important 
features within a dataset, which can then be used to predict outcome in a new 
dataset. There are different methods of classifying data. An example is the use of 
SVM (Support Vector Machines). They can used to classify different data, for 
example lung cancer patients at high risk and low risk of cachexia. The benefit 
being that SVM can separate non-linear data, meaning it can separate data into 2 
groups that are not obviously distinct when plotted on a scatter chart. In this 
situation methods such as logistic regression could not be used. Machine learning 
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has not previously been applied to identifying prognostic markers in nutritional 
status for lung cancer.  
2.2 Rationale for study 
In view of the multiple co-morbidities, high symptom burden and the fact that 
many patients are older and less fit, lung cancer is a difficult illness to treat. It also 
commonly occurs in patients that are older, less well-off and less educated, 
resulting in higher rates of admission to hospital than other common cancers [31]. 
They are a more vulnerable population and weight loss is known to predict for 
outcome [32].  
 
Standard practice at St Luke’s Cancer Centre (SLCC) is for health care professional-
guided referrals to a Macmillan Oncology Dietitian. As described previously, 40% 
of patients with advanced lung cancer are malnourished, with a further 40% at 
risk. Our own audit data suggests that 75% of patients with advanced lung cancer 
are cachectic when first reviewed by the dietitian. (Cachexia in this context is 
defined as >5% weight loss from usual body weight). A quarter of patients had 
refractory cachexia (survival <90 days) when referred to the dietitian. This 
suggests that a strategy to screen patients for malnutrition/cachexia on diagnosis 
is advisable. It also allows for the earliest possible nutritional intervention.  
 
Early symptom intervention with specialist palliative care in patients with 
metastatic lung cancer has been shown to provide a significant improvement in 
overall survival of 11.6 months vs 8.9 months (p=0.02)when their anti-cancer 
treatment was the same[33]. Nutritional support is a simple and inexpensive 
intervention that may improve symptoms and outcomes in lung cancer. There is a 
paucity of data in prospectively assessing nutritional outcomes in lung cancer 
[34].  
 
A previous study randomizing patients to dietary advice +/- nutritional 
supplements did not show a significant difference, but compliance with taking the 
nutritional supplements and completing food diaries was low [35]. Standard 
dietetic practice usually involves first line food fortification advice, followed by 
nutritional supplements if patients are not able to maintain adequate oral intake. 
A systematic review of dietetic intervention in advanced cancer suggests that 
intervening can have a positive effect on weight and calorific intake, but study 
heterogeneity makes it difficult to prove this conclusively [36]. Chemotherapy 
may improve muscle mass in advanced lung cancer [37].  
In this study we want to better understand the proportion of patients with 
advanced lung cancer who present with cachexia, malnutrition and/or sarcopenia, 
before their treatment is initiated. This will subsequently establish the extent of 
the need for dietetic intervention in this patient group.  We anticipate that the 
results of this initial study will then inform a further randomized study looking at 
the effects of dietetic intervention in lung cancer patients.   
 
3. Trial Objectives 
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3.1 Primary Objectives 
 To identify the proportion of patients diagnosed with advanced Non Small Cell 
Lung Cancer who are malnourished, cachectic and have sarcopenia before 
anti-cancer treatment. 
 To identify the proportion of lung cancer patients who would require dietetic 
review before anti-cancer treatment. 
3.2 Secondary Objectives 
 To identify whether malnutrition, cachexia and sarcopenia affect overall 
survival in advanced NSCLC. 
 To identify whether sarcopenia predicts for a poor outcome in NSCLC 
 
4. Trial design 
The trial will be a prospective cohort study, open to all patients at SLCC in the 
Royal Surrey County Hospital (RSCH) and Ashford and St Peters Hospital (ASPH) 
receiving treatment for advanced primary NSCLC.  
5. Patient Population  
The study will recruit 100 patients. Patients are eligible for the study if all 
the inclusion criteria are met and none of the exclusion criteria apply. 
5.1 Inclusion criteria 
 Patients >18 years old who are able to consent to entry into a clinical trial 
 Biopsy confirmed Advanced Non Small Cell Lung Cancer (stage IIIb and IV). 
 Patient receiving first line anti-cancer treatment 
5.2 Exclusion criteria 
 Inability to consent to treatment 
 Patient declines anti-cancer treatment 
5.3 Sample Size calculation  
This is a pilot study to identify the incidence of malnutrition, cachexia and 
sarcopenia in patients with advanced NSCLC. The size of the difference in outcome 
between those is not known. The aim of this study is to quantify these differences 
to aid sample size calculations for a larger study.  
6. Patient Recruitment  
Patients will be identified by the clinical team and invited to participate by the 
research team when attending the new patient clinic.  
 
If the patient is interested, the research team will explain the study and give them 
a copy of the patient information sheet to review. The patient will be given the 
opportunity to ask any questions they may have about the study and will be given 
a minimum of 24 hours to decide if they would like to participate.  
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Eligible patients will be invited to consent when they attend their next 
appointment. Consent will be obtained by a suitably qualified person in 
accordance with international GCP guidelines. It is anticipated that many patients 
will be entered into the trial when they attend their nurse led clinic appointment.  
 
The research team will emphasize that non-participation will not adversely affect 
any aspects of their care.  
 
7. Trial Treatment 
Each patient consented to the study will receive 1 mandatory assessment. If this 
assessment suggests that a patient needs to be reviewed by a dietitian, they will 
be referred to their local dietetic service.8. Schedule of Assessment 
Assessment Visit 1  
Visit 1 is to be completed before or on the day that the patient has completed their 
first dose of systemic chemotherapy.  
 
The following assessments will be completed and recorded by the research team 
during the visit; 
 PG-SGA  
 Charslon Co-morbidity Index 
 EORTC QLQ C30 core module and LC13 lung cancer module 
 ECOG performance Status 
 SPARC assessment 
 Spirometry 
 Hand grip strength 
 Weight and BMI 
 Routine blood tests (FBC, U+E, LFT) 
 
In addition to the above, by consenting to the study the patients are allowing the 
research access to their diagnostic CT scan. The scan will undergo texture analysis 
to assess body composition pre-treatment and access for sarcopenia. Scans will 
imported into the eclipse radiotherapy planning system. The relevant section of 
the appropriate muscle will be outlined. The CT scan will be exported and 
anonymised. It will be transferred to a password protected University of Surrey 
PC as DICOM data. The texture analysis will take place on a University of Surrey 
computer and does not require any patient identifiable information.  
 
If the results suggest that a patient needs to be reviewed by a dietician, they will 
be referred to their local dietetic service as per standard practice. 
 
Follow up  
Patients will be seen by a dietitian following their assessment as clinically 
indicated. These visits will not form part of the study. Once the patient has 
completed their baseline assessment they have completed their participation in 
the trial. 
Patients will not be required to attend any follow up visits however survival status 
will be monitored at the following time points 
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 6 month  
12 month  
9. Data Management   
Data will be collected using paper data sheets that will be kept in the patients 
notes and transcribed onto an electronic CRF. Electronic data will be stored on a 
password protected computer and encrypted USB storage device. Both paper 
and electronic files will be stored securely in a locked office.  
 
Data will be stored in accordance with the data protection act 1998. Access to data 
will be restricted to members of the research team. Patient data will be 
anonymised by assigning a unique study number and all identifiable patient 
information will be removed. 
9.1 Data Analysis 
Data will be analysed by the research team with help from statisticians from the 
Surrey Clinical Research Centre. An initial analysis will occur at the completion of 
the study to describe the treatment received by patients who are 
malnourished/cachectic/sarcopenic, and those who are not malnourished. 2 
planned survival analyses will occur at 6 months and 1 year.   
 
For a cohort of 100 patients, survival to, or death before 1 year will be observed, 
death beyond 1 year being regarded as censored data. Time to death will be 
analysed in a Cox proportional hazards model, with explanatory variables being 
the following baseline patient characteristics: a) patient 
malnourished/cachectic/sarcopenic (yes/no), b) patient no older than 70 years 
(yes/no) and c) patient exposed heavily to smoking (yes/no). Separately for each 
of these dichotomous explanatory variables, a pair of Kaplan-Meier curves of 
survival will be plotted.  This analysis will be repeated at 1 year. 
In addition machine learning approaches will be used, such as support vector 
machine models. Multivariate analysis (MVA) is a long established technique to 
analysis complex data for correlations between sets of variables and outcome 
measures. 
Machine learning is a set of approaches that are starting to be used in the analysis 
of complex medical data and constitute a fundamentally different approach to 
MVA. As part of the advanced analysis the psoas muscle of the patient will be 
measured to assess its surface area. The muscle will also undergo a form of CT 
analysis called texture analysis, which will be performed on the diagnostic CT 
scan.  
 
Diagnostic CT scans will be requested from the trust where the scan was 
performed through the Image Exchange Portal (IEP) and transferred to the Royal 
Surrey County Hospital for analysis. IEP is a secure and confidential method of 
transferring scans within the NHS.   
 
The diagnostic CT scan data will be imported into eclipse (radiotherapy planning 
software). The relevant structure will be volume. The scan will be exported as 
anonymized DICOM data into a research radiotherapy programme 
Protocol version 1.5 18th November 2016 280 
(Computational Environment for Radiotherapy Research, CERR). The selected 
structure will be extracted and analysed using matlab and software developed 
within the Centre for Vision, Speech and Signal Processing at the University of 
Surrey.  
The goal of using the standard statistical analysis and machine learning, is to 
determine if they show different aspects of the data and hence if we can extract 
more useful information from the combination of approaches. The goal of 
Sarcopenia and textural analysis is to see whether advanced CT analysis can be a 
useful imaging biomarker for outcome or nutritional status in NSCLC.  
  
10. Adverse Events 
The intervention in this study is a dietetic assessment. This is not expected to lead 
to adverse events. It is common for patients to be admitted to hospital with 
metastatic lung cancer. The collection and reporting of adverse events will not 
alter the outcome of our clinical trial.  
11. Trial monitoring 
The CI will facilitate any local monitoring by the R&D quality manager, REC review 
and provide access to source data as required.  
 
Following any monitoring a report will be provided which will summarise the visit 
and documents, along with any findings. The CI will be responsible for ensuring 
that all findings are addressed appropriately. 
 
Additional monitoring will be scheduled where there is evidence of suspicion of 
non-compliance with the Trial protocol. 
12. Withdrawal of a patient 
Patients can withdraw their consent from the trial at any stage. If a patient 
explicitly states that they no longer wish to take part or contribute to the trial, 
their decision must be respected. The patient’s withdrawal from the trial will be 
recorded in the patient’s notes. All data collected up to the point of withdrawal 
will be included in the trial analysis. However if the patient withdraws consent for 
their data to be used the data will be destroyed immediately. 
 
If a patient is considered no longer to be eligible or the responsible clinician feels 
it is no longer appropriate for the patient to take part then this must be 
documented, indicating the reason for withdrawal, in the patient notes. 
13. Trial closure 
13.1 End of Trial 
Upon the end of trial a “declaration of end of trial” form will be submitted to REC, 
as required. 
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13.2 Archiving trial documents 
Following the end of trial arrangements for non-essential confidential documents 
will be destroyed. Essential documents will be securely archived for 5 years. 
13.3 Early closure of the trial 
The trial may be stopped early upon recommendation. 
14. Sponsorship 
The trial will be sponsored by Royal Surrey County Hospital Foundation Trust. 
15. Indemnity 
Royal Surrey County Hospital Foundation Trust holds professional liability 
insurance to meet the potential legal liability of the sponsor and employees for 
harm to participants arising from the design and management of the research. 
 
Indemnity to meet the potential legal liability of the investigators/collaborators 
for the harm of participants arising from the conduct of the research is provided 
by the NHS Indemnity scheme or through professional indemnity. 
16. Publication 
The results of this study will be published by peer-reviewed journals and 
presented at local and international conferences. 
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Appendix 4 
Developing a method for operator independent tumour recognition using 2nd order 
textural analysis of a whole lung, generated from Computer Tomography data   
4.1 Background  
Differentiating between tumour and Radiation Induced Lung Injury (RILI) is difficult, even to 
the expert eye, as radiological features of recurrence can often be seen benign RILI (Huang et 
al., 2012, Nguyen et al., 2017, Ronden et al., 2018). The aim of this work was to attempt to 
solve this difficult clinical problem; to understand whether TA could be used to differentiate 
between a tumour and RILI after SABR for primary lung cancer. This would be achieved by 
identifying a methodology that required limited assumptions regarding the spatial 
characteristics of the tissue, as well as being able to potentially analyse the whole lung and 
differentiate between tissues. By analysing a greater volume of lung using an analysis that 
could take account of spatial variations, more complex interactions could be investigated, 
identified and understood. As well as understanding the spatial variations, analysing large 
volumes of lung tissue overcomes the difficulty in identifying the tumour bed after treatment. 
This is because after SABR, RILI can occur in large parts of the lung. RILI can also cause traction 
within the lung meaning the geographical position of the tumour bed changes.  
4.1.1 Choice of software 
TA can be undertaken using commercial software, such as TexRAD (TexRAD Ltd, Cambridge, 
UK). When using TexRAD the user identifies a region of interest on a single slice of a CT scan. 
This undergoes first order TA and the region of interest generates a single number to 
represent a texture measure, for example skewness or kurtosis. This analysis can then be 
applied to clinical outcome, for example comparing patients with tumours that have relapsed 
early vs never relapsed to see if the texture measures are statistically different.  
TexRAD was considered unsuitable for this project for a number of reasons. Firstly with a first 
order, single slice analysis, it would not be possible to take account of spatial variations or 
patterns, both within a tumour or an area of RILI and between tumour and RILI. Analysis 
needed to take account of sub regions within the lung as both a tumour and RILI could exist 
concurrently. Secondly, by not capturing all of the data regarding either tumour or RILI, it is 
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more difficult to identify any patterns within tumour and RILI, which would allow the different 
areas of the lung to be easily differentiated. This would not be possible with TexRAD. TexRAD 
is very user dependent and would require the user to have sufficient knowledge to identify 
the abnormality or region of interest.  
TexRAD was unable to compare sub-regions within a region of interest without repeatedly re-
drawing contours. These limitations meant TexRAD was not suitable to pursue this project.  
As TexRAD was not thought to be suitable, alternative software that could use second order 
TA was investigated. FiniteRT is software used for TA, it was developed in a collaboration 
between the University of Surrey and the Royal Surrey County Hospital. Before the work 
described in this thesis, finiteRT had been limited to analysing tumours. It was used to 
investigate and correlate intra-tumoural heterogeneity on CT imaging with FDG-PET avidity, 
within the Gross Tumour Volume (GTV) of primary lung cancers, which were to be treated 
with radical radiotherapy (Alobaidli et al., 2017). This means that the previous study by 
Alobaidli et al focused on the analysis of the GTV as the region of interest.  The region of 
interest was extracted from single phase non-contrast images from the CT component of the 
PET-CT scan. As a result it did not have to contend with variables that would need to have 
been taken account of, if larger regions of interest were to be analysed.  
In order to develop as user-independent process as possible, the work outlined in this thesis 
had to take account of many more variables, when compared to the previous project. New 
variables e.g. presence of IV contrast or analysis of larger ROIs needed to be accounted for to 
understand their downstream effect on the TA results. This chapter covers the initial work on 
expanding the region of interest from the tumour to the whole lung. To develop the 
methodology required active participation in developing the software as well as investigating 
the effects of different variables.  
By participating in the software development, it became obvious that this tool could have 
wider applications in analysing CT data, other than in analysing post treatment reponse. Two 
examples of this are explored in themes 2 and 3 of this thesis.  
FiniteRT was chosen as software to persue differentiating between tumour and RILI after 
SABR, principally because it can take account of spatial relationships between sub-regions of 
a texture plot. It achieves this by using a second order feature of TA called grey level co-
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occurrence matrices (GLCM), to create a map of heterogeneity. The GLCM identified runs of 
grey levels in the 13 directions of the 26 surrounding voxels. The heterogeneity is expressed 
as an entropy score. Entropy is a measure of disorder. The calculation used for entropy in 
finiteRT is: 
(Alobaidli, 2017) 
Essentially, the software divides the region of interest into voxels, before making a voxel by 
voxel comparison, assessing its similarity or dissimilarity to the 26 voxels immediately 
surrounding it. The larger the structure the longer it takes the software to process the 
information. For comparison analysing a tumour volume would take several minutes and 
analysing an entire lung would take several hours. Each time a variable within the software is 
changed, the analysis needs to be re-run. 
The software characterises the image using the GLCM to identify how often pairs of pixels 
with a specific value appear relative to the position of the voxel in space. FiniteRT assigns the 
voxel an entropy score. The higher the entropy score, the more dissimilar a voxel is to voxels 
around it. Inversely, a low entropy score means a voxel is similar (more uniform) to the voxels 
around it. Entropy is inversely proportional to uniformity.  
The aim of the project was to differentiate between tumour and RILI. The software has 
different variables that can be altered. It was important to understand how altering these 
variables might maximise the differences between tumour and RILI. Firstly the size of the filter 
can be set. The filter size is the size of the window the software uses to analyse each voxel. 
The software also sets the number of levels the data is divided or digitised into, which are the 
quantisation levels. Quantisation is when a continuous variable is divided into a pre-set 
number of discrete levels. The software makes a comparison between voxels by comparing 
data already divided into quantisation levels, rather than by comparing the absolute value of 
the voxel. The software calculates the quantisation levels for each analysis using a Lloyd Max 
quantiser (LMQ). Quantisation is described as the process of dividing up a continuous range 
of values into non-overlapping sub-ranges. This means that similar absolute values are 
grouped together. A value can then be given to each sub-region. The LMQ then divides 
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absolute values into the set number of levels (bins) exactly half way between each level. The 
LMQ chooses quantisation levels in such a way that the difference between the quantised 
image and the original image are minimised.  The equation used in LMQ was: 
 (Alobaidli, 2017) 
This method of quantisation assigns thresholds  based on the range of values within a region 
of interest. If the contents of the ROI are different, the spread and quantity of specific density 
values are different, the absolute density values at which the software defines the 
quantisation levels will be different. For example if there are 2 ROI’s, one contains just lung 
tissue and one contains lung and bone, the actual values at which the quantisation levels are 
set are likely to be different. This type of quantisation has been termed  individualised 
quantisation.  
It is also possible to standardise the quantisation levels, so that 2 or more structures are 
analysed using identical absolute values for quantising the data. The comparison of two or 
more regions of interest using identical quantisation levels has been termed uniform 
quantisation. The initial version of finiteRT used individualised quantisation. As more work 
was completed it became apparent that uniform quantisation would be useful. Previous data 
has suggested that there are 2 methods to define quantiation levels, one by dividing the range 
of values into equally spaced levels (bins) where the bin size varies for each image and the  
second standardises the quantisation by maintaining a constant intensity resolution. The 
second method, which is comparable to uniform quantisation is more robust to intra- and 
inter-image assessment (Leijenaar et al., 2015). As part of this project finiteRT was developed 
so that it could use either uniform or individualised quantisation.  
The aim of this work was to provide an analysis for large ROIs. As a result there were a wider 
range of variables that needed to be taken account of. Understanding how the texture maps 
and entropy scoring changes when the variables are altered has two benefits. Firstly in 
understanding which variables alter the outcome of the TA and secondly, which variables may 
help maximise the ability to identify the tumour.  
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These variables were divided into 2 groups, relating to understanding the effects of changing 
the software variables in finiteRT altering the results of the TA e.g. number of quantisation 
levels, then in understanding the imaging variables that might affect the pre-TA captured 
image e.g. presence or absence of IV contrast. An overview is given in figure 1.  
The ROI analysed, filter size and number of quantisation levels analysed were TA variables, 
the first group as identified above. Exploring the effect of altering these variables formed the 
first part of the experimental work in this chapter (section 4.2).   
The second category of variables that may influence the analysis were the imaging variables. 
These were thought to include use of multi-phase radiotherapy planning scans, regions of 
interest containing tissues other than tumour or larger than the tumour, effects of intra-
venous contrast, breathing phase of the scan or the ability to interpret post treatment 
imaging. This work describes the process of developing a model to understand the variables 
necessary to process and interpret a texture map of a whole lung, both before and after 
Stereotactic Ablative Body Radiotherapy (SABR). 
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Figure 1, Thesis structure  for Theme 1: TA analysis of primary lung tumours.  
Before any work was done, it was not clear whether finiteRT could generate texture maps for 
structures larger than a tumour. As a result the initial step was to establish whether it was 
possible to generate texture maps beyond a tumour (including surrounding lung) in pre-
treatment and post-treatment CT scans.  
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4.2 Defining the experimental space 1: Preliminary work on software related variables 
4.2.1 Experiment 1: Does the analysis of structures larger than the GTV alter the appearance 
of the texture map?  
Aim: To identify how the appearance of a texture map changes when the contents of the ROI  
are altered, specifically,  when the ROI including Gross Tumour Volume (GTV) is expanded to 
include GTV plus additional lung tissue. The hypothesis is that the appearance does not 
change as the proportion of lung vs tumour within the ROI increases. 
Methods: A generic method for generating a texture map: 
1. Import scan into radiotherapy planning system (Eclipse); each patient has an 
anonymised phantom radiotherapy plan for this purpose as part of the TEXAS trial (see 
appendix 2).  
2. Ensure GTV is outlined on CT planning scan. The GTV is localised on the Maximum 
Intensity Projection (MIP) as an iGTV, using a structure set saved on the CT average. If 
the scan is a post treatment scan, contour abnormal area, portion of lung or whole 
lung as appropriate, check that tumour volume is included within lung volume. This is 
especially important if the tumour is adjacent/abutting the chest wall. For pre-
treatment scans the GTV was outlined by the Clinical lead for SABR and a Consultant 
Clinical Oncologist with 10 years’ experience in treating patients with SABR.  
3. Export DICOM data from eclipse including the radiotherapy structure set.  
4. Load matlab software and CERR software (Computational Environment for 
Radiotherapy Research) (Deasy, 2016). Import DICOM data into CERR and save as a 
matlab file.  
5. Segment (extract) structure from CT scan, using structure number in CERR. 
6. Run TA. Each analysis has 3 variables: these are number of quantisation levels, filter 
size (in mm) and the structure being analysed. The code also stores a patient number. 
7. This gives a map that can be viewed in matlab. These texture maps are displayed in 
grey scale, with a range of entropy values starting at 0 (most homogeneous). The 
higher the score the higher the entropy (heterogeneity). 0 entropy areas are black, 
heterogeneous areas appear as white. The majority of entropy values are below 5.0.   
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For this first experiment, the relevant planning scan was imported into eclipse, pre-existing 
structures were used for these expansions. As a result a patient was identified, who 
underwent radical fractionated lung radiotherapy rather than sabr, as the patient had a GTV, 
CTV and PTV. This patient had a tumour within the lung that was not in contact with central 
structures or the chest wall. The GTV was identified. For the first map generated from the 
pre-treatment scan, the CTV and PTV were used as surrogates for an expanded margin from 
the GTV. This experiment used the 8 quantisation levels and a 5x5mm filter. The filter gives 
the size of subunits that the ROI is broken down into.  
Experiment 1 Results: Figure 2 shows 3 texture maps generated from the GTV, CTV 
(GTV+6mm) and PTV (GTV+11mm) of the same lung tumour. The standard appearance of a 
tumour after TA in previous projects is a black homogeneous centre with a rim of 
heterogeneity (appearing in white)(Alobaidli et al., 2017). All tumours that had been used 
were Non-Small Cell Lung Cancers. Figure 1 illustrates that the appearance of these images 
are similar when more lung is included in the texture map. When a larger area of lung is 
analysed, the central area of homogeneity and the visual structure of the map is maintained 
as the size of the ROI increases. 
 
Figure 2: Texture map analysing a region of interest equivalent to tumour plus a radiotherapy 
planning margin. a) tumour texture map for patient 4, b) tumour texture map + 6mm (CTV) 
and c) tumour texture map +11mm (PTV). Texture map has a stable appearance when 
increasing amounts of lung are included in the ROI. Black central area = homogeneous region= 
tumour, white= greater heterogeneity.  
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Figure 3. CT image defining a region of interest equivalent to tumour plus increasing concentric 
margins. Structures related to patient 3 GTV, GTV +5mm, +10mm, +15mm and +20mm. Pink 
contour represents GTV. 
The second part of this experiment was to perform uniform isotropic expansions of the GTV 
by 5, 10, 15 and 20mm for 3 patients. I wanted to understand how enlarging the ROI, which 
underwent TA affected the resultant texture map. Figure 3 shows how the volumes relate to 
the GTV on the original CT image for patient 3. Figure 4 compares texture maps from 3 
different patients using the same margin expansions. It is interesting to note that the volume 
of the tumour from patient 9, is much smaller and does not appear to have a central 
homogeneous region. A hypothesis to be tested in further experiments could be that tumours 
need to be above a certain size to have a central homogeneous region within the tumour.  
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Figure 4. Texture map defining a region of interest equivalent to tumour plus increasing 
concentric margins for 3 patients.  GTV plus additional maps with a 5, 10, 15 and 20mm 
margin expansion for 3 patients. 
In figure 4, the images from left to right show increasing size of the ROI. Although the images 
appear broadly similar, it was also important to understand the effect of increasing the size 
of the ROI on the individualised quantisation levels selected by the software. Table 1. shows 
the quantisation levels selected by the software for these 3 patients, when the ROI is  
increased. As the quantisation levels are chosen automatically by the software for each 
analysis using LMQ, I wanted to understand the effect of increasing the ROI size on the specific 
values chosen for quantisation. Table 1 shows that the quantisation levels for patient 3 
change subtely as more lung is included in the  ROI. Figure 3 shows that as the volume 
enlarges, an increasing amount of lung is included. As more lung is included the proportion of 
lung parenchyma vs tumour included in the analysed volumes increases. Lung tissue has a 
lower density than tumour when measured in Hounsfield Units. FiniteRT manages this change 
by lowering the value of the first (lowest) quantisation level, but changes the mean distance 
between the levels by less than 10%. Visually the texture maps do not appear significantly 
different; however, there are subtle changes in the automatic individualised quantisation 
levels, selected by finiteRT. This experiment shows that increasing the proportion of lung 
tissue within the ROI does not change the gross appearance of the texture map, but it does 
affect the precise values at which the data is quantised. When comparing GTV against GTV 
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with more lung tissue in the analysed volume, the range of values increased and the maximum 
and minimum values were further apart in intensity; hence the mean intensity distance 
between each level increased.  
In patients 4 + 9 there are significant differences between the quantisation levels for the GTV 
and the other analysed structures (illustrated in table 1). The volumes are illustrated in figure 
5. It shows that the GTV structure includes lung and tumour, but all other structures for 
patients 4 and 9 have a portion of chest wall included.  
  Pt Structure Filte
r  
size 
Q-
levels  
        
   1 2 3 4 5 6 7 8 Mean diff 
between 
Q levels  
3 GTV 5x5 184 279 382 503 633 772 916 1036 121.7 
3 GTV+5mm 5x5 135 204 303 424 569 724 883 1032 128.1 
3 GTV+10mm 5x5 123 183 263 374 517 680 859 1027 129.1 
3 GTV+15mm 5x5 109 162 228 330 467 638 833 1021 130.3 
3 GTV+20mm 5x5 115 169 237 339 475 647 842 1023 129.7 
            
9 GTV 5x5 255 324 400 502 613 727 833 943 98.3 
9 GTV+5mm 5x5 243 340 509 725 930 1106 1270 1452 172.7 
9 GTV+10mm 5x5 234 331 496 736 983 1113 1258 1425 170. 
9 GTV+15mm 5x5 228 320 484 745 1007 1131 1266 1429 171.6 
9 GTV+20mm 5x5 224 314 480 743 1014 1144 1292 1471 178.1 
            
4 GTV 5x5 201 319 435 568 702 834 959 1050 121.3 
4 GTV+5mm 5x5 172 290 438 623 835 1038 1220 1442 181.4 
4 GTV+10mm 5x5 147 237 359 513 690 874 1038 1229 154.5 
4 GTV+15mm 5x5 135 214 321 468 659 878 1034 1248 159 
4 GTV+20mm 5x5 133 233 361 554 785 1011 1184 1433 185.7 
Table 1. Comparing the optimised quantisation levels selected using the Lloyd Max Quantiser 
in a sequential analysis of 3 patients. GTV quantisation levels are similar in 3 tumours from 
different patients GTV= Gross tumour volume, 1-8 indicate levels of quantisation selected by 
finiteRT software. Q-levels=quantisation levels. Mean diff between Q levels= mean difference 
between quantisation levels 1-8 for each structure. Pts 4 + 9 includes tumour, lung and a large 
amount of chest wall, as chest wall is dense the higher quantisation levels are very different 
in pt4 + pt 9 GTV+20 compared to pt 3 GTV+20. The differences in the structures is illustrated 
in figure 3. Distortions as isotropically grow GTV argue for per patient calibration  
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Figure 5. Illustrating how growing isotropic margins around primary lung tumours commonly 
includes other tissues and structures. Comparing 3 GTVs (most central structure) as well as 
GTV+5mm, 10mm, 15mm and 20mm. a) = patient 3, b) = patient 4, c) = pt 9. Red= structures 
involving lung, tumour and chest wall, Green=structures involving lung and tumour. This 
means that generating the ROI is not completely user independent, but quantising a ROI 
including chest wall affects the quantisation and may affect the subsequent analysis.  
Experiment 1 Discussion: This experiment shows it is possible to generate texture maps that 
are recognisable from ROIs when they include regions beyond the limit of the tumour, when 
compared to texture maps of the tumour alone. The contents of the ROI changes the absolute 
quantisation levels, although the appearance of the TA map images in this preliminary 
analysis remain the same. This would need to be confirmed by increasing the number of ROIs 
analysed in this dataset.  
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4.2.2 Experiment 2: Does the appearance of a texture map alter when varying filter sizes 
are used in the analysis?  
Aim: As part of the preliminary work it is important to understand the effects of the different 
parameters that affect the analysis of a ROI texture map. In this experiment changes in filter 
size were investigated. The filter size is the size of subunit analysed as part of the texture map. 
Understanding the effects of altering the filter size could affect future analyses.  
Methods: Using the same method as previously a texture map was generated for the GTV, 
Further ROIs were generated from the GTV plus an isotropic margin of 5, 10, 15 and 20mm. 
This meant each GTV generated five different ROIs, which were each analysed as a separate 
structure. These structures were initially analysed using 8 quantisation levels and a 5x5mm 
filter. Previous work was completed with a 5x5 filter and it was felt reasonable to test a larger 
and smaller filter than previously investigated.  The ROIs analysed with a 5x5mm filter were 
compared with the same ROIs analysed with a 3x3mm and 7x7mm filter.  
Results: Figure 6 shows the same slice of the texture map, with increasing margins (in mm), 
these ROIs were analysed with filters set at 3x3mm, 5x5mm and 7x7mm. Original work  using 
finiteRT was carried out using a 5x5mm filter. The result of this experiment was that using a 
different filter size does not broadly change the appearance of the texture maps. This means 
the appearance of the texture maps are robust to changes in filter size, however, it does 
appear to alter the level of detail. When reviewing all the slices of each texture map the size 
of the homogeneous central region did not appear significantly different and the 
nomenclature of the texture map remains the same. Reducing the filter size from 5 x 5mm to 
3 x 3mm  or increasing it to 7x7mm did not seem to give any extra information, so a pragmatic 
decision was made to continue with a 5x5mm filter, as previous work had used this filter size. 
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Structure Filter size Q level        
  
1 2 3 4 5 6 7 8 
GTV 3x3 184 279 382 503 633 772 916 1036 
GTV+5 3x3 135 204 303 424 569 724 883 1032 
GTV+10 3x3 123 183 263 374 517 680 859 1027 
GTV+15 3x3 109 162 228 330 467 638 833 1021 
GTV+20 3x3 115 169 237 339 475 647 842 1023 
          
GTV 5x5 184 279 382 503 633 772 916 1036 
GTV+5 5x5 135 204 303 424 569 724 883 1032 
GTV+10 5x5 123 183 263 374 517 680 859 1027 
GTV+15 5x5 109 162 228 330 467 638 833 1021 
GTV+20 5x5 115 169 237 339 475 647 842 1023 
          
GTV 7x7 184 279 382 503 633 772 916 1036 
GTV+5 7x7 135 204 303 424 569 724 883 1032 
GTV+10 7x7 123 183 263 374 517 680 859 1027 
GTV+15 7x7 109 162 228 330 467 638 833 1021 
GTV+20 7x7 115 169 237 339 475 647 842 1023 
Table 2: Texture analysis of same ROI using 3 different filter (subregion) sizes. The results 
suggest that the when comparing a 3x3mm, 5x5mm and 7x7mm filter within FiniteRT, the 
values at which the LMQ sets the quantisation levels is independent of filter size., e.g. GTV 
with 3x3, 5x5 and 7x7 filters highlighted in green all have the same values.  
The quantisation levels used in the analysis displayed in table 2, were set using individualised 
quantisation. Table 2 shows that the quantisation levels using the LMQ is independent of filter 
size in this analysis. 
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Figure 6: Comparing texture maps of the same Regions of Interest with different filter sizes. 
3x3mm filter compared to 5x5mm and 7x7mm filter with different expanded volumes 
around GTV (in mm). The images are organised in the same way with a central 
homogeneous region seen in black with a rim of high heterogeneity seen in white. This is 
surrounded by a region of lower heterogeneity representing lung tissue. The resolution of the 
lung tissue is more clearly seen in the image using a 3x3mm filter compared to 5x5 and 
7x7mm filters.  
Experiment 2 Discussion: The result of this experiment suggests that using different filter 
sizes do not broadly change the appearance of the texture maps illustrated in figure 6. The 
central homogeneous region of the tumour is present in all of the texture maps in figure 6. 
Altering filter size does appear to change the resolution of the sub-region of the ROI that 
represents lung tissue, a smaller filter size gives more detail, which is perhaps a predictable 
result. Altering the filter size does not appear to change the absolute values assigned to the 
different quantisation levels illustrated in table 2. The observations from this preliminary 
analysis would ideally need to be tested in a larger cohort of patients. There is sufficient 
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variation between filter sizes, that it generates the hypothesis that when comparing different 
ROIs the same size filter should be chosen and used in all comparisons.  
 
4.2.3 Experiment 3: Does the appearance of a texture map alter when a different number 
of quantisation levels are used in the analysis? 
Aim: Is the appearance of the texture map sensitive to the number of levels that the data is 
quantised into? 
Experiment 3 Methods: The same structures were analysed as in experiment 2; however in 
this experiment the filter size was kept constant at 5x5mm and the analysis was re-run with 
8, 16 and 32 quantisation levels. Results are shown in figure 7. 
Experiment 3 Results : 
 
Figure 7: texture maps of a ROI including tumour plus a margin using different numbers of 
quantisation levels. (e,g, GTV+5 =GTV + 5mm margin) analysed with a 5x5 filter using 8, 16 
and 32 quantisation levels. The central area of homogeneity became less distinct as the 
number of quantisation levels increased. The central homogeneous region representing the 
centre of the tumour became less black and increasingly grey. This illustrates that the 
previously homogeneous central region of the tumour becomes less uniform as the number of 
quantisation levels increases.  
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Experiment 3 Discussion: From experiment 1 and 2 it seemed that increasing the size of the 
texture map to include more lung tissue did not affect its ability to identify areas of 
homogeneity. Therefore It was decided at this point to standardise the number of 
quantisation levels to 8 for two reasons, firstly previous work identified the homogeneous 
region of the tumour and its relationship to PET avidity used 8 quantisation levels (Alobaidli 
et al., 2017). Secondly and most importantly, using 8 levels appeared to maintain the central 
homogeneous region of the tumour more robustly than 16 or 32 levels. Maintaining the 
central  homogeneous region of the tumour meant the tumour should be easy to identify in 
the texture map image.  Although this decision was revisited at a later date when much larger 
ROIs were analysed, the principle of maintaining intra-tumoral homogeneity remained a 
central feature in the subsequent analysis, so the tumour centre could be easily identified.  
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4.3 Defining the experimental space 2: Preliminary work on image related variables  
4.3.1 Experiment 4: Does the breathing phase from a 4DCT affect the appearance of a 
texture map, when a GTV is analysed? Effects of tumour movement on the texture map of 
the GTV 
Experiment 4: Understanding the effects of tumour movement on the GTV   
Aim: From the work in experiments 1-3 it was established that although the texture map 
subtlely alters when the contents of the analysed ROI are altered, altering the number of 
quantisation levels and the filter size does not lead to obvious or gross changes in the 
appearance of the texture map.  Whichever settings are used the central homogeneous 
region of the tumour is maintained and therefore it is easier to identify a pre-treated tumour 
within the texture map. The preliminary texture related experiments were all completed on 
scans from 1 scanner. Radiotherapy CT scans are not used for diagnosis and aim to provide a 
model of the patient for planning radiotherapy treatment. When a tumour of the upper 
abdomen or thorax is treated with radiotherapy, a 4DCT scan can be used to assess and 
compensate for tumour movement during respiration. The scan divided respiration into 10 
phases (CT0, CT10 … CT90). CT0 correlates with maximum inspiration and CT50 with 
maximum expiration. Two composite volumes are standardly generated from these 10 
phases, which are the AVIP (Average Intensity Projection) and the MIP (Maximum Intensity 
Projection). A single phase gives the best image definition, MIP illustrates the maximum 
motion related to a structure and the AVIP is equivalent to the average position of a structure 
i.e. the position of a structure during most of its time during the breathing cycle. As a result 
standard practice is to contour organs at risk on the AVIP sequence and use the MIP to ensure 
the tumour’s position has been covered in all of the breathing cycle. Using this technique 
minimises the risk of a systematic error caused by a geographical miss of the tumour, due to 
respiratory movement. Data has shown that using the MIP and reviewing the 4DCT ensures 
best coverage of the tumour (Ezhil et al., 2009). 
Methods: The GTV was copied from the AVIP to the MIP, CT0 and CT50 phases of the 4DCT 
of a patient that met the criteria for SABR for a primary lung tumour. These structures were 
then analysed allowing the software to choose optimised quantisation levels for each 
structure. All the 4D scans were completed using Advantage 4D software (General Electric), 
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the binning was completed using amplitude. Quality control is completed 3 monthly for the 
4D acqusitions, compared to monthly and daily Quality Control for normal scanning. 
Experiment 4 Results: 
 
Figure 8: showing texture map analysing a Region of Interest equivalent to the GTV using 4 
different phases of the 4DCT radiotherapy planning scan. These maps analysed the GTV for 
patientt 5 using data extracted from CT0, CT50, CTAVIP and CTMIP. 
 
1 2 3 4 5 6 7 8 
CT0 192 291 398 516 646 776 906 1016 
CT50 228 311 410 526 652 784 908 1017 
CTAVIP 246 340 442 549 661 777 897 1012 
CTMIP 293 396 509 620 736 848 952 1038 
Table 3, showing the 8 quantisation levels for the four phases of the GTV illustrated in figure 
7. 
CT0 and CT50 are very similar in appearance, with the rim of the tumour in slightly different 
positions showing the data is taken from different phases of the breathing cycle. The CTAVIP 
shows a blurred heterogeneous rim, which would be explained by the fact that the AVIP is an 
average over the whole breathing cycle. The image from the CTMIP shows the largest 
homogeneous region of tumour and that the heterogeneous rim fits the outer edge of the 
structure, explained by the MIP accounting for all positions of the tumour. The images do not 
appear significantly different. The ITV for pre-treatment analyses was taken from the CTAVIP. 
This was a pragmatic decision as the AVIP contained the radiotherapy structure set and 
planning data. It was encouraging that all of the maps in figure 6 maintain the central 
homogeneous region, as post treatment scans would likely take place in an equivalent of CT0 
(deep inspiratory breath hold). It also means that if patients are unable to hold their breath 
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during a scan, any blurring in post treatment scans would not cause the loss of the central 
homogeneous region.  
Experiment 4 Discussion: Analysing ROIs (seen in figure 8) corresponding with the GTV 
segmented from different phases of the 4DCT does not obviously change the appearance of 
texture map relating to the tumour. Most importantly it does compromise the presence of 
the central homogeneous region of the tumour. These images were taken from a ROI that 
corresponded with an iGTV, which accounted for tumour motion. As a result CT0 and CT50 
are single phases of the 4DCT, where as CTAVIP and MIP are composite volumes from all 
phases of the scan. For this reason it is not suprising that the central homogeneous regions 
of the ROIs in figure 8 are subtley different shapes.  
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4.3.2 Experiment 5: Does the presence of intra-venous contrast affect the appearance of a 
texture map generated from the GTV? 
Aim: Contrast is known to affect the texture of tumours (Dennie et al., 2016). IV (intra-venous) 
contrast used in CT scans is radio-opaque and has a high density when measured in Hounsfield 
Units. As tumours are likely to take up contrast I wanted to compare tumours for the same 
group of patients from the AVIP of the radiotherapy planning scan with the CT component of 
their diagnostic PET-CT scan. Use of IV contrast was standard in SABR patients treated at RSCH 
using a standard protocol, in all patients who had adequate renal function and did not have 
an obvious contra-indication to IV contrast.  
The CT component of the PET-CT is performed in free breathing, so should be similar in nature 
to the AVIP. The PET-CT scan is often the final imaging diagnostic test before a patient is 
considered for SABR, so these scans were chosen as changes due to progression of the tumour 
were kept to a minimum.  
Experiment 5 Methods: The GTV from the AVIP (GTV-AVIP) was registered and copied to the 
CT of the PET-CT scan (GTV-PET). GTV-AVIP and GTV-PET were segmented from their 
respective scans and analysed using finiteRT. 
Figure 9, Comparing the effects of contrast on the appearance of texture maps from contrast 
and non-contrast CT scans. This was achieved by comparing appearance of a texture map from 
CT from non-contrast PET-CT, with pre-treatment contrast enhanced radiotherapy planning 
scan for 3 different patients.  
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Table 4, showing 8 quantisation levels for GTV+20mm from a PET-CT and radiotherapy 
planning CT for 3 patients.  
Experiment 5 Results: Figure 9 shows there is no noticeable difference in appearance of the 
central homogeneous region of the texture map, whether or not the scan contains contrast.  
Although the contrast slightly alters the quantisation levels seen in table 4, they are not very 
different, but it does show that contrast is a variable that needs to be considered.  
Experiment 5 Discussion: Contrast does not change the way the way the image is configured 
in these 3 patients, but does affect quantisation. Ideally in comparing ROIs between patients 
the scan images would either all be taken with or without contrast. To confirm this finding, 
ideally a larger cohort of patients would be need to be analysed.  
 
 
 
Pt Scan Contrast Q 
levels 
Filter 
size 
1 2 3 4 5 6 7 8 
pt 3 CT plan Yes 8 5x5 115 169 237 339 475 647 842 1023 
pt 3 PET-CT No 8 5x5 95 143 209 312 445 612 800 992 
pt4 CT plan Yes 8 5x5 133 223 361 554 785 1011 1184 1433 
pt4 PET-CT No 8 5x5 106 198 340 534 770 1009 1160 1378 
pt5 CT plan Yes 8 5x5 197 288 436 638 871 1009 1224 1525 
pt 5 PET-CT No 8 5x5 192 286 412 570 774 998 1159 1332 
Pt Scan Contrast Q 
levels 
Filter 
size 
1 2 3 4 5 6 7 8 
pt 3 CT plan Yes 8 5x5 115 169 237 339 475 647 842 1023 
pt 3 PET-CT No 8 5x5 95 143 209 312 445 612 800 992 
pt4 CT plan Yes 8 5x5 133 223 361 554 785 1011 1184 1433 
pt4 PET-CT No 8 5x5 106 198 340 534 770 1009 1160 1378 
pt5 CT plan Yes 8 5x5 197 288 436 638 871 1009 1224 1525 
pt 5 PET-CT No 8 5x5 192 286 412 570 774 998 1159 1332 
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4.3.3 Experiment 6: What is the effect of Stereotactic Ablative Body Radiotherapy on the 
appearance of a lung tumour in a texture map?  
Aim: As the aim of this project was to use the texture analysis tool in both pre- and post-
treatment scans, it is important to understand the effect of treatment on the texture map. It 
is also likely that patients will have their follow-up scan in a different hospital, on a different 
scanner to the radiotherapy planning scan, which needs to be taken into account, as well as 
the effects of treatment. It is very unlikely that patients will have any follow up scans on the 
same scanner, on which they had their radiotherapy planning scan. As well as the difference 
in scanner, the scanning protocol is likely to be different. There are 3 potential different scans 
that a patient is likely to undergo, initially a diagnostic CT, then a PET-CT for more accurate 
staging and finally a radiotherapy planning CT. The CT component of the PET-CT is performed 
in free breathing and the patient receives an intra-venous radioactive tracer rather than IV 
contrast, secondly the radiotherapy planning CT scanner with IV contrast and the average 
phase composed of multiple phases of a patient breathing freely, the third type of scan is a 
diagnostic CT scanner with the patient in inspiration breath hold using IV contrast.  
Methods: 3 patients had all available CT imaging assessed. The region of interest (GTV) was 
identified in a pre-treatment CT component of PET-CT, radiotherapy planning CT and post 
treatment scans. The GTV was isotropically expanded using eclipse radiotherapy planning 
software, to create GTV + 20mm. In all the analyses 8 quantisation levels and a 5x5mm filter 
were used.   
Results:  
Figure 10 shows the changes in tumour bed after treatment over time. The first and second 
columns of figure 10 show that the presence or absence of contrast as also seen in figure 9. 
This experiment was testing texture appearance on different scanners and response to 
tumour over time. It is well established that after SABR there can be significant post treatment 
inflammation in the lung, which can make it difficult to identify the treated tumour as well as 
the fact that the tumour bed can change position in the lung as a result of the inflammation. 
Post treatment lung injury can be termed RILI (Radiation Induced Lung Injury). RILI can be 
difficult to distinguish from tumour (Huang et al., 2015).  
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Figure 10: comparing texture maps of GTV+20mm between CT of PET-CT, radiotherapy 
planning scan and diagnostic post treatment CT scans. All analysis used 8 quantisation levels 
and a 5x5mm filter. These 3 patients were chosen as they had not had a recurrence >2 years 
post SABR treatment. 
In patient 4 the central region is visible on the diagnostic PET-CT and planning scan, it is 
smaller at 4 months and is not obvious at 20 months, but reappears at 26 months. It may be 
that as the acute lung reaction has settled and more organised fibrosis is establishing itself, 
this forms a homogeneous region. In patients 3 and 5, the central homogeneous region of the 
tumour disappears after treatment and does not reappear.  
Experiment 6 Discussion: These results suggest that the textural appearance of lung tumours  
treated with SABR can significantly change after treatment. In these 3 examples of patients 
whose tumour  has not reccured after SABR, the central homogeneous region gets smaller 
and disappears after treatment. The distortion of the central homogeneous region of the 
tumour can be seen in the first post treatment scan in all 3 patients and continues in the 
second post treatment scan. This experiment raises the question of whether it may be 
possible to differentiate between tumour and RILI early after SABR. This would need to be 
tested on a larger cohort of patients, ideally with similarly timed post treatment imaging.   
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4.3.4 Conclusion of work from section 4.1-4.3 
From the work outlined in section 4.2 and 4.3, it can be concluded that all the variables affect 
the appearance of the texture map, but mostly in subtle ways. In combination these could 
have a profound effect on the ability to compare similar structures between patients. The aim 
of this preliminary work was to understand, which variables were important. Perhaps 
unsurprisingly, all the identified variables are important, however although these factors 
influence the analysis, they do not appear to affect the architecture of the texture map and 
its appearance is largely unchanged. In conclusion the appearance of the texture map 
generated from the analysis is robust to these variables. To maximise the accuracy of future 
analysis further work aimed at standardising the analysis needed to be completed, to 
minimise the effect of as many independent variables as possible.  
At this point it was felt that any future analysis would need to fix the filter size and number 
of quantisation levels and consider exploring uniform quantisation. Analysis would also aim 
to use scans with IV contrast in an identified breathing phase. 
It was felt that fixing the quantisation levels using uniform values, rather than allowing the 
software to choose individualised quantisation levels, would mean that differences in the 
texture maps were due to the tumour, not the software. It offered two other benefits. Firstly, 
it would also allow the entropy (disorder) scores generated from the analysed structures to 
be directly compared. Secondly, fixing quantisation levels means the quantisation levels are 
not determined by the content of the texture map. For example, by fixing the quantisation 
levels it does not matter whether a dense structure, such as chest wall, is inadvertently 
included in a region of interest, which should only include lung and tumour. In a clinical 
context it reduces the need for specialist knowledge to volume a region of interest and 
minimises the effects of any errors in generating a region of interest.  
Going forward from this point, it was felt that further analyses should aim to include either 
large sections of lung or if possible the whole lung. Generating a contour of the lung requires 
less specialist knowledge than identifying the tumour bed (particularly in post treatment 
imaging) and ensures that all post treatment inflammation would be included. To date all 
work had been completed on the GTV plus a margin of lung. If further analysis were to include 
large sections of lung tissue, then this would lead to a more complex analysis of the texture 
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map, as the appearance of normal tissue as well as abnormal tissue would need to be 
accounted for. The texture analysis would also take a lot longer to process using finiteRT.  
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4.4 Calibrating the texture map analysis 
4.4.1 Experiment 7: Generating texture maps of large sections of lung containing tumour 
Aim: As discussed above, analysing larger sections of lung allows for the need for less 
specialist knowledge in voluming the tumour. It also allows for a more agnostic (user-
independent) approach to generating the texture maps. The aim of this experiment was to 
see whether it was technically possible to segment and process large regions of interest 
equivalent to large sections of lung. It was also important to understand whether analysing 
large ROIs affects the texture map appearance. Understanding the effects of analysing larger 
sections of lung was important as it requires less specialist knowledge to contour a volume of 
lung when compared to voluming a tumour or area of lung injury.   
 
Figure 11: A comparison between GTV and 3 expanded volumes, including the whole lung 
circumferentially with 2, 3 and 5cm superiorly and inferiorly to the GTV. Below the texture 
maps is the original pre-treatment CT image. 
Methods: In this experiment the GTV and 3 expansions on the GTV were analysed. All 3 
expansions include all lung tissue circumferentially around the GTV, the volume was then 
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grown 2, 3 and 5 cm superiorly and inferiorly within the lung. The volume was edited back to 
only include lung tissue and  tumour, aiming to  exclude chest wall and mediastinal structures.  
 
Figure 12:Comparing texture maps of slices of whole lung from a CT scan between CT of PET-
CT, radiotherapy planning scan and diagnostic post treatment CT scans.  shows the same 
analysis as in figure 11, but for the pre-treatment CT scan and 2 post treatment CT scans. The 
appearance of the texture maps are unchanged in this patients when the amount of lung 
tissue included in the texture map is increased.  
Results: 
Figure 11 shows the appearance of slices of texture analysis of all of the lung tissue in the axial 
plane. Figure 12 shows the same analysis in sequential scans both before and after treatment.  
The maps do not appear any different, so including more lung does not alter the appearance 
of the texture map.  
Experiment 7 Discussion: This experiment shows that in multiple axial CT images of this 
patient including a large proportion of lung tissue in a  texture map, does not alter the 
appearance of the texture map. Figure 11 shows that increasing the volume of lung in a 
cranial-caudal direction does not affect the appearance of the axial texture map.  
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4.4.2 Experiment 8: Standardising quantisation of lung sections to GTV  
Aims: The aim of this experiment was to see if there was a difference in the appearance of 
the image standardised to GTVs generated from 3 different phases of the 4D radiotherapy 
planning scan, because it was important to understand the effects of using different phases 
of the 4DCT as a ROI for TA. Analysing different breathing phases of the 4DCT did not affect 
whether a central homogeneous region of the tumour was detected within the texture map, 
as discussed in experiment 4, but it was important to ensure that it did not have an effect on 
the analysis of large volumes of lung.  
Methods: A section of lung including all lung circumferentially and 5cm superior and inferior 
to the GTV was extracted from the CT scan, this included most of the lung ipsilateral to the 
tumour. A limited region including GTV only was analysed by finiteRT using optimal 
quantisation separately for CT0, CTAVIP and CTMIP. This was to see what effect of the 
individualised quantisation using the LMQ was for the different phases of the 4DCT. The CT0, 
MIP and AVIP were then used to standardise the quantisation of the much larger lung section 
seen in figure 12.    
Results: 
FiniteRT took account of the large proportion of lung compared to tumour in calculating the 
optimised quantisation levels using the Lloyd Max quantiser. The effect of the individualised 
quantisation was that more heterogeneity in the lung parenchyma was identified compared 
to using individualised quantisation from the analysed structured when compared to using 
quantisation levels from the analysis of the GTV from either CT0, CTAVIP or CTMIP. In all 4 
analyses the central homogeneous region was visible and broadly similar, but the structures 
analysed using uniform quantisation levels standardised to tumour showed a lot less 
heterogeneity within the lung parenchyma. Figure 13 shows a post treatment scan taken 6 
months after delivery of SABR. All of the lung appears heterogeneous in the optimally 
quantised structure (column a), whereas the images generated using uniform quantisation 
(columns b), c) and d)), differentiate between post treatment RILI on the left of these images 
(also seen in column e) on the original CT image) and the uninflamed lung on the right of the 
image. 
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Figure 13: analysis of whole lung section standardised to different uniform quantisers. Column 
a) uses optimal quantisation, column b-d) use uniform quantisation to CT0, CTAVIP and CTMIP. 
Column e) shows the original CT image.  
From this analysis, the quantisation levels appropriate to a tumour, aid interpretation of the 
lung parenchyma texture map. All of the analyses show an area on the left outer rim of the 
image that is consistent with the previously irradiated tumour bed, although it is not clear 
whether this is tumour or RILI. By comparing the tumour bed seen in figure 12 and 13, it 
illustrates how it changes position within the lung after treatment.   
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Figure 14: Comparison of texture maps of a CT scan 6 months after SABR using different 
uniform quantisers. Column a) uses individualised quantisation, column b-d) use uniform 
quantisation to CT0, CTAVIP and CTMIP. Column e) shows the original CT image. In column a) 
all of the lung is heterogeneous, whereas in column b-d) only the inflamed lung appears 
heterogeneous. 
Experiment 8 Discussion: Standardising large volumes of lung tissue from post-treatment 
imaging to quantisation levels from the GTV of CT0, CTAVIP or CTMIP from the pre-treatment 
scan, means that it is possible to differentiate between RILI and normal lung, when  compared 
to analysis using individualised quantisation from the lung volume. This can be seen by 
comparing column a) to columns b)-d) inclusive in figure 14.  
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4.4.3 Experiment 9: Combining CT images and texture maps 
Aim: From the texture analyses to this point, it was evident that the tumour could be 
identified before treatment, but the tumour bed was more difficult to identify after treatment 
as the central homogeneous region of the tumour became disrupted, particularly in the first 
few months after treatment. Would the combination of original CT data and the texture map 
give greater information about the response of the tumour and the lung to radiotherapy?  
Tumour is represented as a black homogeneous region in the texture map and as a grey/white 
(depending on windowing) dense region in the original CT image. As a tumour is dense and 
has low entropy, if the texture map was inverted, i.e. low entropy/high homogeneity would 
appear white. This experiment aimed to combine an inverted texture map with the CT data, 
potentially meaning a white region would represent low entropy and high density, a grey 
region would represent either a low entropy and low density or high density and high entropy 
and a black region would represent high entropy and low density.  
Methods: I collaborated with a PhD student in CVSSP to adapt the  finiteRT code to display 
both the standard texture map of a section of lung and an inverted texture map. The image 
was converted from a Matlab file into a NifTi file . The same code generated a NifTi file for the 
edited lung volume using the original CT data. These 3 files were then overlaid in an imaging 
programme called ITK Snap (Yushkevich et al., 2006). 
Results and Discussion: Slice 38, 39 and 40 of figure 15 shows that the combination of 
inverted texture map and CT scan clearly identifies the tumour before treatment. Figure 16 
shows the most representative slice of pre-treatment and post treatment images for a single 
patient showing the tumour identified as a region of low entropy and high density.   Row a) 
shows the pre-treatment image. Row b) shows a slice of CT scan, texture map and combined 
map 3 months after SABR. In the whole texture map for this patient, the only homogeneous 
solid (i.e. white region) is seen in this slice. The high density low entropy region seen in white 
in the centre of the 3 images decreases in size very significantly when comparing the pre-
treatment and 3 month post treatment image. This change occurs despite the fact the tumour 
appears broadly similar on the pre-treatment and 3 month post treatment CT image. It 
suggests that since the treatment, the gross appearance of the tumour is unchanged on CT, 
but the grey levels of the tumour have become a lot more heterogeneous after treatment. 
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This can be seen comparing the combined texture map (central image) in row a) and b) in 
figure15. The combination of textural analysis and CT data gives a lot more information about 
an area, which is essentially unchanged on a CT scan after SABR. 
 
 
Figure 15: Comparison of texture map, CT data and combined inverted texture map and CT 
data of a tumour before SABR. The central white area of the combined map illustrates tumour.  
A central low homogeneity region is re-established 6 months after treatment, this is seen in 
figure 15 row c) and maintained 1 year after treatment, seen  in row d). However, this region 
is grey, rather than white suggesting there is a difference between the pre-treatment tumour, 
which is dense and low entropy and the post-treatment lung reaction, which is dense, but not 
of low entropy, so appears grey rather than white.  
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 Figure 16, comparison of texture map, CT data and combined texture and CT data pre-
treatment and post treatment after SABR for a patient who did not relapse (patient 5).  
The area of homogeneity seen in figure 16 row c) is much closer to the chest wall, than the 
previously treated tumour. Its gross appearance on CT suggests it is the tumour bed, which 
has moved position in response to RILI, it is not clear whether 6 months after treatment, this 
represents a degree of residual tumour or an organised area of homogeneous fibrosis. 
Interestingly 1 year after treatment, the central homogeneous region has disappeared, it has 
been replaced by a grey region, different in appearance to the white region of the pre-
treatment tumour in the ipsilateral upper lobe, which suggests a dense, but non-uniform area 
of fibrosis. This grey region can be seen in figure 15, row d). 
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Figure 17, comparison of texture map, CT data and combined texture and CT data pre-
treatment and post treatment after SABR for a patient who had a late relapse 3.5 years after 
radiotherapy (patient 3).  
From this experiment it seems that the changes in the tumour and lung can be mapped using 
this combined analysis. It suggests that adding texture analysis to a standard CT scan does 
increase the amount of information available; it may also help to understand and map the 
process of acute lung injury and subsequent fibrosis after SABR. In contrast figure 17 
compares a patient who had a late relapse after radiotherapy. The central homogeneous 
white region that represents tumour, can be seen in row a). This patient had FDG PET-CT 
proven likely nodal relapse at 3.5 years. Although the patient had no proven relapse earlier 
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than 3.5 years, an area of dense homogeneity can be seen 1 and 2 years after treatment.  This 
is much larger at 3.5 years after treatment and correlates with the area of FDG avidity.  
This analysis technique may help for further work in the future and formed part of the analysis 
in the final study. The most significant finding so far is illustrated in figure 16 rows a) and b), 
which shows just how significantly the texture of the primary tumour changes, pre and post 
SABR, when the radiological abnormality on CT imaging appears very similar. This suggests 
that the texture map could differentiate between ‘active’ pre-treatment tumour and ablated 
post treatment tumour.   
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4.4.4 Experiment 10: identifying a tumour signature 
Aim: The texture map generates an image, based on entropy scores. Entropy is a measure of 
disorder, the higher the entropy, the higher the disorder and the lower the uniformity or 
similarity. The tumours appeared as lower entropy structures in the texture map. This is 
different to most published data, where heterogeneity is associated with tumours and high 
heterogeneity is often associated with a poorer prognosis (Phillips et al., 2017).  
Entropy usually produces a score between 0.00 and 4.99 in finiteRT. With most values being 
below 4.0. The centre homogeneous region of a tumour would have an entropy value of 0. 
The aim of this project was to see if different tumours had similar entropy scores.  
Methods: ITK snap is an imaging programme that was used to combine the texture map with 
the CT data by converting the data into Nifti file format. It was able to provide histograms of 
the range of intensities seen within an image. The maximum and minimum entropy intensities 
from the texture map alone were measured and the maximum and minimum intensities of 
the inverted texture map combined with the CT scan data. This is seen in table 5. The entropy 
scores were derived directly from the texture map. The combined score from the inverted 
texture map and the CT scan was generated by inverting the texture map by taking the 
maximum value of heterogeneity and subtracting the whole texture map, which maintained 
the 0 entropy central region of the tumour. This gives a range of intensities and a range of 
texture entropy values, with positive and negative values possible.  
Experiment 10 Results and Discussion: Table 5 shows the range of intensity values found in 
this experiment. The values for the tumour entropy score are all similar. From this data, it 
appears that for tumours to have a homogeneous region, which is seen as a white region on 
the combined texture/CT data image the tumour needs to be above a certain size. The 
maximum intensity values for the tumours of patient 6 and 9 were much lower than the other 
8 patients, viewing the texture maps for patients 6 and 9 confirmed they do not have a central 
homogeneous region. This suggests that in this case series the tumours with a volume of 
greater than 3.1cm3 to have a central homogenous region, whether a minimum resolution 
exists above a specific value requires many more tumours to be analysed.  
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Table 5, this table shows the maximum and minimum entropy scores from the texture map of 
the tumour. It also shows the range of intensity values per tumour when an inverted texture 
map is combined with the density data from the CT scan. The 2 smallest tumours have a lower 
maximum combined intensity as they do not have a visible low entropy core of the tumour. 
 
Figure 18, nomenclature of texture map from combined data from inverted texture map and 
CT data. Central homogeneous region seen on texture map correlates to an intensity value of 
above 4000. It is surrounded by a very negative intensity region, which then decreases as 
distance from tumour rim increases.  
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Figure 18 shows the appearance of an example of a texture map containing a tumour with a 
central homogeneous region. This existed for all combined data for all patients in table 5 
except patients 6 and 9. 
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4.4.5 Experiment 11: Identifying the signature of organs at risk   
Aim: To identify whether certain organs at risk have a specific entropy value/texture signature 
that can be identified within a texture plot. If organs at risk/normal structures could be 
identified in the texture maps, these values could be excluded, potentially leaving the 
remaining data points as the tumour.  
Experiment 11 Methods: 4 different organs were identified, these were lung tissue, liver, 
bone and aorta/contrast. A volume defined by a 3cm diameter circle of lung or liver tissue 
repeated on 8 consecutive slices (slices 2.5mm apart) within a region of lung or liver, for bone 
and aorta a 2cm diameter circle was used. For the bone volume of interest 5 consecutive 
slices within a thoracic vertebra were identified. For the aorta 8 consecutive slices of the 
descending aorta were volumed.  
The first time that texture maps for liver, bone and aorta were generated, finiteRT was not 
able to generate texture maps because the lesions were too homogeneous. The regions of 
interest for liver, bone and aorta were redrawn to include the organ of interest and an area 
of lung, ensuring sufficient heterogeneity to generate a texture map.  Figure 19 shows the 4 
final volumes.   
 
 
324 
 
 
 Figure 19, Volumes for liver, bone and aorta had to include a region of lung so that there was 
sufficient heterogeneity for finiteRT to generate a texture map. a) liver, b) bone, c) lung and 
d) aorta regions of interest. Texture maps containing only bone, liver and contrast did not have 
sufficient heterogeneity to allow a texture map to be generated.  
Experiment 11 Results and Discussion: Table 6 shows data from the texture maps. The 
maximum and mean entropy for each patient are similar. The mean of the maximum entropy 
for bone and aorta are higher than liver and lung suggesting that bone and aorta have a 
greater degree of heterogeneity than liver and bone. It could be expected that liver 
parenchymal tissue is homogeneous, but for lung this is more surprising as it is a section of 
lung which is an interaction between airways, blood vessels and alveoli. Density information 
from the scan was then combined with the inverted texture map. The wider range of scoring 
was seen in the 2 densest structures, aorta (containing radio-opaque IV contrast) and bone. 
Whereas the range between maximum in liver was narrower and in lung narrower still. From 
this experiment in a very small sample of patients, the range of texture values did not 
obviously differentiate a signature for different organs.  
As a result, it was necessary to consider a more complex analysis of the numerical values 
generated from a texture map.   
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Patient 
no. 
Max entropy score Min entropy score TextInv Max TextInv Min 
Lung 1 4.65 0 1001 -1030 
 
2 3.08 0 644 -729 
 
3 3.89 0 822 -907 
 
4 4.38 0 1114 -1164 
 
5 2.63 0 741 -701 
 
Mean 3.73 0 864.4 -906.2 
Aorta 1 4.00 0 4600 -4460 
 
2 3.99 0 4585 -4445 
 
3 4.23 0 6258 -7425 
 
4 4.16 0 5324 -5204 
 
5 4.08 0 4316 -4198 
 
Mean 4.09 0 5016.6 -5146.4 
Liver 1 3.80 0 4342 -4141 
 
2 3.79 0 4339 -4138 
 
3 3.49 0 3866 -3629 
 
4 2.92 0 3347 -3194 
 
5 1.94 0 2123 -1967 
 
Mean 3.18 0 3603.4 -3413.8 
Bone 1 3.98 0 5129 -5028 
 
2 3.92 0 5049 -5052 
 
3 3.92 0 5680 -5700 
 
4 
    
 
5 3.71 0 5139 -5235 
 
Mean 3.88 0 5249.25 -5253.75 
 
Table 6, showing max and minimum entropy scores for each patient for different normal 
structures. TextInv Max and Min show maximum and minimum values from combined data 
from inverted texture map and CT data. It was not possible to generate a texture map from 
bone for patient 4. 
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4.4.5 Conclusion of section 4.4 
Experiment 7 showed that it was technically feasible to generate a texture map for large 
sections of lung from a CT scan. Experiment 8 showed that it was possible to generate texture 
maps for the same large sections, as well as then standardising the quantisation levels to pre-
determined levels. This meant that uniform standardisation could be achieved if different 
structures were compared using the same quantisation levels. Experiment 9 tried to gain 
greater information from combining the texture map using entropy scores with the density 
data from the original CT scan. Using an inverted texture map, so that white was low entropy 
and increased density was white, meant it was possible to identify dense regions with a low 
entropy score. For the first experiment (seen in figure 15) the combined texture map showed 
that the tumour on the pre-treatment and 3 months post treatment CT scan had a similar 
radiological appearance, but looked very different on the combined map. Unfortunately this 
result was not repeated in other patients. It was felt that although visually interesting, the 
combination of entropy score and density did not add more information. Experiment 10 and 
11 attempted to identify whether different tumours had similar combined entropy/density 
scores, as well as seeing if different organs had different combined scores.  
In summary these combined texture maps required artificial manipulation of the texture data 
and this was felt it could introduce a source of error, or allow the results to be manipulated 
to show differences between patient populations when there wasn’t an actual difference.  
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4.5 The ‘elephant plot’ An expression of combined CT and texture data as a hypothesis 
generating tool  
From the previous work in this chapter, it appeared that adding more complexity to the 
analysis did obviously help differentiate between tumour and other structures.  
Each data point had 3 pieces of information: a density score, an entropy score and its position 
in space. These analyses did not use these pieces of data to the greatest advantage.  
As a result the data was plotted with a density score on the x axis and the entropy score on 
the y axis. This was initially plotted for a whole lung containing tumour and as a separate 
analysis, the whole contra-lateral lung that did not contain tumour. These can be seen in 
figure 20. The data plot labelled a) shows the lung containing tumour and the data plot 
labelled b) shows the contra-lateral lung, which does not contain tumour.  
In this example the tumour makes up approximately 1% of the lung volume and yet it is easy 
to see that when compared to the lung that doesn’t contain tumour, the ‘trunk’ of the 
elephant plot, which is analogous with tumour is easy to identify. At this point it was felt that 
the elephant plot may be a useful tool in determining the presence of tumour in a lung, 
following SABR for primary lung cancer. Chapter 5 explores the initial analysis using the 
elephant plot.  
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Figure 20, An ‘elephant plot’, a data plot of density (x axis) vs entropy score (y axis) for each 
data point from a whole lung segmented from a radiotherapy planning CT scan. a) is the lung 
ipsilateral to the tumour, b) is the contra-lateral lung. The absence of the ‘trunk’ of the 
elephant in b) suggests that this may be a useful tool to identify the presence of tumour in a 
lung.  
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Figure 21 compares a data plot of density and entropy comparing a whole lung vs a whole CT 
scan of the thorax. For both plots (x axis, density score = Hounsfield Unit + 1000 = electron 
density) and entropy (y axis), figure a) = whole scan, figure b) = whole lung ipsilateral to the 
tumour.  
The elephant plot illustrated in figure 20 shows how data points were distributed when a 
whole lung was identified and analysed. From the initial project concept the aim was to keep 
the ROI as simple as possible to minimise the technical knowledge needed to process it. 
Despite processing the whole lung, it is still possible to easily identify the tumour within the 
elephant plot. As a step on from identifying the whole lung, a whole scan was processed using 
both the LMQ quantisation method and a uniform quantisation, which is discussed in chapter 
5. Figure 21 shows the elephant plots for a whole scan. This shows that analysing a whole 
scan rather than a whole lung leads to a very wide trunk, making it difficult to differentiate 
between structures. From figure 21 it is possible to see that some localisation of the ROI is 
required, when compared to the elephant plot for the lung.  
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